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Abstract 
Bleomycin (BLM) is an antineoplastic agent known to cause pulmonary fibrosis as a side-
effect, and is often used to model fibrotic disease in rodents. Although human BLM-
induced pulmonary fibrosis (BPF) results from intravenous BLM delivery, rodent 
modelling today primarily uses the intratracheal delivery method. However, BPF following 
both dosing routes is characterised by inflammatory cell influx into the lung. Though it is 
thought that intratracheal dosing causes intrapulmonary injury, cytokine release, and 
resultant immune cell recruitment, the mechanism by which intravenous dosing causes 
immune cell influx is less clear. 
Endothelial cells are critically involved in immune cell extravasation to the site of injury, 
through adhesion molecule expression and cytokine release. This work assessed whether 
BLM induces endothelial adhesion molecule expression and cytokine release. It was found 
that the treatment of HUVECs and PMVECs with pharmacologically-relevant 
concentrations of BLM resulted in increased ICAM-1, VCAM-1, and (in HUVECs) E-selectin 
expression, and increased MCP-1 and IL-8 release. Endothelin-1 release was decreased by 
treatment. These alterations were regulated at a mRNA transcriptional level. Endothelial 
cell treatment with BLM also supported increased neutrophil tethering and adhesion to 
endothelial monolayers, although this appeared unrelated to increased ICAM-1 or E-
selectin expression.  
This work reports the novel finding that pharmacologically-relevant concentrations of 
BLM increase adhesion molecule expression in both HUVECs and PMVECs, and compares 
the expression of adhesion molecules and cytokines in these cell types in response to 
BLM. This thesis also reports the unique discovery that  BLM treatment increases 
leukocyte adhesion to endothelial monolayers under flow in vitro. Finally, the finding that 
endothelial adhesion molecule expression and cytokine release is increased in response 
to treatment with etoposide, another agent which causes lung fibrosis, is presented. This 
work suggests a potential mechanism which may contribute to the development of 
human BPF via immune cell recruitment to the lung. 
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AUC -   area under the curve 
B2M -   beta-2-macroglobulin 
BAL -   bronchoalveolar lavage 
BALF -   bronchoalveolar lavage fluid 
Bax -   BCL-2-associated protein 
Bcl-Xl -  B-cell lymphoma extra large protein 
BH -   bleomycin hydrolase 
BLM -   bleomycin 
bp -   base pairs 
15 
 
BPF -   bleomycin-induced pulmonary fibrosis 
BSA -   bovine serum albumin 
C'4 -   DNA base carbon 4 
Ca+ -   calcium 
CCL2 -   C-C motif ligand 2 
CCR2 -   chemokine receptor type 2 
CD106 -  cluster of differentiation 106 
CD11 -   cluster of differentiation 11 
CD16 -   cluster of differentiation 16 
CD162 -  cluster of differentiation 162 
CD18 -   cluster of differentiation 18 
CD31 -   cluster of differentiation 31 
CD32 -   cluster of differentiation  32 
CD36 -   cluster of differentiation 36 
CD43 -   cluster of differentiation 43 
CD44 -   cluster of differentiation 44 
CD50 -   cluster of differentiation 50 
CD54 -   cluster of differentiation 54 
CD62E -  cluster of differentiation 62E 
CD62P -  cluster of differentiation 62P 
CD64 -   cluster of differentiation 64 
CD99 -   cluster of differentiation 99 
cDNA -  complementary DNA 
cm -   centimetres 
Cmax -  maximum plasma concentration 
CMT-93 -  mouse rectum carcinoma cells 
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CO2 -   carbon dioxide 
COLIA2 -  collagen alpha-2(I) chain 
Cq -   quantification cycle 
CS -   cleavage site 
Css -   steady-state plasma concentration 
CTGF -   connective tissue growth factor 
CXCR1 -  IL-8 receptor alpha 
CXCR2 -  IL-8 receptor beta 
DAG -   diacylglycerol 
DAS -   diallyl sulphide 
DEPC -   diethylpyrocarbonate 
DMSO -  dimethyl sulfoxide 
DNA -   deoxyribonucleic acid 
dNTP -  doexynucleotide 
DOX -   doxorubicin 
DSB -   double strand break 
dyn/cm2 -  dynes per centimeter squared 
ECs -   endothelial cells 
ECM -   extracellular matrix 
EDTA -  ethylenediaminetetraacetic acid 
EGF -   epidermal growth factor 
ELISA -  enzyme linked immunosorbent assay 
EMSA -  electrophoretic mobility shift assay 
EMT -   epithelial mesenchymal transition 
EpC -   epithelial cell 
ERK1/2 -  extracellular signal related kinase 1 and 2 
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ESL-1 -  E-Selectin Ligand 1 
ET-1 -   endothelin 1 
F(ab')2-  fragment antigen binding  
FACS -   fluorescence activated cell sorting 
Fas -   Fas receptor 
Fas-L -   Fas ligand 
Fc -   fragment crystallisable 
Fe -   iron 
Fig. -   figure 
FITC -   fluorescin isothiocyanate 
FSC-H -  forward scatter 
G2-M -  G2 metaphase checkpoint 
GAGs -  glycoaminoglycans 
GAPDH -  glyceraldehyde 3-phosphate dehydrogenase 
GC -   guanine cytosine 
gDNA -  genomic DNA 
GlyCAM-1 -  glycosylation-dependent cell adhesion molecule 1 
GPCRs -  G protein coupled receptors 
G-pyr -  guanine-pyrimidine bond 
H+ -   hydrogen 
H2O2 -  hydrogen peroxide 
hCT2 -   human carnitine transporter 2 
HEK -   human embryonic kidney cells 
hPMVECs -  human pulmonary microvascular endothelial cells 
HUVECs -  human umbilical cord endothelial cells 
I.M. -   intramuscular 
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I.P.-  intraperitoneal 
I.T. -   intratracheal 
I.V. -   intravenous 
ICAM-1 -  intercellular adhesion molecule 1 
ICAM-2 -  intercellular adhesion molecule 2 
ICAM-3 -  intercellular adhesion molecule 3 
IFN-g -   interferon gamma 
IGF -   insulin like growth factor 
IgG1 -   immunoglobulin G1 
IIP -   idiopathic interstitial pneumonia 
IL-10 -   interleukin 10 
IL-1B -   interleukin 1 beta 
IL-1R -   interleukin 1 receptor 
IL-4 -   interleukin 4 
IL-6 -   interleukin 6 
IL-6 -   interleukin 6 
IL-8 -   interleukin 8 
IP3 -   inositol triphosphate 
IPF -   idiopathic pulmonary fibrosis 
JAM-A -  junctional Adhesion Molecule A 
JNK -   c-JUN N-terminal kinase 
Kb -   kilobase 
l -   litres 
LAP -   latency associated peptide 
LFA-1 -  lymphocyte function associated antigen 1 
LPAM-1 -  leukocyte beta7 integrin 
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LPS -   lipopolysaccharide 
mAb -   monoclonal antibody 
Mac-1 -  macrophage antigen 1 
MaDCAM-1 -  mucosal addressing cell adhesion molecule 1 
MAPK -  mitogen activated protein kinase 
MCP-1 -  monocyte chemoattractant protein 1 
Mg -   magnesium 
mg -   milligrams 
MIP-1a -  macrophage inflammatory protein 1 alpha 
ml -   millilitres 
mM -   millimolar 
MMP -  matrix metalloproteinase 
MMP2 -  maxtrix metalloproteinase 2 
MMP9 -  maxtrix metalloproteinase 9 
mRNA -  messenger ribonucleic acid 
MTS -   (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium),  
mU -   milliunits 
n -   number 
NF-kB -  nuclear factor kappa B 
ng -   nanograms 
NKT -   natural killer T cells 
nm -   nanometers 
nM -   nanomoles 
No RT -  no reverse transcriptase 
NSIP -   non-specific interstitial pneumonia 
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O2 -   oxygen 
OH-   hydroxide 
p53 -   tumour protein p53 
PAECs -  pulmonary artery endothelial cells 
PBS -   phosphate buffered saline 
PCR -   polymerase chain reaction 
PDGF -  platelet derived growth factor 
PDGF-BB -  platelet derived growth factor BB 
PDGFR -  platelet derived growth factor receptor 
PECAM-1 -  platelet endothelial cell adhesion molecule 1 
pH -   per hydrogen 
PI -   propidium iodide 
PI3K -   phosphoinositol 3 kinase 
PLC -   phospholipase C 
PLCgamma -  phospholipase C gamma 
PMNs -  polymorphonucleocytes 
PMVECs -  pulmonary microvascular endothelial cells 
PSGL-1 -  P-Selectin glycoprotein ligand 1 
qPCR -   quantitative polymerase chain reaction 
RLP13A -  ribosomal protein L13a  
RNA -   ribonucleic acid 
ROS -   reactive oxygen species 
RT -   reverse transcriptase 
S.C. -   subcutaneous 
Smad -  mothers against decapentaplegic 
SPECT/CT -  single positron emission computed tomography/computed tomography 
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SRB -   sulphorhodamine B 
SSB -   single strand break 
SSC-H -  side scatter 
Syk -   spleen tyrosine kinase 
t1/2b -  terminal half-life 
TC -   transmigratory cup 
TEM -   transendothelial migration 
TGF-b -  transforming growth factor beta 
Th1 -   T helper 1 
TNF-a -  tumour necrosis factor alpha 
TSP-1 -  thrombospondin 1 
U/ml -   units per millilitre 
UBC -   ubiquitin C 
UIP -   usual interstitial pneumonia 
v. -   version 
v/w -   volume per mass 
VCAM-1 -  vascular cell adhesion molecule 1 
VEC -   vascular endothelial cells 
VLA-4 -  very late antigen 4 
w/v -   mass per volume 
WPB -   Wiebel Palade Body 
YWHAZ -  tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, zeta 
α4β1 -   alpha 4 beta 1 integrin 
αVβ3 -  alpha v beta 3 integrin 
αvβ6 -   alpha v beta 6 integrin 
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ΔΔCq -  delta delta quantification cycle  
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1 General Introduction  
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1.1 Pulmonary Fibrosis Pathology and Incidence 
 
Pulmonary fibrosis, considered the end-stage of many heterogenous lung conditions, is a 
devastating condition and a key characteristic of a range of interstitial lung diseases 
(Datta, et al., 2011; Meltzer and Noble, 2008). Though pathological features vary by 
disease, recent reviews outline common features including excessive ECM protein 
deposition in the interstitium and parenchyma (Datta, et al., 2011; Chua, et al., 2005), 
fibrotic lesion formation (Wilson and Wynn, 2009; Chua, et al., 2005) alveolar destruction, 
and respiratory failure (Datta, et al., 2011), often leading to a swift death.  
The aetiology of fibrosis varies; a review by Wilson and Wynn (2009) discussed potential 
causes, including irradiation, exposure to silica and asbestos, sarcoidosis, and asthma. 
Generally, pulmonary fibrosis is considered to occur in response to lung injury, resulting in 
inflammatory and coagulation cascade activation, inflammatory mediator release, 
inflammatory cell infiltration, fibroblast proliferation and differentiation, and ECM 
synthesis and deposition. Excess ECM deposition due to dysregulation at any stage of 
wound healing, or in response to a persistent injurious stimulus, may lead to fibrosis 
(Wynn, 2011; Chua, et al., 2005). However, while inflammation occurs in sarcoidosis-, 
drug-, radiation, and asthma-associated fibrosis (Wilson and Wynn, 2009; Selman and 
Pardo, 2002), broad heterogeneity is seen in fibrotic lung conditions, and often, the 
aetiology remains unclear. In such cases, the disease is referred to as an idiopathic 
interstitial pneumonia, or IIP.   
The most common IIP is idiopathic pulmonary fibrosis (IPF) (Garantziotis, et al., 2004). IPF 
is mainly a disease of older adults (Nalysnyk, et al., 2012) and an estimated 15,000 people 
in the UK suffer the disease, with around 5,000 new cases diagnosed each year and an 
overall incidence rate of around 7.5 cases per 100,000 person-years (Navaratnam, et al., 
2011), although this is increasing (Raghu, et al., 2011). As IPF is untreatable, with a mean 
survival time of 3-5 years following diagnosis (Datta, et al., 2011), worse than many 
cancers, this is becoming an increasing problem.   
IPF is characterised by usual interstitial pneumonia (UIP) (Nalysnyk, et al., 2012), patchy 
areas of established fibrosis and others of ongoing fibroblastic proliferation and 
collagenation (fibroblastic foci) (Dempsey, et al., 2006; Nicholson, et al., 2002). Symptoms 
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include abnormal pulmonary function and restriction (Dempsey, et al., 2006), dyspnoea, 
cough, and respiratory failure (Nalysknyk, et al., 2010: Raghu, et al., 2011). Subpleural and 
basilar abnormalities may be seen , and as disease progresses, alveolar fusion and matrix 
deposition result in pulmonary honeycombing (Dempsey, et al., 2006).  
As an IIP, the causes of IPF are poorly defined. Within the lung, type I alveolar epithelial 
cells (AECI) are the thin alveolar “lining” cells which provide the gas exchange surface of, 
while type II alveolar epithelial cells (AECII) proliferate and differentiate to repair damage 
to the delicate AECI (Ward and Nicholas, 1984; Barkauskas, et al., 2013). In IPF, AECI 
necrosis and AECII reactive hyperplasia are common, and it is thought that this may lead 
to disease development via aberrant wound repair – as AECII fail to repair AECI injury – 
and dysregulated epithelial-mesenchymal “cross-talk” as abnormal AECII express 
profibrotic factors, leading to excess ECM deposition (Horowitz and Thannickal, 2008; 
Selman and Pardo, 2002). If inflammation plays a role remains controversial, with this 
hypothesis having fallen out of favour due to reports in the mid-2000s discussing a lack of 
an obvious role of immune cells in IPF (Selman and Pardo, 2002), though immune cell 
infiltration of the lung has been reported in the disease over the years, as discussed in a 
recent review by Williamson, et al. (2015). 
While the cause of IPF remains unknown, pulmonary fibrosis is a recognised side-effect of 
several drugs, including amiodarone (Fan, et al., 1987) and methotrexate (Bedrossian, et 
al., 1979), but the most studied agent is bleomycin (BLM). BLM is known to cause 
pulmonary fibrosis in both rodents and in patients given the drug, and is often used to 
model fibrotic lung disease, e.g. IPF, non-specific interstitial pneumonia (NSIP) and 
bleomycin-induced pulmonary fibrosis (BPF), though these types of study have mainly 
been carried out using rodent models. Human BPF is under-researched, and how it 
develops is unresolved. Though rare, the condition has limited the use of the a efficacious 
chemotherapeutic agent, and so a greater understanding of the disease is desirable. 
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1.2 The Chemistry and Mechanisms of Action of BLM  
 
The BLMs are anti-neoplastic antibiotics designated BLM A1-6, A2, and B1-6 (Alberts, et al., 
1978)  isolated from Streptomyces verticillus (Umezawa, et al., 1966; Umezawa, 1971; 
Umezawa, et al., 1967), used to treat head and neck cancer and lymphoma (Suzuki, et al., 
1969; Schein, et al., 1976) as well as testicular cancer, for which it is still used today 
(Samuels, et al., 1975; Aouida, et al., 2010). However, while the drug is still used, how it 
induces cell death remains uncertain. At the most basic level, BLM binds DNA (Suzuki, et 
al., 1970; Chien, et al., 1977) and induces cell death via DNA scission, as the drug induces 
single (SSB) and double-stranded breaks (DSB), with the latter responsible for toxicity 
(Huang, et al., 1981; Tounekti, et al., 2001), though even how these are formed remains a 
topic of debate. 
 
1.2.1 DNA Scission by BLM – An ROS-Independent Mechanism? 
 
BLM requires metals and divalent oxygen  as cofactors for DNA cleavage (Burger, et al., 
1998). While early work suggested (BLM)-FeII oxidation produced DNA-damaging oxygen 
radicals (Sugiura and Kikuchi, 1978; Sausville, et al., 1978) - electron spin resonance 
spectra suggestive of OH- formation were reported when analysing the reaction of (BLM)-
FeII with O2 (Sugiura and Kikuchi, 1978) - the lack of specificty that this would show is 
incompatible with BLM (Decker, et al., 2006), which cleaves preferentially at G-pyr’3 sites 
(d’ Andrea and Haseltine, 1978; Takeshita, et al., 1978), and so the role of reactive oxygen 
species (ROS) in this particular process seems unlikely.   
Indeed, neither Burger et al. (1979) nor Kuramochi, et al. (1981) observed ROS production 
by (BLM)-FeII undergoing oxidation; Kuramochi, et al. (1981) proposed that binding of the 
BLM metal-binding domain to FeII, reaction with O2, and reduction produced the active 
intermediate (BLM)-FeIII-OOH (ABLM). ABLM is the final intermediate seen prior to 
scission (Decker, et al., 2006) and by abstracting the C’4 H+ of a DNA deoxyribose sugar 
(primarily pyrimidine), induces SSBs (Liu, et al., 2010, Chow, et al., 2008, Decker, et al., 
2006). H+ abstraction results in a radical centred on the deoxyribose C’4, and (BLM)-
FeIV=O (able to induce DSBs by further abstraction) (Decker, et al., 2006) . DNA cleavage 
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may then occur via oxidation, reduction, and substitution reactions (Fig 1.1).This is the 
favoured theory of how BLM induces DNA cleavage today (Decker, et al., 2006).   
However, how BLM binds DNA remains debated, though the BLM biathiazole domain may 
be involved in this process. It has been posited that the bithiazole may bind to the DNA 
minor groove (Manderville, et al., 1994), or intercalate between bases at specific sites 3’ 
of the cleavage site (CS) (with or without binding to a guanine residue 5’ of the CS) 
(Vanderwall, et al., 1997; Goodwin, et al., 2008). This binding would position the reactive 
metallo-BLM-OOH in an area in which it is capable of abstracting the pyr-C’4 H+. While 
this seems feasible, all studies investigating this potential phenomenon have  used ABLM 
analogues (such as BLM with cobalt, or zinc, rather than iron), and so no firm conclusions 
can be drawn.  
Moreover, while it is thought that a single molecule causes DSBs, it is also uncertain how 
this occurs; some suggest ABLM is regenerated by a secondary reaction with the 
generated C’4 radical – possibly peroxidation or reduction – without unbinding from DNA 
(Steighner and Povirk, 1990), while others than an intermediate form of ABLM generated 
by the first H+ abstraction - (BLM) Fe(IV) =O – is able to abstract a second H+ while BLM 
remains bound via rearrangement of the metal binding region (Decker, et al., 2006), a 
theory similarly echoed by Vanderwall, et al. (2007) who instead suggested bithiazole 
rearrangement. Further, others suggest BLM may abstract two H+ concurrently via placing 
of the reactive centre near a CS on one strand (specific cleavage), and an adenine 
nucleotide on the second (non-specific cleavage) (Keck, et al., 2001). That none of these 
critical features of BLM and its mode of action are well-defined, and that almost all 
attempts to determine such mechanisms use either BLM analogues or artificial modeling, 
leave a gap in our understanding of how BLM works. All that is agreed upoin is that the 
generation of DSB appears a “single-hit” reaction (Keck, et al., 2001; Steighner and Povirk, 
1990).  
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Figure 1.1: DNA Strand Scission by BLM 
A schematic diagram of the generation of strand scission by ABLM following the abstraction of a deoxyribose sugar hydrogen from the C’4 position 
under aerobic conditions (adapted from van den Berg (2008), Hecht (2000), Pogozelski and Tullius (1998), and Burger (1998). Reaction of the C’4 
radical with O2 forms a peroxyl radical which is reduced, reacts with water, and rearranges, leading to DNA fragmentation. Only under aerobic 
conditions may double strand scission take place (van den Berg, 2008).   
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1.2.2 Other Mechanisms of BLM-Induced Cell Damage – A Role for ROS?  
 
While DNA scission by BLM does not appear linked to the generation of ROS and free 
radicals, BLM may induce cell damage via ROS-dependent processes such as lipid 
peroxidation (Ekimoto, et al., 1985). Sato, et al. (2008) reported lipid-derived free radical 
adduct production in lung lipid extracts from mice treated with intratracheal BLM, and 
suggested that this resulted from iron-mediated peroxidation, causing cellular injury via 
protein damage. Lipid peroxidation via ROS may feasibly represent a mechanism of cell 
death seperate from DNA scission, as cell membranes degrade, destroying the cell 
(Kalayarasan, et al., 2008). That the iron chelator deferoxamine decreased both airway 
inflammation and free radical formation implies a role for ROS in BLM-induced cell 
toxicity (Sato, et al., 2008).  
Interesestingly, Kalayarasan, et al. (2008) also reported decreased lipid peroxidation in 
lung tissue from mice treated with both BLM and the antioxidant diallyl sulphide (DAS) 
which correlated with decreased fbirosis. DAS also diminished BLM-induced NF-κB 
activation in the lung, the activation of which may be an result of ROS generation via 
nitric oxide synthetase upregulation. Asai, et al. (2007), meanwhile, reported decreased 
BPF in rabbits co-treated with edarovone, a hydroxyl scavanger, but no mechanism of 
action was suggested. However, fewer apoptotic lung cells were seen.      
It is feasible that ROS generation may also induce cell death via apoptotic processes. 
Wallach-Dayan, et al. (2005) reported increased ROS levels in BLM-treated cells, followed 
by caspase-8 activation, mitochondrial leakage, and apoptosis in vitro; this was 
attenuated by the antioxidant glutathione. Therefore, while the cleavage of DNA may not 
require ROS, other cell damaging processes may do. 
 
1.2.3 BLM-Induced Cell Death – Mechanimsm of Cytotoxicity 
 
It may be expected that cells undergoing high levels of DNA damage would die by 
undergoing intrinsic apoptosis, involving p53 activation, cytochrome C release, and the 
sequential activation of caspases 3 and 9. However, much like many of the aspects of BLM 
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and its mechanisms, the mode of cell death induced remains uncertain; pseudoapoptosis 
(like apoptosis, with very rapid DNA fragmentation) and mitotic cell death (cells arrest in 
the G2-M stage of the cell cycle, divide aberrantly and die within 3 doubling times, 
potentially via caspase-mediated apoptosis) have been suggested, depending on whether 
high or medium levels of the drug enter the cell, respectively, and intracellular drug 
availability (Tounekti, et al., 2001; Tounekti, et al., 1993; Mekid, et al., 2003).  
More recently, true apoptosis has  been suggested as a method by which BLM may induce 
cytotoxicity, but in a counter-intuitive form: extrinsic apoptosis. Both Wallach-Dayan, et 
al. (2007) and Mungunsukh, et al. (2010) reported the activation of caspase 8  – a marker 
of extrinsic apoptosis - occurring prior to the activation of caspase 9  – a marker of 
intrinstic apoptosis – suggesting that, while proteins involved in intrinsic apoptosis are 
activated by BLM,  extrinsic apoptosis processes occur primarily. How this is triggered is 
unknown – while Wallach-Dayan, et al. (2007) suggested ROS-induced caspase-3 
activation may lead to caspase-8 activation and further capsase 3 activation – a complex 
interplay between caspases that extends beyond the typical linear models of intrinsic and 
extrinsic apoptosis -  Mungunsukh, et al. (2010) suggested true extrinsic apoptosis 
initiation, whereby caspase 8 activation leads to caspase 3 activation (noted in this study 
at around the same time-points as caspase 8 activation) and cell death, overlooking 
caspase 9. It is becoming clear that  apoptotic pathways are not distinct, particularly 
those induced by chemotherapeutic drugs (Lin, et al., 2004; Tang, et al., 2000), although 
much more work is required to fully define the mechanism by which BLM induces cell 
death – be it by apoptosis, pseudoapoptosis, or mitotic cell death.  
To induce DNA damage through the mechanisms described above, BLM must presumably 
enter the cell, but how this happens is unknown. That electropermeablisation, which 
increases the entry of BLM to the cell, greatly potentiates cytotoxicity (Tounekti, et al., 
1993), however, implies that BLM entry to the cell is important in its mechanism of 
action.  BLM is unable to cross the plasma membrane efficiently via passive diffusion 
(Pron, et al., 1999), though possible BLM receptors were  identified on hamster lung 
fibroblasts and human head and neck cancer cell lines (Pron, et al., 1993; Pron, et al., 
1999), which may specifically bind to, and endocytose, BLM.  Further, Aouida, et al. (2010) 
noted high hCT2 (a carnitine transporter) expression on testicular cancer cells; this 
34 
 
correlated with increased BLM-A5 uptake and toxicity, implying this receptor may 
internalise BLM A5. hTC2 was also seen at high levels in a BLM A5-hypersensitive non-
Hodgkin’s lymphoma cell line, further suggesting BLM is internalised by hTC2,  that 
toxicity is related to this internalisation, and that susceptibility may be receptor-
dependent, but more work is needed to determine how BLM is internalised. 
However, cell entry is only the first step. Within the cell, BLM may be neutralised by BLM 
hydrolase (BH), a cysteine protease that deamidates the BLM β-aminoalanine moiety, 
producing less toxic metabolites (Lefterov, et al., 1998; Lazo and Humphreys, 1983), 
which, though widely conserved, has no known natural function (Schwartz, et al., 1999). 
The susceptibility of lungs has been associated with low levels of BH (Burger, 1998); 
indeed, low levels of BLM inactivation were seen in lungs of BLM-treated mice by 
Umezawa, et al (1972), and Lazo and Humphreys (1983) noted the lack of BH in lungs 
from BPF-susceptible mice, and proposed a lack of BLM inactivation as a cause of toxicity. 
Further, BLM-susceptible Hodgkin’s lymphoma cells express less BH than BLM-resistant 
Burkitt’s lymphoma cells (Ferrando, et al., 1996), and human lungs have only low-to-
moderate levels of BH mRNA (Brömme, et al., 1996), so perhaps BH levels determine 
human cell BLM susceptibility. 
Taking all the evidence together, it is clear that little is known about how BLM induces cell 
death; it appears to bind DNA, but exactly how is poorly defined. It does induce cell 
death, but the mechanisms causing this are unknown. Even how BLM gains access to the 
DNA target is uncertain. However, BLM remains an effective anti-cancer therapy 
modality, though a better understanding of its mechanisms of action may be needed 
before the mechanisms behind its unfortunate side-effects are delineated.   
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1.3 Bleomycin Pulmonary Fibrosis in Man – Symptoms and Risk Factors 
 
Early links between BLM and fibrosis were made by the Clinical Screening Co-operative 
Group of the European Organization for Research on the Treatment of Cancer (1970) and 
Halnan, et al. (1972) who noted BLM-treated patients developed fatal lung fibrosis. 
Statistics regarding occurrence vary;  O’ Sullivan, et al. (2003) saw BPT incidence rates of 
6.8% in treated patients, with 14% of those dying, although Sleijfer (2001) stated the 
incidence of BLM-induced pneumonitis to be 0-46%, with a 3% mortality rate. Moveover, 
it has been recorded that BPF may develop up to 2 years post-BLM (Uzel, et al., 2005), 
though this is an isolated report. 
The characteristics of human BPF are not widely reported, however. BPF is a 
predominantly fibrotic condition (O’ Sullivan, et al., 2003; Simpson, et al., 1998; Jones, et 
al., 1978; Bedrossian, et al., 1973), in which patients develop pulmonary distress, 
dyspnoea, and a non productive cough (Bedrossian, et al., 1973; Blum, et al., 1973). Such 
restrictive syndromes may gradually worsen, resulting in hypoxia prior to patient death 
(Simpson, et al., 1998).  Post-mortem analyses of patient lungs notes AECI loss with AECII 
hyperplasia, with concurrent mild vascular endothelial cell (VEC) oedema and injury and 
alveolar collapse. The location of fibrosis is sub-pleural, may be interstitial and intra-
alveolar, and is notably diffuse, with fibrosis being non-uniform, (Jones, 1978; Bedrossian, 
et al., 1973; Hoshino, et al., 2009; Borzone, et al., 2001; Karam, et al., 1998; Sleijfer, et al., 
2001; Chua, et al., 2005; Blum, et al., 1973). Though not well characterised, it seems  
immune cell infiltration also occurs in man  (Hoshino, et al., 2009).  
Much like with IPF, there is no “golden bullet” treatment available for patients with BPF, 
and no known way of preventing the condition developing (Reinert, et al., 2013). 
Corticosteroids are most often used when patients present with the condition, though no 
controlled trials have been conducted in patients with confirmed BPF (Sleijfer, et al., 
2000; Reinert, et al., 2013), a success rate of only around 50% has been reported, and  
patients are also known to relapse (White and Stover, 1984). Often, decreasing the dose 
of BLM, or ceasing dosing, and then allowing the condition to run its course is the only 
way forward (Sleijfer, et al., 2000; Reinert, et al., 2013).    
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It is worth noting that not all patients given BLM as part of a chemotherapeutic regimen 
develop BPF. Of the many risk factors for BPF development, including total dose and 
exposure to therapeutic oxygen, poor renal function is the most strongly associated one 
(O’Sullivan, et al., 2004). As BLM is renally metabolised, with around 70% of the total dose 
cleared in 24 hours (Azambuja, et al., 2005; Hall et al., 1982) impaired drug clearance due 
to renal insufficiency may increase lung exposure, increasing the likelihood of BPF (O’ 
Sullivan, et al., 2003; Simpson, et al., 1989). Indeed, poor renal function increases the 
terminal half-life of the drug, which is usually -2-5 hours (Alberts, et al., 1978) but can be 
up to 33 hours in patients with renal failure (Broughton, et al., 1977), dramatically 
prolonging the time over which BLM remains in circulation.  
Further, dosing route may also be a risk factor, possibly due to increased drug plasma 
concentrations  achieved immediately after  dosing. After an I.V. bolus dose, 
concentrations may be as high as 6μg/ml (Alberts, et al., 1978), while I.V. infusion 
achieves a low steady-state plasma concentration of up to 180ng/ml (Broughton, et al., 
1977) (Table 1.1). It has been stated that I.V. infusion is “less dangerous” than I.V. bolus, 
and I.V. bolus less dangerous than intramuscular dosing (Samuels, et al., 1976; Haas, et 
al., 1976), and that I.V. bolus delivery of the drug is a risk factor for BPF development 
(O’Sullivan, et al., 2003). That this is the case suggests that the the higher the plasma 
concentrations of the drug, the greater the risk of fibrosis development; bolus delivery 
results in increased plasma concentrations (see Table 1.1), though there have been very 
few studies directly observing BLM pharmacokinetics over long time periods and 
comparing the dosing routes. Table 1.1 shows all of those available. Moreover,while it is 
known that renally insufficient patients clear BLM at a much slower rate (Broughton, et 
al., 1977), and that patients with renal insufficiency are at a higher risk of developing BPF, 
there have been no studies into the clearance of the drug following different dosing types 
in such patients. It is possible that BLM concentrations high enough to trigger fibrosis 
(though these levels remain undefined) persist for hours in patients with poor renal 
function.  
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Dosing Route Terminal half-
life (t1/2β) 
Plasma concentration (Cmax) in renally sufficient patients Plasma concentration (Cmax) in renally insufficient patients 
    Immediately after 
dose 
6H After Dose 12H After Dose 24H After Dose Immediately 
after dose 
6H After Dose 12H After 
Dose 
24H After Dose 
15U/m2 I.V. 
bolus dose 
(Alberts, et 
al., 1978) 
Mean t1/2β 4.0 
hours. 
1 -10mU/ml 
(0.56μg/ml–
6.6μg/ml) 
determined by 
radioimmunoassay 
(RIA) 
0.3 - 
0.8mU/ml 
(200-
500ng/ml) 
0.08-0.2mU/ml 
(0.50-130ng/ml) 
0.05-0.5mU/ml 
(3-30ng /ml) 
Not 
determined 
Not 
determined 
Not 
determined 
Not determined 
15U I.V. bolus 
total dose 
(Hall, et al., 
1982) 
Mean t1/2β 2.3 
hours 
Mean (n=6) peak 
plasma 
concentration of 
1.5mU/ml (0.84 
μg/ml). 
80μU/ml 
(50ng/ml) 
Not determined Not determined Not 
determined 
Not 
determined 
Not 
determined 
Not determined 
30U S.C. dose 
(Hall, et al., 
1982) 
Mean t1/2β 4.3 
hours 
1mU/ml (0.6 μg/ml) 
peak plasma 
concentration 
determined by RIA 
50-400μU/ml 
(30-260ng/ml) 
Not determined Not determined Not 
determined 
Not 
determined 
Not 
determined 
Not determined 
30U/day I.V. 
infusion (10 -
20U/m2/day) 
(Broughton, 
et al., 1977) 
Mean t1/2β 
8.93 hours in 
renally 
sufficient 
patients.  
Not done; average 
steady-state plasma 
concentration (Css) 
148.5ng/ml (range 
80-180ng/ml) (n=8).  
After 
cessation of 
dosing, 30-
80ng/ml 
After cessation 
of dosing, 12-
30ng/ml 
After cessation 
of dosing, 5-
8ng/ml 
Not done; 
average 
steady-state 
plasma 
concentration 
(Css) 
600ng/ml.  
After 
cessation of 
dosing, 
350ng/ml 
After 
cessation of 
dosing, 
250ng/ml 
After cessation 
of dosing, 
210ng/ml 
Table 1.1: BLM Pharmacokinetics in Man 
 The terminal half life of BLM, and peak plasma concentrations of BLM, delivered via various routes after various times, as determined by 
pharmacokinetic studies. Note the wide range of concentrations present in renally sufficient patients and the disparate results obtained from 
renally insufficient patients.  
38 
 
Despite the condition being long-recognised, there are few reported studies assessing the 
pathology of BPF in man and little is known about how the disease develops. There are, 
however, a wealth of studies investigating the development of BPF in rodents, though 
even in rodents, the pathogenesis remains incompletely delineated. These may be of 
limited use, however, due to one main factor – the route of BLM delivery.  
When BLM is used to model fibrotic lung disease in rodents, intratracheal (I.T.) dosing is 
most commonly used, as this induces the rapid development of BPF, but  intramuscular 
(I.M.) or subcutaneous (S.C.) delivery may also be used (Sleijfer, 2001). Intravenous 
delivery, favoured by earlier researchers, is rarely used now, but comes with one distinct 
advantage; BLM given to humans is most often delivered I.V. (O’Sullivan, et al., 2003), and 
so represents a more physiologically relevant model of human disease. Furthermore, it 
has been suggested that rodent BPF, stemming from I.T. delivery, does not wholly mimic 
human BPF (Borzone, et al., 2001).  
A comparison of the disease caused by I.T. dosing and I.V. dosing is shown in Table 1.2. As 
can be seen, many features are very similar, potentially suggesting similar pathogenic 
processes in rodents and in man. The primary differences between BPF resulting from I.T. 
delivery and I.V. delivery are the localisation of BPF and the primary injury to the 
endothelial cells.   
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Similarities and Differences between I.T. and I.V. Dosing in Animals 
I.T. Dosing Features I.V. Dosing: Similarities I.V. Dosing: Differences 
No explicit reports of 
endothelial cell (EC) damage in 
works using I.T. dosing. 
 Endothelial blebbing and bas-
ement membrane denuda-
tion the initial injury in mice 
(Adamson and Bowden, 
1977; Adamson and Bowden, 
1974). No injury beyond VEC 
in some mice (Adamson, 
1984). 
Perivascular oedema reported 
in rats (Thrall, et al., 1979; 
Karmouty-Quintana, et al., 
2007), with interstitial oedema 
also reported (Azuma, et al., 
1998; Cortijo, et al., 2001)  
Interstitial oedema is also 
reported in mice and dogs 
(Adamson and Bowden, 1974; 
Fleischman, et al., 1971). 
Endothelial oedema appears 
to occur prior to interstitial 
oedema, and may relate to 
the perivascular oedema 
seen (Adamson and Bowden, 
1977; Adamson and Bowden, 
1974; Adamson, 1976)  
Lymphocyte and polymorpho-
nucleocyte influx into the lung 
interstitum, parenchyma, and 
perivascular regions, as det-
ermined by bronchoalveolar 
lavage (BAL) and histology 
(Kumar, et al., 1985; Izbicki, et 
al., 2002; Giri, et al., 1986; 
Thrall, et al., 1979; Karmouty-
Quintana, et al.,2007; Saito, et 
al., 2008; Sato, et al., 1999) . 
Alveolar, interstitial, and intra- 
pulmonary immune cell 
infiltration by lymphocytes and 
polymorphonucleocytes in dogs 
and mice, as determined by BAL 
and histology; perivascular 
cellular infiltrates have also 
been reported (Fleischman, et 
al., 1971; Hagiwara, et al., 
2000; Adamson, 1976). 
 
AECI damage and death with 
associated AECII/epithelial 
hyperplasia (Kumar, et al., 
1985; Izbicki, et al., 2002)., 
which may be the initial injury 
in this manifestation (Moore 
and Hogaboam, 2008) 
AECI death in mice with 
reactive AECII proliferation and 
hyperplasia has also been 
reported following BLM dosing 
(Adamson and Bowden, 1979; 
Adamson and Bowden, 1977; 
Adamson, 1976) 
 
Alveolar septal thickening 
(Kumar, et al., 1985; Izbicki, et 
al., 2002). 
Alveolar thickening has also 
been reported in mice 
(Hagiwara, et al., 2000). 
 
Patchy/diffuse, dense sub-
pleural, intraalveolar and 
interstitial fibrosis noted 
(Izbicki, et al., 2002; Serrano-
Mollar, et al., 2007; Hagiwara, 
et al., 2007; Peng, et al., 2013; 
Kumar, et al., 1985; Adamson, 
et al., 1984) but fibrosis may 
be more bronchiolocentric 
(Borzone, et al., 2001).  
Extensive, sub-pleural fibrosis 
noted, with fibrosis in the 
parenchyma and alveoli, in 
perivascular locations, and the 
interstitium in dogs and mice. 
Fibrosis is diffuse. (Fleischman, 
et al., 1979; Hagiwara, et al., 
2000; Adamson, 1976; 
Adamson and Bowden, 1977; 
Adamson and Bowden, 1974)  
 
 
Table 1.2: Characteristics of BPF Following I.V. and I.T. BLM Dosing 
Reported characteristics of BPF in models that have used intratracheal and intravenous 
dosing routes of BLM. The similarities and differences  are highlighted. 
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While BPF due to I.T. delivery of BLM initially appears to feature similar histological 
characteristics to that of I.V.-induced BPF and human BPF, such as interstitial and intra-
alveolar fibrosis with parenchymal involvement and a sub-pleural localisation, this may 
not be the case. In the only current study to assess long-term fibrotic changes and the 
localisation of fibrosis in rodents, Borzone, et al. (2001) saw initial bronchiolocentric 
injury following I.T. dosing, which became more widespread, involving coalescent areas of 
parenchyma. Fibrosis developed only in inflamed areas, and 120 days post-BLM,  focal 
inflammation and peribronchial focal fibrosis were noted. That this has not been 
previously observed was attributed to the initial wide-spread nature of early-stage 
pulmonary fibrosis caused by BLM, while later stage disease was far more focussed in 
localisation. That the disease caused by I.T. delivery may focus around bronchioles is 
becoming a popular theory, and if this is the case, then I.T.-BLM induced BPF may not 
mimic human BPF as described above, or human IPF/UIP (Borzone, et al., 2001), which 
are diffuse and/or patchy. It could be said human disease may be more closely mimicked 
by I.V. BLM dosing in animals.  
Moreover, single doses, as often used when rodents are given I.T. BLM, often result in 
resolving disease (Brown, et al., 1988), less common in man, though BPF may be 
reversible before fibrosis begins definitely (Sleijfer, et al., 2001). Further, while human 
BPF is  restrictive, characterised by increasing dyspnoea and lung failure, this is not a 
feature of rodent BPF (Borzone, et al., 2001). 
The seemingly unique feature of BPF induced by I.V. BLM is damage to the vascular 
endothelium, and this is likely to be the most important difference between the two 
conditions. This is the primary injury, and in some animals given I.V. BLM, the only injury 
seen is here. This is not observed in mice given I.T. BLM, a delivery route which bypasses 
the endothelium altogether.  
As endothelial damage is the first injury seen in animals given BLM via the same delivery 
route as humans, it is feasible that it may also be the initial injury in man, and that the 
effect of BLM on pulmonary VECs impacts the pattern of disease observed, though  there 
are very few reports of endothelial damage in human BPF. However, the endothelium 
may play a strong role in features of the pathogenesis of BPF – for example, in immune 
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cell recruitment. Immune cell recruitment is seen in rodent BPF and human BPF, and 
while movement into the lung in I.T.-induced BPF may be due to intra-pulmonary injury, 
in I.V.-induced BPF in humans and rodents, the endothelium may also play a role. 
Moreover, endothelial injury may well play a role in the oedema seen arounds the lung in 
I.V.-dosing-induced disease, and has been postulated to allow BLM and immune cells 
access to the lung itself (Moore and Hogaboam, 2008). 
To better understand the potential pathogenic processes involved in human BPF 
development, what is currently known about the mechanisms of BPF development in 
rodents given I.T. BLM, and how this may apply to human disease, must be considered. 
From here, potential roles for the endothelium in the pathogenic processes of human BPF 
may be determined.  
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1.4 The Development of Bleomycin Pulmonary Fibrosis in Rodents 
 
Iyer, et al. (2000) suggested rodent BPF development to be a multi-stage process. This 
begins with the “acute stage”, characterised by AEC damage, inflammatory cell 
recruitment to the lung, and proinflammatory mediator release, with oedema and 
increased vascular permeability potential features. This is followed by the “sub-acute 
stage”, in which profibrotic cytokine release predominates, AECII proliferate and 
differentiate to repair AECI injury, and fibroblasts proliferate and differentiate at the 
injury site. This then leads to the final stage, characterised by increased collagen and ECM 
protein deposition in damaged areas of the lung, which leads to fibrosis (Fig 1.3).  
When BPF is modelled in rodents, these multiple steps and stages can be broadly broken 
down into two distinct phases – the inflammatory phase (in which AEC injury, 
proinflammatory cytokine expression, and immune cell influx occur) and the fibrotic 
phase (in which aberrant AECII proliferation peaks, fibroblasts transdifferente and 
proliferate, and fibrosis develops).    
When I.T. dosing is used, AEC injury, cytokine release, and immune cell recruitment to the 
lung and associated inflammation occurs rapidly, within 7 days (the inflammatory phase). 
After around 14 days, the inflammatory stage recedes, and gives way to the fibrotic phase 
of BPF development, in which fibroblast transdifferentiation in response to lung cell-
expressed profibrotic cytokines, increased collagen deposition,  and associated fibrosis 
development begins, with a maximal fibrotic response noted by 28 days post-dosing. 
Thereafter, the fibrotic disease induced by BLM may resolve (Thrall, et al., 1979; Rydell-
Törmanen, et al., 2012; Williamson, et al., 2015). This bi-phasic model of fibrosis 
development in response to I.T. BLM dosing is highlighted in Figure 1.2.  
Using other dosing routes, the timescale of fibrotic development, and the shift from 
inflammatory to fibrotic development phases differs, though the processes remain largely 
analogous.  Subcutaneous dosing results in a far longer development time of up to 1-2 
weeks for the peak of the inflammatory disease phase, after which time the fibrotic phase 
occurs and fibrosis persists for up to six weeks after dosing ceases (Rydell-Törmänen, et 
al., 2012). Repeated intraperitoneal (I.P.) dosing, meanwhile, results in endothelial injury 
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after 14 days, inflammatory cell infiltration after 28 days, with the switch from 
inflammation to fibrosis occuring at 8 weeks (Adamson, 1974).   
 
 
 
 
 
 
 
 
I.V. dosing, while taking a similar time to cause fibrosis as I.T. dosing, follows the I.P. 
pattern; endothelial injury occurs after 2-5 days, followed by inflammation at 7 days and 
peak AECI injury by 14 days. Hereafter, AECII proliferation and fibrotic development begin 
to take hold. However, inflammation may persist throughout disease development 
(Adamson and Bowden, 1977; Adamson and Bowden, 1979; Hagiwara, et al., 2000).  
Thus, while the various dosing routes generate disease processes which demonstrate 
different time-scales for fibrosis development, and I.V. dosing may be seen to be the most 
clinically relevant, inducing disease which  more closely resembles human BPF with 
extensive, diffuse, and sub-pleural fibrosis (while I.T. dosing causes bronchiolocentric 
disease) (Adamson and Bowden, 1977; Adamson and Bowden, 1979; Hagiwara, et al., 
2000; Chua, et al., 2005; Borzone, et al., 2001), it is notable that BPF caused by any BLM 
dosing route is characterised by an inflammatory stage of development. This also appears 
to be the case in the development of BPF in man (Hoshino, et al., 2009).  
Figure 1.2: The bi-phasic development of BPF following I.T. BLM dosing. 
The process and time-scales of pulmonary fibrosis development in rodents following I.T. 
BLM dosing are highlighted. Other routes, such as I.V. dosing, follow a similar 
progression to this, though the initial injury is to the endothelium and not directly to 
AECI.  
44 
 
Figure 1.3: The Development of BPF in Rodents 
  The introduction of BLM to the lung induces AEC damage and injury, leading to proinflammatory 
mediator release. Immune cells are recruited to the site of injury and may perpetuate AEC injury 
and express further proinflammatory and pro-fibrotic cytokines. AECII cells proliferate incorrectly, 
and  add to the cytokine milieu. Profibrotic cytokines induce fibroblast transdifferentiation to 
myofibroblasts, leading to increased collagen synthesis and the formation of fibroblastic foci.   
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1.4.1 Alveolar Epithelial Cell Injury in Bleomycin Pulmonary Fibrosis 
 
The notion that AECI and II injury may be one of the initial injuries in BPF stems from the 
current paradigm that states that this is the case in IPF (Degryse, et al., 2011; Wang, et al., 
2000). This notion was initially proposed by Selman and Pardo (2002), who stated  fibrosis 
resulted from inappropriate epithelial-mesenchymal cross-talk, and was due to epithelial 
injury and incorrect wound healing. This may be the case in BPF: AECI injury and AECII 
derangement appears early in BPF (Kumar, et al., 1985),  and AECI death is noted as the 
initial injury post I.T. BLM. This has been deemed “the most critical cellular event”, and 
BLM appears particularly toxic to AECI (Adamson, 1984). Moreover, the degree of AEC 
damage correlates with fibrosis severity (Wang, et al., 2000; Adamson, et al., 1984). AECI 
death is normally followed by the proliferation of AECII, which differentiate into AECI to 
repair injury, although in BPF this may be abnormal (Moore and Hogaboam, 2008; Kumar, 
et al., 1985; Adamson, 1984; Adamson and Bowden, 1979) or inadequate (Serrano-
Mollar, et al., 2007; Aoshiba, et al., 2003), with fibrosis perhaps due to incorrect re-
epithelialisation. 
This has proven an attractive theory for some; Wang, et al. (2000) suggested 
inappropriate AEC apoptosis eliminates anti-fibrotic epithelial functions allowing 
profibrotic environment development, fibroblast proliferation and transdifferentiation, 
and accordingly, the group noted an AEC apoptosis inhibitor reduced BPF. Indeed, several 
groups over the years have suggested that deranged interactions of epithelial and 
mesenchymal cells may contribute to excess ECM protein deposition, and a story of 
impaired repair and association intrapulmonary derangement has gradually been built.   
This theory – that AEC injury induces fibrotic development - probably began with the 
work of Adamson (1984), who proposed that AECI death and AECII meta- and hyperplasia 
result in disordered repair, perhaps due to the effects of BLM on AECII (Adamson and 
Bowden, 1979). Aberrant and abnormal repair may not restore normal antifibrotic 
epithelial-mesenchymal mechanisms in which epithelial cell  factor expression prevents 
fibroblast growth, and fibroblast-expressed factors promote epithelial cell  growth. 
Indeed, abnormal epithelial cells  isolated from animals 6 weeks post-BLM lacked 
fibroblast growth inhibitory activity, and fibroblasts prevented epithelial cell growth in co-
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culture, but induced differentiation when cell-cell contact occured, suggesting fibroblasts 
induce aberrant epithelial cell  proliferation or block the re-epithelialisation of the lung in 
BPF (Young and Adamson, 1993), and so this theory may have some merit.  
Further, Kawamoto and Fukuda (1990) noted low AECII proliferation post-BLM dosing 
which may prevent re -epithelialisation, and this may induce fibrosis, as fibroblast 
migration through damaged epithelium or epithelial-mesenchymal interaction is 
disrupted (Serrano-Mollar, et al., 2007; Kawamoto and Fukuda, 1990). The cause of 
impaired repair is unknown, though it has been reported that BLM-exposed AECII show 
signs of senescence that may limit proliferation (Aoshiba, et al., 2003), and that AECII 
transplantation into rats reversed BPF and reversed injury, potentially due to epithelial 
repair, or antifibrotic factor expression (Serrano-Mollar, et al., 2007) implies AECII 
abarrance plays a role in BPF.   
Though BLM-mediated DNA damage is a known cause of cell death, particularly when 
BLM is introduced intratracheally, several other pathways resulting in AEC apoptosis have 
been explored (Table 1.3). However, there is no agreed mechanism of AECI death in the 
lungs of BLM treated rodents, though it appears certain that it happens. Further, that AEC 
death directly contributes to fibrosis development has also not been exhaustively 
researched, though works which have induced AECII apoptosis (in this case, using Fas 
antibodies) report this injury results in fibrosis (Hagimoto, et al., 1997b), while the 
administration of a soluble Fas antigen or anti-Fas ligand antibody was seen to prevent 
both AEC apoptosis and BPF development in BLM-treated mice (Kuwano, et al., 1999).  
While this mechanism may indeed be important, and AEC death is certainly seen in BPF, 
more research explicitly investigating the role of AEC death in this pathogenic process is 
required. It is expected that AEC death follows insult with BLM, but this may not be the 
first step in the process and may not be the whole story. There are indeed many other 
cells in the lung which may contribute to the deposition of collagen and eventual fibrosis. 
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Authors Method of AEC apoptosis in 
response to BLM. 
Supporting Evidence Contradicting 
Evidence 
Hagimoto, 
et al. 
(1997) 
AEC Fas mRNA and lymphocyte 
Fas-L mRNA overexpression, 
seen in response to BLM, was 
associated with AEC apoptosis. 
Corticosteroids decreased Fas 
/Fas-L expression, apoptosis, 
and fibrosis. It was suggested 
Fas-/Fas-L mediated apoptosis 
may contribute to BPF. 
Inhalation of anti-Fas 
antibody, simulating 
Fas/Fas-L interaction, 
induced AEC apoptosis 
in rats (Hagimoto, et 
al., 1997b). 
Blockade of Fas-FasL 
interaction prevented 
apoptosis and BPF 
(Kuwano, et al., 1999). 
Epithelial cell 
apoptosis still 
occurred in BLM-
treated Fas/FasL 
deficient mice 
(Aoshiba, et al., 2000). 
Fas-L inhibitors did not 
prevent apoptosis 
(Wallach-Dayan, et al., 
2005) 
Li, et al, 
(2003), 
ANGEN mRNA upregulation in 
AECII in response to BLM, 
conversion of ANGEN to ATII 
and autocrine ATII signalling 
may induce apoptosis. Blocking 
ATII signalling at any point 
prevented apoptosis. 
Myofibroblast-derived 
angiotensin seen to 
induce AEC apoptosis 
(Wang, et al., 1999). 
Angiotensin induces 
AEC apoptosis in vitro 
(Wang, et al., 1999b). 
None available. 
Lee, et al. 
(2005) 
JNK-mediated Bax activation by 
BLM resulted in epithelial cell  
mitochondrial apoptosis. Cells 
overexpressing Bcl-XL, which 
prevents Bax activation, were 
resistant to apoptosis. 
None available. None available. 
Fridlender, 
et al. 
(2007) 
BLM initially increases, but then 
decreases, telomerase activity, 
resulting in epithelial cell  
apoptosis, potentially due to 
factors expressed by neigh-
bouring mesenchymal cells.  
None available. None available. 
Wallach-
Dayan, et 
al. (2005) 
BLM induces increased ROS 
production, causing caspase 
8/9 activation, mitochondrial 
leakage, and intrinsic 
apoptosis. This was blocked by 
antioxidants but not Fas-L 
inhibitors.  
None available. None available. 
Table 1.3: BLM Mechanisms of AEC Injury 
A definitive summary of the theories of the occurence of alveolar epithelial cell damage 
and apoptosis in BPF. 
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It is interesting that some have reported an overlap between angiotensin and Fas-Fas-L 
mediated apoptosis; Wang, et al. (2000), noted that the angiotensinogen-convering 
enzyme inhibitor captopril prevented AEC apoptosis via inihibition of Fas-mediated 
apoptosis. It was suggested that angiotensin peptides are required for Fas-mediated 
apoptosis (Wang, et al., 1999c), and so perhaps these two aspects overlap and both 
contribute to BLM-induced AEC apoptosis.  
 
1.4.2 Pulmonary Cell Cytokine Expression in Bleomycin Pulmonary Fibrosis 
 
Following BLM stimulation,  AEC and other alveolar cells (notably alveolar macrophages 
(AM)) express proinflammatory cytokines and chemokines , which may contribute to 
fibrosis. A wide range of cytokines and chemokines have been implicated in the 
pathogenesis of the condition, and while many of these may be expressed by infiltrating 
immune cells, as will be discussed, several are also expressed by resident lung cells. Table 
1.4 shows the inflammatory mediators expressed at increased levels in the lungs of BLM 
treated rodents in vivo, only where an intrapulmonary cellular source of cytokines has 
been identified.  
 
Proinflammatory Mediators Expressed by 
Alveolar Epithelial Cells  
Proinflammatory Mediators Expressed by 
Alveolar Macrophages 
TNF-α – proinflammatory mediator expressed 
at elevated levels following BLM dosing (Song, 
et al., 1998; Cavarra, et al., 2004).  
MIP-1α – proinflammatory cytokine expressed at 
by alveolar macrophages during rodent BPT/BPF 
(Smith, et al., 1994) 
IL-6 – repeatedly observed at increased levels 
in BLM-treated rodent BALF. AECII reported to 
be a source (Aumiller, et al., 2013). 
MCP-1 – chemotactic factor and activating 
chemokine expressed during early stages of BLM-
induced injury (Sakanashi, et al., 1994).  
IL-1β – expressed by AECII explanted from 
BLM-treated rodents; increased BALF IL-1β 
levels also reported (Aumiller, et al., 2013). 
TNF-α – elevated levels are expressed by AM post 
BLM dosing in rodents (Cavarra, et al., 2004; 
Chen, et al., 1996; Everson and Chandler, 1992). 
AM are the primary source (Ortiz, et al., 1998b).  
 IL-1β – seen at increased levels in rodent lungs 
post BLM (Gasse, et al., 2009; Cavarra, et al., 
2004) and in rodent BPF (Gasse, et al., 2007).  
Table 1.4: Proinflammatory Cytokine Expressed in BPF 
Proinflammatory cytokines expressed by AECs and AMs post-BLM in the lungs of rodents.   
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TNF-α is a multi-functional cytokine with a number of functions which may contribute to 
BPF. TNF-α in the lung may induce fibroblast collagen synthesis and proliferation (Piguet, 
et al. (1989) – though this has been debated by some (Tufvesson and Westergren-
Thorsson, 2000; Solis-Heruzo, et al., 1988), and also induce TGF-β expression (Sullivan, et 
al., 2009)  while also inducing significant AEC necrosis (Piguet, et al., 1989) and AEC 
apoptosis, reportedly via angiotensinogen (ANGEN) synthesis (Wang, et al., 2000b), 
potentially leading to the aberrant epithelialisation seen in the lung. Moreover, TNF-α 
induces the expression MIP-1α (Smith, et al., 1998) which may contribute to the immune 
cell influx associated with BPF. Several studies have suggested that TNF-α is important to 
the pathogenesis of BPF; the administration of soluble TNF-α receptors to BLM treated 
rodents prevented BPF (Piguet and Vesin, 1994), while TNF-receptor knockout mice were 
impervious to BLM (Ortiz, et al., 1998; Ortiz, et al., 1999). Moreover, the administration of 
recombinant TNF-α was seen to result in fibrosis in rodent lungs, associated with immune 
cell influx (Sime, et al., 1998). 
IL-1β may be a key mediator in inflammation leading to BPF (Gasse, et al., 2007), and, like 
TNF-α, there is a wealth of evidence to support this. It was reported that the direct 
application of IL-1β to the murine lung induces the expression of PDGF, TGF-β, and TNF-α 
(Kolb, et al., 2001), resulting in severe fibrosis; indeed, Lappalainen, et al. (2005) noted 
transgenic mice expressing human IL-1β in the lung epithelium experienced lung 
neutrophil influx and developed subpleural and alveolar fibrosis. It has also been noted 
that IL-1R antagonists prevent or revert fibrosis in BLM-treated mice (Piguet, et al., 1993), 
and mice dosed with BLM or IL-1β experienced pulmonary neutrophil infiltration and 
fibrosis. Administration of an IL-1β neutralising antibody attenuated this, while IL-1R 
knockout mice saw less neutrophil influx and fibrosis, indicating a role for IL-1 and 
signalling in BPF (Gasse, et al., 2007). Moreover, both TNF-α and IL-1β may induce EC 
adhesion molecule expression required for immune cell diapedesis (Male, et al., 2006; 
Madan, et al., 2000; Rahman, et al., 1998), e.g., into the lung.  
Unlike TNF-α and IL-1β, MCP-1 and MIP-1α act primarily as chemoattractants for 
monocytes and  macrophages, and lymphocytes, respectively (Sakanashi, et al., 1994; 
Deshmane, et al., 2009; Smith, et al., 1994), with the former implicated in the influx of 
macrophages to the lung following BLM dosing (Sakanashi, et al., 1994; Okuma, et al., 
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2004). While the roles of MIP-1α in BPF are poorly delineated, more is known about MCP-
1. In addition to leukocyte recruitment, MCP-1 has a suspected profibrotic role; MCP-1 
was identified as a mitogen for fibroblast collagen production via signalling effects on 
fibroblasts and autocrine TGF-β upregulation by Gharaee-Kermani, et al. (1996). Later 
work showed that knockout mice demonstrate decreased fibrosis following BLM, and that 
MCP-1 may suppress the synthesis of prostaglandin E2, an inhibitor of fibroblast 
collagenation and proliferation, by AECs. Thus, increased MCP-1 permits fibrosis (Moore, 
et al., 2003).  MCP-1 may also induce fibroblast IL-6 production, which may act in an 
autocrine fashion and prevent apoptosis (Liu, et al., 2007). Lastly, MCP-1 plays a role in 
monocyte-endothelium adhesion, which will be discussed.    
Finally, increased IL-6 levels have been noted in BLM-treated rodent lungs by several 
groups (Smith, et al., 1998; Aumiller, et al., 2013). IL-6 induces MIP-1α expression (Smith, 
et al., 1998), and it was found that IL-6 knockout mice experience decreased immune cell 
infiltration and lung collagenation in response to BLM than wild-type animals (Saito, et al., 
2007). IL-6 may also activate neutrophils, potentially important in BPF development 
(Borish, et al., 1989), and, as suggested above, may prevent lung fibroblast apoptosis in 
BPF (Moodley, et al., 2003). Lastly, IL-6 upregulates endothelial ICAM-1 expression 
(Wung, et al., 2004), which may contribute to increased immune cell recruitment.     
While these works are suggestive of a strong role for these cytokines in the development 
of BPF, the studies in the table above used I.T. and intranasal administration of BLM to 
induce fibrosis. When exposing lung cells to such an immediate insult, one would expect 
an inflammatory response.  It is also uncertain whether  this cytokine expression is a 
direct result of BLM, or whether the cells would react similarly and express cytokine as 
“distress signals” if another stimulus were used (though in this case, whether such a 
response was BLM-mediated may be irrelevant).  
Regardless, the expression of these cytokines within the lung may induce  immune cell 
recruitment, either by their chemoattractant properties or their effects on other cell 
types, and this  is an important part of the pathogenic processes of both human and 
rodent BPF  
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1.4.3 Immune Cell Infiltration of the Lung in Bleomycin Pulmonary Fibrosis 
 
Pulmonary immune cell infiltration is widely reported in rodent BPF; neutrophils, 
macrophages, eosinophils, and lymphocytes have been seen to infiltrate the lung (Giri, et 
al., 1986; Helene, et al., 1999; Sakanashi, et al., 1994; Zhu, et al., 1996). Though the order, 
and duration, of infiltration by each cell type is debated (Giri, et al., 1986; Thrall et al., 
1982), neutrophils represent the majority of immune cells in bronchoalveolar lavage fluid 
– fluid extracted from the lung -  2 days post-BLM, with macrophage and lymphocyte 
counts increasing up to 21 days post-BLM (Giri, et al., 1986). Indeed, Izumo, et al (2009) 
noted sequential infiltration, beginning with neutrophils (as noted by Izbicki, et al., 2002), 
then macrophages, and lymphocytes. However, the full contribution of immune cell 
infiltration to BPF is undefined. Neutrophils and macrophages, though, have been the 
subject of several compelling works, and seem likely to contribute to the development of 
fibrosis due to BLM. The potential contribution of each cell type will therefore be 
reviewed. 
 
1.4.3.1 Neutrophils 
 
Work directly studying the role of neutrophils in BPF gives conflicting results, with some 
reporting that inhibition of neutrophil and macrophage infiltration prevents BPF 
development (Li, et al., 2002), and others that reduced neutrophil infiltration does not 
ameliorate BPF (Matsuse, et al., 1999), suggesting pathogenesis may be neutrophil-
independent. Indeed, it has been stated that while neutrophils enter the lung first, their 
transient presence suggests no direct contribution to fibro-genesis, but a neutrophil-
mediated inflammatory cascade leading to fibrosis (Izbicki, et al., 2002).  
This seems likely; neutrophilic ROS and elastase may induce further AEC injury (Serrano -
Mollar, et al., 2002; Taooka, et al., 1997) and activate TGF-β, adding to the profibrotic 
milieu (Chua, et al., 2007). Neutrophil expressed IL-18, which is associated with BPF, may 
also be involved, as IL-18 knockout mice appear protected from BPF (Hoshino, et al., 
2009). In addition, neutrophils also express high levels of TGF-β1 and MMP9 in BPF 
(Izumo, et al., 2009; Kim, et al., 2009), the latter of which is a gelatinase which may 
activate TGF-β (Yu and Stamenkovic, 2001) and also degrade the basement membrane, 
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allowing the migration of immune cells and fibroblasts into the lung, though this is 
controversial (Fattman, et al., 2008). 
 
1.4.3.2 Exudate Macrophages 
 
In contrast to neutrophils, the role of macrophages is more well understood. Studies 
assessing their contribution to BPF have reported increased exudate macrophage 
numbers in the lung post-BLM, with MCP-1 deemed to have induced recruitment 
(Sakanashi, et al., 1994), and that macrophage influx inhibition may attenuate the 
development of the condition (Li, et al., 2002). As MCP-1 knock-out decreased 
macrophage recruitment, MMP2 and 9 expression, and fibrosis (Okuma, et al., 2004), it 
may be suggested that MCP-1 is  involved in BPF. Macrophages are also rich sources of 
proinflammatory and profibrotic factors.  
The increased levels of MMP2/9 observed in BPF may be macrophage-derived (Okuma, et 
al., 2004), while both ET-1 (Mutsaers, et al., 1998) and TGF-β1 (Izumo, et al., 2009), 
potent inducers of collagen synthesis and fibroblast proliferation and transdifferentiation, 
have been identified as macrophage-derived in rodent BPF. Moreover, IL-4, which may 
regulate fibroblast collagen synthesis, has been seen to be expressed in higher levels in 
the lungs of rodents treated with BLM (Gharaee-Kermani, et al., 2001) may also be 
macrophage-derived. Further, while not directly assessed in BPF, activated macrophages 
are a ready source of IL-1β (Gasse, et al., 2007), and express TNF-α (Baer, et al., 1998). 
Therefore, the argument for macrophages playing a role in BPF appears strong. 
 
1.4.3.3 Lymphocytes and Eosinophils 
 
Lymphocytes and eosinophils, though also reported to infiltrate the lung, have been the 
focus of far less work. While eosinophils infiltrate the lung, release cytotoxic mediators 
and oxygen radicals exacerbating injury, and express factors implicated in BPF, e.g. MCP-1  
(Zhang, et al., 1994), their role is unresolved; some show that eosinophil depletion 
attenuates BPF (Gharaee-Kermani, et al., 1998), while others report that it  had no effect 
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(Hao, et al., 2000). Roles for lymphocytes in BPF are also uncertain. While infiltration is 
seen and factors expressed by lymphocytes, e.g. TNF-α (Huaux, et al., 2003), and IL-4 may 
be T-cell-derived in BPF (Gharaee-Kermani, et al., 2001), these factors are also expressed 
by macrophages and AM. Moreover, though Schrier, et al. (1983) stated athymic, T-cell 
deficient, mice were protected against BPF, other work using nude mice noted BPF 
development in the absence of T-cells (Helene et al., 1999). Thus, the contribution of 
lymphocytes and eosinophils remains obscure. 
The cascade of damage incurred by the death of AECs, the expression of cytokines by 
pulmonary cells, and the entry of immune cells to the lung, invariably results in a cytokine 
storm. This may then lead to the defining feature of fibrotic disease, the aberrant 
expression of collagen by mesenchymal cells.     
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1.5 The Myofibroblast in Bleomycin Pulmonary Fibrosis 
 
As with all fibrotic diseases, collagen deposition is a defining feature of BPF, and the 
primary cell involved is the myofibroblast. These cells are the main source of procollagen-
I mRNA expression in rodent lungs post-BLM, (Zhang, et al., 1994b), and are deemed 
“responsible for the increased collagen gene expression” in BPF, present as they are in 
greater numbers in BPF lungs than control lungs (Zhang, et al., 1996) and in BPF lesions, 
becoming more numerous as BPF progresses (Zhang, et al., 1996; Zhang, et al., 1994). 
Though the origin of myofibroblasts in pulmonary fibrosis has been questioned, and both 
endothelial-mesenchymal transition and fibroblastic pre-cursor cell migration into the 
lung have been suggested (Tanjore, et al., 2009; Hashimoto, et al., 2004), there is no 
compelling evidence for the existence of pre-cursor cells, and there is evidence to suggest 
EMT does not contribute (Yamada, et al., 2008; Rock, et al., 2011), and so it appears resi-
dent fibroblasts are the primary source of myofibroblasts in the fibrotic lung.  The switch 
from fibroblast to myofibroblast (transdifferentiation) may be initiated by a host of pro-
fibrotic cytokines, which may be expressed by pulmonary cells (Table 1.5). This expression 
can result in increased numbers of α-smooth muscle actin (α-SMA) and vimentin positive 
myofibroblasts that synthesise excess collagen and ECM proteins (Phan, 2002).  
Profibrotic Mediators Expressed by 
Alveolar Epithelial Cells 
Profibrotic Mediators Expressed by 
Alveolar Macrophages 
TGF-β1 –  expressed following BLM exposure 
(Azuma, et al., 2005). However, AEC expression 
of TGF-β post-BLM was questioned by Kumar, 
et al. (1996). 
TGF-β1 – expressed during periods of ongoing 
disease (Khalil, et al., 1989), AM deemed a key 
source in BPT/BPF (Nakagome, et al., 2006). 
PDGF – profibrotic mediator expressed by AECII 
at elevated levels following BLM exposure 
(Song, et al., 1998) 
PDGF – elevated mRNA expression by AM seen 
post-BLM dosing (Gurujeyalakshmi, et al., 
1999). 
Endothelin 1 – expressed by AECII following 
BLM exposure, also implicated in human 
BPF/BPT development (Mutsaers, et al., 1998; 
Park, et al., 1997).  
 
CTGF – expressed by AECII in mice treated with 
bleomycin; potentially due to autocrine TGF-β 
signalling (Yang, et al., 2014). 
 
Table 1.5: Profibrotic Cytokines Expressed in BPF 
Profibrotic factors expressed by AECs and AMs following exposure to BLM. 
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Interestingly, fibroblasts and myofibroblasts may also be a source of profibrotic cytokines. 
TGF-β expression by myofibroblasts has been reported following BLM dosing (Zhang, et 
al., 1995), and this may stimulate the synthesis of connective tissue growth factor (CTGF) 
from mesenchymal cells, as suggested in Fig. 1.4; there have been reports of increase 
CTGF expression in fibroblastic cells isolated from the BLM-treated murine lung (Ponticos, 
et al., 2009), so this is a possibility. The autocrine signalling that could potentially result 
from this may lead to further fibroblastic activation and collagen synthesis.  
It is also known that human lung fibroblasts express basal ET-1 levels (Ahmedat, et al., 
2012) and it has been demonstrated that TGF-β induces the expression of ET-1 by  human 
lung fibroblasts (Ahmedat, et al., 2012). These fibroblasts also express ET-1 receptors, 
permitting an autocrine system of fibroblast ET-1 expression and subsequent fibroblast 
collagen synthesis in response to ET-1 receptor binding (Ahmedat, et al., 2012), which 
may lead to furtherfibrosis. Though fibroblast endothelin-1 expression, or increase 
expression in response to TGF-β, has not yet been demonstrated in BPF, it is a feasible 
that this process occurs in this environment. The expression of other profibrotic 
cytokines, such as PDGF by fibroblasts is yet to be described in the BPF model, however.  
 
1.5.1 TGF-β in the Bleomycin-Treated Lung 
 
The most widely implicated factor is TGF-β, reported at increased levels in the lungs of 
BLM-treated rodents, with TGF-β1 being the predominant isotype (Coker, et al., 1997). A 
role for this cytokine in BPF and excess collagenation has long been suspected, with early 
reports noting increased numbers of myofibroblasts at 24h post-BLM located in areas of 
excess collagen. These cells increased in number over time, and the phenotypic alteration 
was associated with TGF-β expression and signalling (Vyalov, et al., 1993). With regard to 
studies that have focussed on the expression of the cytokine itself, it was reported that 
TGF-β1 is expressed at increased levels in the lungs at a gene expression level following 
BLM insult (Coker, et al., 1997), at mRNA and protein level in both the inflammatory and 
the reparative stages of BPF, particularly by alveolar macrophages and bronchial 
epithelia, respectively (Santana, et al., 1995; Khalil, et al., 1989). This, together with 
reports of temporal and spatial concordance between maximum TGF-β expression in the 
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lung and maximum collagen production, and of TGF-β localisation in areas of fibrotic 
repair (Khalil, et al., 1989), suggests TGF-β has an important role in rodent BPF.  
TGF-β induces fibroblast α-SMA expression and modulates transdifferentiation and 
collagen expression via multiple signalling pathways (Fine and Goldstein, 1987; 
Desmoulière, et al., 1993). These include the complex  Smad signalling pathways, which 
induce increased collagen expression via stimulation of COLIA2 gene transcription 
(Cutroneo, et al., 2007), and α-SMA gene expression via Smad3 (Hu, et al., 2007). TGF-β 
receptor binding causes Smad3 phosphorylation and complexing with Smad 4, which 
translocates to the nucleus and binds Smad-binding elements, inducing gene transcription 
(Ponticos, et al., 2009).  
TGF-β may also act by inducing synthesis of, and responsiveness to, CTGF by fibroblasts 
via autocrine CTGF signalling (Fig. 1.4) (Grotendorst and Duncan, 2005; Grotendorst, et 
al., 2004; Duncan, et al., 1999; Kothapalli, et al., 1997). CTGF mRNA upregulation and 
protein expression have been reported in murine lungs post-BLM dosing and prior to 
fibrosis, potentially mediated by TGF-β stimulation (Lasky, et al., 1998) and are associated 
with increased fibroblast collagen synthesis in BLM-treated mice (Ponticos, et al., 2009).  
Moreover, application of CTGF to mice can itself induce pulmonary fibrosis (Bonniaud, et 
al., 2003), so CTGF may play a role in the colleagenation of the lung post-BLM. Indeed, 
CTGF blockade was found to reduce BPF in rodents (Yang, et al., 2014) Interestingly, AECII 
are known to express CTGF in IPF patients (Pan, et al., 2001). 
Interestingly, increased active TGF-β levels in the lung post-BLM have been reported 
(Russo, et al., 2009; Atzori, et al., 2004). TGF-β requires activation - conversion to a 
biologically active form - to exert activity, and latent TGF-β is secreted with the latency-
associated peptide (LAP) or the latent TGF-β-binding protein (LTBP) (Annes, et al., 2004). 
Latent TGF-β  may be activated by MMP 2/9 (Yu and Stamenkovic, 2000), present in the 
lungs and increased levels in BPF (Okuma, et al., 2004; Kim, et al., 2009); and 
thrombospondin-1 (TSP-1) (Schultz-Cherry and Murphy-Ullrich, 1993), expressed by AM 
post-BLM (Yehualaeshet, et al., 2009). In BPF, these proteins may interact, with  MMP2/9-
mediated activation, dependent on interaction with AM CD36-bound TSP-1 
(Yehualaeshet, et al., 1999), activating TGF-β, potentially explaining the increase in 
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alveolar macrophage active TGF-β expression (Khalil, et al., 1996; Khalil, et al., 1993). 
Activation may  also be isoform-dependent; when secreted with LTBP-1, latent TGF-β is 
activated by interaction with αvβ6 and fibronectin (Annes, et al., 2004; Fontana, et al., 
2005; Zhou, et al., 2009), the former expressed at increased levels by epithelial cells  post-
BLM (Nakagome, et al., 2006). 
 
 
Figure 1.4: CTGF Induction in Mesenchymal Cells 
 
 
 
 
 
 
Considering its potential importance, there is surprisingly little direct research into the 
contribution of TGF-β to the development of BPF. Wang, et al. (1999d) and Arribillaga, et 
al. (2010) saw decreased collagenation post-BLM in hamsters treated with soluble TGF-β 
receptors, and fewer myofibroblasts and fibrosis post-BLM in mice treated with TGF-β1 
peptide inhibitor, respectively, appearing to confirm earlier suspicions of a role of TGF-β 
in fibrogenesis. Meanwhile, TGF-β signalling blockade was reported to decrease fibroblast 
transdifferentiation and BPF (Kurotani, et al., 2011), as was inhibition of the activation 
and synthesis of the cytokine using IL-10 gene delivery (Nakagome, et al., 2006), 
Adapted from Grotendorst and Duncan (2004). Activation of rodent fibroblasts by TGF-β 
induces fibroblast proliferation via induction of CTGF production and priming of cells to 
become responsive to CTGF. CTGF is a downstream mediator of TGF-β functions. 
Presence or absence of other growth factors, e.g. epidermal growth factor (EGF) and 
insulin -like growth factor (IGF) mediates the biological response. Notably, ICF and ECF 
alone do not mediate proliferation or transdifferentiation.  
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suggesting a strong role for this cytokine in the generation of fibrotic disease. Of course, 
these are not the only effects of TGF-β. In addition to fiboblast proliferation, TGF-β is a 
chemoattractant for monocytes (Reibman, et al., 1991), and may act upon lung epithelial 
cells, preventing the proliferation of AECII (Khalil, et al., 1994; Zhang, et al., 2004; Yue and 
Mulder, 2001), and inducing the apoptosis of lung epithelial cells via caspase-3 activation 
(Hagimoto, et al., 2002). This may precipitate the AEC death that so characterises fibrotic 
diseases such as BPF, and TGF-β may therefore contribute to the pathogenesis of the 
disease in many ways. 
 
1.5.2 Other Profibrotic Cytokines in the Bleomycin-Treated Lung 
 
Though their direct effects have not been investigated, ET-1 and PDGF may contribute to 
BPF. Park, et al. (1997) noted increased ET-1 expression in airway epithelia, AECII and 
immune cells in BLM-treated rats, and the inhibitor bosentan reduced fibrosis. Meanwhile 
Gurujeyalakshmi, et al. (1999) noted increased PDGF-A and –B mRNA levels in BLM-
treated hamster AM; BALF from BLM-treated hamsters co-treated with the inhibitor 
pirfenidone showed decreased mitogenic activity on fibroblasts, possibly due to 
decreased PDGF protein expression via decreased mRNA translation. 
PDGF is a potent fibroblastic mitogen, inducing the survival and proliferation of 
myofibroblasts, and may also induce myofibroblast collagen expression via interaction 
with PDGFRα and β receptors and the associated signalling cascades, reviewed by Bonner, 
et al. (2004). PDGF, particularly the B isoform, has been implicated in non-BLM lung 
fibrosis (Lo Re, et al., 2011; Hoyle, et al., 1999), and the overexpression of PDGF-B mRNA 
by AM has been seen in IPF and interstitial lung disease patients (Antoniades, et al., 1990; 
Nagaoka, et al., 1990; Martinet, et al., 1987). Moreover, the concomitant expression of 
PDGF and TGF-β is associated with fibrosis in rodents (Yoshida, et al., 1995) and man 
(Bergmann, et al., 1998), suggesting that this cytokine may play a role in the development 
of fibrotic disease.  
Also profibrotic, ET-1 is expressed by many cells including AECII (Giaid, et al., 1993), AMs 
(though this has not necessarily been observed in rodent BPF) (Fagan, et al., 2001), and 
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endothelial cells (ECs) (Yanagisawa, et al., 1988), and its release is induced by factors such 
as TGF-β (Fonseca, et al., 2009). ET-1 mediates fibroblast chemotaxis, proliferation 
(Peacock, et al., 1992) and transdifferentiation (Shi-Wen, et al., 2004; Ross, et al., 2009), 
potentially via NF-κB and CTGF induction (Ross, et al., 2009), and promotes increased 
collagen production by mesenchymal cells (Fonseca, et al., 2009). Further, TGF-β and ET-1 
together may induce myofibroblast apoptosis resistance (Kulasekaran, et al., 2009), 
prolonging collagen deposition. Roles for ET-1 in fibrosis are poorly defined, though lung 
and BALF samples from IPF patients contain increased levels of ET-1 (Saleh, et al., 1997; 
Reichenberger, et al., 2001), with neutrophils, macrophages, and AMs potential sources 
in fibrotic disease (Saleh, et al., 1997; Shahar, et al., 1999), suggesting many sources for 
ET-1 in fibrosis, one of which may be ECs, that could potentially contribute to fibrosis.  
Interestingly, BLM itself may result in increased collagen expression by fibroblasts. 
Koslowski, et al. (2004) saw increased collagen production in rat fibroblasts cultured with 
BLM, while Lu, et al. (2009) and Moseley, et al. (1986) noted human fibrolast proliferation 
in response to BLM alone and in combination with PDGF. In addition, it has been reported 
that treatment of fibroblasts with BLM may induce pro-collagen-I and –III expression, as 
well as that of TGF-β (Breen, et al., 1992), suggesting that in BPF, BLM itself may induce 
the expression of collagen and cytokines. 
 
1.6 The Potential Role for Vascular Endothelial Cells in Bleomycin 
Pulmonary Fibrosis 
 
Of course, when I.T. BLM dosing is used, as it so often is in rodent modelling studies, the 
primary site of injury would be expected to be to the AECs, and no damage would be 
expected to vascular endothelial cells (VECs), as this cell type is bypassed by I.T. drug 
delivery.  However, the disease caused by this delivery route may not mimic that seen in 
humans (Borzone, et al., 2001), and though the pathogenesis of the disease caused by I.T. 
BLM is better defined, it may be missing a vital step.   
When BLM is delivered intravenously, as it is in humans, VECs (notably pulmonary VECs) 
may be the first cell type of the lung to come into contact with the drug. It has indeed 
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been reported that, when I.V. BLM is used in animal works, the vascular endothelium is 
the site of initial, and in some cases, sole injury. As I.V. dosing is rarely used in 
experimental modelling, many aspects of the potential model of BPF development either 
bypass or ignore the potential role of VECs in these processes. However, some current 
research suggests that the vascular endothelium is more than a passive bystander in the 
development of BPF. 
 
1.6.1 Endothelial Cell Junction Permeability 
 
It has been reported that I.T. BLM delivery in the rat results in endothelial tight junctions 
being held in an open state following dosing (Yin, et al., 2012). This was suggested to 
potentially increase immune cell influx into the lung, as open cell-cell junctions permit 
easier passage through the endothelium, but it is also possible that this increased vascular 
permeability accounts for the oedema reported in BPF, and may also allow the movement 
of systemic cytokines or blood-borne BLM into the lung, which may precipitate the AEC 
injury and damage that so characterises the disease. 
 
1.6.2 Endothelial Cell Profibrotic Cytokine Expression 
 
Interestingly, BLM appears to induce the expression of profibrotic cytokines in rodent 
endothelia. It was reported that TGF-β expression is induced in vitro by rodent 
endothelial cells exposed to BLM (Phan, et al., 1991), while Yin, et al. (2011) reported 
TGF-β1 and CTGF synthesis and expression by PMVECs isolated from I.T. BLM-treated rats 
7 days post-BLM. This correlated with the development of interstitial fibrosis in BLM-
dosed rodents, and with interstitial fibroblast transdifferentiation as determined by 
fibroblast α-SMA and collagen synthesis. PMVECs isolated from BLM-treated rats also 
promoted fibroblast transdifferentiation and collagen I protein expression  when co-
cultured in vitro.    
Of course, it is difficult to assign a role for BLM in this process; profibrotic cytokine 
expression may have been induced by AEC and AM-expressed cytokines acting on VECs. 
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Moreover, as I.T. BLM administration results in a cytokine storm within the lung, then AEC 
or AM expressed cytokines may have induced interstitial fibroblast transdifferentiation. 
Work assessing this phenomenon using I.V. BLM dosing would be required to delineate 
whether BLM is directly causing these effects. 
However, if such cytokine expression is BLM-mediated, it is possible that VEC-expressed 
cytokines, as diffusible mediators, may translocate into the lung and interstitium, though 
no current research has directly tracked endothelial cytokine movement into these areas. 
The increased endothelial permeability caused by BLM (Yin, et al., 2011), may feasibly 
assist this, allowing fibroblast transdifferentiation to occur and fibrosis to develop in 
these regions.  
If such profibrotic cytokine release also occurs in man, then this may be a contributing 
factor to the development of BPF. Human endothelial cells express a broad range of such 
factors. Endothelin-1 is expressed by endothelial cells of various types including HUVECs 
and pulmonary VECs in response to various stimuli (Golden, et al., 1998; Wang, et al., 
1993; Kurihara, et al., 1989; Bilsel, et al., 2000; Stow, et al., 2011), while PDGF may also be 
expressed by endothelial cells from the umbilical vein and lung microvasculature (Collins, 
et al., 1987; Kourembanas and Faller, 1989; Albelda, et al., 1989; Harlan, et al., 1986). 
TGF-β is also synthesised and expressed by  HUVECs and human intestinal endothelia 
(Nilsen, et al., 1998; Pintervorn and Ballerman, 1997) and PAECs in rodents (Phan, et al., 
1992) and potentially in response to BLM (Yin, et al., 2012), and the diffusion of these 
mediators into the lung or their effects on the fibroblasts in the interstitium may result in 
fibrosis development leading to BPF. 
 
1.6.3 Endothelial Cell Adhesion Molecule and Proinflammatory Cytokine 
Expression  
 
Immune cell infiltration is clearly a major feature of rodent BPF development to which 
VECs may contribute, and VECs are also a ready source of proinflammatory cytokines,  
such as MCP-1 and IL-8 which may recruit and activate immune cells which may then 
migrate into the lung, increasing pulmonary cellularity. Further, endothelial cells likely 
play a large role in the recruitment of immune cells to the lung by expression adhesion 
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molecules which are vital in the anchoring of immune cells to the luminal surface of 
vessels, the first step of diapedesis. Interestingly, both proinflammatory cytokine release 
and adhesion molecule expression have beeenreported in the literature in human and 
rodent endothelial cells.  
In rodents, the amount of research is relatively low. However, there have been reports of 
cytokine expression by VECs explosed to BLM in vitro, such as those of increased 
expression of IL-6 (Karmiol, et al., 1993;), while in in vivo studies,  strong E-selectin mRNA 
induction in response to intravenous BLM in pulmonary vasculature of rodents was 
reported by Azuma, et al. (2000), with increased lung myeloperoxidase levels suggesting 
neutrophil infiltration in I.V. BLM dosed mice. At a functional level,  Li, et al (2002) and 
Matsuse, et al (1999), both having used I.V. dosing, noted significant lung infiltration by 
neutrophils, lymphocytes, and macrophages in BLM-treated rodents which was decreased 
when ICAM-1 and VCAM-1 were blocked with antibodies and macrolides, respectively. 
This suggests that adhesion molecules are expressed, and function in immune cell 
recruitment in this model, though while the blockade of ICAM-1 expression by Matsuse, 
et al. (1999) did not ameliorate BPF, the blockade of VCAM-1 by Li, et al. (2002) did, and 
so the roles of these molecules in rodent BPF remain unclear. 
Interestingly, there are  reports of endothelial cell adhesion molecule expression 
stemming from I.T. BLM dosing, and these are more numerous. Perhaps the most 
relevant is the work of Weiner, et al. (1998), which using an indium-labelled anti-ICAM-1 
antibody, noted ICAM-1 upregulation in the lung within 4 hours of dosing, though 
increased P-selectin expression post-I.T. BLM dosing in rodents has also been reported 
(Serrano-Mollar, et al., 2002), as has ICAM-1 upregulation by pulmonary VECs isolated 
from rats post-I.T. BLM dosing by Sato, et al. (2000). This increased ICAM-1 expression 
was seen to have a functional relevance, resulting in increased leukocyte rolling and 
entrapment in venules and capillaries. More recently, Wang, et al. (2011) noted leukocyte 
migration across pulmonary venules to the perivascular space, associating with ICAM-1 
and VCAM-1 in areas of transmigration, which also signifies a functional relevance of 
adhesion molecules in the lung post-BLM.  Further, Hamaguchi, et al. (2002) noted 
decreased collagen deposition, leukocyte infiltration, and cytokine production in the lungs 
of I.T. BLM-treated, ICAM-1 knock-out mice, compared to treated wild-type mice, 
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suggesting ICAM-1 may be particularly relevant; thus, it appears adhesion molecules may 
be expressed by VECs when I.T. dosing is used, and  this  may contribute to  BPF.  
The importance of the Weiner, et al. (1998) work extends beyond the identification of 
ICAM-1 upregulation in the lung post-BLM. Other organs assessed, the liver and spleen, 
did not show such upregulation until 24-hours post-dose, and even then, this was less 
significant. It was also reported that LFA-1, a CD18-bearing ligand for ICAM-1, was 
upregulated on polymorphonucleocytes (PMNs), potentially “priming” these cells for 
interaction with ICAM-1. This is the only study to assess adhesion molecule upregulation 
in various organs of the BLM-treated mouse, and not only suggests that ICAM-1 is 
upregulated in the lung, but that this is an organ specific effect, and may be why the lung 
is the most affected organ following dosing. However, this work only examined ICAM-1 
expression in three organs, and so a blanket statement cannot be made about ICAM-1 
upregulation in non-assessed organs. However, this work provides a valuable framework 
on which to build other studies. It would surely be very interesting to assess where and 
when adhesion molecules are upregulated in response to BLM in a wider variety of 
organs.   
However, in rodents, the role of these adhesion molecules is uncertain, as shown above 
with the work of Li, et al., and Matususe, et al., whereby adhesion molecule blockade did 
and did not ameliorate BPF, respectively. Furthermore, Horikawa, et al. (2006), reported 
that  E-selectin knock-out mice treated with anti-P-selectin monoclonal antibody endured 
increased fibrosis and mortality, and demonstrated decreased numbers of IFNγ-
expressing natural killer T-cells (NKT) in BALF compared with wild-type mice. The lack of 
IFN-γ expressing NKT cells may have been deleterious, as IFN-γ inhibits collagen 
production (Rosenbloom et al., 1984), and downregulates TGF-β expression 
(Gurujeyalakshmi and Giri, 1995). Thus, the role of the adhesion molecules in rodent BPF 
requires more study, though they appear to induce the recruitment of immune cells. In 
addition, none of these works assessed whether adhesion molecule and cytokine 
expression was mediated by BLM directly, or by the action of AEC/AM-expressed factors. 
For once, in vitro work may be preferable, as this would allow researchers to determine 
whether such upregulation is indeed BLM-related. Of course, research into adhesion 
molecule expression by BLM-treated human cells has been just that.  
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Work assessing adhesion molecule expression in BLM treated human cells  has revealed 
E-selectin and ICAM-3 mRNA and protein expression, and IL-8 and MCP-1 secretion by 
HUVECs stimulated with BLM (Miyamoto, et al., 2002), though the protein expression of 
IL-8 and MCP-1 was only induced to high levels when cells were incubated with BLM over 
48 hours,  not a typical exposure time in BLM-treated patients. In other work, Ishii and 
Takada (2002) observed increased E-selectin expression by HUVECs treated with between 
1 and 7µg/ml  BLM in vitro, potentially mediated by direct activation of the E-selectin 
promoter, so  it appears that BLM may also upregulate the expression of this particular 
adhesion molecule. While ICAM-1 expression in HUVECs was not noted by Miyamoto, et 
al. (2002), this is in contrast to the only other published work in this field, the work of 
Fichtner, et al. (2004), who noted BLM-induced increased ICAM-1 protein and IL-8 
expression by human pulmonary microvascular ECs (PMVECs), though again, at supra-
pharmacological concentrations of around 50µg/ml. Therefore, there is no real 
agreement observed in these studies, other than that E-selectin is upregulated in BLM-
treated HUVECs, that IL-8 is expressed by VECs exposed to high-dose  or long-duration 
BLM treatment, and that the expression of these proteins is most likely BLM-related.  
A further  question is how stimulation by BLM in vitro mediates cytokine and adhesion 
molecule expression. Ishii and Takada (2002) suggested NF-κB/Rel activation by BLM-
associated ROS induces NF-κB/Rel nuclear translocation and transcriptional activation of 
the E-selectin gene, as NF-κB/Rel, but not AP-1, inhibition attenuated E-selectin 
expression, but no ROS source was suggested. E-selectin expression requires NF-κB 
activation and NF-κB binding to the promoter (Montgomery, et al., 1991; Read, et al., 
1994; Schindler and Baichwal, 1994), along with high-mobility-group protein I(Y) binding 
(Lewis, et al., 1994; Whitley, et al., 1994) and  JNK/p38 activation, (Read, et al., 1997; Min 
and Pober, 1997), so this seems feasible. Moreover, ICAM-1 induction following VEC 
stimulation depends on NF-κB signalling (Ledebur and Parks, 1995; Rahman, et al., 1999; 
Guo, et al., 2012), as does VCAM-1 expression in response to TNF-α, IL-1β, and LPS 
(Ahmad, et al., 1998; Iademarco, et al., 1992; Marui, et al., 1993) though PI3K and MAPK 
have also been implicated (Binion, et al., 2009). Thus, if BLM initiates NF-κB activation, 
then this may result in the expression of several molecules.   
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The expression of  IL-8 and MCP-1 may also depend on NF-κB activation (Tanner, 2004; 
Brasier, 2010; Molestina, et al., 2000), though Fichtner, et al. (2004), noted that BLM 
induced P38 MAPK phosphorylation and activation, the inhibition of which decreased IL-8 
expression. IL-8 expression by BLM-treated VEC may be MAPK-mediated, though the 
authors conceded the involvement of P38 MAPK in IL-8  expression was cell type- and 
stimulus-dependent. Both, or either, pathway may induce expression. Currently, no 
literature exists clarifying the mechanisms of factor or adhesion molecule upregulation 
and expression by BLM-stimulated VECs, so no inferences can be made regarding how or 
if BLM stimulation induces this expression. However, this would be an interesting avenue 
for future research into this field. 
Currently, publications by Miyamoto, et al. (2000), Fichtner, et al. (2004), and Ishii and 
Takada (2002) are the only works assessing adhesion molecule and cytokine expression 
by human endothelial cells exposed to BLM. As immune cell recruitment is a feature of 
the disease in man as well as mouse, and VECs are known to express many cytokines 
which may contribute to immune cell recruitment and fibrosis, then this is an area 
desperate for new research. Of particular interest would be studies using 
pharmacologically-relevant concentrations of the drug over relevant time points, and 
further investigation into  which adhesion molecules and cytokines are upregulated in 
response to BLM.  
Previous work in  into this field is limited, much concerns rodents, and some is at supra- 
pharmacologically-relevant BLM concentrations. Of the three studies studies assessing 
the response of human cells to BLM, one used  concentrations of BLM that would not be 
encountered in the circulation of patients receiving the drug (Fichtner, et al., 2004), and 
another, a narrow range (Ishii and Takada, 2000). One would expect the adhesion 
molecule expression and cytokine release in response to supra-pharmacological  
concentrations to be higher than when cells were subject to pharmacologically-relevant 
BLM concentrations.Therefore, the findings of these works, while interesting, may not be 
totally relevant. Work assessing endothelial adhesion molecule expression and cytokine 
release using a range of pharmacologically-relevant concentrations, outlined in Table 1.1, 
would be more applicable to the true environment initiated by BLM treatment in man, 
and may give results that more accurately mirror the endothelial response to BLM.  
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Further, work assessing the response of the most relevant cell type, PMVECs, to 
pharmacologically-relevant BLM concentrations, would be of particular use. By doing this, 
a better picture of the processes ongoing in the human lung following BLM dosing may be 
built, and how the effect of the drug on the pulmonary endothelium may contribute to 
the inflammation which precedes BPF development may be better elucidated. The 
expression of profibrotic cytokines in this environment will also be invaluable, to 
determine whether this is another role for VECs in BPF onset. 
As all of the adhesion molecules and pro-inflammatory cytokines mentioned above are 
involved in the  diapedesis cascade - whereby immune cells are recruited to, adhere to, 
and traverse through, the endothelium, the role of these proteins - and others - in this 
process must be discussed. From this, appropriate adhesion molecules and cytokines to 
assess in future works may be determined.  
 
1.7 The Process of Diapedesis and the Adhesion Molecules and 
Cytokines Involved 
 
The diapedesis cascade, by which immune cells enter the site of injury, is a multi-step 
process, as shown in Fig. 1.5. First, immune cells may be recruited to the endothelium by 
chemoattractant cytokines such as IL-8 and MCP-1, in the case of the relevant cell types in 
this work (monocytes and neutrophils) and from here,  cells may tether to the 
endothelium. This tethering is mediated by a wide range of adhesion molecules and 
ligands. ICAM-1, E-selectin, P-selectin, PECAM-1, PSGL-1, and a many other molecules are 
involved in immune cell-endothelial interaction, adhesion and diapedesis (Ley, et al., 
2007), and each stage of the multi-step process of transmigration involves different 
molecules, ligands, and chemokines, summarised briefly in Table 1.6. 
Adhesion molecule expression profiles determine the immune cells that tether to the 
endothelium, as each binds specific ligands (Table 1.6). VEC E-selectin (Rahman, et al. 
1999) VEC/platelet P-selectin, and potentially PSGL-1 on VEC and leukocytes (da Costa 
Martins, et al., 2007) mediate tethering by binding leukocyte ligands. Such interactions 
slow cells, inducing rolling on the endothelial surface, and slowed cells may subsequently 
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be triggered by selectin ligation (Ley, et al., 2007) or by chemokines at the endothelial 
surface - bound to glycosaminoglycans (GAGs), VEC-released, or tissue-expressed and 
transported across the endothelium - which bind specific G-protein coupled receptors 
(GPCRs) on tethered cells (van Gils, et al., 2009; Male, 2006). 
 
Adhesion 
Molecule 
Function/Cell 
Type 
Functional Ligands 
E-selectin Mediates rolling 
and tethering of 
neutrophils, 
monocytes, and 
subsets of T-
cells.  
 Binds CD44, ESL-1, and Mac-1 (αMβ2) on neutrophils 
(Zarbock, et al., 2009; Zen et al., 2007) 
 Binds monocyte PSGL-1 and CD44 (Ley, 2007), PSGL-1 on 
previously activated “memory” T-cells (Borges, et al., 
1997) 
 Binds ESL-1 and CD43 on TH1 and T-lymphocytes, 
respectively (Zarbock, et al., 2011) 
Endothelial 
P-selectin 
Mediates rolling 
and tethering of 
neutrophils, 
monocytes, and 
T lymphocytes.  
 Binds PSGL-1 on neutrophils and monocytes 
(Zimmerman, 2001), memory T-cells (Borges, et al., 
1997), and eosinophils (Woltmann, et al., 2000).  
ICAM-1 Mediates 
adhesion of 
lymphocytes, 
neutrophils, 
monocytes, and 
eosinophils. 
 Binds LFA-1 (αLβ2) expressed on lymphocytes, Mac-1 and 
LFA-1 expressed on neutrophils (Hopkins, et al., 2004; 
Lefort and Ley, 2012; Hertzen, et al., 2000) 
 Binds monocytes and eosinophil LFA-1 and Mac-1 (van 
Gils, et al., 2009; Jia, et al., 1999). LFA-1 also binds to 
ICAM-2, inducing adhesion (Yusuf-Makagiansar, et al., 
2002).  
VCAM-1 Mediates 
adhesion of 
monocytes, 
eosinophils, and 
neutrophils. 
Mediates rolling 
and tethering of 
lymphocytes.  
 Binds VLA4 on monocytes, eosinophils, (Yusuf-
Makagiansar, et al., 2002), and may mediate rolling and 
tethering of lymphocytes via VLA-4 interaction (Alon, et 
al., 1995)  
 VLA4 may also be expressed by neutrophils (Lomakina 
and Waugh, 2009), while this had not previously been 
supposed (Yusuf-Makagiansar, et al., 2009).  
 May also bind to lymphocyte LPAM-1 (Yang, et al., 1998).  
Endothelial 
PSGL-1 
Mediates leu-
kocyte rolling, 
tethering, and 
adhesion. 
 Binds P-selectin expressed on platelets and L-selectin 
expressed on monocytes and neutrophils (da Costa 
Martins, et al., 2007; Sperandio, et al., 2003; Spertini, et 
al., 1996).  
Table 1.6: Endothelial Cell Adhesion Molecules 
 
Molecules involved in the rolling, tethering, and adhesion of immune cells to the 
endothelium in  man.  
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Chemokine triggering induces integrin activation, resulting in conformational changes to 
immune cell integrins (van Gils, et al., 2009; Ley, et al., 2007) such as LFA-1 and VLA-4, 
inducing increased-affinity binding of these ligands to adhesion molecules. Outside-in 
signalling by bound integrins stabilises adhesion (Ley, et al., 2007). VEC ICAM-1/2 and 
leukocyte Mac-1/LFA-1 dependent crawling (Phillipson, et al., 2006; Schenkel, et al., 2004) 
may then deliver leukocytes to migration locations. 
Junction molecules - those located in the endothelial cell-cell junctions - are also involved 
in extravasation, including PECAM-1, CD99, and possibly JAM-A; homophilic interaction 
between VEC and leukocyte PECAM-1 and CD99 occur during diapedesis (Ley, et al., 2007) 
while JAM-A may undergo heterophilic interactions with LFA-1 (Ostermann, et al., 2002). 
Both are important in diapesesis, and may guide leukocytes through the junction and, in 
the case of BPF, potentially into the lung. 
Many of these adhesion molecules are involved is several steps of diapedesis, and their 
expression is controlled in many different ways within the endothelial cell. Therefore, 
each of these molecules will be discussed independently, and their role in the process of 
immune cell transmigration considered. Further, MCP-1 and IL-8, both involved in the 
recruitment of immune cells to the site of adhesion molecule expression prior to 
adhesion molecule tethering, and also involved in the activation of immune cells prior to 
their adhesion to the endothelium, must also be investigated. 
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Figure 1.5: The Transendothelial Migration Cascade 
 
The process of diapedesis. Selectins, e.g. P- and E-selectin, mediate leukocyte rolling and tethering as bonds are formed and broken rapidly, slowing the cell. Slowed 
cells are activated by cytokines, e.g. IL-8 and MCP-1. Activated cells then bind to ICAM-1 and VCAM-1 via β-2 integrin ligation to adhesion molecules. Leukocytes may 
then crawl along the endothelium to the site of transmigration (usually cell-cell junctions), through which leukocytes move via interactions between leukocyte and 
junctional ligands such as PECAM-1, expressed on both cell types. As described in Table 1.6, the immune cells recruited depend on the adhesion molecules expressed. 
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1.7.1 Rolling and Tethering – The Initial Step in Transendothelial Migration 
(TEM) 
 
The initial step in transendothelial migration (as shown in Fig. 1.5) is the rolling of 
immune cells captured from circulation and the tethering of these cells to the vascular 
endothelium. This may be mediated by molecules including E-selectin and P-selectin, but 
may also be mediated  by molecules such as PSGL-1. 
 
1.7.1.1 E-selectin (CD62E) 
 
E-selectin, exclusively expressed by ECs, is involved in the initial capture and tethering of 
circulating immune cells (Ley, et al., 2007; Rahman, et al., 1998). E-selectin expression 
occurs in response to cytokine stimulation, for example, by TNF-α, IL-1, and LPS 
(Bevilacqua, et al., 1987; Carlos, et al., 1991; Haraldsen, et al., 1996), and peaks rapidly, 
within around four hours, before expression tapers off after 24-30 hours (Male, et al., 
2006). 
E-selectin binds fucose-rich glycoproteins containing sialylated LewisX oligosaccharides as 
a minimal recognition motif, mainly PSGL-1 and CD44 in humans (Ley, et al., 2007; 
Rahman, et al., 1998; Foxall, et al., 1992), and upon tethering, induces the rolling of 
leukocytes, allowing chemokine-mediated ligand activation. E-selectin binds ligands with 
rapid on/off rates – meaning that bonds form quickly but also break quickly (McEver and 
Zhu, 2010) - allowing leukocyte capture, slowing the cell, while dissociation allows rolling. 
This appears to be a triphasic binding system involving both slip (rapid transient binding) 
and catch (more enduring, stable binding) bonds (Wayman, et al., 2010), though 
neutrophil adhesion to E-selectin may also occur under static conditions (Simon, et al., 
2000), and so the nature of E-selectin mediated binding is uncertain. Regardless, binding 
of E-selectin by its ligands may induce signalling leading to TEM. 
It appears binding of leukocyte PSGL-1 to E-selectin may induce integrin affinity 
modulation allowing the adhesion of leukocytes to the endothelium, though this is not 
well resolved. Simon, et al. (2000) reported that human neutrophils adhered stably to E-
selectin-transfected L-cells in a β2 integrin-mediated fashion, and that E-selectin-PSGL-1 
71 
 
interaction-mediated affinity modulation of β2 integrins was caused by MAPK and p38 
signalling, as blockade of either prevented stable adhesion. The affinity modulation of β2 
integrins allowed the adhesion of the neutrophils to other adhesion molecules. Later, 
Kuwano, et al. (2010) suggested the binding of neutrophil PSGL-1 to VEC E-selectin, via 
Syk activation, leads to LFA-1 activation. This led to decreased neutrophil rolling velocity 
and firm adhesion, potentially to ICAM-1, which was expressed concurrently with E-
selectin. E-selectin binding to CD44 may also induce inside-out signalling - Green, et al. 
(2004) noted neutrophil ligation to E-selectin resulted in the focal redistribution and 
clustering of L-selectin, PSGL-1, and β2 integrins in human neutrophils – though the 
functions of this are unknown. However, it does appear that E-selectin binding may not 
only slow the cell and allow rolling, but alter the affinity of other ligands on the rolling 
immune cell, allowing these cells to tether to other adhesion molecules.  
Finally,  E-selectin ligation may lead to VEC junction opening. Lorenzon, et al. (1998) 
observed ligation of E-selectin with mAb induced intracellular Ca2+ increases and stress 
fibre formation. E-selectin associates with cytoskeletal components, and its ligation may 
result in PLCγ recruitment and tyrosine phosphorylation, thus Ca2+ mobilisation and 
cytoskeletal rearrangement, which may contribute to TEM, potentially via junctional 
remodelling (Kiely, et al., 2003). 
 
1.7.1.2 P-Selectin (CD62P) 
 
P-selectin, expressed by endothelial cells and platelets, (Ley, 2003), is also involved in the 
tethering of immune cells, via interaction with leukocyte PSGL-1(Borges, et al., 2004; 
Zimmerman, et al., 2001; Woltmann, et al., 2000). Unlike E-selectin, P-selectin is  
constitutively synthesised (Liu, et al., 2010b) and is stored in Wiebel-Palade Bodies (WPB), 
rod-shaped cytoplasmic components that contain many proteins (Weibel and Palade, 
1964; Metcalf, et al., 2008; McEver, et al., 1989). Expression by HUVECs occurs rapidly in 
response to thrombin and histamine and peaks around 10 minutes post-stimulation, with 
the molecule beinginternalised again within 30-60 minutes (Hattori, et al., 1989; Sugama, 
et al., 1992; Vestweber and Blanks, 1999), though it may also be expressed constitutively 
by low-passage HUVECs in vitro (Melrose, et al., 1998).  
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Like that of E-selectin, P-selectin tethering occurs with high on-off rates, and binding 
requires the expression of sialylated LewisX oligosaccharides in the ligand (McEver and 
Zhu, 2010), though the binding of P-selectin is impacted by shear force.  Increases in 
shear increase the mean time of tethering, mediated by catch-bonding. As shear 
increases further, the duration of tethering decreases, representing a shift to slip-bonding 
(Marshall, et al., 2003b), and the rolling cell slows.  
Compared to other adhesion molecules, the role of P-selectin appears to be restricted. 
However, there is evidence that the binding of P-selectin to neutrophil PSGL-1 may give a 
higher affinity conformation of neutrophil Mac-1, increasing neutrophil adhesiveness to 
the substrate (in this case, fibrinogen) (Ma, et al., 2004), though other reports have stated 
that this does not augment adhesiveness of neutrophils to physiological adhesion 
molecules such as ICAM-1 in humans (Blanks, et al., 1998). Further, an overlapping 
function for P-and E-selectin has been reported in mice, where blockade of one did not 
prevent TEM, but blockade of both did (Subramaniam, et al., 1997) and in work where 
genetic knockout of both E- and P-selectin was required to prevent neutrophil TEM 
(Homeister, et al., 1998). Whether this is the case in man is uncertain, but as P-selectin is 
known to be involved in the initial tethering of immune cells to VECs, and therefore must 
be considered here. 
 
1.7.1.3 P-selectin glycoprotein ligand (PSGL-1; CD162) 
 
P-selectin glycoprotein ligand 1 (PSGL-1) is expressed by many cell types including 
leukocytes, and also ECs, on which it is constitutively expressed, and not impacted by 
treatment with TNF-α, IL-1β, or other secretagogues (da Costa-Martins, et al., 2006). EC 
PSGL-1 may bind monocyte L-selectin (da Costa-Martins, et al., 2006), and this may 
induce rolling, though it has been reported that this only occurs on TNF-α-treated 
HUVECs, and this was suggested to be due to alterations in glycosylation of EC PSGL-1 by 
TNF-α treatment. Blocking EC PSGL-1 or monocyte L-selectin also decreased monocyte 
rolling, so it seems that this adhesion molecule may also have a role in the tethering of 
monocytes to the endothelium. However, the aforementioned study is the only one 
available in the literature. 
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1.7.2 Immune Cell Activation – The Second Step in TEM 
 
Once slowed on the endothelium and tethered, recruited immune cells may be activated, 
or “triggered”, by a wide range of cytokines which may bind to cellular receptors. Two 
cytokines involved in this process are MCP-1 and IL-8, both of which may also be 
implicated in the directional migration of immune cells towards the endothelium and 
through the endothelium after triggering. 
 
1.7.2.1 Monocyte Chemoattractant Protein 1 (MCP-1) 
 
MCP-1 has a strong role in inflammation. It is a potent monocyte and macrophage 
chemoattractant, and induces directional migration to the site of expression (Mukaida, et 
al., 1998; Matsushima, et al., 1989). EC consititutively synthesise MCP-1, which is stored 
in granule 2 in the cell (Øynebråten, et al., 2005), from where it may be expressed in 
response to secretagogues such as histamine and forskolin. MCP-1 is soluble or bound to 
glycosaminoglycans (GAGs) (Lau, et al., 2004), though it is uncertain whether soluble or 
GAG-bound MCP-1 induces directional migration (Weber, et al., 1996; Weber, et al., 1999; 
Kuschert, et al., 1999; Hardy, et al., 2004).  
As with many chemokines, MCP-1 activates cells via receptor binding, and is involved in 
monocyte and macrophage activation (Mukaida, et al., 1998; Matsushima, et al., 1989). 
Upon tethering of monocytes by E-selectin, MCP-1 triggers adhesion to molecules such as 
ICAM-1 and VCAM-1 via α4 and β2 integrin affinity modulation (Gerszten, et al., 1999), or 
VLA-4 and -5 activation, which may also induce monocyte shape change and TEM (Weber, 
et al., 1996). Further, the binding of MCP-1 to monocyte CCR2 initiates multiple pathways 
such as GPCR signalling, leading to phospholipase C activation, Ca2+ release, and protein 
kinase C and NF-κB activation, causing directional motion of the monocyte (Melgarejo, et 
al, 2009), while MAPK activation and p38 MAPK signalling may also induce chemotaxis 
(Yen, et al., 1997; Ashida, et al., 2001). Thus, MCP-1 may induce monocyte influx to the 
lung, and could be an important factor involved in diapedesis following BLM insult. 
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1.7.2.2 Interleukin 8 (IL-8) 
 
IL-8, also expressed by endothelial cells exposed to BLM, is a strong neutrophil 
chemoattractant (Huber, et al., 1991). When expressed, IL-8 may  bind GAGs, such as 
heparan sulphate (Webb., et al., 1993) forming chemotactic gradients along which 
neutrophils migrate (Marshall, et al., 2003; Rot, et al., 1996; Tanaka, et al., 1993).  
 
IL-8 is synthesised by VECs and stored in granules or WPB in many endothelial cell types, 
though it may also be stored in the Golgi apparatus. However, its appearance  in WPB 
often only occurs after stimulation of the cell with inflammatory cytokines (Metcalfe, et 
al., 2007). Its expression is stimulated by cytokines or secretagogues, and it has been 
suggested that the cellular source of IL-8 may be determined by the type of secretory 
stimulus or  cell (Harada, et al., 1994; Utgaard, et al., 1998; Wolff, et al., 1998; Hol, et al., 
2012); in HUVECs, stimulation with mediators such as IL-1β causes release from the Golgi 
apparatus, while stimulation with IL-1β followed by withdrawal and the addition of 
histamine releases IL-8 from WPB (Wolff, et al., 1998)  
Similar to MCP-1 acting on monocytes, IL-8 activates neutrophils (Kuijpers, et al., 1992; 
Daniels, et al., 1992). Neutrophils express two IL-8 receptors, CXCR1 and -2 (Godaly, et al., 
2000), and binding of IL-8 to these may activate or modulate the affinity of LFA-1 and 
Mac-1, and in fact  increase Mac-1 expression, inducing neutrophil arrest on adhesion-
molecule expressing VECs (Takami, et al., 2002; Seo, et al., 2001; Detmers, et al., 1990) via 
binding of integrins to appropriate molecules including ICAM-1. As well as modulating 
integrin affinity, IL-8 receptor binding may also mediate neutrophil exocytosis and 
degranulation, mediated by  Ca2+  flux, a result of PLC, IP3 and DAG activation (Zeilhofer 
and Schorr, 2000). Such Ca2+  flux may also polarise cells, inducing the formation of a 
psudopod at the head of the cell, allowing directional migration (Schaff, et al., 2008). 
Therefore, IL-8-mediated neutrophil activation may be vital for neutrophil 
transendothelial migration. 
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1.7.3 Adhesion to the Endothelium – The Third Step in TEM 
 
Following the activation of recruited immune cells, adhesion to the endothelium occurs 
via interaction between immune cell integrins and VEC-expressed adhesion molecules 
such as ICAM-1 and VCAM-1. This step is vital prior to the movement of recruited immune 
cells through the endothelium to the site of injury. 
 
1.7.3.1 Intercellular Adhesion Molecule 1 (ICAM-1; CD54) 
 
ICAM-1 is expressed constitutively by VECs (Hopkins, et al., 2004) and is induced by TNF-
α, IFN-γ, IL-1β, and LPS (Pober, et al., 1986; Swerlick, et al., 1991; Haraldsen, et al., 1996), 
with protein expression increasing over time and reaching peak levels between 24-48 
hours after stimulation (Haraldsen, et al., 1996).  
 
ICAM-1 mediates immune cell tethering via binding to LFA-1 and Mac-1 integrins on 
leukocytes, and these integrins may then undergo integrin affinity and valency changes as 
VEC-bound chemokines interact with leukocyte G-coupled protein receptors (GCPR). PLC-
dependent inside-out signalling may then induce integrin conformation changes, causing 
high and intermediate-affinity binding of leukocytes to ICAM-1, as outside-in signalling 
stabilises this adherence (Ley, et al., 2007). ICAM-1-to-integrin binding may also alter 
ICAM-1 expression and localisation, and may result in VCAM-1 and IL-8, synthesis, 
inducing further immune cell recruitment (Rahman and Fazal, 2009). 
ICAM-1 has many roles in diapedesis. ICAM-1 localises to EC microvilli and cell-cell 
junctions (Millán, et al., 2006; Thompson, et al., 2002), and upon ligation, clusters. 
Ligation by monocytes resulted in ICAM-1 clustering around the cell, promoting adhesion 
and spreading (Wójciak-Stothard, et al., 1999). ICAM-1 is also present in the intercellular 
junctions, and interaction with LFA-1 or Mac-1 at this stage may aid the transmigration of 
leukocytes (Ley, et al., 2007), while the ligation of ICAM-1 increases intracellular Ca2+, 
activating myosin light chain kinase, promoting VEC contraction and junction opening, 
allowing increased leukocyte transmigration (Huang, et al., 1993; Su, et al., 2000; Etienne-
Manneville, et al., 2000).  
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Interestingly, ICAM-1-LFA-1 ligation may induce the formation of cup-shaped projections 
rich in ICAM-1, which engulf adhered leukocytes (Carman, et al., 2003). Both para- and 
transcellular TEM of leukocytes have been associated with the formation of this 
“transmigratory cup” (TC) (Carman and Springer, 2004), as leukocytes migrating via both 
mechanisms were engulfed by the TC prior to transmigration. This has also been observed 
when assessing lymphocyte migration (Millán, et al., 2006). Therefore, it appears ICAM-1 
has many roles in the diapedesis cascade after adhesion.  
 
1.7.3.2 Vascular Cell Adhesion Molecule 1 (VCAM-1; CD106) 
 
VCAM-1 is also involved in the adhesion of leukocytes to the endothelium, and binds the 
leukocyte integrin α4β1 (Cook-Mills, 2002), or very late antigen (VLA) 4 following the 
tethering and triggering of circulating immune cells and subsequent VLA-4 activation via 
GPCR and PLC activation resulting in intracellular Ca2+ flux (Cook-Mills, 2002; Weber and 
Springer, et al., 1998; Hyduk, et al., 2007), permitting the firm adhesion of VLA-4 to 
VCAM-1. VCAM-1 is not constitutively expressed, but appears on endothelial cells in 
response to TNF-α, IL-1β, and LPS (Chuluyan, et al., 1995; Osborn, et al., 1989; Carlos, et 
al., 1990; Swerlick, et al., 1991; Haraldsen, et al., 1996). 
 
Like ICAM-1, VCAM-1 plays many roles in TEM. Barreiro, et al. (2002) reported that a 
similar docking structure to the TC is formed by the ligation of VCAM-1 with VLA-4; 
VCAM-1 clustered around T lymphoblasts upon adhesion to, and spreading on, the EC. 
Carman and Springer (2004) also noted that both ICAM-1 and VCAM -1 were expressed in 
TCs that surrounded adherent leukocytes prior to transmigration, thus this may be a 
further contribution of VCAM-1 to TEM. Further, van Buul, et al. (2010) saw VCAM-1 
clustering with ICAM-1 following ICAM -1 engagement, augmenting adhesion. Thus 
VCAM-1 appears to contribute to adhesion; furthermore, VCAM-1 may assist leukocyte 
crawling. Weber and Springer (1998) stated VCAM-1-VLA4 interactions were required for 
adherent monocyte migration along the endothelium, while Ronald, et al. (2001) noted 
that VCAM-1 induced morphological alterations associated with leukocyte spreading such 
as pseudopodia and lamellipodia formation; when VCAM-1 was blocked, there was no 
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shape change, a 30% decrease in migration and a decreased migration distance. Thus, 
VCAM-1 mediates both adhesion and transit. 
 
Lastly, VCAM-1 ligation may open endothelial junctions. VCAM-1 ligation by VLA-4 
induced signalling pathways which stimulate NADPH oxidase, which enters cells and 
generates ROS which activate cell-surface MMPs, altering VEC shape. In addition, H2O2 
generated from superoxide may diffuse into the cell altering actin structure, inducing 
junction separation (Cook-Mills, 2002; Matheny, et al., 2000). This may result from VCAM-
1 cross-linking; van Wetering, et al. (2003) reported VCAM-1 crosslinking resulted in ROS 
generation with stress fibre formation and junction opening, dependent on Rac and p38 
MAPK signalling.  
 
1.7.4 Migration Through the Endothelium – The Final Step in TEM 
 
Following the tethering, activation, and adhesion of immune cells to the endothelium, 
and the migration to sites of transendothelial migration, the final step of this process is 
the movement of immune cells through the endothelial barrier to the site of injury. This 
in itself involves adhesion molecules, with perhaps the primary molecule being PECAM-1. 
 
1.7.4.1 PECAM-1 (CD31) 
 
PECAM-1 is constitutively expressed by ECs, at cell-cell junctions (Newman, 1994; 
Thompson, et al., 2001) where it mediates cell-cell adhesion (Albelda, et al., 1991), and by 
monocytes and neutrophils (Privratsky, et al., 2010; Newman and Newman, 2003), and 
though not upregulated by inflammatory mediators, PECAM-1 expression may be 
decreased (Stewart, et al., 1996) or the distribution altered (Romer, et al., 1995) by IFN-γ 
and TNF-α.  
PECAM -1 mediates paracellular leukocyte transmigration via homophilic intereactions 
between EC and leukocyte PECAM-1 (Liao, et al., 1995), and it has been widely reported 
that PECAM-1 blockade prevents TEM (Privratsky, et al., 2010; Ley, et al., 2007; Muller, et 
al., 1993; Lou, et al., 2007) while leukocytes that lack PECAM-1 are less capable of 
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diapedesis (Duncan, et al., 1999; Thompson, et al., 2001), though the extent of the role of 
these interactions depends on the stimulus inducing TEM (Thompson, et al., 2001; 
Wakelin, et al., 1996). 
PECAM-1 may be internalised and targeted to areas of the junction in which diapedesis is 
occuring (Mamdouh, et al., 2003), potentially dependent on interaction between 
leukocyte and EC PECAM-1. This may facilitate leukocyte TEM either by increasing 
junctional surface area, or providing a pool of PECAM-1, unencumbered by ligation to 
adjacent ECs (Mamdouh, et al., 2003). Further, the direct cycling of PECAM-1 to areas of 
transcellular migration may create a channel through which leukocytes migrate, while 
PECAM-1 blockade may prevent this (Mamdouh, et al., 2009). Moreover, ligation of EC 
PECAM-1 with monoclonal antibody  or soluble PECAM-1 induces a prolonged Ca2+  
transient (O’Brien, et al., 2001), which assists in EC-EC junction opening (Huang, et al., 
1993). Therefore, PECAM-1 may be heavily involved in the movement of leukocytes 
through the endothelium.   
Though the primary role of PECAM-1 in TEM appears to be in the movement of 
leukocytes through the endothelium, PECAM-1 binding to neutrophils may activate Mac-
1, allowing stronger binding in  a Mac-1-dependent manner (Berman and Muller, 1995), 
while homophilic interactions of neutrophil and EC PECAM-1 induced increased 
expression of the neutrophil integrin α6β1, involved in neutrophil migration at the basal 
lamina (Dangerfield, et al., 2002).  
Based on the wide range of known roles of these adhesion molecules in the diapedesis 
cascase, these are obvious choices to assess the expression of by BLM-treated HUVECs. 
However, the relevance of some of these molecules in the transendothelial cascase in the 
lung may be questioned due to the heterogeneity demonstrated by pulmonary VECs, and 
the mechanisms of immune cell recruitment to the lung. 
 
1.8 The role of  Lung Endothelium in BPF Development 
 
Endothelial cells demonstrate a degree of heterogeneity, dependent on their location 
within the body, and even  within a series of vessels. While the information above 
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pertains largely to the systemic circulation, many organs including the lungs are 
somewhat different. Not only must immune cells exiting the lung vasculature cross two 
barriers, the vessel and the alveolar epithellium (Aird, et al., 2007), but some lung vessels 
utilise very different immune cell recruitment mechanisms.  
The primary site of immune cell sequestration and migration in the lung is the pulmonary 
micro-vasculature (Doerschuk, 2001). However, these vessels express few endothelial 
adhesion molecules; the selectins are absent, although as transit through pulmonary 
microvessels is slow and requires immune cell deformation, the velocity-dependent 
adhesion achieved by selectins is precluded (Doerschuk, 2001). Only ICAM-1 appears to 
be induced in lung capillary VECs by inflammatory stimuli (Doerschuk, 2000; Aird, 2007; 
Segel, et al., 2011), and even then, this depends on the stimulus; for example, E. coli LPS 
increases ICAM-1 expression, but S. pneumonia infection does not (Doerschuk, 2000; 
Doerschuk, 2001). Therefore, immune cell recruitment through capillaries may be said to 
be either CD18 (therefore ICAM-1) dependent or independent, based on the stilumus.  
This suggests that the role of adhesion molecules in immune cell recruitment in the 
pulmonary capillaries may be minor, with only ICAM-1 involved. Of course, if 
pharmacologically-relevant concentrations of BLM induce ICAM-1 upregulation – as 
supra-pharmacological ones  do in pulmonary vessel VECs (Fichtner, et al., 2004), then 
this may contribute to the increased numbers of neutrophils and monocytes – the CD18-
harbouring immune cells – in the lung, though no other adhesion molecules would be 
considered to be involved, so perhaps do not need to be investigated?    
However, while the main site of leukocyte migration is the pulmonary capillary bed, 
immune cell migration may also occur through post-capillary venules (Gane and Stockley, 
2011; Wang, et al., 2011), which utilise the more typical adhesion cascade seen in the 
systemic circulation (Doerschuk, et al., 2001; Aird, 2007; Feuerhake, et al., 1998). VECs in 
these vessels express a range of adhesion molecules including ICAM-1, VCAM-1, and E-
selectin under inflammatory conditions (Doerschuk, et al., 2000). While little literature 
assesses which lung VECs express adhesion molecules in response to BLM, the two 
studies that have suggest increased adhesion molecule expression may occur in both lung 
venules and capillaries, offering multiple sites of immune cell recruitment.  
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Wang, et al. (2011)  reported neutrophil infiltration of the perivascular interstitium in 
BLM-treated rodents via venules; groups of sequestered neutrophils were noted along 
the luminal surface  and moved through the endothelium at sites of notable ICAM-
1/VCAM-1 expression. Sequestration, infiltration, and adhesion molecule expression at 
sites of trans-migration occurred concurrently, suggesting that ICAM-1 expression was 
related to the movement of leukocytes into the perivascular interstitium from the 
venules. Meanwhile, Sato, et al. (2000) reported both increased pulmonary  capillary and 
venule ICAM-1 expression in response to BLM treatment, resulting in increased leukocyte 
slow rolling in the venules and increased sustained entrapment in the capillaries, both of 
which could be blocked by anti-ICAM-1 antibodies. This concurrent ICAM-1 expression 
and leukocyte rolling and entrapment also mirrored the times at which perivascular and 
peribronchiolar  leukocyte infiltration were observed.   
Therefore, at least in rodents, BLM induces increased expression of ICAM-1 and VCAM-1 
in the lung  venules and  capillaries, resulting in immune cell sequestration and infiltration 
of the lung and surrounding areas. This may also occur in man, and the potential 
relevance of this is high – if , as in rodents and in vitro, BLM induces the increased 
expression of adhesion molecules in human pulmonary venule and capillary endothelial 
cells, and this has functional relevance, then this may contribute to the inflammation 
seen in BPF and we may be a step closer to elucidating the pathogenesis of human BPF.  
As a wider range of adhesion molecules are expressed by pulmonary venule VECs than 
capillary VECs, then molecules other than ICAM-1 also require investigation, to determine 
whether they may contribute to immune cell recruitment into the lung in human BPF as 
they do in rodents.  
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1.9 Aims of the Work 
 
Pulmonary fibrosis is a devastating condition which has often been modelled in rodents 
using the chemotherapy agent BLM , which is known to cause pulmonary fibrosis as a side 
effect when given to human patients as part of therapy regimens. While a considerable 
amount is known about BLM-induced fibrosis when induced in rodents using BLM 
delivered by intratracheal dosing routes - the primary injury appears to be alveolar 
epithelial cell death followed by intense inflammation and a period of cytokine release 
within the lung, leading to fibroblast proliferation, profibrotic cytokine release, and lung 
scarring - little is known about the processes involved in the development of the human 
equivalent of the disease, which is similar in that AEC death, subsequent inflammation, 
and fibrosis are noted, but has some differences from the rodent version of BPF.  
In patients who develop BPF, the drug is delivered intravenously. This method was 
originally used to model the disease in rodents, but was superseded by intratracheal 
delivery which was faster and cheaper, and delivered BLM directly to the lung. Of course, 
in doing this, researchers are ensuring the initial injury is to alveolar epithelial cells, which 
then leads to fibrosis. In humans with BPF, this is unlikely to be the initial injury; in 
rodents given BLM intravenously, the first injury is often seen to be to the endothelium of 
the vessels surrounding the lung, and this may also be the case in humans who develop 
BPF. 
The endothelium has many roles that may contribute to the development of lung fibrosis. 
Most notably, it is a rich source of both proinflammatory and profibrotic cytokines, and 
expresses adhesion molecules vital for immune cell recruitment. A handful of in vitro and 
in vivo studies in rodents have characterised cytokine and adhesion molecule expression 
patterns in endothelial cells, and even assessed the functional relevance of these 
molecules, though little such research has been conducted using human cells, and to our 
knowledge, there is no functional research in publication. The intimate positioning of 
pulmonary vasculature and alveoli suggests that such expression by endothelial cells 
could potentially contribute - either via inflammatory cell recruitment or cytokine release 
- to the development of this condition in human patients. 
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Therefore, based on previous research in man and mouse and the known functions of the 
endothelium in inflammation, it is hypothesised that the effect of BLM on human 
endothelial cells may contribute to the development of BPF via cytokine release and 
adhesion molecule expression which may lead to inflammation and fibrosis in and around 
the lung.  
In this work, the expression of a panel of adhesion molecules - some of which have known 
roles in the adhesion of immune cells to the endothelium, and others of which do not - 
will be assessed by flow cytometry on HUVECs  treated with concentrations of BLM which 
may feasible be encountered in the human body following dosing. To our knowledge, this 
is the first work to assess the panel of adhesion molecules chosen, and to use 
pharmacologically-relevant  concentrations of BLM. Whether the expression of the 
adhesion molecules seen to be upregulated is regulated at an mRNA level will be assessed 
by qPCR. Again, to our knowledge, this has not previously been attempted.  
Concurrently, the release levels of the pro-inflammatory cytokines IL-8 and MCP-1 will be 
assessed by ELISA in BLM-treated HUVECs, while the release of three profibrotic cytokines 
- TGF-β, PDGF-BB, and Endothelin-1 - by BLM-treated HUVECs will also be determined. To 
our knowledge, the expression of PDGF-BB and Endothelin-1 by BLM-treated HUVECs has 
not been previously assessed. This will also be confirmed by qPCR. 
As endothelial cells within different regions of the same vascular bed - and most definitely 
between different sites of origin - demonstrate substantial heterogeneity, the expression 
of the aforementioned panel of adhesion molecules by PMVECs - pulmonary 
microvascular endothelial cells, a mixture of cells from vessels surrounding the lung 
including venules, arterioles, and capillaries - will be assessed by flow cytometry. In 
addition, the release of IL-8, MCP-1, and Endothelin-1 by BLM-treated PMVECs will be 
assessed be ELISA. To our knowledge, this represents the first time that the expression of 
many of the adhesion molecules chosen to be in the panel, and Endothelin-1 release, 
have been assessed in PMVECs. These results will then be compared to those obtained 
from HUVECs to determine whether HUVECs may represent an adequate model for the 
behaviour of BLM-treated PMVECs in future experiments, and whether endothelial cell 
heterogeneity extends to the responses seen when cells are treated with BLM. 
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The functional relevance of any increased adhesion molecule expression will then be 
assessed using flow chamber systems, in which isolated human neutrophils from healthy 
donors adhere more or less strongly to BLM-treated endothelial cells when flowed over 
the monolayer. This will represent the first instance of a functional study investigating 
what relevance any increased endothelial cell adhesion molecule expression in response 
to BLM has to the development of the disease. Increased neutrophil adhesion may 
suggest that the response of endothelial cells to BLM is at least in part responsible for the 
inflammation that is seen to precede the development of fibrosis in man as well as in 
mouse models. To determine which, if any, adhesion molecules are responsible for any 
increased adhesion observed, blocking studies will be carried out to assess which 
molecule  is responsible for any increased neutrophil adhesion to the BLM-treated 
monolayer.  
Finally, to assess whether any observed increases in adhesion molecule and cytokine 
expression are of particular relevance to the development of BPF in man, the response of 
HUVECs to other chemotherapeutic agents which operate in a similar fashion to BLM, but 
are not associated with the development of pulmonary fibrosis, will be assessed by flow 
cytometry and ELISA.  
By attempting to generate a more complete picture of the response of endothelial cells to 
BLM – with a focus on adhesion molecule expression and cytokine release by various 
endothelial cells in response to BLM – and by assessing the functional relevance of such 
expression, it is hoped that a slightly better or broader understanding of the pathogenic 
process of human BPF, particularly with regards to the role of endothelial cells in the 
pathogenesis of the disease, will be obtained.  
Should this work allow the development of a greater understanding of the pathogenesis 
of BPF – or, indeed, contribute in any way to our current understanding - then perhaps 
this work will represent a stepping stone towards developing better therapies or 
preventative treatments, to supercede the “watch and wait” and decreased-dosing 
methods used to treat BPF when it occurs today.  
This work may also proffer some advice for other researchers on how to model such 
reactions to BLM – if endothelial cells do react to BLM, then perhaps utilising a dosing 
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method which avoids the endothelium is counter-productive, and should be retired or 
replaced in future works.  
In addition, by comparing the expression of adhesion molecules and the release of 
cytokines by multiple endothelial cell types, this work will draw conclusions regarding 
which cell types are suitable for use when modelling the reponse of pulmonary 
microvascular endothelial cells to drugs in vitro.  
In an attempt to begin to confirm any conclusions that are drawn regarding the 
involvement of endothelial cells and their reaction to BLM in the development of BPF, it 
will be determined whether the response of endothelial cells to BLM is unique, or 
whether it is a general response to the application of cytotoxic drugs. If the latter is the 
case, then perhaps the effect of BLM on endothelial cells is not necessarily the reason 
that fibrosis is such a common side-effect of BLM, and this may act as a “warning bell” to 
other researchers to proceed in this line of research with caution, and to not infer any 
adhesion molecule or cytokine upregulation as a sign that the action of BLM on the 
endothelium is a sign that such reactions induce the stark inflammation seen in BPF.  
Of course, negative results obtained from the functional assays carried out in this work 
would provide a similar caveat; if adhesion molecules are seen to be upregulated, but do 
not increase immune cell adhesion to the endothelium, then caution must be exercised in 
making any such inferences. If the former is the case, and not all chemotherapy agents 
induce adhesion molecule and cytokine expression, then  it is hoped that the results 
obtained in this work will act as a further gentle suggestion to encourage future 
researchers to re-adopt the intravenous method of BLM administration in rodents, 
despite the additional time and costs incurred; if a probable role for the endothelium in 
BPF can be inferred from this work, then perhaps a method of BLM delivery that 
essentially bypasses the endothelium altogether will no longer appear the logical choice 
when attempting to model fibrotic diseases such as BPF in rodents.        
85 
 
 
2 General Materials and Methods 
  
86 
 
2.1 Human Umbilical Vein Endothelial Cell Culture 
 
Three batches of human umbilical vein endothelial cells were purchased from from TCS 
Cellworks, Buckingham, United Kingdom and Promocell GmbH, Heidelberg, Germany. 
Cells were cultured to passage 3-5 in 75cm2 Corning flasks (Gibco) with 10ml media and 
incubated in an atmosphere containing 5% CO2 at 37°C.  The medium used was 
endothelial cell basal medium (Promocell GmbH) containing foetal calf serum (2%), 
endothelial cell growth supplement (0.4%), recombinant human epidermal growth factor 
(0.1ng/ml), recombinant human fibroblast growth factor (1ng/ml), hydrocortisone 
(1μg/ml) (Promocell GmbH) penicillin (100μg/ml)-streptomycin (100U/ml) (PAA, Pasching, 
Austria), and L-glutamine (2nM) (Lonza, Basel, Swtizerland)  Cells were not cultured 
beyond passage 5. 
 
2.2 Pulmonary Microvascular Endothelial Cell (PMVEC) Culture 
 
PMVECs were purchased from Promocell and stored in liquid nitrogen until use. When 
seeded, PMVECs were thawed at room temperature and seeded into 25cm2 flasks (Gibco) 
or 75cm2 flasks  at a concentration of 10,000 cells per cm2 in 10 ml endothelial cell media 
MV (Promocell) supplemented with fetal calf serum (5%), endothelial cell growth 
supplement (0.4%), recombinant human epidermal growth factor (10 ng/ml), heparin (90 
μg/ml) and hydrocortisone (1 μg/ml) supplements (Promocell); penicillin (100μg/ml )-
streptomycin (100U/ml) (PAA, Pasching, Austria); and L-glutamine (2nM) (Lonza, Basel, 
Swtizerland). Cells were then  incubated in an atmosphere containing 5% CO2 at 37°C until 
confluent. Cells were not cultured beyond passage 5. 
 
2.3 Cell Dissociation from Culture Flasks 
 
When confluent, the cells were washed with Dulbecco’s PBS (PAA) (5ml), aspirated, rinsed 
with TrypLE ™ Express (Gibco, Paisley, United Kingdom) (2ml), aspirated, and incubated 
with TrypLE™ Express (3ml). For HUVECs, the incubation lasted for 1 minute in an 
atmosphere containing 5% CO2 at 37°C. If cells remained adherent, a further 1 minute 
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incubation took place. This continued until the cells were no longer adherent, to a 
maximum time of 3 minutes. Endothelial cell medium (5ml) as described above was 
added to each flask to quench the activity of TrypLE ™ Express.  PMVECS required longer 
incubation time with TrypLETM to dissociate from the flask. Therefore, cells were allowed 
to incubate with TrypLETM for three minutes before being aspirated from the flask. 
Endothelial cell media MV (as described above) (5ml) was added to quench the activity of 
the TrypLE and cells were centrifuged as HUVECs.  
The cell-containing media was centrifuged at 205 x g for 5 minutes. The supernatant was 
discarded and the pellet re-suspended in either endothelial basal cell medium (1ml) or 
endothelial cell medium MV (1ml) and cell number was determined by haemocytometry 
(section 2.4). 
 
2.4 Cell Viability Determination and Cell Counting 
 
Cell suspension (10μl) was added to Trypan Blue (0.4% v/w) (10μl) (Sigma Aldrich) and 
applied to a Neubauer haemocytometer. Viable cells were visualised by microscopy. Cells 
staining blue were considered unviable as dead cells cannot extrude the Trypan Blue dye 
(Strober, et al., 2001). The number of viable cells was determined by counting cells in the 
1mm x 1mm x 0.1mm central square. To determine cells/ml, this number was multiplied 
by 1 x 104, and multiplied by 2 to account for dilution with Trypan Blue.  The suspension 
was diluted in endothelial basal cell medium or endothelial cell medium MV to the 
required concentration of viable cells for either cell passage or assays. 
 
2.5 Flow Cytometric Analysis of Surface Adhesion Molecule Expression 
 
Cell suspension (100μl) contaning a pre-defined number of cells was pipetted into each 
well of a 96-well multi-plate (Costar, Sigma Aldrich) inlaid with a round-bottomed cell 
insert (Costar, Sigma Aldrich) to prevent cells adhering to the flat bottom of the 96-well 
plate. The cells were centrifuged for three minutes at 250 x g in a plate centrifuge cooled 
to 4°C, and the PBS aspirated. To each well, PBS 0.1% w/v  BSA (50μl) was added, and the 
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cells centifuged again, to wash away any media. The cells were then incubated with a 
range of primary antibodies at a final concentration of 20µg/ml (40μl): 
 
 Purified mouse IgG1 negative control (Serotec, Oxford, United Kingdom) 
 Purified mouse anti-human CD31 (clone WM59) isotype IgG1 (κ) (Biolegend, San 
Diego, California, USA) 
 Purified mouse anti-human CD50 (clone MEM-17) isotype IgG1 (κ)  (Biolegend) 
 Purified mouse anti-human CD51/61 (clone 23C6) isotype IgG1 (κ)  (Biolegend) 
 Purified mouse anti-human CD54 (clone HA58) isotype IgG1 (κ)  (Biolegend) 
 Purified mouse anti-human CD62E (clone HAE-1f) isotype IgG1 (κ)  (Biolegend) 
 Purified mouse anti-human CD62P (clone AK4) isotype IgG1 (κ)  (Biolegend) 
 Purified mouse anti-human CD106 (clone STA) isotype IgG1 (κ)  (Biolegend) 
 Purified mouse anti-human CD162 (clone KPL-1) isotype IgG1 (κ)  (Biolegend) 
 Rabbit F(ab’)2 anti-mouse IgG:FITC (Serotec). 
The cells were incubated with the primary antibody for 30 minutes on ice, in darkness. 
Following incubation, cells were washed. 50μl PBS 0.1% w/v BSA was added to each well, 
and the cells were centrifuged for three minutes at 250 x g in a plate centrifuge (Thermo 
Scientific, Waltham, Massachusetts, USA) cooled to 4°C, and the PBS aspirated. To each 
well, 80μl PBS 0.1% BSA was added, and the cells centrifuged again, as above, for three 
minutes. To each well containing cells treated with primary antibody, anti-mouse FITC 
secondary antibody (polyclonal rabbit F(ab)’2 anti-mouse IgG:FITC, (Serotec)) at a 
concentration of 20µg/ml (40μl) was added. Cells were then incubated on ice for 20 
minutes in darkness.  
Following incubation, 50μl PBS 0.1% BSA was added to each well, and the cells were 
washed again, as outlined above. The cells were resuspended in 50 μl PBS 0.1% BSA, and 
25μl of this suspension was added to Leukogate tubes containing PBS 0.1% BSA (300μl). 
The cells were then analysed using the FACSCalibur (Beckton Dickinson and Company, 
New Jersey, USA) flow cytometer on the CellQuest programme. Ten thousand cell events 
were counted in this analysis unless otherwise indicated. During analysis, a gate (G2) was 
applied to the live cell population based on side and forward scatter characteristics, to 
ensure the expression of adhesion molecules only by live cells was counted.  
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The data were presented as average geometric mean without correcting using a gating 
method whereby expression is determined as a difference in fluorescence from the 
isotype control, as this may augment apparent expression by over-emphasising the 
contribution of events occuring within a “tail” (small number of events with very high or 
very low fluorescence) (personal communication, Dr S. Hart). This is demonstrated in Fig. 
2.1, where the application of a gate ignores the antigen expression of 56% of cells in the 
analysis, and provides an overestimation of the fluorescence intensity in this sample. 
Using the non-gating method, marker expression the same as that of the binding of the 
control antibody may be therefore regarded as no expression. The geometric mean of the 
control antibody (secondary antibody only) was included on all graphs unless otherwise 
stated, to highlight the lack of expression of markers in particular experiment sets. The 
reason for using the secondary antibody alone as the negative control is discussed in 
Section 4.3.2. In brief, this is related to the impact of treatment with BLM, TNF-α, and 
other mediators on the binding of the negative control antibody to endothelial cells, 
while the binding of the secondary antibody only to endothelial cells was not impaced by 
the treatment of cells with chemotherapuetic agents or inflammatory mediators. This is 
demonstrated in a tabular format in Table A.1. 
The geometric mean was obtained from readouts generated by CellQuest. The geometric 
mean represents the central tendency of a series of values by determining the mean from 
the product, rather than the sum, and is better suited to calculating means when 
determined on a logarithmic scale, as outliers do not skew the mean so dramatically. The 
geometric mean of each sample was recorded and plotted onto bar graphs. This includes  
samples treated with the target antibody (“test” samples) and seconday antibody only 
(“control”) samples. To denote “no expression” or expression due to non-specific binding 
alone, the seconday antibody only-treated “control” geometric mean results were plotted 
alongside the target antibody-treated “test” sample geometric mean results on all graphs, 
unless otherwise stated. Fluorescence above the “no expression” level (the geometric 
mean of  secondary antibody-treated “control” samples) was regarded as “positive 
expression”, or specific binding to the target antigen suggestive of the expression of the 
target antigen or protein. Statistical analysis on all generated bar charts was carried out 
using the Mann-Whitney-U test in SPSS v. 19 statistical analysis software.  
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In Figures 2.1, 3.5, 4.3, 4.5, 5.1, and 5.2, raw data is shown with gating applied. This was 
generated by applying a gate to the control (secondary antibody) peak and incorporating 
as close to 1% of the events in this read-out within the gate, as is standard practice. Note 
that this method was NOT used for determining expression (expression was determined 
using uncorrected data and plotted on graphs as outlined above). Gates are only applied 
to these images to show the peak-shift and increase in positive cells when cells were 
treated as stated in the figures.  
Figure 2.1: Representative raw data from flow cytometry experiments 
 
  
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 5000 100.00 100.00 6.79 4.21 200.19 3.92 1
File: Data.003 Log Data Units: Linear Values
Sample ID: UT 2ndry  Ab Patient ID: 
Tube: Panel: 
Acquisition Date: 12-Feb-14 Gate: No Gate
Gated Ev ents: 5000 Total Ev ents: 5000
X Parameter: FL1-H (Log)
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 3409 100.00 68.18 4.90 3.95 92.22 3.79 3
M1    19,  9910 51 1.50 1.02 30.59 28.70 42.98 27.63 19
File: Data.003 Log Data Units: Linear Values
Sample ID: UT 2ndry  Ab Patient ID: 
Tube: Panel: 
Acquisition Date: 12-Feb-14 Gate: G2
Gated Ev ents: 3409 Total Ev ents: 5000
X Parameter: FL1-H (Log)
R2
M1
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 5000 100.00 100.00 43.03 15.75 297.61 14.86 1
File: Data.006 Log Data Units: Linear Values
Sample ID: UT CD54 Patient ID: 
Tube: Panel: 
Acquisition Date: 12-Feb-14 Gate: No Gate
Gated Ev ents: 5000 Total Ev ents: 5000
X Parameter: FL1-H (Log)
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 3355 100.00 67.10 39.54 19.66 251.16 16.85 11
M1    19,  9910 1484 44.23 29.68 75.94 48.02 185.81 39.24 24
File: Data.006 Log Data Units: Linear Values
Sample ID: UT CD54 Patient ID: 
Tube: Panel: 
Acquisition Date: 12-Feb-14 Gate: G2
Gated Ev ents: 3355 Total Ev ents: 5000
X Parameter: FL1-H (Log)
R2
M1
Repr sentative raw data from flow cytometry experiments to determine surface marker 
expression on PMVECs. Using the control (secondary antibody only) sample (A), gate M1 was 
drawn. This gate was drawn to incorporate as close to 1% of the control peak as possible. M1 was 
then applied to other geometric mean read-outs, to demonstrate the peak-shift only and show 
that cells were positive for the antigen tested. While there is a definite peak shift when ICAM-1 
expression was assessed in untreated cells (B), 44% of cells fall within gate M1. Assessing the 
geometric mean of the cells in gate M1 in B, the average geometric mean in 48.02, compared to 
19.66 when all cells are taken into account. However, this does not take into account the 56% of 
cells which are outside of gate M1, thus bi ses the calculated geometric mean by giving more 
weight to the fluorescence values recorded for events which fall within the “tail” of B, generating 
unrepresentatively high results values.   
A 
B 
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2.6 BLM Treatment of Endothelial Cells  
 
Cells were cultured as outlined in 2.1 and 2.2. When confluent, cells were incubated in 
serum-contaning culture medium containing BLM sulphate, purchased from Carbosynth 
(Carbosynth, Compton, United Kingdom) (at concentrations of 0.1µg/ml, 1µg/ml, and 
10µg/ml) for 6 and/or 24 hours and incubated as outlined in 2.1. The volume of BLM-
containing medium used was dependent on the experimental protocol being undertaken. 
BLM was weighed and dissolved in endothelial cell culture medium (endothelial cell basal 
media or endothelial cell media MV) to a concentration of 1mg/ml. This was vortexed to 
ensure dissolution and stored for up to 24 hours in a refrigerator. Dilution of this stock 
concentration was carried out to ensure correct final concentrations. 
 
2.7  Supernatant Collection for Cytokine ELISAs 
 
Cells were cultured to confluence as outlined in 2.1 and 2.2. Cells were split and re-
seeded at a concentration of 2 x 106 cells per T75 flask in 10ml serum-containing media 
(endothelial cells basal or endothelial cell media MV) dependent on cell type for at least 
24 hours to ensure adhesion to the flask. When adherent, cells were treated as 
appropriate for each experiment. The required drugs were dissolved in serum contaning 
media (3ml), used to ensure high levels of cell viability. Cells were then incubated as 
described in 2.1 for the appropriate amount of time 
Negative control cells were incubated in serum-containing media (3ml) for 6 and 24 hours 
to show baseline cytokine expression. 3ml of media was used as this was sufficient to 
cover the base of the flask and ensure cell viability over time, while also producing 
suitable concentrated supernatants.  
Positive control supernatants were generated as required for each experiment. Cells were 
incubated with medium containing TNF-α (10ng/ml) for 6 and 24 hours to act as a positive 
control for IL-8 and MCP-1 expression (Hu, et al., 2009; Choe, et al., 2009; Hashimoto, et 
al., 2001; Yang, et al., 2004; Ahmed, et al., 2009; Murao, et al., 1999; Park, et al., 2004); 
human plasma thrombin (henceforth referred to simply as thrombin) (Calbiochem, 
MerckMillipore, Feltham, UK) (4U/ml) for 6 and 24 hours to act as a positive control for 
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endothelin-1 expression (Bilsel, et al., 2000; Marsen, et al., 1995); and thrombin (3U/ml) 
for 6 and 24 hours to act as a positive control for PDGF-B expression (Bowen-Pope, et al., 
1989; Harlan, et al., 1986; Starksen, et al., 1987; Kavanaugh, et al., 1988). No reliable 
positive control treatment condition could be found for TGF-β.    
Following incubation, the media was aspirated and centrifuged at 205 x g for 5 minutes. 
The supernatant was then aliquoted into 0.5ml eppendorf tubes and stored until required 
in a -80⁰C freezer. Supernatants were not subjected to repeated freeze-thaw cycles to 
ensure no loss of protein. 
 
2.8 ELISAs for Proinflammatory and Profibrotic Cytokine Expression 
 
ELISA kits for a range of cytokines were purchased. ELISA kits for interleukin-8 (IL-8), 
monocyte chemoattractant protein-1 (MCP-1), and latent transforming growth factor β 
(TGF-β) were purchased from Biolegend. An ELISA kit for platelet-dervied growth factor 
dimer BB (PDGF-BB) was purchased from Sigma Aldrich. An ELISA kit for endothelin-1 (ET-
1) was purchased from R&D Systems (Abingdon, UK).  All ELISA were conducted in 
accordance with the instructions provided.  
Prior to running the ELISA, supernatants were removed from the freezer and thawed at 
room temperature. Initial ELISA experiments sought to determine the ideal 
concentrations of supernatant to use with the ELISA kits, and a range of dilutions were 
tested. All test plates were run with the standards present in duplicate. Ideal 
concentrations of supernatant (those detectable by the plate reader which did not result 
in optical density readings too high or low to be detected by the plate reader) were 
determined for all sets of supernatants. Plates were read using a plate-reader (Thermo 
Multiskan FC, Thermo Scientific) at the wavelengths instructed by the manufacturers. Due 
to the low number of replicates and that the data were not expected to be normally 
distributed, data were analysed using Mann-Whitney-U tests in SPSS v. 19 statistical 
analysis software.    
A standard curve for each ELISA conducted was carried out using the absorbance readings 
obtained from the plate-reader and the Graphpad data analysis software (GraphPad 
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Prism v. 5.04). Standard curves were used to determine the realibility of the standards 
and to ensure the reliability of the concentrations of protein per well as determined by 
the plate reading software. Standard curves can be found in the appendix (section A.2). 
  
2.9 RNA Extraction, Reverse Transcription, and cDNA Synthesis 
 
Cells were cultured as outlined in 2.1 and treated with BLM (as outlined in 2.7) or positive 
control cytokines. In these experiments, cells were either treated with BLM (at 
concentrations of 0.1µg/ml, 1µg/ml, and 10µg/ml) for 6 and 24 hours, TNF-α (10ng/ml) 
for 6 and 24 hours to act as a positive control for ICAM-1, VCAM-1, and E-selectin, or as 
outlined in 2.8 to act as a positive control for IL-8, MCP-1, Endothelin-1, and PDGF-BB. No 
reliable positive control for TGF-β was found.   
Cells were dissociated from culture flasks as outlined in 2.3. Cells were washed in ice-cold 
PBS (5ml) and centrifuged at 205 x g for 5 minutes. RNA extraction was conducted in line 
with the instructions of the ReliaPrep™ RNA Cell Miniprep System (Promega, Madison, 
Wisconsin, United States of America). Extracted RNA was stored at -80⁰C until such time 
that RNA could trascribed to cDNA for use with quantitative PCR.  Samples were thawed 
at room temperature and the RNA content of the sample quanitifed using the Qubit 
quantification kit, as per manufacturer’s instructions. The total RNA in each sample was 
determined. 
The amount of sample containing 1μg total RNA was determined. This was transferred to 
a sterile, RNAse-free tube. To this, Oligo(DT) (1 μl) (Thermo Scientific) and  10mM dNTP 
mix (1μl) (Thermo Scientific) was added. The solution was made up to 14.5μl using 
diethylpyrocarbonate (DEPC)-treated water (produced in-house). To this, 5X RT buffer 
(4μl) (Thermo Scientific), Ribolock RNAse inhibitor (0.5μl) (Thermo Scientific) and 
Revertaid Premium Reverse Transcriptase (1μl) (Thermo Scientific) was added, to a total 
volume of 20μl, giving a total RNA content of the sample of 1μg RNA per 20μl (50ng/μl). 
The sample was mixed gently and vortexed. 
In addition, No RT samples were generated. These samples contain no reverse 
transcriptase and therefore the conversion of RNA to cDNA is prevented. The amount of 
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sample containing 1μg total RNA was determined. This was transferred to a sterile, 
RNAse-free tube. To this, Oligo(DT) (1 μl) (Thermo Scientific, Waltham, Massachusetts, 
USA ) and  10mM dNTP mix (1μl) (Thermo Scientific) was added. The solution was made 
up to 15.5μl using DEPC-treated water (produced in-house). To this, 5X RT buffer (4μl) 
(Thermo Scientific) and Ribolock RNAse inhibitor (0.5μl) (Thermo Scientific) was added, to 
a total volume of 20μl, giving a total RNA content of the sample of 1μg RNA per 20μl. 
The samples were then subject to reverse transcription. The Techne TC-3000 thermal 
cylinder (Bibby Scientific, Stone, Staffordshire, UK) was used. The reverse transcription 
was carried out according to manufacturer’s instructions; in brief, as an oligo(dT) primer 
was used, the sample was incubated at 50⁰C for 30 minutes, and the reaction was 
terminated by heating the samples to 85⁰C for 5 minutes. The samples were stored at -
80⁰C, until used. 
 
2.10 Primer design and acquisition for qPCR and optimisation 
 
All primers used in both optimisation and qPCR experiments were designed by 
PrimerDesign Ltd (Southampton, United Kingdom). All Mastermix used in qPCR 
experiments and optimisation was also provided by PrimerDesign. Primers for human 
ICAM-1 (CD54), E-selectin (CD62E), VCAM-1 (CD106), TGF-β, PDGF-BB, Endothelin-1, MCP-
1 (CCL2), and IL-8 were obtained and all followed the sequences and product lengths 
shown below. . In addition, primers for reference genes were generously gifted to the 
group by PrimerDesign. Only the details (accession number, product size)  for UBC 
(ubiquitin C), the reference gene used for this work, is shown below. Accesion numbers  
for the other reference genes used are shown in Table 3.2. 
 
2.11 Generation of Graphs 
 
All graphs were generated using the GraphPad Prism software (V 5.04) unless otherwise 
explicity stated.  
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Table 2.1: Primers used in optimisation and qPCR experiments and their sequences 
Primer Sense/Antisense Primer Product Length 
ICAM-1 (Homo sapiens intercellular 
adhesion molecule, CD54) 
Sense:  
CCTATGGCAACGACTCCTTC 
Antisense: 
TCTCCTGGCTCTGGTTCC 
 
111bp 
VCAM1_24444 (Homo sapiens vascular 
cell adhesion molecule VCAM1, transcript 
variant 1) 
Sense: 
TGTGAATCCCCATCTTTCTCCT 
Antisense: 
CTCAGGGTCAGCGTGGAAT 
 
 
95bp 
IL-8 (Homo sapiens interleukin 8). Sense: 
CAGAGACAGCAGAGCACAC 
Antisense: 
AGCTTGGAAGTCATGTTTACAC 
 
95bp 
MCP-1 (Homo sapiens chemokine (C-C 
motif) ligand 2 (CCL2)). 
Sense: 
ACCGAGAGGCTGAGACTAAC 
Antisense: 
AATGAAGGTGGCTGCTATGAG 
 
122bp 
E-selectin (Homo sapiens selectin E 
(endothelial adhesion molecule 1 (SELE)). 
Sense: 
TTCTTGCCTACTATGCCAGATG 
Antisense: 
AGGAAAGGGAACACTGAGTCT 
 
123bp 
PDGF-BB (Homo sapiens platelet-derived 
growth factor beta polypeptide (simian 
sarcoma viral (v-sis) oncogene homolog) 
(PDGFB), transcript variant 1) 
Sense: 
AGCACACGCATGACAAGAC 
Antisense: 
GGGGCAATACAGCAAATACCA 
 
108bp 
ET-1 (Homo sapiens endothelin 1 (EDN1), 
mRNA.) 
Sense: 
TGAGAATAGATGCCAATGTGCTA 
Antisense: 
GAACAGTCTTTTCCTTTCTTATGATT 
 
132bp 
TGF-β1 (Homo sapiens transfroming 
growth factor, beta 1 (Camurati-
Engelmann disease (TGFB1) mRNA) 
Sense: 
CACTCCCACTCCCTCTCTC 
Antisense: 
GTCCCCTGTGCCTTGATG 
 
83bp 
UBC (Homo sapiens ubiquitin C) Not available: 
Accession number: NM_021009 
Anchor nucleotide: 452 
 
192bp 
   
  
A list of the primers used in both qPCR optimisation and final qPCR experiments, and their 
respective sequences as provided by PrimerDesign. 
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2.12  Statistical Analysis 
 
Statistical analyses were carried out using SPSS statistical software (version 19) unless 
otherwise stated. The test used was the Mann-Whitney-U test, unless otherwise stated. 
This non-parametric test was used due to the low number of repeats conducted in 
experiments, meaning Gaussian distribution could not be guaranteed, but data was 
presented using a parametric format (bar charts).  
In all cases, error bars on graphs are representative of the standard error of the mean 
(SEM) calculated and overlaid on the charts using GraphPad software (GraphPad Prism 
version 5.04). Statistical significance (p=≤0.05) was determined using the results obtained 
from statistical analysis using SPSS unless otherwise stated.  
In all cases, where statistical significance (p=≤0.05) is denoted by an asterisk on bar 
charts, this refers to a statistically significant difference in the observed value in the test 
sample compared to the observed value of baseline (untreated) sample in each 
experiment, unless otherwise stated. For example, an asterisk above a bar denoting a 
sample treated with 10µg/ml BLM demonstrates a statistically significant difference in the 
expression of the protein assessed, compared to the expression of this protein in the 
baseline (untreated) sample.    
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3 Optimisation of Methods for Flow 
Cytometry and qPCR  
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3.1 Introduction 
 
Prior to the assessment of adhesion molecule expression and cytokine release by BLM-
treated HUVECs, optimisation is required. Firstly, suitable concentrations of BLM to be 
used throughout this work required determination. Such concentrations would be 
pharmacologically-relevant  (as outlined in table 1.1), and fall within and around the 
range of around 10ng/ml to 6.6µg/ml as observed in renally competent patients 
immediately after, and 24 hours after dosing, respectively (Broughton, et al., 1977; 
Alberts, et al., 1978) - though, as renally impaired patients experience impaired BLM 
clearance, higher concentrations will also be assessed. Ideal concentrations would also 
not cause high levels of endothelial cell death, as this is not reported in BPF (Adamson 
and Bowden, 1974; Jones, et al., 1978; Bedrossian, et al., 1973; Adamson, 1984). 
As BLM does not efficiently enter cells (Pron, et al., 2003) incubation time may impact 
cytotoxicity. While the terminal half-life of BLM is 2-6 hours in healthy patients (Alberts, 
et al., 1978), in renally impaired patients, this may be up to 33 hours (Broughton, et al., 
1977), so some patients may be exposed to cytotoxic concentrations of BLM for extended 
periods. Therefore, to assess how viability is impacted by incubation time would also be 
of value. Assessment of cell viability can be conducted in a variety of ways, though here, 
the sulphorhodamine B (SRB) and MTS assays have been selected, as both are widely 
used and well-validated assays for determining cell viability and proliferation. 
The MTS assay determines the number of living cells by measuring formazan, produced 
by enzymatic degradation of MTS by dehydrogenases in metabolically active cells. The 
amount of formazan, measured by the absorbance of the sample at 490 nm, is 
proportional to the number of living cells. This assay assumes dead cells cannot reduce 
the MTS tetrazolium component (Rinne, et al., 2004) and so the colour and absorbance 
change reported reflect the number of live cells. Described by Skehan, et al (1990), the 
SRB assay determines cell number by binding to basic amino acid residues in 
trichloroacetic acid-fixed cells, providing a cellular protein content value relative to the 
cell number. The optical density of the SRB stain read at between 490nm and 564nm is an 
accurate representation of the total amount of protein in the sample, and a total cell 
count can be inferred, though this method cannot distinguish between living and dead 
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cells, and relies on dead cells being removed by washing. The results may therefore offer 
a conservative estimate of the number of viable cells present (Rinne, et al., 2004). 
In this thesis, flow cytometry will be used to assess adhesion molecule expression, and so 
optimisation is required to determine the correct population of cells upon which to gate. 
For this, a propidium iodide assay will be carried out to ensure that only the live 
population of cells is gated. Furthermore, as adhesion molecule expression is to be 
determined, several methods of cell dissociation were trialled, to ensure adhesion 
molecules were not cleaved during dissociation. Dissociation using 0.05% w/v Trypsin 
0.02% w/v EDTA is the standard method (Mutin, et al., 1996), though in this laboratory, 
cells are dissociated using TrypLE ™ Express, a synthetic protease-like reagent, which may 
cleave adhesion molecules, resulting in inaccurate molecule quantification.  
Finally, optimisation of the positive control will be carried out; a single adhesion molecule 
upregulated by a particular treatment, e.g., ICAM-1, would be ideal, though there appears 
to be no consensus as to which mediators induce the highest expression of endothelial 
adhesion molecules. Three that are often used are TNF-α, IFN-γ, and lipopolysaccharide 
(LPS). TNF-α induces ICAM-1, VCAM-1, and E-Selectin expression (Zhang and Issekutz, et 
al., 2001; Asimakopolous, et al., 2001; Haraldsen, et al., 1996), while IFN-γ increases the 
expression of ICAM-1, E-Selectin, VCAM-1, and PECAM-1 (Lou, et al., 1997;Weber, et al., 
1995; Zhang and Issekutz, 2001; Konstantopoulos, et al., 1997; Romer, et al., 1995) and 
LPS , the upregulation of E-Selectin, ICAM-1, and VCAM-1 (Yan, et al., 2002; Schumann, et 
al., 1996; Biffl, et al., 1996; Haraldsen, et al., 1996; Carlos, et al., 1991). However, there 
are no publications directly comparing the efficacy of these mediators save that of 
Haraldsen, et al. (2006), which used only a limited panel of adhesion molecules. As a 
broad range of concentrations of all of the aforementioned mediators has been used, the 
ideal mediator and mediator concentration to use as a positive control will be assessed.  
Furthermore, optimisation is required to allow the development of the qPCR component 
of this work in line with the MIQE guidelines (Bustin, et al., 2009). The selection of an 
appropriate reference gene is an important component of qPCR. Though GAPDH is often 
used as a reference gene for PCR experiments, the stability of this gene as a reference 
gene in qPCR may be questionable (Kozera and Rapacz, 2013). Moreover, it is required 
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that genomic DNA (gDNA) has not contaminated any samples prepared for experiments, 
as this may provide erroneous results as incorrect (gDNA) transcripts, rather than (or as 
well as) the target mRNA transcripts are amplified in the qPCR reaction. The use of No RT 
samples in qPCR experiments (samples which contain no cDNA as reverse transcriptase is 
omitted when conducting reverse transcription) is the primary method of determining the 
presence of gDNA contamination (Laurell, et al., 2012), as the presence of DNA in No RT 
samples is suggestive of gDNA contamination which may also affect the other samples 
being used. No RT samples will therefore be used in all qPCR experiments. Agarose gels 
will also be used to ensure that gDNA contamination has not occurred, while ensuring 
that the primer is specific for the target transcripts.  
Finally, primer efficiency will be determined. Efficiencies between 90-110% will be 
regarded as comparable and the standard ΔΔCq or Livak method will be used to analyse 
results. In instance where this is not the case, the Pfaffl method will be used to normalise 
the results (Pfaffl, 2001).  
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3.2 Materials and Methods 
 
3.2.1 MTS and SRB Concentration-Effect/Time-Effect Assay 
 
Cells were cultured as outlined in 2.1, dissociated as outlined in 2.3, and counted as 
outlined in 2.4. Into each well of a 48-well plate, cells were seeded at a density of 10,000 
cells per well in 500μl media (20,000 cells/ml). The cells were incubated for 24 hours in 
serum-containing media. Twenty-four hours prior to treatment with BLM, the medium 
was aspirated and replaced with serum-free endothelial basal cell medium containing 
endothelial cell growth supplement (0.4%), recombinant human epidermal growth factor 
(0.1ng/ml), recombinant human fibroblast growth factor (1ng/ml), hydro-cortisone 
(1μg/ml) (Promocell GmbH) and penicillin (100μg/ml)-streptomycin (100U/ml) (PAA). This 
was aspirated immediately prior to BLM treatment. BLM sulphate (Carbosynth, Compton, 
United Kingdom) was prepared to a concentration of 2mg/ml in serum-free media as 
described above. A range of dilutions (0.01, 0.05, 0.1, 0.25, 0.5, 1, 5, 10, 100μg/ml) was 
prepared using serial dilution.  Serum-free medium was use to retard further cell growth. 
Each concentration of BLM sulphate (500μl) was added to six wells of HUVECs at the 
appropriate time-points and was not replaced for the duration of the time-course. The 
plates were incubated for 6, 12, 24, 48, and 72 hours. The positive control was incubated 
in serum-containing media for 24 hours; serum-free media, for 24 hours; and 10mM 
hydrogen peroxide (Fisher Scientific, Loughborough, United Kingdom) in serum-free 
media, added at the same time points as BLM. The negative control was incubated in 
serum containing media for 24 hours, serum-free for 24 hours; and fresh serum-free 
media (500μl) for as long as treated cells.   
The results of each triplicate were expressed as a percentage viability of the negative 
controls to allow the comparison of BLM cytotoxicity over each time point and at each 
concentration while acknowledging cell death due to time spent in unchanged media. 
Each assay was run in triplicate, with each positive and negative control also run in 
triplicate. This was carried out for the MTS assay and the SRB assay. Following incubation 
with the required concentrations of BLM for the required times, the media containing 
BLM in each well was aspirated and replaced with serum-free endothelial cell basal media 
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(500μl). Cells were then prepared for assay by both MTS and SRB assay, to assess the 
toxicity of BLM. 
 
3.2.1.1 MTS Assay for Cell Viability 
 
The CellTiter 96 AQueous non-radioactive cell proliferation assay (Promega, Madison, 
Wisconsin, United States of America) was used to determine the number of viable cells in 
each well post-BLM. 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium was combined with phenazine methosulphate as directed, 
and a volume as stated in the kit (100μl) was added to the fresh medium in the cell-
containing vessel, as outlined in the CellTiter 96 AQueous protocol. The plate was incubated 
for two hours in an atmosphere containing 5% CO2. MTS-media solution (100µl) was 
pipetted into wells of a 96 well multiplate. The absorbance at 492nm was read using the 
Thermo Multiskan FC plate reader. Data were analysed using Mann-Whitney-U tests in 
SPSS v. 19 statistical analysis software. 
    
3.2.1.2 SRB Assay for Cell Viability 
 
The SRB assay, as described by Skehan, et al. (1990), was also used to measure cell 
cytotoxicity. The SRB plates were read at at 492nm. Culture medium was removed from 
the cells, the cells were rinsed with PBS 0.1% w/v BSA (500µl) to remove dead cells and 
debris, and media (500μl) was added to each well. To this, trichloroacetic acid (Sigma 
Aldrich) (250μl) was added, and cells were incubated on ice for an hour to fix. Following 
fixation, the supernatant was aspirated and the wells washed four times with deionised 
water. Sulphorhodamine B solution (acetic acid (Sigma Aldrich) 0.4% w/v 
sulphophodamine B (Sigma Aldrich)) (50µl)  was added to the wells. This was left to 
incubate for thirty minutes. The stain was aspirated and the wells washed four times with 
1% v/v acetic acid and left to dry for 24 hours. Stained cells were then dissolved in 10mM 
TRIS  base (Sigma Aldrich), pH10 (607.5mg TRIS base in 500ml distilled water) (100μl). 
Stained TRIS base was transferred into wells of a 96-well multi-plate and read at 492nm 
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on the plate reader. Data were analysed using Mann-Whitney-U tests in SPSS v. 19 
statistical analysis software 
 
3.2.2 Cell Dissociation Assessment 
 
Cells were cultured to confluence as outlined in 2.1. When confluent, HUVECs were 
treated with TNF-α (10μl, to give a final concentration of 10ng/ml) (Sigma Aldrich). The 
cells were left to incubate for 24 hours. Following treatment and incubation, the cells 
were washed with Dulbecco’s PBS (PAA)  (5ml).  One flask of cells not treated with TNF-α 
was prepared and dissociated using TrypLE ™ Express. This provided a baseline expression 
of adhesion molecules, by which to compare the expression of TNF-α treated cells 
dissociated by each method. These methods included dissociation as outlined in 2.2, but 
also dissociation by 1mM EDTA in PBS,  0.05% trypsin 0.02% EDTA, chilling in PBS for 30 
minutes, and scraping. When dissociated, cells were counted as described in 2.4, diluted 
to a concentration of 1x106/ml in serum-containing endothelial cell basal medium, and 
subjected to flow cytometric analysis as outlined in 2.5 using the same range of 
antibodies.  
 
3.2.2.1 Dissociation by 1mM EDTA in PBS 
 
Cells were rinsed with 1mM EDTA in PBS (2ml) (produced in-house), aspirated, and were 
then incubated with 1mM EDTA in PBS (3ml) in an atmosphere containing 5% CO2 at 37°C. 
This often required prolonged incubation of between five and 30 minutes, depending on 
the passage number of the cells. Earlier passage cells required longer incubation times. 
Cells were incubtaed with EDTA for a maximum of 60 minutes. Endothelial cell medium 
(5ml) as described above was added to each flask to quench the activity of EDTA. The cell-
containing media was centrifuged at 205 x g for 5 minutes. The pellet was resuspended in 
endothelial basal cell medium (1ml) and cell number was determined by haemocytometry 
as outlined in 2.4. 
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3.2.2.2 Dissociation by 0.05% Trypsin 0.02% EDTA 
 
Cells were rinsed with 0.05% w/v Trypsin 0.02% w/v EDTA (Sigma-Aldrich) (2ml), 
aspirated, and incubated with 0.05% w/v Trypsin 0.02% w/v EDTA (3ml) for 1 minute in an 
atmosphere containing 5% CO2 at 37°C; If the cells remained adherent, a further 1 minute 
incubation took place. This continued until the HUVECs were no longer adherent, for a 
maximum time of three minutes. Endothelial cell medium (5ml) as described above was 
added to each flask to quench the activity of 0.05% Trypsin 0.02% EDTA. The cell-
containing media was centrifuged at 205 x g for 5 minutes. The pellet was resuspended in 
endothelial basal cell medium (1ml) and cell number was determined by haemocytometry 
as outlined in 2.4. 
 
3.2.2.3 Dissociation by Chilling in PBS 
 
PBS (PAA) at a temperature of 4°C was added to the flask, and the cells were incubated 
with the PBS in the refrigerator at a temperature of 4°C. The cells were checked every ten 
minutes to determine the number of cells dissociated. Cells were incubated in the 
refrigerator until all cells were dissociated. This incubation occurred for a maximum time 
of 60 minutes. The cell-containing PBS 0.1% BSA was centrifuged at 205 x g for 5 minutes. 
The pellet was resuspended in endothelial basal cell medium (1ml) and cell number was 
determined by haemocytometry as outlined in 2.4. 
 
3.2.2.4 Dissociation by Scraping 
 
Confluent cells were dissociated using a cell scraper, ensuring that all cells were 
dissociated from the bottom of the flask. The cell-containing media was centrifuged at 
205 x g for 5 minutes. The pellet was resuspended in endothelial basal cell medium (1ml) 
and cell number was determined by haemocytometry as outlined in 2.4. 
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3.2.3 Propidium Iodide Assay 
 
The propidium (PI) iodide assay was used to determine the live cell population in flow 
cytometric dot-plots. Apoptotic cells, or those with membrane damage, are unable to 
exclude PI, while live cells may exclude the dye, due to its membrane impermeability. 
Within the cell, PI binds to DNA, and when analysed by flow cytometry, cells containing 
DNA-bound PI are shown to have a greater mean fluorescence when measured by FL2 (or 
FL3) than live counterparts (Davies and Hughes, 2000; Frey, 1995). In this experiment, FL2 
has been used. This allows the determination of populations of living and dead cells.   
1ml of cell suspension was transferred into a 5ml leukogate polyurethane FACS tube. To 
this, 10 µl of propidium iodide (Sigma Aldrich) solution in PBS was added (at a 
concentration of 500µg/ml, to permit a concentration of 5µg/ml PI in each sample). Tubes 
were incubated on ice for five minutes before being run on a FACSCalibur flow cytometer. 
One stained and one unstained tube of cells was analysed for each of the three different 
HUVEC cell lines assessed. The viability of the cells in the gated area was determined by 
the average geometric mean fluorescence of cells within this gated area, and the fact that 
cells staining positive for PI were not present within this gate. By gating around 
populations of cells that showed no staining, gating around a live population of cells could 
be ensured. 
 
3.2.4 Determination of an Ideal Positive Control; Adhesion Molecule and 
Inflammatory Mediator 
 
Cells were cultured as outlined in 2.1. Upon reaching confluence, cells were treated with 
LPS, TNF-α, IFN-γ, or left untreated as a control, at final concentrations of 1 ng/ml, 3 
ng/ml, 10 ng/ml, and 30 ng/ml TNF-α (Promokine GmbH, Heidelberg, Germany) 100 U/ml, 
300 U/ml, 1000 U/ml, and 3000 U/ml IFN-γ (Biolegend), and 100 ng/ml, 300 ng/ml, 1 
µg/ml, and 3 µg/ml LPS (Sigma Aldrich). The required amount of each was added to a 
flask of HUVECs containing 10ml  serum-containing media. In addition, all experiments 
were run with a negative control. The cells were then incubated for the required amount 
of time in  an atmosphere containing 5% CO2 at 37°C before being dissociated as outlined 
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in 2.3, counted as described in 2.4, resuspended to a concentrations of 1 x 106 cells/ml, 
and prepared for flow cytometric analysis of adhesion molecule expression as outlined in 
2.5, using the same panel of antibodies. 
 
3.2.5 Agarose Gel Electrophoresis to Determine RNA Quality and Viability  
 
To ensure the purity of the cDNA samples generated in 2.9, and to ensure the RT process 
occured correctly, an agarose gel was run. Prior to the running of the gel, the cDNA 
samples underwent a PCR reaction to amplify a target gene (GAPDH) within the samples.  
The cDNA and No RT samples generated in 2.9 were prepared for PCR. A master mix was 
created by combining DreamTaq Green buffer (Thermo Scientific) (5μl), 2mM dNTP mix 
(Thermo Scientific) (5μl) GAPDH primer (1:15 dilution) (MWG Eurofin, Luxembourg) (4μl) 
and Taq polymerase (Thermo Scientific) (0.25μl). To this, the template cDNA sample 
prepared earlier (2μl) was added, and DEPC-treated water was added to make up to a 
final volume of 50μl. This mixture was created for all samples. The GAPDH primer 
specifications were as shown in Table 3.1. Sequences were obtained from Sun, et al., 
(2012).  
 
 
Table 3.1: GAPDH primer sequence 
Primer Sense/Antisense Sequence GC Content Tm 
GAPDH Sense: 
GAGCCCGCAGCCTCCCGCTT 
Antisense: 
CCCGCGGCCATCATCACGCCACAG 
Sense: 75% 
Antisense: 76.2% 
Sense: 67.6 oC 
Antisense: 69.6 oC 
 
 
 
 
The sequence of the GAPDH primer used for PCR experiments to determine the quality of 
the cDNA samples generated. Sequences were obtained from Sun, et al., (2012). GC 
content and melt temperature were obtained from PrimerBlast.  
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In addition, a No cDNA sample was generated. DreamTaq Green buffer (Thermo 
Scientific) (5μl), was combined with 2mM dNTP mix (Thermo Scientific) (5μl) GAPDH 
primer (MWG Eurofin, Luxembourg), and Taq polymerase (Thermo Scientific) (0.25μl). 
DEPC-treated water was added to make up to a final volume of 50μl. No cDNA was 
included in this sample. 
PCR was run using the Techne TC-3000 thermal cylinder (Bibby Scientific, Stone, 
Staffordshire, UK). In brief, an initial denaturing stage of 3 minutes at 95⁰C was followed 
by 35 cycles of denaturing (30 s at 95⁰C), annealing (30 s at 58⁰C) and Elongation (45 s at 
72⁰C), with a final elongation stage of 10 minutes at 72⁰C. The resultant cDNA samples 
were then frozen at -20⁰C until required. An agarose gel was run using these PCR 
products to ensure the purity and viability of the cDNA, and that the initial reverse 
transcription step had proceeded as required. 
Agarose gel was made by combining 2.6g agarose (Fisher Scientific UK Ltd, Loughborough, 
UK) with 200ml 1 x TAE solution (produced in-house) and boiling until clear. Ethidium 
bromide (8μl) (Sigma) or Midori Green (10μl) (Nippon Genetics, Düren, Germany) was 
added and the gel was transferred into a mould and allowed to set for one hour. Combs 
were inserted to create wells.    
Each sample, including the no cDNA negative control sample and the No RT sample, was 
pipetted onto the agarose gel (25μl). A sample of cDNA isolated from HEK-259 cells by the 
group previously, or cDNA isolated from HUVECs earlier in this work, was used as a 
positive control. The reference ladder used was the Gene Ruler 1Kb plus DNA ladder 
(Thermo Scientific) unless otherwise specified. The ladder was prepared by combining 
one part DNA ladder with one part 6x DNA Loading Dye (Thermo Scientific) and 4 parts 
deionized water. Ladder (25µl) was then loaded onto the gel, and the gel was run at 87 
volts for 30 minutes or until the dye had reached the end of the gel.  The gel was read 
using a UVP Lab Products EPI Chem II Darkroom and visualised using the ethidium 
bromide or Midori Green setting with the transilluminator control on. Results were 
analysed using LabWorks v4.6.0.00.  
The presence of a single band corresponding to the molecular weight of GAPDH (around 
700kb) suggested that the reverse transcription had been successful. In instances where 
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multiple bands appeared, or no band appeared, samples underwent reverse transcription 
and PCR again, or new samples were generated from treated cells, to ensure a pure cDNA 
sample was available. cDNA was stored in a -20 °C freezer for up to one month. 
 
3.2.6 Performance of PCR to Assess Primer Specificity and Sample gDNA 
Contamination 
 
Samples were generated as outlined in 2.9. For this work, positive control samples (cDNA 
isolated from cells treated with TNF-α and thrombin) were used for assessing ICAM-1, E-
Selectin, VCAM-1, IL-8, MCP-1 (CCL2), ET-1, and PDGFB primers. cDNA samples from 
untreated cells were used to assess the specificity of the UBC and TGF-β primers. The 
quality of the cDNA samples was assessed as outlined in 3.2.6. These samples were 
prepared for additional polymerase chain reaction (PCR). 
 
DreamTaq Green buffer (Thermo Scientific) (5μl) was combined with 2mM dNTP mix 
(Thermo Scientific) (5μl), Taq polymerase (Thermo Scientific) (0.25μl), and the required 
primer (6.6μl) (as outlined in 2.1). To this, cDNA or No RT sample as generated in 2.9 (2µl) 
was added. The cDNA contaning samples used for this work were the positive control 
samples generated as outlined in 2.9. For TGF-β samples, cDNA collected from untreated 
cells was used. DEPC-treated water was added to given a final volume of 50µl, with an 
overall primer concentration of 20μM. A no cDNA sample was also generated. In this 
case, the cDNA or No RT sample was omitted from the mixture and replaced with DEPC-
treated water.  
 
The samples were placed in the Techne TC-3000 thermal cylinder and run. An initial 
denaturing stage of 3 minutes at 95⁰C was followed by 35 cycles of denaturing (30 s at 
95⁰C), annealing (30 s at 53⁰C) and elongation (45 s at 72⁰C). The sample was then stored 
at -20⁰C until required.  
An agaorse gel was made as previously described (section 3.2.6). The gel was run for 60 
minutes and the banding on the gel visualised using a transilluminator (UVP Lab Products 
EPI Chem II Darkroom).  
109 
 
Primer specificity was assessed by examining band locations on the resulting gel. If single 
bands were seen to appear at points on the gel representative of the known size of the 
primer target (Table 2.1), primer specificity was assumed. The presence of gDNA 
contamination was also assessed using these gels. The presence of multiple bands or a 
smeared band is suggestive of gDNA contamination of the sample, as is presence of a 
band in the No RT sample. If only a single band was observed in the samples, and no band 
was observed in the No RT sample, gDNA contamination was considered to be absent.  
In instances were visible bands were not achieved, a secondary PCR was run. Samples 
were exposed to 20 cycles of denaturing (30 s at 95⁰C), annealing (30 s at 53⁰C) and 
elongation (45 s at 72⁰C). Samples were then run on an agarose gel as outlined in 3.2.6, 
and analysed as outlined above. 
 
3.2.7 GeNorm Analysis to Identify a Stable Reference Gene 
 
Prior to use with the qPCR, samples were thawed at room temperature. Samples from 
untreated cells and from cells treated with each concentration of BLM were diluted 1 in 
100 in RNAse and DNAse free water (PrimerDesign) to give a final concentration of 
0.5ng/μl. Initially, a suitable reference gene for use with the PCR was determined. Primers 
for several known candidate reference genes (GAPDH, B2M, UCB, ATP5BN, YWHAZ, and 
RPL13A) were a kind gift from PrimerDesign. Each primer was diluted with RNAse/DNAse 
free water (PrimerDesign) to a final concentration of 0.5ng/µl, and kept on ice during use. 
Reference gene primer details are shown in Table 3.2. 
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Table 3.2: Reference genes used in GeNorm experiment 
Primer Accession Number Product Size 
ATP5B (Homo sapiens ATP synthase, 
H+ transporting, mitochondrial F1 
complex, beta polypeptide) 
NM_001686 119bp 
B2M (Homo sapiens beta-2-
microglobulin) 
NM_004048 114bp 
GAPDH (Homo sapiens 
glyceraldehyde-3-phosphate 
dehydrogenase, transcript variant 1) 
NM_002046 110bp 
UBC (Homo sapiens ubiquitin C) NM_021009 137bp 
YWHAZ (Homo sapiens tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
zeta, transcript variant 1) 
NM_003406 120bp 
RLP13A (Homo sapiens ribosomal 
protein L13a , transcript variant 1) 
NM_012423 153bp 
 
 
 
 
Using these reference gene primers, a Mastermix was generated by combining 2 x 
Precision  master-mix containing SYBR Green and Taq polymerase (PrimerDesign) (10µl), 
RNAse/DNAse free water (PrimerDesign) (4µl), and the appropriate primer (1µl). 
Mastermix (15μl) was then pipetted into each well of a 48-well qPCR plate 
(PrimerDesign). To each well, 5μl of diluted cDNA extracted from untreated cells and 
treated cells was added at a concentration of 0.5ng/μl, to give a total concentration of 
2.5ng/well, as recommended by PrimerDesign. qPCR assays were run in triplicate (three 
technical replicates) to ensure reliability of results. Each reference gene was trialled, in 
triplicate, for each sample, and the results averaged using the GeNorm software 
provided. Each sample was run with each primer. 
 
 
  
The putative reference gene primers used in the GeNorm experiment. Sequences for these 
primers were not available, however the accession numbers and product size were 
supplied by PrimerDesign.  
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3.2.8 Standard Curve Generation to Ensure Primer Efficiency 
 
Following the determination of a reliable reference gene for use with qPCR assays, a 
standard curve was carried out for each of the genes to be assessed. All primers were 
generated by PrimerDesign and 100% efficiency was guaranteed, although standard 
curves were carried out for confirmation. All standard curves were conducted in duplicate 
using the Mastermix described above, and five ten-fold dilutions of samples, as outlined 
in work by Lai, et al. (2005) and used by Rajeevan, et al. (2001), Noble, et al. (2010), and 
Johnson, et al. (2012). The layout used to determine the standard curve is shown in Figure 
3.1. Standard curves were generated using the Eco software (version, 5.0.16.0, Illumina). 
For all experiments, a concentration of 1ng/μl cDNA was generated by combining 1μl 
cDNA with 49μl DNAse/RNAse free water. In each well containing this dilution, 5ng cDNA 
would be present. Dilutions of the cDNA were prepared via serial dilution (1ng/μl, 
0.1ng/μl, 0.01ng/μl, 0.001ng/μl, and 0.0001ng/μl) using RNAse and DNAse free water. In 
wells containing these dilutions, 5ng, 0.5ng, 0.05ng, 0.005ng, and 0.0005ng of cDNA were 
present. These were run in accordance with the example layout. For the PDGFB primer, 
concentrations of 2ng/μl, 0.2ng/μl, 0.02ng/μl, 0.002ng/μl, and 0.0002ng/μl were used for 
the standard curve, due to the scarcity of the target gene.  
 
1ng/µl cDNA 
(ICAM1) 
1 in 10 Dilution cDNA 
(ICAM1) 
1 in 100 Dilution 
cDNA (ICAM1) 
1 in 1000 Dilution cDNA 
(ICAM1) 
1 in 10000 Dilution 
cDNA (ICAM1) 
1ng/µl cDNA 
(ICAM1) 
1 in 10 Dilution cDNA 
(ICAM1) 
1 in 100 Dilution 
cDNA (ICAM1) 
1 in 1000 Dilution cDNA 
(ICAM1) 
1 in 10000 Dilution 
cDNA (ICAM1) 
Figure 3.1: qPCR standard curve template. 
 
 
 
The results from duplicate standard curve experiments were plotted on linear regression 
graphs using GraphPad (version 5.04). The efficiency of the primer could be determined.  
The template used to generate standard curves to determine primer efficiency.  
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In some cases, wells failed as the amount of mRNA in the well was insufficient to give a Cq 
value and instead generated a primer-dimer. If this occured in only the lowest well, then 
this result was excluded and the linear regression generated using four Cq values, as this is 
deemed acceptable.  If this occurred in more than one well, then a higher concentration 
of cDNA was used, until a concentration in which only the lowest, or indeed no 
concentrations, produced a primer dimer. In cases where the highest concentration 
offered potentially erroneous results, as there was overlap between the highest and the 
second-highest concentration due to the mRNA content exceeding the limit of detection, 
standard curves were run again. In instances where this exceedance occurred repeatedly, 
the range of dilutions used was altered. 
 
3.2.9 Purification and Secondary Amplification of cDNA from Agarose Gel 
 
In instances in which the target mRNA was too scarce to be able to accurately generate a 
standard curve, a secondary PCR experiment was run to amplify the target DNA. Samples 
were prepared as outlined in 3.2.7. This was placed in the Techne TC-3000 thermal 
cylinder and run. An initial denaturing stage of 3 minutes at 95⁰C was followed by 35 
cycles of denaturing (30 s at 95⁰C), annealing (30 s at 55⁰C) and elongation (60 s at 72⁰C). 
The sample was then stored at -20⁰C until required. 
An agarose gel was made as previously described (3.2.6). The banding on the gel was 
visualised using a transilluminator (UVP Lab Products EPI Chem II Darkroom) and the 
bands cut from the gel using a scalpel. The excised gel was then placed in a DNAse/RNAse 
free eppendorf and  the cDNA prepared for quantification using the Macherey-Nagel 
Nucleospin RNAII kit (Macherey-Nagel, Düren, Germany). This step was carried out 
according to manufacturer’s instructions. The cDNA content was then determined using 
the Qubit quantification kit, as outlined in 2.13. If sufficient cDNA was present to achieve 
a total concentration of at least 50ng/μl, as discussed in 2.13, the cDNA was stored and 
used to generate standard curves. If not, the sample was again amplified as described 
above.     
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3.3 Results 
 
3.3.1 Concentration-Effect Assay to Determine the Cytotoxic Effects of BLM on 
HUVECs 
 
The cytotoxicity of BLM at a range of concentrations was assessed to determine the 
concentrations of BLM to be used in future assays. Fifty percent was chosen as a cut-off 
point, to ensure sufficient cells were viable for subsequent analysis; time points and 
concentrations that induced >50% cell death were discarded. Cell death is expressed as a 
percentage of the number of viable cells in the untreated “0 hour” group, incubated only 
in serum free media for the same time as treated cells. An untreated group was included 
for each time-point to allow the elimination of senescence-mediated death which may 
overestimate BLM-induced death. The concentrations and time-points were selected as 
being representative of pharmacologically-relevant  concentrations and times at and 
during which BLM may be present in the blood in renally competent and impaired 
patients. 
Generally, as incubation time and BLM concentration increased, cell death increased. 
Unexpectedly, however, high levels of cell death were observed when cells were treated 
with 250ng/ml. The reasons for this are unknown, and may represent anomalous results, 
though this was observed in all three repeats. There was generally good agreement in 
levels of cell death between the two assays, though the SRB results show decreased 
viability compared to the MTS results at longer times. The reasons for this are currently 
unknown but may be due to the differences in the method; the SRB method requires cells 
to be washed prior to staining, and live cells may have been lost during the washing step 
of this protocol. 
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Table 3.3: MTS assay cell viability results 
 
Incubation Time with BLM – MTS Assay 
 
0 hours 6 hours 12 Hours 24 Hours 48 Hours 72 Hours 
Concentration 
     
 
0.01µg/ml 100 101.1 98.6 81.2 * 71.8 * 68.6 * 
0.05µg/ml 100 97.3 95.4 * 82.0 * 78.4 * 61.0 * 
0.1µg/ml 100 103.6 101.4 94.8 * 89.4 75.2 * 
0.25µg/ml 100 71.3 * 64.6 * 56.4 * 57.5 * 59.1 * 
0.5µg/ml 100 83.1 87.8 72.7 * 57.8 * 58.1 * 
1µg/ml 100 103 96.1 78.7 * 68.6 * 64.1 * 
5µg/ml 100 108 89.3 * 67.8 * 69.0 * 55.6 * 
10µg/ml 100 88.3 * 78.8 * 59.6 * 54.9 * 39.1 * 
100µg/ml 100 58.0 * 48.5 * 38.4 * 22.5* 24.7 * 
 
 
 
Incubation Time with BLM – SRB Assay 
 
0 Hours 6 Hours 12 Hours 24 Hours 48 Hours 72 Hours 
Concentration 
 
      0.01µg/ml 
100 90.7 * 83.6 * 86.7 * 74.2 * 45.8 * 
0.05µg/ml 
100 85.6 * 78.5 * 76.8 * 64.5 * 44.5 * 
0.1µg/ml 
100 89.2 * 82.1 * 83.4 80.9 41.8 * 
0.25µg/ml 
100 56.1 * 46.6 * 47.3 * 41.3 * 22.8 * 
0.5µg/ml 
100 77.0 * 73.6 * 74.2 * 58.8 * 30.4 * 
1µg/ml 
100 87.3 * 81.8 * 74.6 * 52.5 * 35.1 * 
5µg/ml 
100 84.0 * 67.1 * 53.6 * 51.2 * 28.8 * 
10µg/ml 
100 67.8 * 54.2 * 47.4 * 55.3 27.8 * 
100µg/ml 
100 62.6 * 45.2 * 30.0 * 3.8 * 0.0* 
 
MTS and SRB Assay Cell Viability Results. Average (n=3) percentage cell viability as compared to 
un-treated cells (0 hour time-point, negative control) in HUVECs treated with various 
concentrations of BLM for various times. Statistically significant decreases in cell viability from 
baseline are denoted by an asterisk (p=<0.05).    
Table 3.4: SRB cell viability results 
>100% 
viability 
100-75% 
viability 
75-50% 
viability 
<50%  
viability 
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3.3.2 Identification of Population of Viable HUVECs 
 
The identification of a viable population of HUVECs on which to gate was assessed by 
propidium iodide assay to ensure that only live populations of cells were assessed using 
flow cytometric analysis. Representative results from one assay are shown. Within the 
gated area, the majority of the cells were viable. Therefore, this area will be gated in all 
future experiments and used as the representative area of live cells (Figure 3.2, Figure 
3.3). The cells in the second peak (at an FL2-H of around 103) were dead. Notably, the 
level of dead cells was almost nil in the gated area.  
 
Figure 3.2: Propidium iodide experiment results (FSC-H vs. FL2-H) 
A representative series of results from propidium iodide experiments to determine the 
viability of the gated area by flow cytometry using FSC-H vs. FL2-H. A) the dot-plot 
obtained. B) the histogram showing the viability of all cells in the dot-plot. C) the 
histogram showing the viability of cells in the gated area only. PI-positive cells (dead) are 
visible in the top-left quadrant of A. Results are representative of three experiments. 
 
A 
B 
C 
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Figure 3.3: Propidium iodide experiment results (FSC-H vs. SSC-H). 
 
The propidium iodide results obtained in 3.2, expressed as FSC-H vs. SSC-H to 
demonstrate the viable cell population as visualised when conducting flow cytometry 
using the FL-1 setting (used during all non-propidium iodide experiments in this work). A) 
the dot-plot obtained from this experiment. B) the histogram showing the viability of all 
cells in the dot-plot. C) the histogram showing the viability of cells in the gated area only. 
Results are representative of three experiments.   
A B C 
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3.3.3 Cell Dissociation from Flasks 
 
As endothelial adhesion molecule expression was being measured, a method for HUVEC 
dissociation which would not cleave adhesion molecules was required. Analysis of 
adhesion molecule expression by TNF-α-treated cells dissociated using 1mM EDTA and 
using a cell scraper could not be conducted, as incubation with 1mM EDTA for one minute 
did not dissociate cells, and incubation for 5 and 30 minutes resulted in extensive cell 
death. Very few live cells were detected by the flow cytometric analysis. When scraped, 
cells dissociated from the bottom of the flask in large sheets. It was not possible to 
determine the number of live cells remaining following dissociation by haemocytometry. 
When analysed by flow cytometry, again, very few cells were viable.  
When cells were dissociated using PBS and chilling, few cells dissociated from the flask 
within 30 minutes. Cells were incubated in the refrigerator for another 30 minutes in PBS 
0.1% w/v BSA. Still, very low number of cells dissociated from the base of the flask. Those 
that were dissociating were lifting in sheets. When cells were removed, centrifuged, and 
counted, an insufficient number of cells were present to run flow cytometric analysis. 
 
3.3.3.1 Dissociation by TrypLE ExpressTM and 0.05% Trypsin 0.02% 
EDTA 
 
Cells dissociated from flasks easily within 1 to 2 minutes of treatment with TrypLE 
ExpressTM. Cells dissociated from culture flasks using 0.05% w/v Trypsin 0.02% w/v EDTA 
dissociated efficiently within the same time-scale as those treated with TrypLE ExpressTM. 
In both cases, cells were found to be mostly viable by haemocytometry, and when 
assessed using flow cytometry, around 70% of cells fell within the gated area denoting 
viable cells. To determine which method is preferable, adhesion molecule expression by 
cells dissociated with each method was assessed (Figure 3.4). No significant difference 
was observed.  
  
D C 
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A Comparison of the Expression of Adhesion Molecules by TNF--treated
HUVECs when  Dissociated using  TrypLETM Express versus 0.05%
Trypsin 0.02%  EDTA
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TNF- + .05%
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Figure 3.4: Adhesion molecule expression by HUVECs dissociated by two different 
methods 
Adhesion molecule expression by TNF-α treated HUVECs dissociated with TrypLETM 
Express and 0.05% Trypsin/ 0.02% EDTA. There was no significant difference between 
adhesion molecule expression by cells dissociated using TrypLE ExpressTM and 0.05% w/v 
Trypsin 0.02% w/v EDTA. N = 3. 
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3.3.4 Positive Control Determination for Adhesion Molecule Expression 
Experiments 
 
In addition to a negative control, a positive control was needed. The expression of a panel 
of adhesion molecule in response to various concentrations of inflammatory mediators 
(LPS, TNF-α, and IFN-γ) was assessed. These molecules were PECAM-1, ICAM-3, ICAM-1, 
αVβ3 integrin, P-selectin, E-Selectin, VCAM-1, and PSGL-1. Concentration-effect 
experiments were conducted to determine the ideal cytokine, and the ideal 
concentration of this, to use to upregulate adhesion molecules for use as a positive 
control. 
Only the expression of ICAM-1, E-Selectin, and VCAM-1 was seen to be substantially 
increased by treatment with inflammatory mediators. Six and 24 hour TNF-α and LPS 
treatment induced increased ICAM-1, E-Selectin, and VCAM-1 expression. IFN-γ 
treatment at all concentrations for six hours increased ICAM-1 expression, but this 
expression was increased by only 3000U/ ml concentrations when treated for 24 hours. In 
all groups, there was a significant increase in the binding of the isotype control antibody 
to cells treated for 6 and 24 hours (demonstrated in a tabular format in Appendix A, Table 
A.1). The upregulation of ICAM-1 expression was the greatest in all cases (Fig 3.6, 3.7, 
3.8).  
Raw data is shown in Fig 3.5. Raw data is shown with a gate applied to highlight the peak-
shift and increase in ICAM-1 positive cells when cells were treated with TNF-α. Note that 
correction using gating was NOT used to determine expression (expression was 
determined using uncorrected data and plotted on graphs as outlined in section 2.5). 
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Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 681.93 434.60 60.88 661.17 1
File: Data.028 Log Data Units: Linear Values
Sample ID: TNF 10ng/ml CD54 Patient ID: 
Tube: Panel: 
Acquisition Date: 17-Dec-12 Gate: No Gate
Gated Ev ents: 10000 Total Ev ents: 10000
X Parameter: FL1-H (Log)
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 6554 100.00 65.54 743.70 673.59 41.99 697.83 697
M1     7,  9910 6545 99.86 65.45 744.72 678.63 41.80 697.83 697
File: Data.028 Log Data Units: Linear Values
Sample ID: TNF 10ng/ml CD54 Patient ID: 
Tube: Panel: 
Acquisition Date: 17-Dec-12 Gate: G2
Gated Ev ents: 6554 Total Ev ents: 10000
X Parameter: FL1-H (Log)
M1
R2
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 25.99 9.72 273.92 10.27 1
File: Data.006 Log Data Units: Linear Values
Sample ID: Negativ e CD54 Patient ID: 
Tube: Panel: 
Acquisition Date: 14-Dec-12 Gate: No Gate
Gated Ev ents: 10000 Total Ev ents: 10000
X Parameter: FL1-H (Log)
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 6157 100.00 61.57 26.85 14.21 254.48 12.98 11
M1     7,  9910 4779 77.62 47.79 33.34 20.47 228.95 17.00 11
File: Data.006 Log Data Units: Linear Values
Sample ID: Negativ e CD54 Patient ID: 
Tube: Panel: 
Acquisition Date: 14-Dec-12 Gate: G2
Gated Ev ents: 6157 Total Ev ents: 10000
X Parameter: FL1-H (Log)
R2 M1
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 3.58 2.37 809.54 2.25 1
File: Data.003 Log Data Units: Linear Values
Sample ID: Negativ e 2ndry Patient ID: 
Tube: Panel: 
Acquisition Date: 14-Dec-12 Gate: No Gate
Gated Ev ents: 10000 Total Ev ents: 10000
X Parameter: FL1-H (Log)
Histogram Statistics
M rker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 7082 100.00 70.82 2.70 2.36 163.87 2.31 1
M1    7,  9910 126 1.78 1.26 12.26 9.40 250.76 8.43 7
File: Data.003 Log Data Units: Linear Values
Sample ID: Negativ e 2ndry Patient ID: 
Tube: Panel: 
Acquisition Date: 14-Dec-12 Gate: G2
Gated Ev ents: 7082 Total Ev ents: 10000
X Parameter: FL1-H (Log)
R2 M1
Raw data for the 
control 
(secondary 
antibody only) 
sample in flow 
cytometry 
experiments. 
1.26% of events 
fall within M1. 
Raw data for 
ICAM-1 expression 
in HUVECs not 
treated with TNF-
α flow cytometry 
experiments. 
77.62% of events 
fall within M1. 
Raw data for 
ICAM-1 expression 
in HUVECs treated 
with 10ng/ml TNF-
α flow cytometry 
experiments. 
99.86% of events 
fall within M1. 
Raw data generated from flow cytometric analysis of negative control samples (top), 
ICAM-1 expression by untreated cells (middle) and cells treated with 10ng/ml TNF-α for 6 
hours (bottom). Gate M1 was drawn to incorporate 1% of the control peak. There was a 
substantial peak shift from baseline ICAM-1 expression when cells were treated with TNF-
α. Rep esentative images of three experiments.  
Figure 3.5: Raw data obtained for flow cytometry experiments using TNF-α 
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HUVEC Adhesion  Molecule Expression in
Response to  Treatment with TNF  for 6
Hours
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HUVEC Adhesion  Molecule Expression in
Response to  Treatment with TNF  for 24
Hours
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Figure 3.6: Adhesion molecule expression by TNF-α treated HUVECs 
A) The expression of ICAM-1, E-Selectin, and VCAM-1 by HUVECs treated with TNF-α for 6 
(A) and 24 (B) hours (n=3). The expression of all three adhesion molecules was significantly 
increased from baseline (p=≤0.05) by treatment with TNF-α of all concentrations.  
* 
* 
* 
* 
* 
* 
A 
B 
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Figure 3.7: Adhesion molecule expression by LPS treated HUVECs 
 
 
A) The expression of ICAM-1, E-Selectin, and VCAM-1 by HUVECs treated with LPS for 6 (A) 
and 24 (B) hours (n=3). The expression of all three adhesion molecules was significantly 
increased from baseline (p=≤0.05) by treatment with LPS of all concentrations. 
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HUVEC Adhesion  Molecule Expression in
Response to Treatment with IFN for 24  Hours
Adhesion Molecule
A
v
e
ra
g
e
 G
e
o
m
e
tr
ic
 M
e
a
n
 (
a
rb
it
ra
ry
 u
n
it
s
)
Control ICAM-1 E-Selectin VCAM-1
0
50
100
150
Untreated
100U/ml IFN-
300U/ml IFN-
1000U/ml IFN-
3000U/ml IFN-
Figure 3.8: Adhesion molecule expression by IFNγ-treated HUVECs 
  A) The expression of ICAM-1, E-selectin, and VCAM-1 by HUVECs treated with IFN-γ for 6 
(A) and 24 (B) hours (n=3). The expression of CD54 was significantly increased from 
baseline (p=≤0.05) by treatment with IFNγ of all concentrations when cells were treated 
for 6 hours, but only by 3000U/ml IFNγ when cell were treated for 24 hours. 
* 
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3.3.5 Comparative Statistics - 6 and 24 Hour Incubations with 
Proinflammatory Mediators 
 
ICAM-1 expression by cells treated with TNF-α at all concentrations for 6 hours was 
significantly greater (p≤0.05) than by cells treated with all concentrations of LPS and IFN-γ 
for 6 and 24 hours, as seen in Fig 3.9. ICAM-1 expression by cells treated with different 
concentrations of TNF-α was not significantly different when cells were treated for 6 
hours, but when treated for 24 hours, there was a significant difference in ICAM-1 
expression in cells treated with 1ng/ml and 3ng/ml, with this difference diminishing as 
concentrations increased. There is no clear concentration-dependent increase in ICAM-1 
expression by cells treated with varying concentrations of TNF-α, suggesting ICAM-1 
expression has achieved a plateau. While VCAM-1 and E-Selectin were also upregulated 
by TNF-α and LPS treatment, this upregulation was less substantial than that of ICAM-1.   
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ICAM-1 Expression by  HUVECs Treated with  LPS,
TNF , and IFN for 6  Hours
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Figure 3.9: ICAM-1 expression by HUVECs treated with TNF-α , LPS, and IFNγ. 
 
A) ICAM expression by HUVECs treated with TNF-α, LPS, and IFN-γ for 6 (A) and 24 
(B) hours. Increases in ICAM-1 expression compared to baseline in response to 
TNF-α were significantly higher (p=≤0.05) than to LPS or IFNγ (n=3). 
* 
* 
A 
B 
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3.3.6 Confirmation of cDNA Purity and Quality 
 
To confirm that the reverse transcription step of this work was conducted correctly, 
agarose gels were run to confirm whether cDNA was present in each sample. A 
representative agarose gel is shown in Fig. 3.10. As a GAPDH primer was used, bands 
were present at around 700bp, as expected. These samples were used to run the GeNorm 
experiments, to determine the preferred housekeeping gene for use with qPCR 
experiments.  
 
3.3.7 Determination of an Ideal Reference Gene using GeNorm Experiments 
 
Six reference genes were used (GAPDH, B2M, UBC, RPL13A, YWHAZ, and ATP5B, a kind 
gift from PrimerDesign) and the stability of these genes in each cell line (28543, 28756, 
and 2062502) under each treatment condition (untreated, 0.1µg/ml/ml, 1μg/ml, and 
10μg/ml for 6 or 24 hours) assessed. Results from each geNorm experiment from each 
cell line under each treatment condition were compiled and analysed using the qBase+ 
programme to determine the most stable reference gene on average. In total, 12 geNorm 
experiments were carried out. The most stable reference gene overall was UBC, the 
ubiquitin C gene (Fig. 3.11), and this was used in all future experiments.  
Using the GeNorm technique, the stability of the reference genes in each sample is 
compared and the stability assigned a value, the GeNorm M value. The qBase+ software 
uses a logarithm based on the work of Vandesompele, et al. (2002), whereby the 
relatively stability of genes to one another is determined and the least stable gene is 
excluded in a stepwise fashion. The M value is used as a marker of the variability of the 
gene expression.  The lower the M value, the higher the stability of the gene 
(Vandesompele, et al., 2002). All graphical outputs are based on those used in this work.   
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Figure 3.10: The quality of cDNA samples used for qPCR experiments as determined by 
PCR using a GAPDH primer.
  Agarose gels showing the quality of cDNA samples following reverse transcription. Light 
blue arrows represent No RT controls for samples to the left of the arrow. The positive 
control was cDNA extracted from HEK cells. Negative control wells contained no cDNA.  
The ladder used in the upper gel was the 1kb ladder; in the lower gel, the 1kb plus 
ladder. These images are representative of three gels carried out. 
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Figure 3.11: The stability of reference genes used in the GeNorm experiment.   
Average Expression Stability of Reference Targets 
 
 
 
Reference Genes 
Untreated 6H Untreated 24H 100ng/ml BLM 6H 100ng/ml BLM 24H +ve control 
1500bp 
The results of the geNorm experiment carried out on all samples of all cell lines assayed, as generated by the BioGazelle qBase+ software. The most 
stable reference gene across all samples assessed was UBC (ubiquitin C), and the least stable ATP5B. All samples were run in triplicate. 
GeNorm 
M 
Value 
Value 
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3.3.8 Assessment of Primer Specificity and gDNA Contamination 
 
To ensure all primers amplified only specified target transcripts, a PCR was run using 
samples as outlined in 3.2.7 and the qPCR primers obtained, and the resulting PCR 
product was run on agarose gels. Using all primers, only a single band which correlated 
with the known size of the product (Table 2.1) was achieved. Representative gels are 
shown in Fig. 3.12 and Fig 3.13. The TGF-β band remained faint in 3 repeats, potentially 
due to low levels of target transcript. However, this band appeared as a band of the 
correct size. While faint bands were detected in the No RT and No cDNA samples for 
VCAM-1 and PDGF-BB, these bands were found to be smaller than that of the target 
transcript. It is feasible that in these samples, primer dimerisation has occurred due to a 
lack of target transcript. The primers were therefore used for further work.   
No RT samples, which contained no cDNA due to the absence of reverse transcriptase in 
sample preparation, were run to assess gDNA contamination. The appearance of a band 
in these samples suggests gDNA contamination, as gDNA does not require reverse 
transcription to be present. Similarly, if banding appears in No cDNA controls, this 
suggests contamination of the reagents used.  That no band appeared in No RT samples 
suggests gDNA contamination has not occurred. Moreover, that a single band was 
observed when cDNA-containing samples were run also suggests there is no gDNA 
contamination, as this would generate more than one band when samples were run.  
  
130 
 
 
Figure 3.12: The specifity of primers used in qPCR experiments. 
 
 
A representative agarose gel showing products when samples of HUVEC cDNA (positive 
control samples for all target transcript primers, negative control sample for UBC 
primer) underwent PCR. In all cases with the exception of UBC (for which a sequence 
was not available due to copyright), a single band of expected size (based on the 
known size of the products outlined in Table 2.1) was generated.  
UBC ICAM VCAM SELE IL-8 
MCP-1 ET1 PDGF 
No CDNA  No RT No CDNA  No RT No CDNA  No RT No CDNA  No RT No CDNA  No RT 
No CDNA  No RT No CDNA  No RT No CDNA  No RT 
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Figure 3.13: The specifity of primers used in qPCR experiments II  
A representative agarose gel showing the PCR products when the MCP-1 and TGF-β 
primers were used in the PCR reaction. As above, the single band of expected size and 
a lack of No RT and No cDNA sample bands was seen.  
MCP-1 
TGF-β 
No CDNA    No RT 
No CDNA    No RT 
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3.3.9 Generation of Standard Curves to Determine Primer Efficiency 
 
Standard curves were generated for all primers as, though the supplier guaranteed 
efficiency within the 90-110% window (denoting 100% efficiency), confirmation of this 
using our cDNA samples was necessary. The results of these standard curves are shown in 
Table 3.5. An example standard curve for the IL-8 primer is shown  in Figure 3.14. 
Standard curves for all other primer assessed can be found in the appendix. In most cases, 
standard curves were generated using five points.  
Tenfold dilutions of 1ng/ml cDNA (5ng – 0.0005ng per well, 1ng/µl - 0.0001ng/µl) were 
sufficient to generate a standard curve for VCAM-1, E-Selectin, IL-8, UBC, MCP-1, and 
Endothelin-1. Tenfold dilutions of 2ng/ml (10ng – 0.001ng per well; 2ng/µl-0.0002ng/µl) 
were required to generate a standard curve for PDGF-BB. 
In cases where the lowest concentration was too low for detection, standard curves were 
generated using four points. Though all efforts were made to generate standard curves 
which did not require the exclusion of any samples, in the case of the PDGFB and SELE 
primer standard curves, the lowest concentration values were discarded as primer dimers 
had formed due to low levels of target transcript in the samples. 
In the case of TGFB1, cDNA purification and amplification was required, as the target 
transcript was very scarce. A total concentration of 2ng/ml pure TGF-β1 cDNA was 
generated. This was then diluted to give concentrations of 0.01ng/µl – 0.0001ng/µl, using 
which a standard curve was generated.   
No standard curve could be generated in-house for the ICAM-1 primer; repeated attemps 
generated curves in which the highest concentration overlapped, and the lowest formed 
primer dimers, and a suitable concentration for use could not be developed. However, a 
standard curve was graciously generated by PrimerDesign using lung cDNA by Rebecca 
Gover at concentrations of 6ng/µl-0.006ng/ µl (30ng-0.03ng/well). The ICAM-1 standard 
curve, as some others, contained only four points as the lowest concentration was unable 
to achieve readable values.  
All primers tested fell within the 90-110% efficiency bracket, including the ICAM1 and 
TGFB primers, therefore the correction of results based on primer efficiency discordance 
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via the Pfaffl method (Pfaffl, 2001) is not needed in this work. Therefore, the ΔΔCq, or 
Livak method, may be used.   
The concentration of 2.5ng/well (0.5ng/µl) for use in qPCR experiments, previously 
suggested by PrimerDesign (3.2.7), was confirmed by standard curve generation to be a 
suitable concentration to use; this concentration falls within the range of concentrations 
seen to produce results that were not the result of a primer dimer, and fell within the 
preferred limit of detection (>10 but <35  cycles required to exceed the threshold) in all 
standard curves produced. This concentration, when then used in later qPCR 
experiments, produced consistent results that again fell within the preferred limit of 
detection and were not the result of primer dimerisation.   
The standard curve generated by Rebecca Gover for the ICAM-1 primer also incorporated 
this concentration, and test runs found this to be a concentration that contained 
sufficient target ICAM-1 transcript to generate results. Although the TGF-β standard curve 
did not incorporate this concentration, test runs again found this amount of cDNA 
contained sufficient target transcript to produce replicable, reliable, results.  
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Figure 3.14: The qPCR efficiency standard curve for the IL-8 primer.  
Slope -3.486 
Y Intercept 20.37 
R2 value 0.997 
P value < 0.0001 
Efficiency 93.58% 
An example standard curve as generated using the results of qPCR standard curve 
experiments. This curve shows that the efficiency of the IL-8 primer lies at 93.85%, 
within the 90-110% threshold for assuming 100% primer efficiency, negating the need 
for correction via the Pfaffl method.  
Logarithmic scale 
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Table 3.5: The efficiency of primers used in qPCR experiments as determined by standard curves. 
Primer Sense/Antisense Primer Efficiency Product 
Length 
Standard Curve 
ICAM-1 (Homo sapiens 
intercellular adhesion 
molecule, CD54) 
Sense:  
CCTATGGCAACGACTCCTTC 
Antisense: 
TCTCCTGGCTCTGGTTCC 
 
95.75% 
(Four 
points) 
 
111bp 
R
2
 value: 0.996 
slope value: -3.428 
Y intercept: 27.49 
VCAM1_24444 (Homo 
sapiens vascular cell 
adhesion molecule 
VCAM1, transcript 
variant 1) 
Sense: 
TGTGAATCCCCATCTTTCTCCT 
Antisense: 
CTCAGGGTCAGCGTGGAAT 
 
 
105.21% 
 
 
95bp 
 
R
2
 value: 0.9944 
Slope: -3.203 
Y intercept: 23.70-
24.45 
IL-8 (Homo sapiens 
interleukin 8). 
Sense: 
CAGAGACAGCAGAGCACAC 
Antisense: 
AGCTTGGAAGTCATGTTTACAC 
 
93.58% 
 
95bp 
R
2
 value: 0.997 
Slope: -3.486 
Y intercept: 20.07-
20.67 
MCP-1 (Homo sapiens 
chemokine (C-C motif) 
ligand 2 (CCL2)). 
Sense: 
ACCGAGAGGCTGAGACTAAC 
Antisense: 
AATGAAGGTGGCTGCTATGAG 
 
99.37% 
 
122bp 
R
2
 value: 0.9986 
Slope: -3.337 
Y intercept: 20.67-
21.05 
E-Selectin (Homo 
sapiens selectin E 
(endothelial adhesion 
molecule 1 (SELE)). 
Sense: 
TTCTTGCCTACTATGCCAGATG 
Antisense: 
AGGAAAGGGAACACTGAGTCT 
 
105.26% 
(Four 
points) 
 
123bp 
R
2
 value: 0.9952 
Slope: -3.202 
Y intercept: 21.56-
22.18 
PDGF-BB (Homo 
sapiens platelet-
derived growth factor 
beta polypeptide 
(simian sarcoma viral 
(v-sis) oncogene 
homolog) (PDGFB), 
transcript variant 1) 
Sense: 
AGCACACGCATGACAAGAC 
Antisense: 
GGGGCAATACAGCAAATACCA 
 
108.73% 
(Four 
points) 
 
108bp 
R
2
 value: 0.9941 
Slope: -3.129 
Y intercept: 24.59 - 
25.18 
 
ET-1 (Homo sapiens 
endothelin 1 (EDN1), 
mRNA.) 
Sense: 
TGAGAATAGATGCCAATGTGCTA 
Antisense: 
GAACAGTCTTTTCCTTTCTTATGA
TT 
 
93.03% 
 
 
132bp 
R
2
 value: 0.9872 
Slope: -3.501 
Y intercept: 23.59-
24.84 
TGF-β1 (Homo sapiens 
transfroming growth 
factor, beta 1 
(Camurati-Engelmann 
disease (TGFB1) 
mRNA) 
Sense: 
CACTCCCACTCCCTCTCTC 
Antisense: 
GTCCCCTGTGCCTTGATG 
 
105.35% 
(Four 
points) 
 
83bp 
R
2
 value: 0.9877 
Slope: -3.200 
Y intercept: 0.124-
2.884 
UBC (Homo sapiens 
ubiquitin C) 
Not available: 
Accession number: NM_021009 
Anchor nucleotide: 452 
 
99.91% 
 
192bp 
R
2
 value: 0.9766 
Slope: -3.324 
Y intercept: 22.63-
24.25 
 
  
The efficiency of primers used in qPCR experiments as determined by standard curves. All 
primers fell within the desired 90-110% efficiency range, suggesting that the efficiency of 
the primers was sufficiently close to 100% to negate the need for normalisation of the 
results using the Pfaffl Method. The linearity of the results was also generally greater than 
R2=0.98, suggesting high reproducibitility between duplicate standard curves. Though the R2 
value acheived when the UBC primer was assessed was 0.976, this was deemed sufficiently 
linear.    
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3.4 Discussion and Conclusions 
 
3.4.1 Cytotoxicity Assay  
 
As 72 hour and 48 hour incubations with many concentrations of BLM induced relatively 
high cell death, not seen in vivo, these time-point were disregarded from further work. 
However, 24, 12, and 6 hour incubations induced acceptable levels of cell toxicity, with 6 
and 12 hour incubation times producing very similar levels of cell death. As 24 hours is 
around the terminal half-life of BLM in renally impaired patients, who are susceptible to 
BPF, and 6 hours represents the terminal half-life of patients who are renally competent, 
these time points will be used in future work. 
As expected, 100µg/ml BLM induced very high cytotoxicity, though concentrations of 
250ng/ml were seen to produce high toxicity also. The reasons for high cell death at 
250ng/ml are unknown; this may simply represent an anomalous result, though all three 
cell lines incurred similar cell death when treated with 250ng/ml BLM.  Neither 
concentration will be used further. Concentrations of 10ng/ml and 50ng/ml caused low 
cytotoxicity, but very similar levels of cytotoxicity as 0.1µg/ml, and so only one will be 
used. All other concentrations caused physiologically relevant cytotoxicity. Therefore, 0.1, 
1, and 10µg/ml will be used in future work.  
Though few groups have studied time and concentration dependence of BLM-mediated 
cytotoxicity in HUVECs, the current results are somewhat similar to those of Miyamoto, et 
al. (2002), who, using [H3]-thymidine incorporation assays, noted HUVECs incubated with 
50ng/ml BLM over 6, 12, and 48 hours remained  around 80% viable. However, cell 
viability after treatment with higher BLM concentrations (0.1µg/ml - 100µg /ml) in the 
Miyamoto work was lower than the cell viability noted in the current work, and almost 
total cell death was noted immediately after HUVECs were treated with 10µg/ml and 
100µg/ml BLM by Miyamoto, et al. (2002). The only similarity between the Miyamoto 
work and the current work at these concentrations is that 10µg/ml and 100µg/ml BLM 
induced substantial death after 48 hour incubation. The difference in method may explain 
this. 
137 
 
The [H3]-thymidine incorporation assay determines cell viability by determining the 
amount of thymidine incorporated into replicating DNA of proliferating cells, therefore 
determining cell proliferation rather than viability. [H3]-thymidine incorporation may be 
impacted by increased or decreased cell proliferation – in this work, cells were incubated 
in serum-free media to retard proliferation. The current work uses the MTS and SRB 
assays, which count all living cells. Todorovic, et al. (2009) used an MTS assay similar to 
that employed by the current study to determine the viability of murine rectum 
carcinoma cells (CMT-93) following exposure to BLM, and, though using a different cell 
line and only a single 16-hour time point, produced similar results to those from our 12 
hour incubation; i.e., low levels of cell death. That the SRB assay suggested a similar, but 
slightly lower, percentage of viable cells than the MTS assay in the current work suggests 
that washing may have removed live cells, though a similar pattern was observed.  
 
3.4.2 Cell Dissociation 
 
It is clear that cell scraping, incubation with 1mM EDTA, and chilling in PBS were not 
suitable as methods of dissociation as cells were largely non-viable after removal. 
Dissociation by both TrypLETM Express and 0.05% Trypsin 0.02% EDTA resulted in a 
sufficient number of cells for FACS analysis, and a high percentage of viable cells, and 
neither induced a higher level of enzymatic adhesion molecule cleavage than the other.  
The method of dissociation selected is TrypLETM Express. Although there is no precedent 
for this, this work has shown that there is no difference between the number of adhesion 
molecules present on cells dissociated by TrypLETM Express or 0.05% Trypsin 0.02% EDTA 
when analysed by FACS. As this product is used to passage HUVECs in our laboratories 
and appears gentle to adhesion molecules, along with the consistency acheived by using 
the same product for passaging and dissociation prior to FACS, this product will be used in 
future work. 
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3.4.3 Positive Control Determination 
 
The results of the control experiment clearly show that ICAM-1 was upregulated to a 
greater degree than all other adhesion molecules assessed, notably VCAM-1 and E-
Selectin, similar to the results of previous works by Zhang and Issekutz (2001), Jägels, et 
al.(2000), and Choi, et al., (2009). This suggests ICAM-1 is the best adhesion molecule to 
use as a positive control. Moreover, that TNF-α was able to upregulate ICAM-1 to a 
greater degree than IFN-γ or LPS at both 6 and 24 hours suggests that TNF-α is the best 
treatment to upregulate adhesion molecule expression over this timeframe.   
That TNF-α induced the expression of  ICAM-1 at similar levels when treated with 3ng/ml, 
10ng/ml, and 30ng/ml TNF-α in the 24 hour experiments and with all concentrations of 
TNF-α in the 6 hour incubation experiments suggests that any concentration would be 
suitable for inducing ICAM-1 expression in future work. Similar reports of a slight, but not 
obvious, concentration dependence have been published by others; Willam, et al. (1999) 
noted a concentration-dependent increase in ICAM-1 expression when treating HUVECs 
with TNF-α of varying concentrations (0.01-100ng/ml); ICAM-1 expression increased from 
0.01ng/ml to 10ng/ml TNF-α, and then plateaued between 10ng/ml and 100ng/ml. Sawa, 
et al. (2007), noted a slight concentration-dependent increase in ICAM-1 expression as 
TNF-α concentration increased (5ng/ml, 10ng/ml, and 20ng/ ml), with a plateau at 
10ng/ml. Therefore, the concentration of 10ng/ml, which upregulated ICAM-1 expression 
to high levels and a level not significantly different from that of 30ng/ml, will be used in 
this work as a positive control. 
 
3.4.4 GeNorm Experiments for the Determination of a Suitable Reference Gene 
 
This work has provided many interesting foci for discussion. Firstly, it was found that the 
most stable putative reference gene was UBC, and not GAPDH, which is widely used and 
is sometimes regarded as the classical reference gene in qPCR (de Jonge, et al., 2007). 
Though there is a tendency in some papers to not validate the reference genes used, or to 
refer back to “the qPCR gold standard”, to justify the choice of gene, the expression of 
GAPDH can vary on a tissue-to-tissue basis, and may be impacted by experimental 
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techniques, as discussed recently in a substantial review, although this is not the only 
putative reference gene for which this is the case (Kozera and Rapacz, 2013). Therefore, 
when a different cell type or tissue is used, a GeNorm experiment or equivalent must be 
conducted.   
This work was carried out on all samples and the results pooled together to give n=3. It is 
interesting to note that UBC was not the most stable reference gene in each individual 
experiment (data not shown), but when all data from each line was analysed using the 
GeNorm software, the average stability of UBC was superior to that of other genes across 
lines, including GAPDH. Therefore, UBC will be used as the reference gene in all qPCR 
experiments. 
 
3.4.5 Standard Curve Generation to Determine Primer Efficiency 
 
While all primers fell within the accepted range of efficiencies (90-110%), the success of 
standard curve experiments to determine this depended on the abundance of the target 
transcript. In cases such as VCAM1_2444, CCL2, IL8, and UBC - where the transcript was 
abundant - such experiments were performed with ease. In cases such as E-Selectin 
(SELE), where the target transcript was more scarce, the lowest dilution often produced a 
primer dimer due to a lack of target amplification. This was also the case with PDGFB, 
where the lowest concentration produced primer dimers regardless of initial 
concentration. In both cases, a standard curve of four points was generated. However, 
that all primer standard curves were run in duplicate and concordance was very high 
suggests that the efficiencies obtained were reliable.  
Although it was not possible to achieve a concentration high enough for TGFB standard 
curves to be generated, gel purification of the TGFB transcript proved sufficient to 
generate a 4-point standard curve. This, however, was not the case for ICAM1, and lung 
cDNA was used to generate a 4-point standard curve by Rebecca Gover at PrimerDesign. 
When an ICAM1 standard curve was attempted in-house, low starting concentrations 
yielded many primer dimers or failed wells, and high starting concentrations yielded wells 
with very similar Cq values - usually the two highest concentrations. A dilution range 
which resulted in neither Cq overlap or primer dimerisation occurred could not be 
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identified. It is also notable that no similar efficiencies could be generated with this 
primer in-house when run in duplicate, mostly due to a high number of failed wells. The 
issue of similar Cq  values may have been due to a narrow range of detection of the ICAM1 
primer, or the excedence of the limit of detection due to transcript overabundance, but 
this remains unknown.  
While neither case is ideal, it is notable that, when running qPCR experiments using a 
concentration of 2.5ng/well cDNA, neither of these target transcripts proved too scarce 
for detection. Indeed, both universally generated Cq values below 35 - an arbitrary cut-off 
point - and neither were beset with problems of primer dimer formation. While the 
reason for the issues generating the standard curve for the TGFB primer are clear, it is 
unknown why the efficiency of the ICAM1 primer could not be determined in-house.   
In conclusion, it was determined that all primer used fell within the required 90-110% 
efficiency bracket, and that obtained results would not need correction using the Pfaffl 
method to be directly compared. 
 
3.4.6 Primer Specificity Assessment 
 
In assessing the specificity of the primers, all bar UBC were seen to generate only a single 
band on agarose gels, suggesting primer specificity in the positive control samples used 
for assessing ICAM-1, E-Selectin, VCAM-1, IL-8, MCP-1, ET-1, and PDGFB primers, and in 
the negative control sample used to assess the TGF-β primer. These experiments were 
conducted as the sequences of the primers were not all intron-spanning, which may have 
resulted in gDNA or incorrect transcript amplification when qPCR experiments were run. 
The group had no control over the primers used, as this work was sponsored by 
PrimerDesign, and the sequence and Tm of UBC were not made available. However,  
assurances were made that this primer was intron-spanning, and the No RT and No cDNA 
samples did not provide a band, so the cause of the additional banding is unknown but 
appears not to be gDNA contamination and amplification. It is feasible that the melt 
temperature used during PCR was too low for the UBC primer, resulting in non-specific 
binding to non-target transcript; when higher melt temperatures (55⁰ versus 60⁰) were 
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used in both preliminary and later qPCR experiments, raw data showed extremely non-
variable Cq values for samples containing the UBC primer (data not shown), and so it was 
regarded the UBC primer was specific when this higher melt temperature was used. Thus, 
the UBC primer was used as the reference gene primer in future qPCR experiments.  
All primers appeared specific, and this experiment suggested that gDNA contamination 
was minimal or absent; in all cases apart from VCAM-1 and PDGF-BB, the No RT sample 
did not generate a band. In these cases, however, the band was very faint, and may be 
due to primer dimer formation, where primers self-hybridise in the absence of target 
transcripts, and are amplified by the DNA polymerase. A No RT sample was still run for 
each sample in each qPCR experiment to further determine whether gDNA contamination 
was present. No RT samples in each qPCR run remain the gold standard for ensuring no 
gDNA contamination (Laurell, et al., 2012).  
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4 Human Umbilical Cord Endothelial Cell 
Adhesion Molecule Expression and 
Cytokine Release in Response to 
Treatment with BLM  
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4.1 Introduction; Adhesion Molecules in the Pathogenesis of BPF 
 
Crucial to immune cell recruitment to the site of injury is the diapedesis cascade, which 
depends on the expression of  endothelial adhesion molecules, described in chapter 1. As 
pulmonary infiltration by immune cells is a feature of BPF prior to fibrogenesis, and 
immune cells are so heavily implicated in the development of the disease, endothelial 
adhesion molecule expression may well contribute to BPF in both humans and rodents. 
Previous reports suggest that BLM treatment upregulates HUVEC E-Selectin expression 
(Ishii and Takada, 2002; Miyamoto, et al., 2000), and PMVEC ICAM-1 expression (Fichtner, 
et al., 2004), though the range of adhesion molecules expressed requires better 
characterisation. Furthermore, Fichtner, et al. (2004) used supra-pharmacological 
concentrations of over  50µg/ml (100mU/ml), which may result in different adhesion 
molecule expression profiles to pharmacologically-relevant concentrations. The 
expression of adhesion molecules by HUVECs in response to BLM of pharmacologically-
relevant concentrations will therefore be investigated. A panel of adhesion molecules 
known to be expressed by HUVECs and/or have a role in diapedesis was chosen  – these 
were PECAM-1, ICAM-3, ICAM-1, αVβ3, P-selectin, E-Selectin, VCAM-1, and PSGL-1 – and 
the effect of various concentrations of BLM  over various incubation durations on the 
expression on these molecules will be assessed. 
In this work, BLM and TNF-α increased isotype control binding to HUVECs. In flow 
cytometry, the isotype control provides a baseline level of non-specific antigen binding so 
that antigen-positive and antigen-negative cell populations (the latter fluorescent due to 
non-specific binding) may be differentiated (Keeney, et al., 1998). It also allows the 
determination of the level of fluorescence on positive cells attributable to non-specific 
binding. Several factors may cause increased non-specific binding readings, including Fc 
receptor expression, or simulate increased non-specific binding, such as increased 
autofluorescence (Hulspas, et al., 2009). Though it has been reported that HUVECs do not 
express Fc receptors (Zhao, et al., 2011), Pan, et al. (1999) observed expression of CD16, 
CD32, and CD64 by HUVECs co-treated with TNF-α and IFNγ. Whether BLM and TNF-α 
induce Fc receptor expression will therefore be assessed. 
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Endothelial cells may also express cytokines to recruit leukocytes, such as IL-8 and MCP-1, 
which attract and activate neutrophils and monocytes/macrophages, respectively 
(Detmers, et al., 1990; Sakanashi, et al., 1994; Mukaida, et al., 1998; Matsushima, et al., 
1989; Huber, et al., 1991), and induce directional and transendothelial migration (Schaff, 
et al., 2008; Weber, et al., 1996; Melgarejo, et al., 2009). These cytokines may be relevant 
to BPF development; for example, MCP-1 expression by BLM-stimulated endothelia has 
been associated with inflammatory cell influx in BPF (Okuma, et al., 2004). Therefore, an 
assessment of the expression of these protein in response to BLM in human cells is also 
desirable.   
Although there have been previous reports of increased IL-8 and MCP-1 release by BLM 
treated HUVECs (Miyamoto, et al., 2002), this increased release was only noted when 
cells were treated with 10ng/ml and 50ng/ml BLM, for 12 hours (IL-8) and 48 hours (MCP-
1). In man, the majority of BLM would have been metabolised within 48 hours. Whether 
higher BLM concentrations, such as those used in this work, and shorter incubation times, 
also affect IL-8 and MCP-1 expression is of interest. 
Finally, TGF-β, PDGF, and Endothelin-1 - which induce fibroblast proliferation, 
transdifferentiation, and collagen synthesis - may be expressed by the endothelium, and 
may induce fibrogenesis in the interstitium and alveoli if such factors diffuse into the lung. 
Though not described in man, endothelial TGF-β and CTGF expression in BLM-treated 
rodents was reported, and suggested to play an important role in the differentiation of 
interstitial fibroblasts to a fibrotic phenotype (Yin, et al., 2012).  This work will therefore 
also assess the expression latent TGF-β1, PDGF-BB, and Endothelin-1 by BLM-treated 
HUVECs .   
Any alterations in cytokine release and adhesion molecule expression will then be 
confirmed by qPCR, a method not previously used when assessing BLM-induced cytokine 
and adhesion molecule upregulation. This will not only confirm previous results at the 
protein level, but also determine whether BLM regulates the expression and release of 
inducible proteins, and impacts the increased expression and release of constitutively-
expressed proteins, at a transcriptional level. qPCR may also detect increases in transcript 
that do not correlate with increases in protein, suggesting that transcription, but perhaps 
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not yet translation and expression, has occurred. This may be of particular use when 
assessing adhesion molecules such as VCAM-1 and E-Selectin, which require NF-κB 
activation in response to cytokines to be expressed (Read, et al., 1994; Lewis, et al., 1994; 
Ahmad, et al., 1998; Iademarco, et al., 1992; Carlos, et al., 1990; Bevilacqua, et al., 1987; 
Carlos, et al., 1991; Osborn, et al., 1989) and may appear “delayed”, and ICAM-1, the 
increased expression of which is also regulated by NF-κB (Guo, et al., 2012; Ledebur and 
Parks, 1995). 
Moreover, while cytokines such as IL-8 and MCP-1 may be constitutively synthesised and 
expressed, they may also be synthesised de novo in response to NF-κB activation, and 
immediately expressed, e.g., from the Golgi body (in the case of IL-8) (Lakshminarayanan, 
et al., 1998; Ping, et al., 2000; Wolff, et al., 1998) or stored in granules for later release via 
exocytosis (Øynebråten, et al., 2005; Utgaard, et al., 1998; Metcalf, et al., 2008). 
Therefore, qPCR may also hint at the mechanism of increased cytokine release; 
transcriptional regulation and direct release, synthesis and storage, or solely exocytosis 
with BLM acting as the secretagogue, depending on whether both transcript and protein 
levels increased, or whether one and not the other was increased. 
qPCR will be conducted for the adhesion molecules and cytokines whose expression and 
release was seen to alter as determined by flow cytometry and ELISA, to assess whether 
increased protein expression is mirrored by increase transcript levels. The transcript levels 
of cytokines not seen to be released at an increase level in response to BLM will also be 
assessed, to determine whether synthesis has occurred, but release has not.   
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4.2 Materials and Methods 
 
4.2.1 HUVEC Adhesion Molecule Expression Determination Following 
Treatment with BLM 
 
Cells were cultured as outlined in 2.1. To appropriate flasks, 10ml of serum-contaning 
endothelial cell basal medium contaning various concentrations of BLM – as outlined in 
2.6 - was added. Cells were treated with BLM for 6 and 24 hours, as outlined in 2.6. The 
negative control used was HUVECs incubated in serum-contaning endothelial cell basal 
medium (10ml) without BLM. The positive control used was HUVECs incubated in 
endothelial cell basal medium contaning 10ng/ml TNF-α (10ml). Both negative and 
positive control cells were incubated for the same time as BLM-treated cells (6 or 24 
hours, as required). After treatment, cells were dissociated, counted, resuspended to a 
concentration of 1 x 106 cells/ml in endothelial cell medium, and prepared for flow 
cytometry and analysed as described in section 2.3, 2.4, and 2.5, respectively.     
 
4.2.2 Fc Receptor Expression by HUVECs 
 
HUVECs were cultured as outlined in 2.1. Cells were pre-treated with TNF-α (final 
concentration 10ng/ml), IFNγ ( final concentration 1000U/ml), or cotreated with both 
cytokines, or treated with various concentrations of BLM as outlined in 2.6. Cells were 
dissociated and counted as outlined in 2.3 and 2.4. Cells were resuspended to a 
concentration of 1x106, plated as outlined in 2.5 and washed as outlined in 2.5. Cells were 
then incubated with antibodies against a panel of Fc receptors: CD16, CD32A, CD32B, and 
CD64. 
 The antibodies used were as follows: 
 Purified mouse IgG1 negative control (Serotec, Oxford, United Kingdom) 
 Anti-CD32 antibody [AT10] - Azide free, isotype IgG1 (Abcam, Cambridge, United 
Kingdom) 
 Purified anti-human CD32 (clone IV3), isotype unknown, produced in house.  
 Purified mouse anti-human CD16 (clone LNK16), isotype IgG1 (Serotec) 
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 Purified mouse anti-human CD64 (clone 10.1), isotype IgG1 (Serotec) 
 Rabbit F(ab’)2 anti-mouse IgG:FITC (Serotec). 
For a positive control, Daisy Cells were used. This is a macrophage-like cell line generated 
in house (Hayman, et al., unpublished data). These cells have previous been shown to be 
positive for CD16 (Hayman, et al., unpublished data). Daisy cells were cultured in RPMI 
1650 (Lonza) supplemented with 10% v/v foetal bovine serum, penicillin (100μg/ml)-
streptomycin (100U/ml) (PAA), and L-glutamine (2nM) (Lonza).  Daisy cells are both 
adherent and non-adherent cells. Adherent cells were harvested using a cell scraper and 
centrifuged and counted as outlined in 2.2 and 2.2.2, respectively.  
To assess the binding of immunoglobulin complexes to BLM-treated endothelial cells, 
HUVECs were cultured, treated with BLM, dissociated, and counted as outlined in 2.1, 2.7, 
2.3, and 2.4, respectively. Cells were plated as outlined in 2.5, and coincubated with heat 
aggregated immunoglobulin G and BXB immunoglobulin complexes. BXB complexes were 
generated in line with Hart, et al. (2004). In brief, biotinylated bovine serum albumin 
(500µg) (Sigma Aldrich) was combined with FITC-conjugated anti-biotin monoclonal IgG1 
(170µg) (Sigma Aldrich) in PBS (1ml) and incubated on ice for 30 minutes. Concentrations 
of 300, 100, 30, and 10µg/ml biotinylated BSA were generated by dilution in PBS/0.1% 
BSA. Heat-aggregated IgG was generated in line with Hart, et al. (2004) by heating FITC-
conjugated human IgG (Sigma Aldrich), at concentrations of 100, 30, and 10µg/ml in PBS, 
for 20 minutes at 63°C. Complexes were stored at 4°C for up to two weeks until required. 
BLM-treated cells were incubated with these complexes on ice for 30 minutes prior to 
binding assessment by flow cytometry. Data were analysed using Mann-Whitney-U tests 
in SPSS v. 19 statistical analysis software.   
 
4.2.3 HUVEC Cytokine Release Determination in Response to BLM Treatment 
 
Cells were cultured as outlined in 2.1 and replated as outlined in 2.7. When adherent, 3ml 
of serum-containing endothelial cell basal medium containing 0.1µg/ml, 1µg/ml, or 
10µg/ml BLM, was added. Cells were treated with BLM for 6 and 24 hours. Positive and 
negative control supernatants were generated as outlined in section 2.7. The 
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supernatants were then collected as outlined in 2.7 and used for cytokine ELISAs. The 
ELISA kits used were as outlined in 2.8. Supernatants for ELISAs were treated as outlined 
in 2.8. Preliminary work for each ELISA was conducted as outlined in 2.8, and all ELISA 
were carried out in accordance with the manufacturer's instructions 
Plates were read using a plate-reader (Thermo Multiskan FC, Thermo Scientific) at the 
wavelengths instructed by the instructions provided with the kits. For IL-8, MCP-1, TGF-
β1, and ET-1, this was an initial reading at 450nm and a subsequent reading at 570nm, 
the second subtracted from the first to reduce background. For the PDGF-BB ELISA, a 
single 450nm measurement was required.  Standard curves and data analysis was carried 
out as outlined in 2.8. 
 
4.2.4 Performance of qPCR Experiments and Data Handling 
 
qPCR samples (cDNA samples and No RT samples) were prepared as outlined in (section 
2.9) and Mastermix was prepared as outlined in section 3.2.7. This Mastermix contained 
either primers for the appropriate target gene or for the reference gene. To 24 wells of a 
48-well plastic qPCR plate, Mastermix (15µl) contaning the target gene primer was added, 
and to 24 wells, Mastermix (15µl) contaning the reference gene primer was added. To 
each well, cDNA (5μl diluted cDNA at a concentration of 0.5ng/µl) from appropriate 
samples was added. All samples were run in triplicate for both target gene and reference 
gene (i.e., sample A was present in three wells containing the target gene primer, and 
three wells containing the reference gene primer). No cDNA samples were also run in this 
way. No cDNA samples used RNAse/DNAse free water (5µl) in lieu of diluted cDNA 
sample, and therefore contained no template. No RT samples were run for each primer-
sample combination (i.e. Sample A plus target gene, Sample A plus reference gene, 
Sample B plus target gene, and so on). Two plates were required for one full experiment 
(one cell batch treated with all concentrations of BLM for 6 and 24 hours, plus No RT and 
No cDNA controls).   
The qPCR was then run using the Illumina ECO qPCR machine (Illumina, Little Chesterton, 
Essex, UK). The qPCR plate was subject to 10 minutes at 95⁰C for polymerase activation; 
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40 cycles of PCR comprising 15 seconds at 95⁰C and 60 seconds at 60⁰C, and a melt curve 
period for which the plate was heated to 95⁰C for 15 seconds, 55⁰C for 15 seconds, and 
again 95⁰C for 15 seconds. The results were then exported as an Excel file. 
 
4.2.5 qPCR Data Analysis 
 
Initial data analysis was carried out manually. The qPCR analysis programme (Eco, version 
5.0.16.0, Illumina) analysed all qPCR experiments and determined the Cq value of each 
sample based on a threshold of 0.02 units of fluorescence. Derviative melt curves were 
analysed for each reaction in a plate to identify outliers and erroneous results.  Results 
stemming from the formation of primer dimers were identified by the low melt 
temperature and the broad-based peak as shown on the derivative melt plot displayed by 
the Eco software (Fig 4.1). These results were often higher or lower in Cq value obtained 
than other wells which contained the same sample (Fig. 4.2). All potential primer dimers 
were identified using both the derivative melt and the amplification plots.  Such results 
were excluded from analysis. 
If more than one result in each triplicate failed, or was a primer dimer, this sample was 
re-run in triplicate. Samples where one of the three replicates was a primer dimer or 
failed, but the other two represented true readings, contained sufficient relibable 
information from which to obtain a mean Cq value for this sample. Each set of results was 
also assessed for the presence of genomic DNA, denoted by a higher than expected melt 
temperature (>90⁰C). This was not expected, as the agarose gel experiments showed no 
genomic DNA in the samples.     
No RT samples and No cDNA  controls were also assessed to ensure gDNA contamination 
had not occurred. Where values were obtained for either sample, it was determined 
whether this was the result  of primer dimer formation. Where this was the case,  these 
values were discarded, and the sample treated as though no value was obtained. These 
No RT and No cDNA results, as well as those that failed to obtain a Cq value, were 
regarded as zero. All no cDNA and no RT sample results were plotted on final results 
graphs.  
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Analysis of results was conducted using Microsoft Excel. A calculator was created in-
house using Microsoft Excel to conduct Livak (ΔΔCq) calculations to determine the fold 
change in mRNA content in each test (treated) sample as compared to its respective 
calibrator (untreated) sample. Repeated-measures ANOVA statistical analyses were then 
carried out on the ΔCT values obtained for each sample using the GraphPad InStat3 
programme (version 3.00, GraphPad Software).  
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Figure 4.1: Example derivate melt curve from qPCR experiments showing primer dimer formation. 
  
An example derivative melt curve showing the derivative melt for a primer dimer (circled). Note the lower melt temperature and a wider-based peak than genuine 
results (seen at melt temperature of around 81-86⁰C). Such primer dimers will give erroneous results. No  derivative melt peak (denoted by the asterisk) repres-
ents a failed reaction. These appear on derivative melt graphs as flat lines.  
* 
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Figure 4.2: An example amplification plot from qPCR experiments showing primer dimer formation.  
2 
1 
An amplification plot showing primer dimer formation (1, 2), characterised by a Cq value that is higher or lower than genuine results. In this graph, genuine 
results have a Cq value between 20 and 30 cycles. Each primer will have a different standard Cq value. Here, for UBC (green lines) this is between 22 and 24; 
for MCP-1 (blue lines), between 20 and 26, though this will differ based on the abundance of the target transcript. Any results that appear to have a Cq value 
of greater than 35 are likely to be the result of a primer dimer  
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4.3 Results 
 
4.3.1 Adhesion Molecule Protein and mRNA Expression Following 6 Hour BLM 
Incubation 
 
The expression of ICAM-1, E-selectin, and VCAM-1 was increased from baseline following 
treatment with BLM for 6 and 24 hours.  Example raw data obtained for this experiment 
is shown in Figure 4.3.Raw data is shown with a gate applied to highlight the peak-shift 
and increase in ICAM-1 positive cells when cells were treated with BLM. Note that 
correction using gating was NOT used to determine expression (expression was 
determined using uncorrected data and plotted on graphs as outlined in section 2.5). 
 
4.3.1.1 ICAM-1 Expression in Response to BLM 
 
Though the expression of ICAM-1 protein increased in cells treated with BLM for 6 hours 
compared to baseline, (Figure 4.4A), this was not significant. qPCR confirmed a slight 
increase in ICAM-1 mRNA transcript levels in HUVECs treated with 10μg/ml BLM for 6 
hours (Fig 4.4C), though again, this was not significant under any treatment condition. In 
this case, the fold-change observed in ICAM-1 transcript levels broadly reflected the 
increases in protein expression observed - a 2-fold increase in transcript and a 1.5-fold 
increase in protein.  
The expression of ICAM-1 protein was significantly greater (p=0.05) in cells treated with 
10μg/ml BLM for 24 hours, compared to untreated cells (Figure 4.4B). When assessed by 
qPCR, there was a significant increase in ICAM-1 transcript levels in samples treated with 
1μg/ml, and 10μg/ml BLM (Fig 4.4D), which reflects earlier results obtained by flow 
cytometry, though in the flow cytometric results, only cells treated with concentrations of 
10μg/ml BLM showed a significant increase in ICAM-1 expression. The fold change 
observed by qPCR when assessing cells treated with 1 and 10µg/ml was, however, 
broadly similar to the magnitude of protein expression increase observed, with a 3-fold 
increase in protein expression matching a 2.5-fold increase in transcript levels. 
* 
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Figure 4.3: Raw data from flow cytometry experiments assessing adhesion molecule 
expression (ICAM-1) by BLM-treated HUVECs. 
  
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 32.14 16.87 217.79 18.43 1
File: Data.006 Log Data Units: Linear Values
Sample ID: Untreated CD54 Patient ID: 
Tube: Panel: 
Acquisition Date: 16-Jan-13 Gate: No Gate
Gated Ev ents: 10000 Total Ev ents: 10000
X Parameter: FL1-H (Log)
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 7401 100.00 74.01 33.75 22.08 151.20 20.91 10
M1     7,  9910 6875 92.89 68.75 35.97 24.92 145.37 23.08 10
File: Data.006 Log Data Units: Linear Values
Sample ID: Untreated CD54 Patient ID: 
Tube: Panel: 
Acquisition Date: 16-Jan-13 Gate: G2
Gated Ev ents: 7401 Total Ev ents: 10000
X Parameter: FL1-H (Log)
R2
M1
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 213.93 82.56 130.45 124.65 1
File: Data.050 Log Data Units: Linear Values
Sample ID: 10ug/ml BLM CD54 Patient ID: 
Tube: Panel: 
Acquisition Date: 16-Jan-13 Gate: No Gate
Gated Ev ents: 10000 Total Ev ents: 10000
X Parameter: FL1-H (Log)
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 6814 100.00 68.14 252.99 162.04 107.10 171.54 273
M1     6,  9910 6801 99.81 68.01 253.47 163.27 106.91 171.54 273
File: Data.050 Log Data Units: Linear Values
Sample ID: 10ug/ml BLM CD54 Patient ID: 
Tube: Panel: 
Acquisition Date: 16-Jan-13 Gate: G2
Gated Ev ents: 6814 Total Ev ents: 10000
X Parameter: FL1-H (Log)
R2
M1
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 4.34 2.21 2340.55 2.04 1
File: Data.003 Log Data Units: Linear Values
Sample ID: Untreated 2ndry Patient ID: 
Tube: Panel: 
Acquisition Date: 16-Jan-13 Gate: No Gate
Gated Ev ents: 10000 Total Ev ents: 10000
X Parameter: FL1-H (Log)
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 7460 100.00 74.60 2.32 2.07 62.72 2.02 1
M1     7,  9910 106 1.42 1.06 10.19 9.47 44.17 8.51 6
File: Data.003 Log Data Units: Linear Values
Sample ID: Untreated 2ndry Patient ID: 
Tube: Panel: 
Acquisition Date: 16-Jan-13 Gate: G2
Gated Ev ents: 7460 Total Ev ents: 10000
X Parameter: FL1-H (Log)
R2
M1
Raw data for the 
control 
(secondary 
antibody only) 
sample in flow 
cytometry 
experiments. 
1.06% of events 
fall within M1. 
 
Raw data for 
ICAM-1 
expression in 
cells not treated 
with BLM in flow 
cytometry 
experiments. 
92.89% of events 
fall within M1. 
 
 
Raw data for 
ICAM-1 
expression in 
cells treated with 
10µg/ml BLM in 
flow cytometry 
experiments. 
99.81% of events 
fall within M1. 
 
Raw data generated from flow cytometric analysis of control (secondary antibody only) 
samples of HUVECs (top), ICAM-1 expression by untreated HUVECs (middle) and HUVECs 
treated with 0µg/ml BLM for 24 hours (bottom). Gate M1 was drawn to incorporate 1% 
of the control peak. There was a notable peak shift from baseline ICAM-1 expression 
when cells were treated with BLM. Respresentative images of three experiments.  
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Figure 4.4: ICAM-1 expression by BLM-treated HUVECs determined by flow cytometry 
and qPCR.  
The expression of ICAM-1 by HUVECs treated with BLM for 6 (A) and 24 (B) hours as 
determined by flow cytometry, and the fold-change  in ICAM-1 transcript levels in cells 
treated with BLM for 6 (C) and 24 (D) hours as determined by qPCR. Statistical analysis 
of qPCR results was conducted using repeated-measures ANOVA (as outlined in 
section 4.2.5).  Statistically significant increases in protein or transcript levels from 
baseline (p=0.05) are denoted by asterisks. N=3.   
A 
B 
D C 
* 
* * 
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4.3.1.2 E-Selectin and VCAM-1 Expression in Response to BLM 
 
The expression of E-Selectin protein was significantly different from baseline (untreated 
cells) in cells treated with 10μg/ ml BLM for 6 hours (Figure 4.6A). The qPCR results 
demonstrate a significant increase in E-Selectin mRNA levels in cells treated with 1μg/ml 
BLM and 10μg/ml BLM (Figure 4.6E). Though the increase in E-Selectin mRNA levels in 
cells treated with 10μg/ml BLM reflects the increase in E-Selectin protein expression, 
increased protein expression by cells treated with 1μg/ml BLM was not observed, and the 
magnitude of the increases in transcript levels is higher than increases in protein 
expression - a 17-fold increase was observed in transcript levels, but only a 2-fold increase 
in protein expression levels was noted.  
The expression of VCAM-1 protein was significantly different from baseline in cells 
treated with 10μg/ ml BLM for 6 hours (Figure 4.6A). There was also a large increase in 
VCAM-1 transcript levels in cells treated with 10μg/ml BLM (Figure 4.6C), and again, this 
was of a greater magnitude than the increase in protein expression; an 8-fold increase in 
transcript levels was observed, compared to a 1.5-fold increase in protein expression 
levels. Therefore, when cells are treated with BLM for 6 hours, the fold-change in 
transcript levels is proportionally greater than the increase in E-Selectin and VCAM-1 
protein expression levels. 
The expression of E-Selectin was significantly greater (p=0.05) in cells treated with all 
concentrations of BLM for 24 hours than at baseline (Figure 4.6B). The results from qPCR 
experiments mirrored this. E-Selectin mRNA levels following treatment of cells with BLM 
for 24 hours closely resemble the increases in E-Selectin protein expression in previous 
experiments (Figure 4.6F). In all cases, there was a statistically significant increase in the 
level of mRNA in cells treated with BLM.  
There was a noticeable increase in the expression of VCAM-1 also, but this was not 
statistically significant (Figure 4.4B). There was also a slight increase in VCAM-1 transcript 
levels in cells treated with all three concentrations of BLM for 24 hours (Figure 4.6D), 
though none of these increases were significant, much like the flow cytometric analyses, 
and the standard error of the mean in this case is high. This is due to one set of results 
from a single cell line in which the VCAM-1 mRNA levels in the cells treated with 10μg/ml 
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BLM was low. However, the fold changes in transcript levels in this experiment closely 
mirror the increases in protein expression observed.  
Raw data obtained from flow cytometry experiments assessing VCAM-1 expression in 
cells treated with BLM is shown in Figure 4.5. Raw data is shown with a gate applied only 
to highlight the peak-shift and increase in VCAM-1 positive cells when cells were treated 
with BLM. Note that correction using gating was NOT used to determine expression 
(expression was determined using uncorrected data and plotted on graphs as outlined in 
section 2.5). 
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Figure 4.5: Raw data from flow cytometry experiments assessing adhesion molecule 
expression (VCAM-1) by BLM-treated HUVECs.  
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 7.33 3.83 609.81 3.28 1
File: Data.054 Log Data Units: Linear Values
Sample ID: 10ug/ml BLM CD106 Patient ID: 
Tube: Panel: 
Acquisition Date: 16-Jan-13 Gate: No Gate
Gated Ev ents: 10000 Total Ev ents: 10000
X Parameter: FL1-H (Log)
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
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File: Data.054 Log Data Units: Linear Values
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Tube: Panel: 
Acquisition Date: 16-Jan-13 Gate: G2
Gated Ev ents: 6947 Total Ev ents: 10000
X Parameter: FL1-H (Log)
R2
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Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 4.34 2.21 2340.55 2.04 1
File: Data.003 Log Data Units: Linear Values
Sample ID: Untreated 2ndry Patient ID: 
Tube: Panel: 
Acquisition Date: 16-Jan-13 Gate: No Gate
Gated Ev ents: 10000 Total Ev ents: 10000
X Parameter: FL1-H (Log)
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 7460 100.00 74.60 2.32 2.07 62.72 2.02 1
M1     7,  9910 106 1.42 1.06 10.19 9.47 44.17 8.51 6
File: Data.003 Log Data Units: Linear Values
Sample ID: Untreated 2ndry Patient ID: 
Tube: Panel: 
Acquisition Date: 16-Jan-13 Gate: G2
Gated Ev ents: 7460 Total Ev ents: 10000
X Parameter: FL1-H (Log)
R2
M1
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 3.67 2.42 359.23 2.17 1
File: Data.010 Log Data Units: Linear Values
Sampl  ID: U treated CD106 Patient ID: 
Tube: Panel: 
Acquisition Date: 16-Jan-13 Gate: No Gate
Gated Ev ents: 10000 Total Ev ents: 10000
X Parameter: FL1-H (Log)
Histogram Statistics
Marker Lef t, Right Ev ents % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 7467 100.00 74.67 2.68 2.23 174.03 2.13 1
M1     7,  9910 232 3.11 2.32 14.35 11.06 160.61 9.22 7
File: Data.010 Log Data Units: Linear Values
Sample ID: Untreated CD106 Patient ID: 
Tube: Panel: 
Acquisition Date: 16-Jan-13 Gate: G2
Gated Ev ents: 7467 Total Ev ents: 10000
X Parameter: FL1-H (Log)
R2
M1
Raw data for the 
control 
(secondary 
antibody only) 
sample in flow 
cytometry 
experiments. 
1.06% of events 
fall within M1. 
Raw data for 
VCAM-1 
expression in 
cells not treated 
with BLM in flow 
cytometry 
experiments. 
2.32% of events 
fall within M1. 
Raw data for 
VCAM-1 
expression in 
cells treated with 
10µg/ml BLM in 
flow cytometry 
experiments. 
30.32% of events 
fall within M1. 
 
Raw data g ner ted from flow cytometric analysis of control (secondary antibody only) samples of 
HUVECs (top), VCAM-1 expression by untreated HUVECs (middle) and HUVECs treated with 10 
µg/ml BLM for 24 hours (bottom). Gate M1 was drawn to incorporate 1% of the control peak. 
There was a peak shift from baseline VCAM-1 expression when cells were treated with BLM, as 
around 30% of cell appeared to express VCAM-1 in response to BLM, but the majority of cells still 
expressed essentially zero VCAM-1, as hown by the population outside the gate (M1) on the 
bottom histogram. Respresent tive images of 3 experiments.  
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E-Selectin and VCAM-1 Expression by HUVECs Treated
with BLM for 6  Hours
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Fold Change in E-Selectin mRNA Levels in  Samples Isolated
From HUVECs Treated with  BLM for 6 Hours
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Figure 4.6: VCAM-1 and E-selectin expression by BLM-treated HUVECs as assessed by 
flow cytometry and qPCR. 
  
The expression of E-Selectin and VCAM-1 by HUVECs treated with BLM for 6 (A) and 24 (B) hours 
as determined by flow cytometry, the fold-change in VCAM-1 transcript levels in cells treated with 
BLM for 6 (C) and 24 (D) hours, and  the fold-change in E-selectin transcript levels in cells treated 
with BLM for 6 (E) and 24 (F) hours as determined by qPCR. Statistical analysis of qPCR results was 
conducted using repeated-measures ANOVA (as outlined in section 4.2.5).  Statistically significant 
increases in protein and transcript levels from baseline are denoted by asterisks (p=0.05). n=3.  
A B 
C D 
E F 
* * * 
* * 
* * * 
* 
* 
* 
160 
 
4.3.2 Fc Receptor Expression by HUVECs 
 
In the first round of experiments using BLM to treat the HUVECs and TNF-α as a positive 
control, and experiments using TNF-α to determine the ideal positive control mediator to 
use, the binding of the isotype control was increased by treatment with both substances 
(Fig. 4.7). This was also noted when HUVECs were treated with IFN-γ and LPS in earlier 
work (Table A.1). As HUVECs did not demonstrate increased autofluorescence in response 
to TNF-α or BLM (which would simulate increase non-specific isotype control binding) 
(Fig. 4.7), if Fc receptor expression was occurring due to treatment was assessed. 
Isotype  Control  Antibody Binding to  HUVECs  Treated
with  BLM for 6  Hours
Adhesion  Molecule
A
v
e
ra
g
e
 G
e
o
m
e
tr
ic
  
M
e
a
n
  
(a
rb
it
ra
ry
 u
n
it
s
)
Cells Only Isotype Control Secondary Antibody
0
5
10
15
Untreated
0.1µg/ml BLM
1µg/ml BLM
10µg/ml BLM
10ng/ml TNF-
Isotype  Control  Antibody Binding to  HUVECs  Treated
with  BLM for 24  Hours
Adhesion  Molecule
A
v
e
ra
g
e
 G
e
o
m
e
tr
ic
  
M
e
a
n
  
(a
rb
it
ra
ry
 u
n
it
s
)
Cells Only Isotype Control Secondary Antibody
0
5
10
15
Untreated
0.1µg/ml BLM
1µg/ml BLM
10µg/ml BLM
10ng/ml TNF-
 
Figure 4.7: Isotype control binding to HUVECs treated with BLM and TNF-α. 
 
 
 
 
It was initially assessed whether Fc receptor expression could be induced by treatment of 
HUVECs with 10ng/ml TNF-α, 1000U/ml IFN-γ, or co-treatment with both cytokines, as in 
work by Pan, et al. (1999). However, no Fc receptor expression was observed (data not 
shown). Similarly, treatment with BLM of various concentrations did not induce the 
expression of CD16, CD32, or CD64 by HUVECs over 6 hour treatment times, though this 
treatment did increase the non-specific binding of the isotype control to the cells. While 
there appeared to be statistically significant increases in the expression of Fc receptors by 
HUVECs treated with BLM for 24 hours, these increases mirror the slight increases in 
binding of the secondary antibody to the cells, and likely represent an artifact (Fig 4.8).   
A B 
* * 
Isotype control binding to BLM and TNF-α treated HUVECs. Treatment with increasing 
concentrations of BLM increased non-specific binding, as did treatment with TNF-α. 
Statistically significant increases in isotype control binding compared to baseline 
(p=0.05) are denoted by an asterisk. n=3.  
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Figure 4.8: Fc receptor expression by HUVECs treated with BLM  
A 
B 
* * * * * 
* 
Fc receptor expression by HUVECs treated with various concentrations of BLM for 
6 (A) and 24 (B) hours. Non-specific binding of the isotype control increased with 
BLM treatment, and though Fc receptor expression appears to increase compared 
to baseline, these increases mirror the binding of the secondary antibody to cells 
and therefore likely represent an artefact.  
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To further determine whether BLM treatment was increasing Fc receptor expression, the 
binding of heat-aggregated IgG1, non-aggregated IgG1, and BXBs (IgG1 complexes) to 
BLM-treated HUVECs was also assessed. As shown in Fig. 4.9-4.11, there appeared to be a 
slight but significant increase in the binding of non- and heat-aggregated IgG1 and BXBs 
to BLM- and TNF-α-treated HUVECs, though again, this mirrored the increased binding of 
the isotype control antibody, and the slight increase in the autofluorescence of the cells 
alone.  It may therefore be said that the increased binding observed when cells were 
treated with BLM and TNF-α was an artifact, and that Fc receptor expression was not 
increased by treatment with BLM of any concentration, or with TNF-α.  
 
 
Binding of Non-Aggregated IgG1 to HUVECs Treated
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Figure 4.9: Non-aggregated IgG binding to HUVECs treated with BLM 
  
* 
* 
* 
* 
* 
* 
The binding of non-aggregated IgG1 to BLM-treated HUVECs. While IgG1 binding 
appears to increase compared to baseline, and some of these increases are statistically 
significant (denoted by asterisks), these increases mirror the increases in cell 
autofluorescence and likely represent an artefact. 
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Binding of Heat-Aggregated IgG1 to HUVECs Treated
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Figure 4.10: Heat-aggregated IgG binding to HUVECs treated with BLM 
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Figure 4.11: BXB binding to HUVECs treated with BLM 
  
* * * 
* 
* 
The binding of heat-aggregated IgG1 to BLM-treated HUVECs. While IgG1 binding appears 
to increase compared to baseline, and some of these increases are statistically significant 
(denoted by asterisks), these increases mirror the increases in cell autofluorescence and 
likely represent an artefact. 
* 
* 
* 
* 
The binding of immune complexes (BXBs) to BLM-treated HUVECs. While IgG1 binding 
appears to increase compared to baseline, and some of these increases are statistically 
significant (denoted by asterisks), these increases mirror the increases in cell 
autofluorescence and likely represent an artefact. 
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As no reason for increased isotype control binding was evident, the batch of isotype 
control used was altered. However, changing the batch or type of isotype control did not 
appear to ameliorate the non-specific binding observed. However, when assessing the 
secondary antibody alone for potential use as a control antibody, is it evident that the 
binding of the secondary antibody to assessed cells did not appear to be impacted as 
dramatically by treatment of HUVECs with TNF-α or BLM, as shown in Figure 4.7.  
Therefore, the secondary antibody alone control sample was used as the “control” 
sample in all experiments.   
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4.3.3 Pro-Inflammatory Cytokine Release by HUVECs Treated with Bleomycin 
 
There was an increase in the release of IL-8 by HUVECs treated with all concentrations of 
BLM over 24 hours, though only when cells were treated with 10µg/ml BLM was this 
increase significant. Increases were seen only in cells treated with 1µg/ml and 10µg/ml 
BLM over six hours (and only cells treated with 10µg/ml BLM exhibited a statistically 
significant increase). Cells treated with 0.1µg/ml BLM over six hours exhibited 
significantly decreased release (Figure 4.12A). When MCP-1 release by BLM-treated 
HUVECs was assessed (Figure 4.13A), release was noticeably increased in response to 
1µg/ml and 10µg/ml BLM over six hours, though over 24 hours, only cells treated with 
10µg/ml BLM showed a large increase in MCP-1 release.  There were no statistically 
significant changes in MCP-1 expression when cells were treated with BLM compared to 
controls.  
The qPCR results obtained for IL-8 are roughly analogous to those obtained in the 
previous ELISA experiments which showed a slight decrease in IL-8 protein release in cells 
treated with 0.1µg/ml BLM compared to baseline, and an increase in IL-8 release by cells 
treated with 10µg/ml BLM compared to baseline, when cells were treated with BLM for 6 
hours (Figure 4.12B). However, the increases shown by qPCR were not significant, unlike 
those seen using ELISA. The increases in transcript levels when cells were treated with 
BLM for 24 hours were very similar to the increase seen in protein expression, but again, 
the increase in transcript levels was not significant, while the increase in IL-8 release by 
cells was, when cells were treated with 10µg/ml BLM (Figure 4.12C). Overall, the 
increases in transcript levels as determined by qPCR were similar to protein levels 
detected by ELISA; there was a slight concentration-dependent increase in IL-8 mRNA 
levels, and this is of roughly the same magnitude as the results of the ELISA would 
suggest.  
Results from qPCR experiments assessing MCP-1 transcript levels did not correlate 
strongly with those obtained by ELISA. When cells were treated with BLM for 6 hours, 
there was a statistically significant increase in the levels of MCP-1 mRNA in cells treated 
with 10μg/ml BLM compared to baseline (Figure 4.13B). This was not reflective of ELISA 
results, in which there was a slight, but non-significant, increase in MCP-1 release when 
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cells were treated with BLM for 6 hours (Figure 4.13A). Moreover, when cells were 
treated for 24 hours, there was only a slight increase in MCP-1 transcript levels above 
baseline in all BLM-treated samples (Figure 4.13C), while the release of MCP-1 as 
determined by ELISA was far more substantial, with the increase in MCP-1 release by cells 
treated with 10µg/ml BLM being far higher than baseline (Figure 4.13A). The results from 
cells treated with BLM for 24 hours in fact more closely resemble those obtained by ELISA 
from cells treated with BLM for 6 hours.  
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Figure 4.12: IL-8 release by BLM-treated HUVECs and IL-8 transcript expression levels in 
BLM-treated HUVECs assessed by ELISA and qPCR. 
  
* 
* 
* 
The release of IL-8 by HUVECs treated with BLM for 6 and 24 hours (A) as determined 
by ELISA and the fold-change in IL-8 transcript levels in cells treated with BLM for 6 (B) 
and 24 (C) hours. Statistical analysis of qPCR results was conducted using repeated-
measures ANOVA (as outlined in section 4.2.5).  Statistically significant increases in 
protein and transcript levels from baseline are denoted by asterisks (p=0.05). n=3. 
A 
B C 
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MCP-1  Release by  HUVECs Treated with  BLM
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Figure 4.13: MCP-1 release by BLM-treated HUVECs and MCP-1 transcript expression by 
BLM-treated HUVECs as assessed by ELISA and qPCR. 
  
* 
The release of MCP-1 by HUVECs treated with BLM for 6 and 24 hours (A) as determined 
by ELISA, and the fold-change in MCP-1 transcript levels in cells treated with BLM for 6 
(B) and 24 (C) hours. Statistical analysis of qPCR results was conducted using repeated-
measures ANOVA (as outlined in section 4.2.5).  Statistically significant increases in 
protein and transcript levels from baseline are denoted by asterisks (p=0.05). n=3. 
A 
B C 
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4.3.4 Pro-fibrotic Cytokine Expression by HUVECs Treated with Bleomycin 
 
Cells treated with BLM did not show any increase in the level of TGF-β released  under 
any treatment condition (Figure 4.14A). This was mirrored by qPCR results which showed 
no increase in trascript levels when cells were treated with BLM for 24 hours (Figure 
4.14B). The expression of PDGF-BB decreased in response to BLM treatment over 6 hours, 
though this was not statistically significant. PDGF-BB expression by BLM treated HUVECs 
was not impacted by treatment with any concentration of BLM over 24 hours (Fig. 4.14C). 
Again, this was mirrored by qPCR results (Figure 4.14D).  
The expression of Endothelin-1, a profibrotic and potentially vasoconstrictive cytokine, 
was impacted by cell treatment with  BLM, however. Increases in expression were noted 
when cells were treated with 1μg/ml and 0.1µg/ml BLM over six and 24 hours, 
respectively (Figure 4.15A), though neither increase was statistically significant (p=0.05) . 
However, the standard error of the mean was high as these samples showed a large 
difference in expression between cell lines. There does appear to be a trend towards 
endothelin-1 expression decreasing when exposed to high concentrations of BLM, 
however, though this was not significant (Figure 4.15A). However, this decrease is 
confirmed by qPCR results, in which treatment of HUVECs with 10µg/ml BLM for 24 hours 
greatly decreased the levels of ET-1 mRNA (though not significant again) (Figure 4.15B), 
and when cells were treated with 0.1µg/ml BLM, the increase in Endothelin-1 release at a 
protein level does mirror the slight increase in Endothelin-1 mRNA levels (Figure 4.15B). 
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TGF-1 Release by  HUVECs Treated with  BLM
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PDGF-BB Release by  HUVECs Treated with  BLM
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Figure 4.14: TGF-β1 and PDGF-BB release by BLM-treated HUVECs and TGF-β1  and 
PDGF-BB transcript expression by BLM-treated HUVECs as assessed by ELISA and qPCR. 
  
The release of TGF-β1 by HUVECs treated with BLM for 6 and 24 hours (A) as 
determined by ELISA;  the fold-change in TGF-β1 transcript levels in cells treated with 
BLM for 24 hours (B); The release of PDGF-BB by HUVECs treated with BLM for 6 and 
24 hours (C) as determined by ELISA;  the fold-change in PDGF-BB transcript levels in 
cells treated with BLM for 24 hours (D). Statistical analysis of qPCR results was 
conducted using repeated-measures ANOVA (as outlined in section 4.2.5).  Statistically 
significant results are denoted by asterisks (p=0.05). n=3. 
A 
D C 
B 
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Endothelin-1  Release by  HUVECs Treated with  BLM
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Figure 4.15: Endothelin-1 release by BLM-treated HUVECs and Endothelin-1 transcript 
expession by BLM-treated HUVECs assessed by ELISA and qPCR. 
 
The release of Endothelin-1 by HUVECs treated with BLM for 6 and 24 hours (A) as 
determined by ELISA, and  the fold-change in Endothelin-1 transcript levels in cells 
treated with BLM for 24 hours (B). Statistical analysis of qPCR results was conducted 
using repeated-measures ANOVA (as outlined in section 4.2.5). Statistically significant 
results are denoted by asterisks (p=0.05). n=3. 
A 
B 
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4.4 Discussion and Conclusions 
 
These results extend our knowledge of how HUVECs respond to BLM treatment, in terms 
of adhesion molecule upregulation and cytokine release. These data show that, when 
HUVECs are incubated with BLM over a 6 hour period, there is a statistically significant 
increase in E-Selectin and VCAM-1  expression in cells treated 10μg/ml BLM, while over 
24 hours, E-Selectin expression was significantly increased in cells treated with all 
concentrations of BLM, and the expression of ICAM-1 was significantly increased in cells 
treated with 10µg/ml BLM for 24 hours. In addition, cells treated with 1µg/ml BLM 
showed an almost significant increase in ICAM-1 expression; further repeats of this 
experiment may allow a statistically significant difference in the expression of ICAM-1 to 
be achieved. Thus, BLM appears to impact the expression of adhesion molecules by 
endothelial cells.  
 
4.4.1 Adhesion Molecule Expression in Response to BLM 
 
While previous literature has reported increased expression of E-Selectin, ICAM-1, and 
ICAM-3 following the treatment of ECs with BLM (Miyamoto, et al., 2002; Ishii and 
Takada, 2002; Fichtner, et al., 2004), this  the first report of increased VCAM-1 expression 
in response to BLM, and of ICAM-1 expression by HUVECs. Miyamoto, et al. (2002) 
reported that treatment of HUVECs with BLM at concentrations of 250-500 ng/ml for 6 
hours induced increased E-Selectin expression, while ICAM-3 expression was induced 
after HUVECs were treated with 100ng/ml -250ng/ml BLM for 24 and 48 hours, but no 
ICAM-1 expression was reported by this group, who stated that the origin of the cell type 
- HUVECs - was the cause of the absence of ICAM-1; indeed, ECs of different origin 
demonstrate heterogeneity, though in this work, strong expression of cell-surface ICAM-1 
in response to BLM (10μg/ml for 24 hours) was observed. Moreover, this work reports no 
increased, or baseline, expression of ICAM-3, which was shown to be upregulated at a 
transcript level via Western Blots by Miyamoto, et al. (2002). In fact, when assessing 
adhesion molecules the only observed similarity between this work and that of Miyamoto 
in the increase in E-Selectin expression observed. 
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That increased E-Selectin expression was seen in the current work also tallies with the 
results of  Ishii and Takada (2002), who noted a time- and concentration-dependent 
increase in  E-Selectin mRNA and protein expression by BLM-treated HUVECs, with 6 hour 
incubations and incubations with 5μM BLM resulting in the strongest upregulation. In this 
respect, the current work adds further weight to the evidence that E-Selectin expression 
may be BLM-mediated. 
There has only been one previous report of ICAM-1 expression increasing in response to 
BLM, and this is in the work by Fichtner, et al. (2004), who observed increased ICAM-1 
protein and mRNA expression in human pulmonary microvascular ECs (hPMVECs) - a 
more physiologically relevant cell type, and one which will be used later in this work - 
treated with 100U/ml (over 50μg/ml) BLM for 24 hours. While this is a different cell type, 
and the heterogeneity of endothelial cells has been discussed, this suggests that ICAM-1 
upregulation in response to BLM is feasible.   
How such adhesion molecule upregulation occurs in response to BLM is unknown. Ishii 
and Takada (2002) suggested increased E-Selectin expression was mediated by activation 
of the promoter. The promoter has three binding sites for NF-κB (Collins, et al., 1995; 
Schindler and Baichwal, 1994), a heterodimer of p50 and p65 (RelA) which, under 
unstimulated conditions, is inactivated by association with IκBα (Anwar, et al., 2004). In 
response to stimulation, degradation of IκBα releases NF-κB, allowing translocation to the 
promoter (Rahman, et al., 2000), which mediates transcription. Ishii and Takada noted 
that BLM treatment resulted in NF-κB/Rel and AP-1 activation, and NF-κB translocation. 
Blockade of NF-κB activation and binding reduced E-Selectin expression (though whether 
AP-1 is necessary for E-Selectin expression is debated (Montgomery, et al.,1991; Read, et 
al.,1997; Min and Pober, 1997)). However, if BLM induces NF-κB activation, required for 
the transcription of other molecules including VCAM-1 and ICAM-1, then this may be the 
cause of adhesion molecule upregulation in response to BLM. 
Assessing the results obtained for qPCR experiments, it is clear that for the most part, the 
levels of adhesion molecule protein by BLM-treated HUVEC was similar to the mRNA 
levels observed. This was the case for ICAM-1, where small increases in mRNA levels 
mirrored small increases in protein expression. Increases in mRNA levels were broadly 
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similar to protein expression increases, and are comparable enough to suggest that ICAM-
1 protein upregulation in response to BLM is controlled at a transcriptional level, and that 
increased ICAM-1 expression when cells were assessed by flow cytometry was not merely 
a chance occurrence.   
However, when the mRNA and protein expression levels of both VCAM-1 and E-Selectin 
were compared, discrepancies were noted in the magnitude of the increase. VCAM-1 and 
E-Selectin are not expressed constitutively and so their expression at a protein level 
requires increased transcription. As the baseline level of VCAM-1 and E-Selectin 
expression is almost identical to the control, which suggests no protein expression at 
baseline, the magnitude of increased transcript levels may in fact mirror the increase in 
protein expression more closely than evident at first glance, as the relative increase in 
protein expression may be higher than first thought. These discrepancies, however, may 
also be related to post-transcriptional and post-translational regulatory processes, 
discussed in section 4.4.5. Regardless, the trends seen in transcript level and protein 
expression increases for both VCAM-1 and E-Selectin were broadly similar, and these 
results suggest BLM regulates increased VCAM-1 and E-Selectin protein expression at a 
transcriptional level.   
There may be other reasons for these discrepancies. Both FACS and qPCR are “snap-
shots” of cellular processes; VCAM-1 is expressed in response to inflammatory stimuli, 
and maximal VCAM-1 protein expression occurs at 8 hours, declining after 12 hours 
(Scholz, et al., 1996; Haraldsen, et al., 1996), while maximal synthesis is noted at 4-6 
hours (Scholz, et al., 1996). It is possible that in our results, synthesis has peaked, but 
expression has not, due to a time-lag in protein expression. However, ICAM-1 protein 
expression peaks at 24-48 hours after stimulation (Haraldsen, et al., 1996) - seen in our 
results – but peak gene expression occurs after 4-6 hours in response to inflammatory 
stimuli (Scholz, et al., 1996). In this work, ICAM -1 transcript levels correlated closely with 
protein expression at both time points, and both were consistently upregulated. This may 
be due to enduring incubation with BLM, though this is speculative. However, 
discrepancies in E-Selectin transcript levels and protein expression cannot be explained in 
this way; E-Selectin is expressed quickly following sitmulation, peaking 4-6 hours after 
stimulation, and decreasing at 24 hours (Khew-Goodall, et al., 1996; Haraldsen, et al., 
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1996). However, gene expression peaks concurrently (Scholz, et al., 1996), and mRNA 
expression mirrors protein expression; both decrease simultaneously, stimulus 
independent (Bevilacqua, et al., 1989; McEver, 1997). Therefore, this gives no clue as to 
why levels of E-Selectin transcript were higher than protein levels.  
Overall, the flow cytometric analyses and qPCR experiments confirm that BLM increases 
ICAM-1, E-Selectin, and VCAM-1 expression at both protein and transcriptional levels. 
These are arguably the most important three adhesion molecules in the diapedesis 
cascade in systemic circulation (though there are some differences in the profile of 
adhesion molecules expressed in the systemic circulation and in lung venules when 
compared to lung capillaries, as discussed in 1.8 and 5.1), and suggest that BLM may 
induce the increased immune cell infiltration into the lung via adhesion molecule 
upregulation. Though not explicitly investigated in this work, this upregulation may be NF-
κB regulated; this would provide a fascinating focus for future work, to unravel the 
mechanisms behind how BLM induces such expression upregulation. 
 
4.4.2 Fc Receptor Expression by BLM and TNF-α Treated HUVECs 
 
As it was observed when initial experiments were carried out that treatment with BLM 
and TNF-α increased the binding of the isotype control antibody to HUVECs, and 
increased autofluorescence which may simulated increased non-specific binding was 
absent, whether these treatments induced Fc receptor expression by HUVECs was 
assessed. However, no expression of any of the assessed Fc receptors by HUVECs treated 
with BLM or TNF-α was reported. That HUVECs do not express Fc receptors in response to 
BLM or TNF-α was confirmed by experiments in which non-aggregated and heat-
aggregated IgG1 and BXB (immune complexes) did not adhere to treated HUVECs. 
Therefore, it can be stated that BLM and TNF-α do not induce the expression of Fc 
receptors by HUVECs.  
This goes against the published literature of Pan, et al. (1999), and fails to explain the 
increased isotype control binding observed when cells were treated with TNF-α and BLM 
in this work.  
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In light of this, the batch of isotype control antibody was replaced, to determine whether 
the batch of isotype control being used was contaminated. However, this made no 
difference to the binding of the isotype control antibody to the treated HUVECs. As the 
increased binding of the isotype control to TNF-α and BLM-treated HUVECs could not be 
explained or prevented, the decision was made to use the secondary antibody control as 
the baseline expression level of markers in this series of experiments and all others. The 
binding of this antibody to cells was not impacted by the treatment of cells with various 
concentrations of BLM or TNF-α, and was thus deemed a more reliable representation of 
non-specific binding of target antibodies to HUVECs in this, and future, series of 
experiments. For this reason, the secondary antibody was also used as the control 
antibody in series of experiments carried out using flow cytometry earlier (those to 
determine the best mediator to use as a positive control). 
 
4.4.3 Cytokine Release in Response to BLM 
 
In this work, it was  observed that the release of MCP-1 and IL-8 are increased in response 
to BLM treatment. It is also worth mentioning that, as IL-8, MCP-1, and Endothelin-1 are 
constitutively released, the differences between 6 hour and 24 hour baseline expression 
were expected.  However, only IL-8 showed statistically significant increases in release 
when cells were treated with BLM. It is surprising that the release of MCP-1 when cells 
were treated with 10μg/ml BLM was not significantly different from baseline as there is 
clearly an increased level of MCP-1 release. However, this was mostly likely due to the 
low number of replicates and the high degree of variation in MCP-1 release by untreated 
cells. Further experiments may generate results showing the increased release of MCP-1 
when cells were treated with 10μg/ml BLM to be significantly different from MCP-1 
release by untreated cells.  
In this respect, the Endothelin-1 results are also curious; increased release was noted 
when cells were treated with 0.1 and 1µg/ml BLM, and 1µg/ml BLM for 24 and 6 hours, 
respectively, but these were not significant. A decrease in Endothelin-1 release was noted 
in  cells treated with 10μg/ml BLM for 24 hours, but again, this was not significant. 
Further experiments generating more repeats may show that Endothelin-1 release by 
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HUVECs treated with these concentrations of BLM over these time points is statistically 
different, or that this increase is not as substantial as suggested. Lastly, there was no 
increase in the release of TGF-β and PDGF-BB in response to BLM.   
When comparing this work to previous publications, it appears that in the current  work, 
the release of IL-8 and MCP-1 was quite different to that reported by Miyamoto, et al. 
(2002). This group reported that, when cells were treated with BLM for 6 and 24 hours at 
various concentrations, there was no increase in IL-8 release. Instead, this group reported 
only significant increases in release at 12 hours, and only at  concentrations of 10ng and 
50ng/ml BLM. Our results instead show that there was a definite dose-dependent 
increase in the release of IL-8 by HUVECs treated with BLM over 24 hours, and at higher 
concentrations of the drug. Few other studies have assessed the release of 
proinflammatory cytokines by endothelial cells in response to BLM, though Fichtner, et al. 
(2004) reported the increased IL-8 release by PMVECs in response to concentrations of 
BLM of over 50μg/ml, and as such a high concentration was used, and on a different cell 
type, the results of Fichtner cannot be directly compared to the results obtained in this 
work.   
With regards to MCP-1, Miyamoto and colleagues reported a slight increase in MCP-1 
release in cells treated with 10ng/ml and 50ng/ml BLM for 12 and 48 hours only. 
However, we noticed a substantial increase in MCP-1 release was observed in this work 
when cells were treated with 10μg /ml BLM, which was not observed by Miyamoto and 
colleagues, who instead reported a cessation of release at high BLM concentrations. 
These differences may be due to the high levels of cell death reported at higher BLM 
concentrations by Miyamoto and colleagues, a phenomenon that not observed in the 
current work.  
There are very few published works assessing pro-fibrotic expression by BLM-treated 
HUVECS. While Miyamoto, et al. (2002) found no significant difference in TGF-β1 release 
by BLM-treated HUVECs, these results were not published, and it is not clear whether 
active or latent TGF-β was being measured in this study, or what the baseline expression 
levels were. Yin, et al. (2012), however, reported increased TGF-β release by endothelial 
cells in I.T. BLM-treated rodents, but the group did not determine whether this increased 
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expression was due to the effect of BLM on endothelial cells, or whether endothelial TGF-
β expression was due to the expression of cytokines in the murine lung affecting the 
endothelium. However, this is worth investigating.TGF-β is recognised as an important 
cytokine in the development of pulmonary fibrosis, and the release of TGF-β by epithelial 
cells in the lung is widely regarded as contributory to BPF development (as reviewed by 
Williamson, et al., 2015).There have been no reports investigating the expression of 
PDGF-BB by HUVECs exposed to BLM. 
That BLM impacts Endothelin-1 release has not previously been reported. It appears that 
treatment with low concentration BLM increases Endothelin-1 release, and this may be of 
importance in future work. Endothelin-1 is a potent pro-fibrotic cytokine, inducing the 
transdifferentiation of fibroblasts (Shi-Wen, et al., 2004; Ross, et al., 2009) and collagen 
synthesis by mesenchymal cells (Fonseca, et al., 2009). Moreover, human lung fibroblasts 
express Endothelin-1 receptors and may produce their own Endothelin-1 in response to 
TGF-β and Endothelin-1 in combination (Ahmedat, et al., 2012), resulting in increased 
numbers of myofibroblasts - which may be apoptosis-resistant (Kulasekaran, et al., 2009) 
- and increased collagen synthesis.  Therefore, endothelially-expressed Endothelin-1 may 
feasibly induce autocrine Endothelin-1 signalling loops in proximate mesenchymal cells, 
contributing to BPF development. However, high BLM concentrations appeared to 
decreased Endothelin-1 release from baseline. The relevance of this is unknown. 
Moreover, the apparent increase in release demonstrated a large standard error in both 
ELISA  results, and so care must be taken in drawing strong conclusions from these 
results.        
Like the results obtained when assessing adhesion molecule mRNA levels, the results 
obtained from ELISAs to determine IL-8 release by BLM-treated HUVECs and the qPCR 
results to assess transcription levels correlate well. In both the 6 hour and the 24 hour 
experiments, protein release mirrored mRNA levels, as treatment with 10μg/ml BLM 
induced a 2.5-fold increase in both protein and transcript levels in both. The decrease in 
IL-8 release induced by 0.1µg/ml BLM was also seen to correlate with mRNA levels, which 
was not expected. Therefore, it appears transcription regulated protein release in IL-8.    
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This was also the case for MCP-1, though the results were less concordant. Slight 
increases in transcript level were seen to mirror  slight increases in protein release in both 
the 6 and 24 hour experiments when cells were treated with 0.1 and 1µg/ml BLM. Only 
the results from cell treated with 10µg/ml BLM appear discordant, though in the 24-hour 
experiment, a transcript fold increase of around 1.5 resulted in a tripling of the protein 
released into the supernatant. In the 6-hour experiment, however, a fold-increase of 
approximately 4 was seen in MCP-1 transcript levels in cells treated with 10µg/ml BLM; 
this was not reflected in protein release, though the large error bars in the qPCR results 
from these samples is notable.  
The results from the IL-8 and MCP-1 qPCR experiments are interesting, however, as they 
confirm that BLM is not acting solely as a secretagogue. IL-8 can be stored in WPB and 
other vesicles, as well as in the Golgi body in response to inflammatory stimuli such as IL-
1β (Wolff, et al., 1998; Utgaard, et al., 1998), with expression from vesicles regulated by 
secretagogues such as histamine (Wolff, et al., 1998). As both de novo synthesis of IL-8 
mRNA and increased release were noted, it appears that, rather than simply inducing the 
release of IL-8 from granules, BLM was actively inducing IL-8 transcription, and the 
protein was potentially released from the Golgi, as previously observed (Wolff, et al., 
1998). It is possible that IL-8 was being synthesised and stored in granules which were 
being exocytosed, but whether IL-8 storing granules were generated could not be 
assessed. It does appear, however, that the increased IL-8 release by BLM-treated 
HUVECs is due to increased transcription.  
Similarly, MCP-1 may also be synthesised and stored in granules in response to 
proinflammatory stimuli, and released in response to secretagogues (Øynebråten, et al., 
2005), or directly released in response to inflammatory stimuli (Makó, et al., 2010; Parry, 
et al., 1998), potentially from the Golgi body, where MCP-1 is present following IL-1β 
stimulation (Øynebråten, et al., 2005).Increased transcript levels broadly followed the 
trend of increased protein release. However, in this case, there appeared to be a peak in 
transcript synthesis at 6 hours in cells treated with 10µg/ml BLM. It is possible that MCP-1 
synthesis has peaked at this time, and a time-lag in release has occurred, resulting in high 
release after 24 hour stimulation with BLM, or that the 6-hour results are the result of cell 
line variability and a low number of repeats. As with IL-8, the intracellular localisation of 
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MCP-1 in response to BLM treatment was not investigated, though the results suggest 
that MCP-1 synthesis was stimulated by BLM, and release appears  direct, not simply the 
result of granule exocytosis, though MCP-1 storage in granules and subsequent exocytosis 
may also have occurred.  
Neither transcript nor protein release levels of TGF-β and PDGF-BB were impacted by 
BLM. These experiments were unertaken to determine whether the protein synthesis was 
occuring although release was not, and in the case of TGF-β, where an ELISA for latent 
TGF-β was used, to determine whether the protein was somehow being activated upon 
release and therefore the ELISA was overlooking altered levels of protein. Neither 
appeared to be the case. However, the results from qPCR examining Endothelin-1 
synthesis show that BLM does in fact appear to be regulating both transcript levels and 
protein release. 
In line with the results of the ELISAs, the reuslts from qPCR suggest that, at low 
concentrations, BLM increases the transcript levels, of Endothelin-1. This results is 
unexpected; though the magnitude of protein release does not perfectly mirror the 
magnitude of transcript level increases, the two correlate reasonably well. Of course, this 
could be the result of low numbers of repeats – the error bars in both sets of data are 
large, and a greater number of repeats may redress this,  reducing the impact of 
unusually high or low transcript or protein release levels . However, it appears that 
treatment with 10μg/ml BLM downregulates the synthesis of the protein and its release.    
Endothelin-1 is expressed both via constitutive and regulated pathways in endothelials 
cells (Russell and Davenport, 1999), with the former localising the protein to constitutive 
secretory vesiscles, and the latter to WPB, which exocytose upon stimulation with 
secretagogues such as thrombin, and environmental factors such as hypoxia, which also 
stimulate further endothelin-1 gene expression and production (Stow, et al., 2011). Both 
pathways rely on mRNA transcription and protein bioavailability (Russell and Davenport, 
1999; Stow, et al., 2011) to mediate Endothelin-1 release  
These results suggest that, as transcript levels mirror protein release, the constitutive 
pathway is at work in response to BLM. This is particularly true of the results obtained 
from cells treated with 10µg/ml BLM. Were BLM to act as a WPB secretagogue alone, 
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increased levels of the protein in supernatants and increased trascript levels, compared 
to baseline, would be expected when cells were treated with 10µg/ml BLM, as both the 
constitutive and regulated pathways would be at work, and WPB exocytosis increases 
transcript synthesis. It is unlikely that BLM acts as a WPB secretagogue whilst also 
decreasing mRNA synthesis. However, were this the case, one may expect to see higher 
or equal levels of endothelin-1 in supernatants collected from  cells treated with 10μg/ml 
BLM than those seen at baseline, as the constitutive pathway may be impeded, but the 
regulated pathway would ensure Endothelin-1 release into the supernatant. Finally, were 
BLM not a secretagogue, but also to have no effect on transcript production, the results 
from cells treated with 10µg/ml would be no different from baseline, as the constitutive 
pathway would continue unimpeded. This also suggests that at the lower concentrations 
of BLM used, where both protein release and transcript levels increased, BLM may not 
have been acting as a secretagogue but instead increasing protein synthesis and release 
via the constitutive pathways.      
As the protein and transcript levels correlate well when cells were treated with BLM for 
24 hours, it appears that BLM actively prevents the synthesis of Endothelin-1 and its 
release via the constitutive pathway at high concentrations (10µg/ml), and at low 
concentrations (0.1µg/ml), it is feasible that BLM increases the synthesis and release of 
Endothelin-1 via the constitutive pathway. While it is also possible that at lower 
concentrations, BLM acts as a WPB secretagogue resulting in the increased Endothelin-1 
transcript synthesis, why the drug would cease to act as a secretagogue at high 
concentrations is now known; thus, control of the constitutive pathway seems the logical 
explanation .  
In all, treatment with BLM increased the release of IL-8 and MCP-1, and both increased 
and decreased the release of Endothelin-1, by endothelial cells. It appears that BLM 
impacted the synthesis of  IL-8, MCP-1, and Endothelin-1, thereby modulating the release 
of these cytokines, though it may have also acted as a secretagogue for IL-8 and MCP-1, 
as well as increasing their synthesis. The role of the increased synthesis and release of 
MCP-1 and IL-8, in particular, may be of great importance in the recruitment of immune 
cells to the endothelium, and their activation, prior to diapedesis and the movement of 
these cells into the lung, and is an important focus for future work in this field.  
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4.4.4 Initial Data Analysis and Issues with the qPCR Experimental Method    
 
Initial data analysis, and the establishment of guidelines relating to this - for example, 
when a sample needed to be re-run, the identification of primer dimers, and 
identification and re-running of samples when technical replicates proved discordant in Cq 
value, proved vital. The reason for this, however, is the nature of the experimental 
technique. The appearance of failed wells - often one of three technical replicates - could 
only be explained by random failure. If more than two wells failed, experiments were re-
run to give an average of at least 2 replicates, deemed necessary, though single 
unexplained failures were tolerated. Further, that no cDNA and no RT samples on 
occasion produced a Cq result, always the result of primer dimer formation, is merely a 
characteristic of the technique, as primers may hybridise and amplify due an an absence 
of target product, and the DNA-binding SYBRGreen dye bound to this. Rarely, this also 
happened to wells containing primers for target genes; in some instances, one of three Cq 
values proved to be a primer dimer. Visualisation of the derivative melt curve (Fig. 5.5) 
was sufficient to identify such primer dimers, though that this analysis had to be 
performed with every experiment run implies that this is a quirk of the qPCR technique. 
However, the formation of primer dimers was not a common occurrence, suggesting the 
primers used were fit for purpose, and when primer dimers did occur, they were easily 
identified.   
Often, intra-assay variation - the acquisition of discordant results for technical replicates, 
which occurred rarely - was also attributed to primer dimer formation, though sometimes 
this was not the case. In the latter instance, samples were re-run in triplicate. In all 
instances, the results of re-run experiments were universally concordant with low inter-
assay variability, and the incorrect result from the initial run made obvious. That is to say, 
when assays were re-run, there was little or no difference in Cq results deemed to be 
correct and concordant between assays, found to be the case in all re-runs.  Again, there 
was no clear reason for this intra-assay variability. As this occurred infrequently, and re-
running of the samples generated concordant results,  this again appears to be a quirk of 
qPCR that must be tolerated and dealt with accordingly.  
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4.4.5 Considerations of the qPCR Technique and the Correlation Between 
mRNA and Protein Levels  
 
While the results of these experiments generally found good correlation between protein 
and mRNA levels, there were of course exceptions, mostly pertaining to the magnitude of 
increases. However, while transcript abundance is used as a surrogate marker for protein 
abundance, there are many regulatory steps in between transcript generation and 
protein expression. This has been expertly reviewed by Vogel and Marcotte (2012). In 
brief, post-transcriptional regulatory processes may modify protein synthesis from 
transcripts, meaning that relvative transcript abundance is only somewhat correlatory 
with relative protein abundance. Protein abundance can not only be affected by mRNA 
synthesis, but also mRNA degradation, translation, and protein degradation, so protein 
expression may be higher than mRNA levels, or vice versa. The pair suggested that, while 
transcription act as a “stochiometric on-off swtich”, post-transcriptional regulation fine-
tunes protein expression. Therefore, perhaps mRNA and protein abundance would not be 
expected to correlate perfectly.  
A recent publication by Schwanhäusser, et al. (2011), also expertly defines the role of 
translation in the correlation between mRNA transcript levels and protein levels. While 
40% of correlation is accounted for by mRNA levels, 55% of protein abundance as 
compared to transcript levels is controlled by translational efficiency, the number of 
proteins generated per transcript per unit of time. Thus, a transcript rapidly synthesised 
but inefficiently translated would appear more abundant than its corresponding protein 
(and vice versa). The “snap-shot” nature of qPCR, FACS, and ELISA - and the method of 
comparing the results of transcriptional analyses to analyses of expression - do not 
account for this, and so one may appear far higher than the other. The remaining 5% of 
correlation is accounted for by transcript and protein stability (which impacts 
degradation) - thus, if one is stable and the other not, then similar discrepancies may be 
noted (Schwannhäusser, et al., 2012).  
This may account for the results observed with IL-8 and MCP-1; IL-8 may conceivably have 
a far higher translational efficiency, allowing transcript and protein to be detected 
concurrently.    
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With these factors in mind, it can be concluded that the increased protein expression 
observed in cells treated with BLM is most likely not due to chance, and that BLM 
increases gene transcription of these proteins through as yet unresolved mechanisms. 
Notably, all proteins seen to be upregulated, save endothelin-1, are associated de novo 
synthesis in response to NF-κB activation. Therefore, work to assess NF-κB activation in 
BLM treated HUVECs would be the next logical confirmatory step, and would provide an 
interesting avenue for other groups to continue research into the impact of BLM on 
endothelial cells.  
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5 Pulmonary Microvascular Endothelial 
Cell Adhesion Molecule Expression and 
Cytokine Release in Response to 
Treatment with BLM 
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5.1 Introduction 
 
In vivo, pulmonary microvascular endothelial cells (PMVECs) line the venules, arterioles, 
and capillaries around the alveoli, representing a barrier between the alveoli and the 
circulation. Previous work suggests that, at least in rodents, dysfunction of this cell type 
may be involved in BPF development (section 1.5). As endothelial cells from different 
sites, and different points within the same site, have high levels of phenotypic 
heterogeneity and demonstrate heterogeneous responses during inflammation (Aird, 
2012; Scott, et al., 2013), the expression of adhesion molecules and cytokines by BLM-
treated HUVECs may not be analogous to that of BLM-treated human PMVECs. In this 
chapter, the adhesion molecule expression and cytokine release profiles of BLM-treated 
PMVECs will be characterised, to develop an understanding of how PMVECs respond to 
BLM, and this will be compared to the expression profiles observed in HUVECs, to assess 
the differences between the responses to BLM of these two cells types.  
The range of adhesion molecules expressed by human PMVECs is not well characterised.  
Shen, et al. (1995) reported that PMVECs are positive for ICAM-1, VCAM-1, and E-selectin 
– with ICAM-1 being expressed constitutively, and ICAM-1, VCAM-1, and E-selectin being 
inducible by TNF-α treatment. In contrast, Jiang, et al. (2005), reported a low level 
baseline expression of ICAM-1 and VCAM-1 in PMVECs, with the expression of ICAM-1 
and E-selectin greatly increased by treatment with TNF-α. Comparing the expression 
profiles of HUVECs and PMVECs, Scott, et al. (2013) noted low-level baseline expression 
of ICAM-1 and VCAM-1 by PMVECs, increased by treatment with TNF-α. HUVECs also 
expressed baseline ICAM-1 levels, but expression of ICAM-1 and VCAM-1 was greater in 
HUVECs than PMVECs both under basal conditions and after treatment with 10ng/ml 
TNF-α. This mirrors the work of Krump-Konvalinkova, et al. (2001) which also found that, 
while E-selectin was inducible in PMVECs using TNF-α, the expression was lower than that 
induced in HUVECs. 
However, PMVEC adhesion molecule expression is related to the site of origin, and the 
works cited above fail to define which vessels the PMVECs used originate from. 
Feuerhake, et al. (1998) stated that while ICAM-1, VCAM-1, and E-selectin were detected 
in alveolar non-capillary vessels, alveolar capillaries were negative for all adhesion 
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molecules. This is in agreement with other works which state that the adhesion molecule 
expression profile in pulmonary venules is more akin to those of the systemic venules 
(Doerschuk, et al., 2000), though capillaries may not be completely devoid of adhesion 
molecules, and may express ICAM-1 under inflammatory conditions (Doerschuk, et al. 
2000; Aird, et al., 2007; Segel, et al., 2011). However, as venules, capillaries, and 
arterioles are all potential sites of leukocyte migration (Doerschuk, et al., 2000; Gane and 
Stockley, 2011), the adhesion molecule expression profiles of all PMVECs may be relevant 
to BLM induced fibrosis and shall be investigated.  
As the results from previous work are often divergent, the full adhesion molecule 
expression profile of this cell type remains only partially resolved. Further, there is only 
one previous study that has assessed the expression of adhesion molecules by PMVECs 
treated with BLM, and this is the work of Fichtner, et al. (2004), which reported an 
upregulation of ICAM-1 by PMVECs stimulated with >50μg/ml BLM, and no studies have 
assessed the expression of adhesion molecules by HUVECs treated with this 
concentration of BLM, so no comparison can be conducted. It will be interesting to assess 
how the expression of other adhesion molecules is impacted by BLM, and how this 
expression compares to that of HUVECs.   
The release of cytokines by PMVECs treated with BLM will also be assessed. Much like 
HUVECs, PMVECs exhibit endothelin-1, MCP-1, and IL-8 release (Star, et al., 2009; Brown, 
et al., 1994; Beck, et al., 1999). In the case of endothelin-1, release may be induced or 
increased by treatment with the secretagogue thrombin (Golden, et al., 1998), but there 
is no work directly comparing the expression of endothelin-1 by HUVECs and PMVECs in 
response to any factors. In the case of IL-8 and MCP-1, both may be induced via 
treatment with IL-1, TNF-α, and LPS in PMVECs though comparative studies show that IL-8 
is released more strongly by cytokine-treated HUVECs than PMVECs (Brown, et al., 1994). 
However, this is also stimulus dependent, with PMVEC releasing more MCP-1 in response 
to IL-1 and LPS than HUVECs. Interestingly, the basal release of both cytokines was seen 
to be higher in PMVECs than HUVECs (Beck, et al., 1999). Thus, the expression of 
cytokines by PMVECs may be different to those of HUVECs in response to BLM.  
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Again, the only previous work that has assessed the release of any of these cytokines by 
PMVECs in response to BLM is Fichtner, et al. (2004), which reported increased IL-8 
expression, though again, there are no studies against which this can be compared. 
Moreover, only IL-8 was assessed, and so whether PMVECs release other cytokines in 
response to BLM is of interest. By assessing PMVEC adhesion molecule expression and 
cytokine release in response to pharmacologically relevant concentrations of BLM, the 
response of these cells to BLM may be better characterised, and by comparing this 
expression to that of HUVECs, differences between the response of the two cell types to 
BLM may be highlighted. Such differences in expression have not previously been 
investigated. In doing so, this work will also confirm whether HUVECs represent a suitable 
surrogate cell type for PMVECs for use in future work. 
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5.2 Materials and Methods 
 
5.2.1 PMVEC Adhesion Molecule Expression Determination Following 
Treatment with BLM 
 
Cells were cultured as outlined in 2.2 in T25 flasks. To appropriate flasks, 10ml of serum-
contaning endothelial cell basal medium containing BLM – as outlined in 2.6 - was added. 
Cells were treated with BLM for 6 and 24 hours. The negative control used was PMVECs 
incubated in serum-containing endothelial cell basal medium (10ml) without BLM. The 
positive control used was PMVECs incubated in endothelial cell basal medium containing 
10ng/ml TNF-α (10ml). Both were incubated for the same time as BLM-treated cells. After 
treatment, cells were dissociated, counted, re-suspended to a concentration of 1 x 105 
cells/ml in endothelial cell medium, prepared for flow cytometry using the same panel of 
antibodies, and analysed  as outlined in 2.3., 2.4, and 2.5, respectively. The same panel of 
antibodies were used as outlined in 2.5. Only five thousand cell events were captured due 
to the low numbers of cell cultured. 
 
5.2.2 PMVEC Cytokine Release Determination in Response to BLM Treatment 
 
Cells were cultured as outlined in 2.2 and re-plated as outlined in 2.7. When adherent, 
3ml of serum-containing endothelial cell basal medium containing 0.1μg/ml, 1µg/ml, or 
10µg/ml BLM, was added. Cells were treated with BLM for 6 and 24 hours. Negative 
control supernatants were generated as outlined in 2.7. Positive control supernatants 
were generated for IL-8, MCP-1, and ET-1, as outlined previously. The supernatants were 
then collected as outlined in 2.7 and used for cytokine ELISAs.  
ELISA kits for IL-8 and MCP-1 were purchased from Biolegend. An ELISA kit for endothelin-
1 (ET-1) was purchased from R&D Systems. All ELISAs were conducted in accordance with 
manufacturer’s instructions. Supernatants for ELISAs were treated as outlined in 2.8. 
Preliminary work for each ELISA was conducted as outlined in 2.8.Plates were read using a 
plate-reader (Thermo Multiskan FC, Thermo Scientific) at the wavelengths instructed by 
the instructions provided with the kits. In brief, this was an initial reading at 450nm and a 
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subsequent reading at 570nm, the second subtracted from the first to reduce 
background.  Standard curves and data analysis were carried out as outlined in 2.8. 
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5.3 Results 
 
5.3.1 Adhesion Molecule Expression and Cytokine Release by PMVECs 
 
There was no statistically significant increase in ICAM-1 expression by PMVECs treated 
with any concentration of BLM apart from 10μg/ml when cells were treated for 6 hours 
(Fig 5.3A). There was a small but statistically significant increase in the expression of 
VCAM-1 and E-selectin when PMVECs were treated with 1 and 10μg/ml BLM, and 
10μg/ml BLM, for 6 hours, respectively (Fig 5.3C), though the increase in E-Selectin 
expression was small. However, given that the expression as baseline was essentially 
zero, it is feasible that low level E-Selectin induction occurred. 
When PMVECs were treated with BLM for 24 hours, there was a statistically significant 
increase in the expression of ICAM-1 by PMVECs treated with 1 and 10μg/ml (Fig 5.3B). 
This was also observed when VCAM-1 expression was assessed, although this increase 
was less substantial than when cells were treated for only 6 hours. When E-Selectin 
expression was assessed, there was no change in the baseline expression of this molecule 
when cells were treated for 24 hours with BLM (Fig. 5.3D). Raw data is shown in Figs. 5.1 
and 5.2. Gating is applied in these images only to highlight the peak-shift and increase in 
ICAM-1 and VCAM-1 positive cells when cells were treated with BLM as stated in 2.5. 
The expression of IL-8, MCP-1, and Endothelin-1, was also assessed, as these three 
cytokines had shown alterations in release due to BLM treatment in HUVECs. Both IL-8 
and MCP-1 release increased in a dose and time dependent fashion in BLM-treated 
PMVECs (Fig. 5.4A and 5.4B), though only when PMVECs were treated with 10µg/ml BLM 
for 24 hours and IL-8 was measured were any of these changes significant. The standard 
error of the mean appeared high in both sets of results obtained. In both cases, a wide 
range of baseline cytokine release and release by cells stimulated with BLM was 
observed. There was also a dose-dependent decrease in the release of ET-1 when 
PMVECs were treated with BLM for 24 hours (Fig 5.4C), although this decrease did not 
reach statistical significance. The results obtained using supernatants from PMVECs 
treated with BLM for 6 hours are more erratic, but also suggest a decrease in ET-1 
release.  
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Figure 5.1: Raw data from flow cytometry experiments assessing adhesion molecule 
expression (ICAM-1) by BLM-treated PMVECs. 
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Figure 5.2: Raw data from flow cytometry experiments assessing adhesion molecule 
expression (VCAM-1) by BLM-treated PMVECs.  
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Raw data generated from flow cytometric analysis ofcontrol (secondary antibody only) samples of 
PMVECs (top), VCAM-1 expression by untreated PMVECs (middle) and PMVECs treated with 
10µg/ml BLM for 24 hours (bottom). Gate M1 was drawn to incorporate as near to 1% of the 
control (secondary antibody only) peak as possible. There was a peak shift from baseline VCAM-1 
expression when cells were treated with BLM, as around 18% of cells appeared to express VCAM-1 
in response to BLM, but the majority of cells still expressed essentially zero VCAM-1, as shown by 
the population outside the gate (M1) on the bottom histogram. Respresentative images of 3 
experiments.  
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E-Selectin and VCAM-1 Expression by  PMVECs  Treated
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Figure 5.3: Adhesion Molecule Expression by BLM-Treated PMVECs 
 
  
The expression of ICAM-1 by PMVECs treated with BLM for 6 and 24 hours (A and B) 
and of VCAM-1 and E-Selectin by PMVECs treated with BLM for 6 and 24 hours (C and 
D). Statistically significant increases in protein expression from baseline are denoted 
by an asterisk. Only 5,000 cell events per experiments were recorded in this series of 
work. n = 3. 
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Figure 5.4: Cytokine release by BLM-treated PMVECs. 
  
Cytokine release by PMVECs in response to BLM for IL-8 (A), MCP-1 (B), and Endothelin-1 (C). 
Statistically significant increases in protein release from baseline are denoted by an asterisk. 2 x 
106 cells per flask were used to generate the supernatants used in this work. n = 3. 
* 
A 
B 
C 
196 
 
5.3.2 A Comparison of PMVEC and HUVEC Adhesion Molecule Expression 
 
The expression of adhesion molecules and cytokines expressed and released by HUVECs 
and PMVECs treated with BLM was compared, and statistical analysis conducted using the 
Mann-Whitney-U test. This test was used due to the low number of repeats in each 
experiment.  
Though ICAM-1 expression was higher at baseline in HUVECs than PMVECs, only ICAM-1 
expression by HUVECs treated with 0.1μg/ml BLM was significantly different to that of 
PMVECs after 6-hour treatment (Fig 5.5A). Only untreated HUVECs and those treated with 
0.1μg/ml BLM expressed significantly higher ICAM-1 levels after 24-hour treatment. In 
both cell types, there was a trend showing a dose-dependent increase in ICAM-1 
expression when cells were treated with BLM for 24 hours (Fig 5.5B). 
In both cell types treated with BLM for 6 hours, ICAM-1 expression increased 1.5-fold 
from baseline when cells were treated with 10μg/ml BLM. When treated for 24 hours, 
there was a 3-fold increase in ICAM-1 expression from baseline in both cell types. While 
HUVECs expressed more ICAM-1, the magnitude of increase in the two cell types was 
similar (Fig 5.5A and 5.5B). 
PMVECs and HUVECs express similar levels of E-Selectin, when compared to the control 
antibody. When cells were treated with BLM, the increase in expression was more 
substantial in HUVECs. There was a two-fold increase in expression in HUVECs treated 
with 10µ/ml BLM, compared to only a 1.5-fold increase in PMVECs when cells were 
treated with BLM for 6 hours (Fig 5.5C). Only very minor increases in E-Selectin expression 
were seen when both HUVECs and PMVECS were treated with all concentrations of BLM 
for 24 hours (Fig 5.5D). 
Assessing VCAM-1 expression, PMVECs and HUVECs express similar baseline levels when 
compared to the control. PMVECs appeared to express significantly higher levels of 
VCAM-1 than HUVECs when treated with all three concentrations of BLM for 6 hours. 
PMVECs treated with 10µg/ml BLM demonstrated around a 3-fold increase in VCAM-1 
expression while HUVECs only a 1.5-fold change. While statistical analyses suggested a 
statistically significant difference in VCAM-1 expression between HUVECs and PMVECs 
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treated with 0.1μg/ml BLM, this may be reflective only the higher baseline VCAM-1 
expression by PMVECs; neither cell type demonstrated a change in expression from 
baseline when cells were treated with 0.1μg/ml BLM (Fig 5.5E). In the 24 hour 
experiments, PMVECs also demonstrated a higher baseline expression of VCAM-1 than 
HUVECs (though slightly higher binding of the control antibody to untreated PMVECs than 
untreated HUVECs may have contributed to this observation). PMVECs treated with 1 and 
10µg/ml BLM for 24 hours expressed significantly higher levels of VCAM-1 than HUVECs; 
PMVECs treated with 10µg/ml BLM exhibited a higher increase in VCAM-1 expression (a 
2.5-fold increase) compared to that seen in HUVECs (a 1.5-fold increase) (Fig 5.5F).   
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Figure 5.5: Comparisons of PMVEC and HUVEC adhesion molecule expression in 
response to BLM treatment. 
  Comparisons of the expression of endothelial cell adhesion molecules ICAM-1 (A, B), E-
selectin (C,D), and VCAM-1 (E,F) in PMVECs and HUVECs treated with BLM for 6 hours 
(A, C, E) and 24 hours (B, D, F). Statistically significant differences in protein expression 
between cell samples are denoted by an asterisk and connecting bars. n = 3. 
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5.3.3 A Comparsion of PMVEC and HUVEC Cytokine Release 
 
The total release levels of both IL-8 and MCP-1 were greater by HUVECs than PMVECs 
when cells were treated with BLM (Fig 5.6A and 5.6B). IL-8 and MCP-1 release by HUVECs 
at baseline and when cells were treated with 0.1 and 1µg/ml BLM were greater than IL-8 
and MCP-1 release by PMVECs treated with these concentrations for 6 hours (Fig 5.6A 
and 5.6B). There was no statistically significant difference in IL-8 release between PMVECs 
and HUVECs when both cell types were treated for 24 hours (Fig 5.6A). Only MCP-1 
release by cells treated with 10µg/ml BLM was significantly different, with HUVECs 
releasing greater levels of the cytokine (Fig 5.6B). However, the magnitude of the 
increased IL-8 and MCP-1 release by HUVECs and PMVECs was broadly similar when cells 
were treated with 0.1 and 1µg/ml BLM. The magnitude increase of IL-8 and MCP-1 
release by PMVECs was greater than that of HUVECs in response to 10µg/ml BLM (Table 
5.1).    
When Endothelin-1 release was assessed, release levels were similar in PMVECs and 
HUVECs. Only when cells were treated with 0.1μg/ml BLM for 6 and 24 hours, and 1μg/ml 
BLM for 6 hours was there a significant difference (Fig 5.6C). However, in these instances, 
HUVEC Endothelin-1 release appeared to be increased from baseline by treatment with 
BLM. This was not observed under any treatment condition in PMVECs, where BLM 
treatment appeared to universally decrease Endothelin-1 expression. With the exception 
of these results, the magnitude decrease in Endothelin-1 release observed was broadly 
similar (Table 5.1). 
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Cytokine Measured Incubation Time Cell Type Assessed Fold Change  from Baseline 
   0.1µg/ml BLM 1µg/ml BLM 10µg/ml BLM 
IL-8 6 hours HUVEC 0.7 1.3 1.8 
PMVEC 1.1 1.8 4.5 
24 hours HUVEC 1.1 1.9 2.5 
PMVEC 1.8 2.8 5.5 
MCP-1 6 hours HUVEC 1.1 1.7 1.8 
PMVEC 1.2 2.0 5.6 
24 hours HUVEC 1.0 1.2 2.4 
PMVEC 1.2 2.6 3.7 
Endothelin-1 6 hours HUVEC 1.0 1.9 0.8 
PMVEC 0.7 0.9 0.8 
24 hours HUVEC 1.9 1.4 0.7 
PMVEC 1.0 0.8 0.5 
Table 5.1: Comparison between HUVEC and PMVEC cytokine release in response to BLM 
 
 
 
  
The fold-change in cytokine release by HUVECs and PMVECs treated with BLM over 6 and 24 hours, assessed by ELISA.  
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Figure 5.6: Comparisons of HUVEC and PMVEC cytokine release in response to BLM treatment 
 Comparisons of the release of IL-8 (A), MCP-1 (B), and Endothelin-1 (C) by PMVECs and HUVECs treated 
with BLM for 6 hours and 24 hours. Statistically significant differences in protein release between 
samples are denoted by an asterisk. n = 3. 2 x 106 cells per flask were used to generate the 
supernatants used in this work. 
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Interestingly, there were statistically significant differences in the maximum levels of E-
Selectin, ICAM-1, and VCAM-1 when cells were treated with 10ng/ml TNF-α (Fig 5.7A-C). This 
was particularly noticeable when E-Selectin was assessed, as the maximum inducible 
expression was far greater in HUVECs than in PMVECs (Fig. 5.7B). Further, maximum 
inducible release of both IL-8 and MCP-1 was significantly greater in HUVECs treated with 
10ng/ml TNF-α than in TNF-α-treated PMVECs (Fig 5.8A, 5.8B). 
Note that, in these graphs, the secondary antibody alone (control antibody) value has been 
subtracted from the geometric mean value obtained from flow cytometric analysis. The 
reason for this is purely related to ensuring the clarity of the images.  
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A  Comparison of the Maximum  Inducible  Expression of
VCAM-1 by HUVECs and PMVECs when Treated with
TNF-
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Figure 5.7: Comparisons of the maximal induction levels of adhesion molecules by TNF-α-treated 
HUVECs and PMVECs. 
Maximal expression of ICAM-1 (A), E-selectin (B), and VCAM-1 (C) by HUVECs and PMVECs treated 
with TNF-α (10ng/ml). Note that the control has been subtracted from the geometric mean for 
clarity. Statistically significant differences in protein expression between cell types are denoted by an 
asterisk. n = 3.  
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IL-8 Release by HUVECs and PMVECs Treated with
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Figure 5.8: Comparisons of the maximal cytokine release levels by TNF-α-treated PMVECs and 
HUVECs.  
The maximal IL-8 (A) and MCP-1 (B) release by PMVECs and HUVECs in response to TNF-α 
(10ng/ml). Statistically significant differences in protein release between cell types are denoted by 
an asterisk. n = 3. 2 x 106 cells per flask were used to generate the supernatants used in this work. 
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5.4 Discussion and Conclusions 
 
Overall, there was an increase in the expression of adhesion molecules when PMVECs were 
treated with BLM. In agreement with the work of Fichtner, et al. (2004), increased ICAM-1 
expression was observed in PMVECs treated with BLM. In addition, increased VCAM-1 
expression and, to a small degree, increase E-selectin expression, was also noted – this has 
not previously been reported. Though a full panel of antibodies was assessed, including 
PECAM-1, ICAM-3, ICAM-1, αVβ3, P-Selectin, E-Selectin, VCAM-1, and PSGL-1, these were the 
only adhesion molecules upregulated. However, there were differences observed in the 
levels of adhesion molecule expression when comparing HUVECs and PMVECs.  
Though the maximum level of ICAM-1 expression by BLM-treated PMVECs in this work was 
not as substantial as that noted in HUVECs, the observed magnitude of increase was similar. 
Higher levels of VCAM-1 expression were noted in PMVECs than were in HUVECs, with a 
higher level of protein and a higher magnitude of change from baseline observed. This 
suggests that the two cell types demonstrate different adhesion molecule expression profiles 
in response to BLM and suggests that BLM may impact PMVEC adhesion molecule expression 
in a different fashion to HUVECs. The increase in E-selectin by PMVECs when treated with 
BLM was broadly similar to that induced in HUVECs, though it is notable that, when 
comparing PMVEC and HUVEC responses to BLM, HUVECs upregulated E-Selectin expression 
to a higher magnitude compared to baseline than PMVECs.  
In the positive control experiments run in parallel to this, there was a far lower upregulation 
of E-selectin expression in PMVECs treated with TNF-α than HUVECs treated with the same 
concentration of the mitogen. Therefore, perhaps an analogous statistically significant 
increase in E-Selectin expression by PMVECs compared to HUVECs was not feasible in this 
scenario. That treatment with TNF-α did not induce high levels of E-selectin and also induced 
lower levels of VCAM-1 and ICAM-1 in PMVECs than in HUVECs agrees with the work of 
Krump-Konvalinkova, et al. (2001) and Scott, et al. (2013). This work is the first to assess 
PMVEC adhesion molecule expression in response to BLM and compare this to the response 
observed in HUVECs.  
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When treated with BLM, PMVECs released increased levels of both MCP-1 and IL-8. This is 
similar to the results of the work carried out using HUVECs, and shows that both cell types 
demonstrate a concentration-dependent increase in cytokine release in response to BLM. 
Though total release levels of MCP-1 and IL-8 were lower in PMVECs than HUVECs, the 
magnitude of the increase was higher in PMVECs than in HUVECs. This highlights the 
difference in baseline expression. This differs from previously published work, which suggests 
MCP-1 expression is constitutively higher in PMVECs (Beck, et al., 1999); the reasons for this 
are unknown. However, the range of measured MCP-1 expression levels when PMVECs were 
assessed is very broad. This was also the case when IL-8 expression was measured. 
Therefore, unusually low results from one PMVEC line may impact the average MCP-1 and IL-
8 expression observed. Further experiments with a greater number of repeats would surely 
give a more accurate picture of cytokine release by PMVECs.  
Assessing Endothelin-1 release, a universal  dose-dependent decrease in endothelin-1 
expression was observed when PMVECs were treated with BLM, unlike the results observed 
when BLM-treated HUVECs were assessed. Significant differences were noted between 
HUVECs and PMVECs treated with 0.1 and 1μg/ml BLM for 6 hours, and 0.1μg/ml BLM for 24 
hours, likely due to the apparent increase in endothelin-1 release by HUVECs under these 
conditions. However, high levels of standard error were seen when HUVECs were assessed, 
and additional experiments would likely give more consistent results. While both PMVECs 
and HUVECs released decreased Endothelin-1 levels compared to baseline when treated with 
10µg/ml BLM, the increase seen when HUVECs were treated with the lower concentrations 
were not seen in PMVECs and therefore it may be said that these two cell types respond 
differently to BLM. The reasons for the apparent disparity between the two cell types is 
unknown. 
These results suggest that PMVECs – a cell type more relevant to human patients receiving 
BLM – also express increased levels of adhesion molecules and release increased levels of IL-
8 and MCP-1 when exposed to BLM. Though there were some differences between the 
expression profiles of these adhesion molecules and cytokines, mostly related to the total 
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levels of proteins expressed and release, both PMVECs and HUVECs demonstrated increases 
and total levels that were similar enough to suggest that HUVECs may be used as a surrogate 
for PMVECs in future work.  
Further, that PMVECs treated with BLM express not only increased levels of ICAM-1, but also 
VCAM-1, builds on previous reports of PMVEC adhesion molecule expression in response to 
BLM (Fichtner, et al., 2004), and may allow a better characterisation and understanding of 
the impact of BLM on the human pulmonary vascular endothelium. Importantly, this 
increased molecule expression may have functional consequences. It seems logical that, as 
PMVEC adhesion molecule and cytokine expression is increased by BLM, then the impact of 
the drug on the pulmonary vascular endothelium may contribute to the inflammation that 
precedes BPF as immune cells are recruited to the lung vessels by chemoattractant cytokines, 
and recruited or already present leukocytes may then adhere to and move through the 
endothelium via the diapedesis cascade. 
The notion that adhesion molecules expressed by pulmonary microvascular endothelial cells 
may induce leukocyte movement into the lung following BLM administration is strengthened 
by recent work. Wang, et al. (2011), for example, reported that the expression of ICAM-1 and 
VCAM-1 in the pulmonary vasculature of the rat is associated with an observed migration of 
leukocytes into the perivascular space and interstitium, while Sato, et al. (2000) noted an 
increase in the expression of ICAM-1 by the endothelium of the pulmonary venules and the 
capillaries following BLM administration in rats, which resulted in increased leukocyte rolling 
along the endothelium, increased leukocyte entrapment in the pulmonary capillaries (which 
was inhibited by a blocking antibody against ICAM-1) and increased leukocyte infiltration of 
the perivascular and alveolar spaces of the rats used.  
This may feasibly occur in humans; the current work reports increased ICAM-1 and VCAM-1 
expression by human PMVECs treated with BLM  which, as in rodents, may lead to the 
increased trapping, migration, and accumulation of leukocytes in and through the pulmonary 
vascular endothelium and in the lung in vivo in man, leading to the inflammation that so 
characterises the early stages of BPF development. While immediate conclusions cannot be 
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drawn from these results – it is unwise to draw parallels between human and rodent work – 
the similarities between the adhesion molecules seen to be expressed in our work and that 
of Sato and Wang are striking, and highlight an area of interest for future work.  
While this work used PMVECs isolated from pulmonary capillaries, venules, and arterioles, 
and work such as that by Wang, et al. (2011) and Sato, et al. (2000) has noted such adhesion 
molecule upregulation in these regions, it is considered that the majority of the leukocyte 
migration in the lung takes place in pulmonary capillaries (though recruitment may also occur 
through larger vessels). One must be careful when inferring roles for ICAM-1 in leukocyte 
recruitment via the capillary beds, as the involvement of neutrophil CD11/CD18 ligands, and 
therefore endothelial ICAM-1, in this region is entirely stimulus specific. ICAM-1 is considered 
to have a role in immune cell recruitment via the capillary beds when inflammation is 
induced by LPS, IL-1, or immune complexes, but no role if induced by hyperoxia or 
Staphylococcus pneumoniae, for example (Doerschuk, et al., 2001).  
Whether pulmonary immune cell recruitment via the capillaries occurs in response to BLM in 
man, and if so, whether it is a CD18-dependent or independent process, requires elucidation, 
though it appears it may be dependent, at least in rodents (Sato, et al., 1999). This would be 
an interesting avenue for future research. Regardless, leukocyte recruitment may occur 
through the pulmonary venules and arterioles, and so increased adhesion molecule 
expression here may partially account for the increase in immune cells in the lung, and 
adhesion and transmigration from these regions is likely to be at least partially ICAM-1-CD18 
interaction dependent, as this molecule is expressed in the pulmonary venules (Doerschuk, 
et al., 2000) and appears to have a role in rodent BPF (Sato, et al., 1999; Wang, et al., 2013).  
While neither of the pro-inflammatory cytokines discussed here has been inferred in the 
recruitment of leukocytes to the lung vasculature in BPF, it is entirely feasible that the 
increased expression of MCP-1 and IL-8 increases the movement of neutrophils and 
monocytes to this area, and may contribute to the increased leukocyte transit into the lung 
observed in works such as that of Wang, et al. (2011) and Sato, et al. (2000). This would 
require further research to delineate, though it is a logical contribution of these cytokines, as 
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both are potent chemoattractants (as discussed in section 1.7.2.1 and 1.7.2.2). However,   
the relevance of the observed decrease in Endothelin-1 release by BLM-treated PMVECs is 
unknown. 
Endothelin-1, in addition to being a pro-fibrotic cytokine, is also a potent vasoconstrictor 
(Stow, 2011), and it was reported by Sato, et al. (2000) that, although vessel diameter 
decreased in the early stages of rodent BPF, by the end of stage of condition (day 42), vessel 
diameter was increased compared to baseline. Decreased Endothelin-1 release may have 
contributed to this. To the author’s knowledge, this is not an avenue of research that has 
previously been explored, but the relevance of decreased endothelin-1 expression to BPF 
may be an interesting topic to investigate.  
Finally, as HUVECs demonstrate similar expression levels of all involved adhesion molecules, 
it may be possible to model the BLM-treated vasculature using this cell type. A flow-chamber 
model will be used in which leukocytes will be flowed over BLM-treated HUVEC monolayers 
(to mimic BLM-treated PMVECs), to assess not only if BLM treatment and the associated 
increase in adhesion molecule expression increase leukocyte adhesion to the human 
endothelium under flow, but also to assess which, if any, adhesion molecules are primarily 
responsible for any increases in adhesion seen.  
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6 The Functional Relevance of Endothelial 
Adhesion Molecule Expression in 
Response to BLM Treatment   
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6.1 Introduction 
 
To determine the functional relevance of increased adhesion molecule expression, the 
adhesion of neutrophils to BLM-treated monolayers was investigated. Both neutrophils and 
monocytes – involved in the development of BPF - utilise adhesion molecules such as ICAM-1 
and E-Selectin to roll on and adhere to the endothelium (Table 1.6) and so increased 
expression may mediate increased interactions. As neutrophils are readily activated in the 
experimental setting and are the first cell type to infiltrate the lung during BPF development, 
this cell type will be assessed. 
 
6.1.1 Neutrophil Recruitment and Adhesion in the Systemic Circulation 
 
In the systemic circulation, neutrophil rolling is mostly mediated by interactions between 
neutrophil ligands (PSGL-1, CD44) and endothelial selectins, such as E-selectin. Selectins bind 
with rapid on/off rates, with the rate dependent on the ligand to which the selectin is binding 
and the shear stress exerted on the cells (McEver and Zhu, 2010; Wayman, et al., 2010), and 
this allows transient leukocyte capture and rolling. In addition, selectins have an optimal 
shear at which tethering is frequent due to increased interaction (McEver and Zhu, 2010; 
Yago, et al., 2007) and E-selectin appears to use a triphasic system, at least when binding to 
PSGL-1. It was reported that, as shear increases from 0 dyn/cm2, neutrophils increasingly 
interacted with endothelial E-selectin via easily-broken slip-bonds. At around 0.3 dyn/cm2, 
catch-bonds (strong bonds) became more frequent as shear reached the optimum of 0.5 
dyn/cm2 and the duration of the bonds increased while the rolling velocity decreased 
(Wayman, et al., 2010). The slowing and tethering of leukocytes via interaction with selectins 
in this fashion allows may then be followed by stronger adhesion, via interactions between 
leukocyte integrins and endothelial ligands, such as ICAM-1.  
The firm binding of neutrophil ligands such as Mac-1 (CD11b/CD18) and LFA-1 (CD11a/CD18) 
to ICAM-1 requires integrin activation, mediated by chemokines such as IL-8, which activates 
both integrins (Takami, et al., 2002; Seo, et al., 2001; Lum, et al., 2002), and was released by 
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BLM-treated endothelial cells in this work. Such cytokines interact with neutrophil receptors, 
activating ligands via outside-in G-coupled protein signaling. This alters integrin conformation 
from low to high or intermediate affinity conformations, allowing integrin-ligand binding 
(Lum, et al., 2002; Lomakina and Waugh, et al., 2010; Ley, et al., 2007; Lefort and Ley, 2012; 
Smith, et al., 1991; Zeilhofer and Schorr, 2000). Interestingly, neutrophil LFA-1 is also 
activated constitutively, though the binding of unstimulated neutrophils to ICAM-1 via LFA-1 
is infrequent and brief (Smith, et al., 1989; Hentzen, et al., 2000; Green, et al., 2006). 
Alternatively, integrin activation may be induced by neutrophil interaction with E-selectin, as 
reported by Simon, et al. (2000). This group demonstrated that neutrophil-to-E-selectin  
binding under flow increased adhesion to ICAM-1, related to β2 integrin conformational 
changes via PSGL-1-E-selectin binding. Indeed, the binding of neutrophil PSGL-1 to E-selectin 
is now known to induce the intermediate affinity conformation of LFA-1 (Yago, et al., 2010; 
Zarbock, et al., 2008; Kuwano, et al., 2010), as well as both activating Mac-1 and inducing its 
movement to the cell surface, allowing further ligand binding upon Mac-1 activation (Simon, 
et al., 2000).  
While neutrophils express Mac-1 and LFA-1 in equal amounts, and the blockade of neutrophil 
adhesion to ICAM-1 can only be achieved by blocking both (Seo, et al., 2001; Hentzen, et al., 
2000; Takami, et al., 2002) the two are thought to have overlapping but differing functions, 
with LFA-1 required for adhesion to the endothelium, and Mac-1 required for the 
stabilisation of this adhesion and leukocyte crawling along the endothelium (Ding, et al., 
1999; Hentzen, et al., 2000; Li, et al.,2013). However, LFA-1 and Mac-1 both appear involved 
in the initial rolling step of transmigration. Green, et al. (2006) stated neutrophil adhesion to 
ICAM-1 via LFA-1 was conformation dependent; intermediate affinity LFA-1 allowed rolling, 
and high affinity, adhesion, while, Chesnutt, et al. (2006) noted that, when activated by E-
selectin interaction, LFA-1 was primary responsible for rolling adhesion on ICAM-1, but Mac-
1 also contributed. This was supported by Ding, et al. (1999), who reported that while LFA-1 
knockout mice exhibited far lower neutrophil adhesion to ICAM-1-only expressing cells, Mac-
1 knockout neutrophils also decreased their adhesion, but less severely. Thus, both integrins 
appear to play a role in the tethering of neutrophils to ICAM-1.  
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Following integrin activation, neutrophils bind  ICAM-1 in the presence of cations (Petruzzelli, 
et al., 1998) and this may then initiate ICAM-1 outside-in signaling events which stabilize this 
adhesion (Lum, et al., 2002; Ley, et al., 2007; Giagulli, et al., 2006). From here, neutrophil 
spreading and migration lead to the movement of neutrophils across the endothelium into 
the site of injury. Similar adhesion events may occur with VCAM-1; though interactions 
between neutrophils and VCAM-1 are less well defined, it has been reported that neutrophils 
are capable of binding to VCAM-1 via VLA-4 (Lomakina and Waugh, 2009), and the role of 
VCAM-1 is similar to that of ICAM-1, inducing firm adhesion, though this requires further 
investigation before any definite conclusions may be drawn.  
 
6.1.2 Neutrophil Recruitment and Adhesion in the Pulmonary Circulation  
 
However, the process of transmigration – in which cells roll, undergo firm adhesion and 
arrest, and eventually migrate through the endothelium  - does not occur in all vessels. As 
discussed previously (1.8), the main site of pulmonary neutrophil sequestration – the process 
by which leukocytes “accumulate in the inflamed lung in preparation for migration” - is the 
capillary bed, an area devoid of selectins (Doerschuk, et al., 2001). Instead, neutrophil 
binding via integrins such as Mac-1 to endothelial ICAM-1 may promote leukocyte adhesion 
to the capillary endothelium (Doerschuk, et al., 2001; Aird, et al., 2007; Segel, et al., 2011), 
but while only ICAM-1 appears to be induced by inflammatory stimuli in the capillaries, the 
involvement of ICAM-1 is stimulus-dependent. It is unknown whether BLM induces ICAM-1 
dependent or independent adhesion. Previous work by Sato, et al. (2000) reported increased 
ICAM-1 expression in rodent pulmonary capillaries in response to BLM, leading to increased 
leukocyte entrapment and sequestration in the vessels, and this suggests that BLM may 
induce a CD18-dependent migration pattern for neutrophils in lung capillaries. If this is the 
case, then increased neutrophil infiltration of the lung following BLM treatment may be 
related to increased ICAM-1 expression in the capillary beds, though other vessels may also 
be sites of leukocyte transmigration in the lung.    
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This may include pulmonary venules. Pulmonary venules utilise a more systemic-like 
adhesion cascade involving VCAM-1, ICAM-1, and E-selectin under inflammatory conditions, 
and may also be sites of neutrophil accumulation and migration (Gane and Sotckley, et al., 
2011; Wang, et al., 2011; Doerschuk, et al., 2001; Aird, et al., 2007). Previous research 
suggests that this may have functional relevance; Wang, et al., (2011) reported increased 
ICAM-1 and VCAM-1 expression in the venules of BLM-treated rats, and neutrophils gathered 
around areas expressing the adhesion molecules. Neutrophil infiltration of the perivascular 
interstitium occurred via these vessels, and neutrophil infiltration of the lung was observed 
concurrently with adhesion molecule expression. This suggests venular ICAM-1 and VCAM-1 
may support firm adhesion and promote transmigration. However, Sato, et al. (2000) 
reported increased ICAM-1 expression and concurrent leukocyte slow rolling in the 
pulmonary venules of BLM-treated mice, which was blocked by anti-ICAM-1 antibody, but 
firm adhesion to venular walls was not observed. Entrapment was only noted in the 
capillaries. However, as increased slow rolling in the venules and increased entrapment in 
the capillaries occurred simultaneously with increased ICAM-1 expression and increased 
peribronchiolar and perivascular leukocyte infiltration, increased adhesion molecule 
expression may have led to increased neutrophil movement of into the lung. Capillary 
entrapment may have played a larger role in neutrophil transmigration in this study, 
however, but it appears increased adhesion molecule expression permits increased 
infiltration.  
Previous results from this work have demonstrated increased ICAM-1 and VCAM-1 
expression by PMVECs in response to BLM. If such increased expression occurs in vivo, then 
this may contribute to the inflammation that precedes fibrosis. However, as the PMVECs 
used were isolated from both pulmonary venules and capillaries, no definitive conclusions 
can be drawn regarding the precise role of each molecule and each cell type in this process. 
By assessing whether treatment of the endothelium with BLM increased neutrophil rolling on 
and adhesion to the endothelium, a better understanding of how the impact of BLM on the 
human endothelium – particularly the endothelium of the pulmonary venules and capillaries 
- leads to the inflammation seen in BPF may be developed. 
215 
 
6.1.3 Experimental Design 
 
To determine whether increased adhesion molecule expression by BLM-treated endothelial 
cells may contribute to neutrophil adhesion and infiltration in vivo, an in vitro model of 
circulation was used. An experimental system similar to that developed by the Nash group 
(Cooke, et al., 1993; Rainger, et al., 1995) and a protocol devised by McGettrick, et al. (2010) 
will be used. This will involve a flow chamber system, which mimics the conditions of the 
vasculature, and allows the generation of a confluent endothelial monolayer and the 
application of suspended cells at the shear stress (the force exerted on the endothelium by 
the flow of blood through the vessel) encountered in vivo. The shear required depends on 
the vessel modelled; venules have a shear stress of around 15 dyn/cm2, large veins, around 5 
dyn/cm2 , and post-capillary venules, 1 dyn/cm2 (Papaioannou and Stefanadis, 2005; 
McGettrick, et al., 2010). To mimic the shear stress in the lung microvasculature, including 
the venules and capillaries, the shear stress required would be around 1-5dyn/cm2, although 
this value is not well defined or extensively researched (Kroll and Afshar-Khargan, 2012; 
Kuebler, 2009). Therefore, a physiologically relevant shear rate used previously in flow 
chamber studies will be assessed to model the rolling and adhesion of neutrophils to the 
endothelial monolayer when BLM and TNF-α treated.    
It has been reported that a shear rate of over 1 dyn/cm2, as well as being physiologically 
relevant, prevents integrin-ligand interactions, e.g., between LFA-1 and Mac-1 (CD11a/CD18 
and CD11b/ CD18) and ICAM-1 (Li, et al., 2013; Hentzen, et al., 2000; Ding, et al., 1999) but 
permits those between leukocytes and selectins (Bahra, et al., 1998; Rainger, et al., 1995; 
Lawrence and Springer, 1991).  As such, studies focussing on selectins often use this rate, 
however, this work is not focussed exclusively on selectins, but on all adhesion molecules 
which may be involved in leukocyte adhesion to, and transmigration though, the 
endothelium.  
It has been suggested that ICAM-1 binding may be an important mode of neutrophil 
migration in vessels with low shear, such as in the lung (Hentzen, et al., 2000). Although it is 
often stated that neutrophil adhesion to ICAM-1 without initial binding by selectins does not 
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occur (Chesnutt, et al., 2006; Simon, et al., 2000), experimental work has shown that 
neutrophil adhesion to ICAM-1 may occur at shear stresss of up to 1 dyn/cm2, though 
increasing shear stress decreased neutrophil adhesion to, and spreading on, the ICAM-1 
substrate monolayer, and a shear rate of between 0.2 and 0.5 dyn/cm2 resulted in a greater 
number of adherent neutrophils (Zhan, et al., 2012). Similarly, Lawrence and Springer (1991) 
reported a slight binding of neutrophils to ICAM-1 at shear stresss of up to 0.3 dyn/cm2; this 
may contribute to the movement of neutrophils to sites of injury under low shear stresss. 
As the shear in the pulmonary capillaries is likely to be extremely low because cells deform to 
traverse these vessels; neutrophils roll on ICAM-1 and VCAM-1 in pulmonary venules, at least 
in rodent models; the shear stress in post-capillary venules in man is around 1 dyn/cm2; and 
lung capillaries (and indeed unstimulated lung venules) lack selectins, so neutrophil adhesion 
related to E-selectin mediated integrin activation will not occur in these vessels, using a shear 
of over 1 dyn/cm2 - which precludes ICAM-1-neutrophil interactions - cannot model the 
effects of increased adhesion molecule expression in the lung. Therefore, a range of shears, 
between 0.1 dyn/cm2 and 1 dyn/cm2 will be trialled. 
As treatment of endothelial cells with BLM appeared to increase the expression of 
endothelial E-selectin, ICAM-1, and VCAM-1 in both 6 and 24 hour experiments, increased 
neutrophil adhesion to the monolayer may be observed when neutrophils are flowed over 
BLM-treated endothelium. The adhesion of neutrophils to BLM-treated endothelium will 
therefore be assessed. As several adhesion molecules were noted to be expressed at 
increased levels by BLM-treated endothelial cells, and the shear stress used will not prevent 
adhesion mediated by any one molecule, work will be conducted to determine the adhesion 
molecules responsible for any observed adhesion. Blocking studies using the anti-CD18 anti-
body TS1/18, which blocks the CD18 component of both LFA-1 and Mac-1 will assess the 
contribution of ICAM-1 to neutrophil adhesion, while E-selectin function blocking antibody 
P2H3  will assess this molecule’s contribution to neutrophil adhesion under flow.     
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6.2 Materials and Methods 
 
6.2.1 Construction of the flow chamber system. 
 
µ-Slide I 0.4 Luer flow chambers (ibiTreat, tissue culture treated, sterile), sterile silicone 
tubing with an internal diameter of 1.6mm and Luer elbow connectors were purchased from 
Thistle Scientific (Glasgow, United Kingdom). A 50ml glass syringe was purchased from 
Hawksley (Lancing, Sussex, United Kingdom). BD Connectas, 10ml plastic syringes, male-
male, and female-female connectors were a kind gift from Dr. Rob Bennet (Perfusion, Castle 
Hill Hospital, Cottingham, United Kingdom). Uncoated slides were used, as typical of previous 
work (Y.P. Xiao, personal communication), rather than collagen-coated slides. 
This equipment was combined to create an artificial flow system through which cell 
suspension could be flowed over an endothelial monolayer within the flow chamber 
according to instruction from Dr. Yu Pei Xiao (personal communication, as shown in Fig. 6.1). 
The 10ml plastic syringes were elevated and held in place using a clamp stand. The 50ml glass 
syringe was fitted to a Harvard 2000 PHD pump set to withdraw the cell suspension at a rate 
of 3.8ml/min initially, to generate a shear stress of 5 dyn/cm2 within the flow chamber, as 
determined by the manufacturers of the flow chambers (see application note 11, ibidi). 
Various flow rates, and hence various shear stresss, were used throughout these 
experiments.  
 
218 
 
 
Figure 6.1: A schematic representation of the flow chamber system. 
 
 
 
 
6.2.2 Optimisation of confluent monolayer creation and exposure to shear flow. 
 
HUVECs were cultured to near-confluence (90% confluent) in accordance with ibidi 
application note AN13 and were used between passage 3 and 5. Cell culture was conducted 
as outlined in 2.1. When around 90% confluent, cells were dissociated from culture flasks and 
centrifuged as outlined in 2.2 and 2.3. Cells were then counted using haemocytometry as 
  
  
   
 
 
 
 
 
 
 
 
ibidi µ-Slide I 0.4 Luer, 
ibiTreat, tissue culture 
treated, sterile 
Hawksley 
50ml glass 
syringe 
(diameter 
27mm) 
attached to 
Harvard 
2000 PHD 
pump. 
10ml plastic syringes 
with plunger 
removed; A) contains 
wash (PBS with Mg 
and Ca). B) contains 
leukocyte 
suspension). 
BD 
Connecta 
Female-
female 
connector 
ibidi  1.6mm sterile silicone 
tubing with elbow connectors 
A schematic representation of the set-up used through the flow chamber experiments. 
The 50ml glass syringe was attached to a Harvard PHD 2000 pump while experiments 
were running. The 10ml syringes were suspended from a clamp stand to allow ready flow 
of cell suspensions.  
A  B 
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outlined in 2.4, and re-suspended in endothelial cell basal medium. Cell suspension (100µl) 
was then pipetted into the flow chambers.   
Caps were then placed securely over the media reservoirs of the flow chamber and the 
chambers incubated for 15 minutes to allow the cell suspension to equilibriate within the 
chamber and to cells to begin to adhere to the flow chamber, as outlined in application note 
AN13, after which time, 60µl of fresh media was added to each reservoir. 
To ensure humidity in an otherwise open system, flow chambers were placed within a large 
petri dish containing sterile padding moistened with sterile deinionised water (produced in-
house). The lid was then secured on top of the petri dish and the petri dish placed inside the 
incubator in an atmosphere containing 5% CO2 at 37°C . Cells were checked after four hours 
using a light microscope to ensure cell adherence and determine confluence. Four hours was 
selected as this was demonstrated to be sufficient time for seeded cells to adhere to the flow 
chamber and begin to form a layer in ibidi Application Note AN13. 
 
6.2.2.1 Capture of Images of Flow Chambers 
 
All photographs were taken using the QCapture Pro version 6 software. In brief, flow 
chambers were placed on the stage of a light microscope (Nikon Eclipse TS100, Nikon, Tokyo, 
Japan) and an attached camera (QImaging Retiga 2000R Fast1394, QImaging, Surrey, Canada) 
was switched on. The QCapture software was opened and the cells visualised on screen. 
Using the “single photograph” or “multiple photograph” setting, images were obtained and 
saved as .png files. These files were then converted and saved as .jpg files. 
 
6.2.2.2 Optimisation of the Ideal Seeding Density 
 
Once cultured, dissociated, and counted, cells were re-suspended to variety of 
concentrations: 2.5x105, 5x105, 7.5x105, 1x106, 1.75x106, 2.5x106 per ml. An aliquot (100μl) of 
cell suspension was pipetted into the ibidi μ-slide I0.4 Luer flow chamber, to give a total 
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concentration of 1x104, 2x104, 3x104, 4x104, 7x104, and 1x105 cells per cm of growth area 
within the flow chamber (total growth area, 2.5cm2), thus a total per-slide cell count of 
2.5x104, 5x104, 7.5x104, 1x105, 1.75x105, 2.5x105 per slide. The flow chambers were then 
placed in an incubator as outlined in 6.2.2. After four hours, the cells were removed from the 
incubator and visualised as outlined in 6.2.2.1.  Photographs were taken, and the 
concentration that resulted in the best confluence was noted. All experiments were carried 
out in triplicate. 
 
6.2.2.3 Impact of Incubation Time on Monolayer Confluence 
 
It was then determined whether increased incubation time impacted confluence. Cells were 
seeded at the concentrations described in 6.2.2.2 and cultured for four, 12 or 24 hours as 
outlined in 6.2.2. The confluence and adhesion of cells incubated for each time point was 
then assessed as outlined above. All experiments were carried out  in triplicate. Cells were 
then removed from the incubator and visualised as outlined in 6.2.2.1. The concentration and 
incubation time which resulted in the most favourable cell confluence were assessed via 
visualisation as described in 6.2.2.1. 
 
6.2.2.4 Impact of a Full Media Change on Monolayer Confluence 
 
To determine whether a full media change improved the condition of the monolayers 
achieved, cells were seeded into the flow chambers at the four highest concentrations as 
outlined in 6.2.2.2, and incubated for four hours as outlined in 6.2.2. These cells were also 
subjected to a full media change after four hours of incubation. A full media change was 
performed by carefully aspirating all media from the flow chamber using a pipette tip. Fresh 
endothelial cell basal medium (220µl) was then pipetted into the chamber and the chamber 
placed back inside the petri dish in the incubator. The confluence of the monolayer was then 
either immediately assessed, or the flow chambers were placed back in the incubator and 
allowed to incubate for a further 8 hours or 20 hours, to give a total incubation time of 12 
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and 24 hours as outlined in 6.2.2.3, prior to assessment via visualisation and photography, as 
outlined in 6.2.2.1. All experiments were carried out in triplicate. 
 
6.2.2.5 HUVEC Monolayer Stability in Response to Shear  
 
The stability of HUVEC adhesion to the uncoated ibidi flow chamber when seeded at 
1.75x106 and 2.5x106 per ml (1.75x105 and 2.5x105 per slide)  and incubated for 24 hours was 
then assessed. The flow chamber was then attached to the flow system as shown in Fig. 6.1. 
The Harvard 2000 PHD pump was set to withdraw room temperature PBS over the cells at a 
shear stress of 5 dyn/cm2 in the centre of the flow chamber channel. This was achieved by 
programming the Harvard 2000 PHD pump to withdraw 3.8ml/min with the diameter 
function set to 14.5mm, the diameter of the Hawksley 50ml glass syringe. This withdrawal 
rate was chosen according to the manufacturer’s instructions (ibidi application note 11), 
which was determined by ibidi based on the  equation, derived by Cornish (1928). 
Cells were photographed using the QCapture Pro software, as outlined in 6.2.2.1, prior to the 
beginning of flow. Under conditions of flow, photographs were taken using the software at 
15, 30, 60, 120, 180, and 240 seconds. The stability of adherence was determined by 
analysing the images and determining the number of cells lost under flow conditions. In later 
optimisation experiments, cells were also exposed to a shear flow rate of 1 dyn/ cm2 by 
drawing PBS over the cells within the flow chamber at a rate of 0.72ml/min. 
 
6.2.2.6 Deciding upon Incubation Time and Seeding Density 
 
In all future experiments, cells were seeded at the density which resulted in the best 
confluence (1 x 105 cells/cm2, 2.5x106 cells per ml) and incubated for the time which resulted 
in the best confluence and cell viability (24 hours).  
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6.2.3 Ability to Withstand TNF-α and BLM Treatment. 
 
To ensure treatment with BLM and TNF-α did not impact cell viability within the chamber, 
cells were cultured as outlined in 6.2.2.6, before being treated with various concentrations of 
BLM and TNF-α. In brief, culture medium was aspirated and replaced with culture medium 
containing either 0.1, 1, or 10μg/ BLM, or 10ng/ml TNF-α. Cells were allowed to incubate in 
either BLM or TNF-α for six or 24 hours.  
In cells treated for 24 hours with all concentrations of  BLM and 10ng/ml TNF-α, the initial 
BLM or TNF-α-containing media was removed after 4 hours and replaced with identical BLM 
or TNF-α-containing media, to eliminate the possibility that changes in adhesion of viability 
were due to senescence or cell stress due to spent culture medium. 
The viability of cells and the quality of the monolayer was assessed as outlined in  6.2.2.1. In 
addition, the ability of TNF-α and BLM-treated cells to withstand shear stresss of 5 dyn/cm2 
was assessed as outlined in 6.2.2.4 and visualised accordingly.  
 
6.2.4 Neutrophil isolation 
 
Neutrophils were isolated based on a modified version of the protocol outlined in Rainger, et 
al. (1995) and also via single-step density gradient. Whole blood was collected by 
venepuncture of consenting healthy volunteers and was collected into a syringe containing 
sufficient anticoagulant acid citrate dextrose (ACD) to give an overall concentration of 20% 
ACD in whole blood. Blood collection was kindly performed by members of the Hull Platelet 
Research Group. Neutrophils were then isolated using either a two-step or a single-step 
density gradient. All gradients were conducted in polypropylene tubes to prevent 
granulocyte adherence to the plastic, and all reagents were used at room temperature.   
A two-step density gradient consisting of 7.5ml histopaque 1119 and 7.5ml histopaque 1077 
(Sigma Aldrich, Poole, UK) was overlaid with 15ml whole blood diluted 1:1 in 1x PBS without 
calcium and magnesium. This was centrifuged at 800 x g for 30 minutes at room temperature 
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using an Eppendorf 5207 centrifuge. The plasma layer was then removed and plasma (10ml) 
was filtered through a 0.45μm syringe into a falcon tube. Neutrophils were isolated and 
transferred into a 50ml falcon tube containing 1x PBS (without calcium and magnesium) with 
5% autologous plasma (10ml). Neutrophils were then washed by centrifugation for ten 
minutes at 800 x g. 
When using the single-step density gradient, 15ml diluted whole blood was layered over 
15ml histopaque 1077. This was centrifuged at 400 x g for 30 minutes at room temperature 
using an Eppendorf 5207 centrifuge. The plasma and PBMC layers were removed leaving only 
the erythrocyte pellet containing the neutrophils. Erythrocyte lysis was carried out by adding 
40ml deionised water (pH 6.8) and agitating the pellet gently. 10x PBS (3.6ml) was added to 
restore the isotonicity, and the cells were centrifuged for ten minutes at 800 x g to generate 
a neutrophil pellet. Lysed erythrocytes were discarded  
In both cases, the neutrophil pellet was then suspended in 1x PBS with calcium and 
magnesium, 0.15% bovine serum albumin, and 5mM D-glucose (henceforth referred to as 
supplemented PBS) (5ml) and the number of cells counted using a haemocytometer as 
previously outlined. 
To ensure the purity of the cells isolated (i.e., that neutrophils were not contaminated with 
lymphocytes or mononucleocytes, and that ≤50% of cells in the sample were erythrocytes), a 
cytospin experiment was carried out. The cell suspension was adjusted to a concentration of 
1x106/ml and 100μl was applied to a Polysine slide (Thermo)  using a plastic funnel 
attachment. The slide was centrifuged in a  Cytospin 3 cytocentrifuge (Shandon, Thermo 
Shandon, Cheshire, UK) for five minutes at 800rpm. The slide was air-dried for up to half an 
hour and dyed using the Rapi-Diff staining kit (Atom Scientific, Cheshire, UK). In brief, the 
slide was fixed using methanol (five second exposure), and stained by exposing for five 
seconds each to eosin and methylene blue dyes. The slide was then washed and allowed to 
air dry for up to 30 minutes before mounting using DPX mounting medium (Fluka 
Biochemika, Buchs, Switzerland) and visualisation using light microscopy. Neutrophils were 
identified by the multi-lobed nucleus. Cytospin slides were generated for all experiments. A 
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modicum of erythrocyte contamination was permitted as erythrocytes are non-adherent cells 
under normal conditions (see section 6.4.3).  
Neutrophils were then suspended in supplemented PBS  to a concentration of 5x105 cells/ml 
and loaded into the 10ml plastic syringe shown in Fig. 6.1, ready to be used for the flow 
chamber experiments.   
 
6.2.4.1 Identification and Consenting of Volunteer Blood Donors 
 
Ethical approval was gained from Hull York Medical School for the collection of blood from 
healthy volunteer donors (see approval 13 09 – The Immunology of Bleomycin-Induced 
Pulmonary Fibrosis, Appendix B, Figure B.I). Ethical approval for all documentation associated 
with this work (Patient Information Sheet, Patient De-briefing Sheet, Consent Form) was 
obtained from Hull York Medical School.  
Healthy volunteer blood donors were identified from donor lists used by the Hull Platelet 
Research Group. Donors were approached and consented using the consent form (v1.1). All 
donor information was anonymised and no donor identifiers were used to label collected 
data. Instead, donors were assigned a four-digit code (e.g., 0001) at the time of consent, and 
this code only was used to identify the data once collected. Donor identifiers were re-used if 
the donor gave blood on more than one occasion. Donor samples were not screened for 
blood-borne viruses (as outlined in the patient information sheet (v1.1).  
All attempts were made to gender-match, age-match and ethnicity-match donors used in 
experiments.  In all cases (with the exception of neutrophil flow over 6-hour treated 
endothelial monolayers, which contained two females and one male), each donor group 
contained two males and one female. In all cases (with the exception of neutrophil flow over 
24-hour treated endothelial monolayers, which contained three caucasian donors), all groups 
contained two caucasian donors and one East Asian donor. All donors who gave blood in the 
experiments which were used in the final data were between the ages of 18 and 40 years.  
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6.2.5  Optimisation of Shear Flow Rate 
 
HUVECs were cultured, dissociated, centrifuged, and counted, as outlined in 6.2.2. Cells were 
re-suspended to a concentration of  2.5x106 per ml and seeded into the flow chamber as 
outlined in 6.2.2.2. These were allowed to incubate for 24 hours to ensure a confluent 
monolayer and were treated with 10ng/ml TNF-α or left untreated, for six hours, as outlined 
in 6.2.3. Neutrophils were isolated using the single-step density gradient as shown in 6.2.3, 
the re-suspended to a concentration of 5 x 105/ml prior to use. 
The neutrophil suspension and wash buffer (supplemented PBS) was added to each empty 
plastic syringe as shown in Fig 6.1. Tubing was connected  and wash buffer allowed to flow 
through the tubing for 10 seconds at 10ml/min to ensure no air bubbles were present in the 
tubing. The tubing was then connected to the flow chamber and the  flow chamber was 
washed out by allowing the flow of wash buffer to pass over the monolayer for 30 seconds at 
3.8ml/min (5 dyn/cm2). This was followed by a wash-through of the neutrophil suspension 
for the same time at the same flow rate. The neutrophil suspension was then allowed to flow 
over the monolayer for 80, 160, 800, and 1600 seconds at a flow rate of 0.76 ml/min (1 
dyn/cm2), 0.38 ml/min (0.5dyn/cm2), 0.076 ml/min (0.1 dyn/cm2), and 0.038 ml/min (0.05 
dyn/cm2) prior to photographing, to ensure 1x106 neutrophils were present in the chamber. 
The adhesion of neutrophils to the monolayer at each of these rates was assessed as outlined 
in 6.2.6 and compared. 
 
6.2.6 Data Collection and Offline Analysis of Obtained Photographs of Cell 
Adhesion Under Flow 
 
When assessing neutrophil adhesion to endothelial monolayers under flow conditions, 
photographs were taken at five sites along the mid-line of the flow chamber (as outlined in 
Fig. 6.2). At each site, one photograph was taken per second for a total of twenty seconds, 
giving twenty photographs. This was achieved by placing the flow chamber on the stage of 
the aforementioned light microscope and using the QCapture Pro 6 software. The software 
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was then set to take one photograph per second for a total of twenty photographs. This 
allowed a snap-shot of the neutrophil adhesion activity in this field to be recorded. All images 
were recorded moving left-to-right, i.e. the field furthest from the entrance reservoir was 
recorded first. Each series of 20 photographs required a time period of 20 seconds.  Data 
assessment was carried out offline. 
In brief, the .TIFF files generated by the programme were downloaded and converted into 
.JPEG files using Serif Photoplus 10. Photographs were then loaded into Microsoft Picture 
Manager and played in a loop to detect adhering and rolling cells. These photographs were 
also loaded into Microsoft Word to determine the distance travelled by rolling cells. 
Adherent, rolling, and spreading neutrophils were then identified.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: A schematic plan of image collection for flow chamber experiments. 
 
Direction of fields being photographed 
A schematic of how fields were photographed during flow chamber experiments. 20 pictures  
were taken in each field, along the midline which could be easily distinguished within the flow 
chambers. Pictures were taken against the direction of flow due to ease of photography.  
Field 1 Field 2 Field 3 Field 4 Field 5 
Midline Direction of cell flow  
Exit Entrance 
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6.2.6.1 Identification of Cell Adhesion Events from Obtained Images 
 
Cells were identified by their appearance. Identification was conducted manually as software 
to automatically detect neutrophils was not available. Adherent neutrophils were identified 
as small, round, phase-bright cells, clearly distinguisahble from endothelial cells and not 
moving along the endothelium (Fig 6.3A). Spreading neutrophils were identified as partially 
bright-phase (around the edges of the cell, but not as bright as adherent non-spreading cells), 
and larger but not clearly round, as outlined by Zhan, et al. (2012) (Fig 6.3B). Spreading 
neutrophils were also not seen to move along the endothelium. This spreading behaviour 
was rare compared to adherent and rolling cells; in a representative field, only one event out 
of 21 detected events was a spreading neutrophil, the others all being adherent or rolling. 
However, the spreading neutrophil events also required taking into account. Rolling 
neutrophils were identified as phase bright cells moving slowly along the endothelium. 
 
  
Figure 6.3: Adherent and spreading neutrophils as seen in flow chamber experiments. 
 
 
An adherent (left) and a spreading neutrophil (right), as outlined by McGetterick, et al. 
(2010) and Zhan, et al. (2012).  Both images were obtained from photographs taken in 
this work. More images of adherent neutrophils can be found in the appendix.  
 
A B 
20µm 
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Erythrocytes were identified as small cells which did not adhere to the endothelium and, 
though visible under light microscopy, appeared phase-dark when viewed using the 
QCapture Pro 6 software. These cells were moving rapidly, appeared to “tumble” through the 
chamber, were therefore not as round as neutrophils, and did at no point adhere to the 
endothelium. Non-adherent neutrophils could be clearly identified as white, phase-bright 
blurs moving accross the screen when the images were played in a loop (McGettrick, et al., 
2010) using Microsoft Picture Manager. Images of these cells are not shown due to the 
extreme difficulty of obtaining clear images when cells are flowing along the chamber. 
However, the supplementary videos of neutrophil suspension (marked as 9.4 in the appendix 
and submitted as a supplemenary disc) submitted with this thesis shows non-adherent 
neutrophils travelling along the flow chamber, appaearing as white streaks.   
The nature of rolling neutrophils was also considered. Rolling cells were considered slow 
rolling if the velocity of the cells - as determined by measuring the distance travelled when 
images were loaded into Microsoft Word - was at a velocity of ≤10µm/sec. Phase-bright 
spheres moving  along the endothelium (clearly visible spheres moving at a velocity of ≥10µm 
/sec when measures as outlined above) were regarded as rolling events. These two types of 
cells were combined to give the total number of rolling neutrophils. On occasion, 
granulocytes would appear to adhere to the endothelium in one still, but not be present on 
the next still. These were regarded as non-adherent and non-rolling, and their presence 
attributed to screen-capture timing. Such events were not included in the analysis based on 
the protocol of McGettrick, et al. (2010).  
The number of adherent, rolling, or spreading neutrophils was counted and totalled to give 
the total number of adherent neutrophils in a given field. Events on photographs that did not 
fit any of these profiles were regarded as not being neutrophil adhesion events, and so were 
not counted as such. 
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6.2.7 Assessment of Neutrophil Adhesion to Endothelial Monolayers under Flow 
 
Cells were cultured, removed from culture flasks, centrifuged, and counted as outlined above 
in 6.2.2. Cells were suspended to a concentration of 2.5x106 and 100µl of cell suspension was 
pipetted into each flow chamber used. The flow chambers were incubated for 15 minutes, 
after which time, media was added to the reservoirs, and were subject to a full media change 
after 4 hours. Chambers were then incubated for a further 20 hours to permit monolayer 
formation. When confluent, cells were treated with BLM and TNF-α for 6 and 24 hours, as 
required, as outlined above. Cells treated with TNFα and BLM for 24 hours were subjected to 
a media change at 6 hours. 
The flow chamber system was set-up as shown in Figure 6.1. Tubing was attached to the 
syringe and wash buffer flowed through at 10 ml/min to ensure no air bubbles were trapped 
in the tubing. Tubing was then connected to the flow chamber, which was attached to the 
microscope stage. Wash buffer was run through the flow chamber at a flow rate of 
3.8ml/min (5 dyn/cm2) for 30 seconds to remove any non-adherent endothelial cells and all 
culture medium. Following this initial wash-out step, granulocyte-containing cell suspension 
was run through the system at a flow rate of 3.8ml/min (5 dyn/cm2) for 30 seconds to ensure 
cell suspension was present in the tubing and the flow chamber, and to remove any "dead 
space" in the tubing. This flow rate will allow 1 x 106 granulocytes to have entered the 
experimental set-up, but at a velocity and shear sufficient to prevent any unwanted 
granulocyte adhesion to the endothelial monolayer.   
The flow rate was then decreased to 0.38ml/min (0.5 dyn/cm2) for 160 seconds and 
neutrophils were allow to pass through the chamber. During this period, 5 x 105 neutrophils 
will have passed through the chamber at a rate slow enough to allow adhesion or rolling on 
the surface of the cells, and the shear rate required will have been achieved and maintained.   
Photographs were then taken along the midline as outlined in figure 6.2 and section 6.2.6. 
Each series of 20 photographs (five series in total) required a time period of 20 seconds. A 
gap of 20 seconds was left between each field to allow a further 5x105 cells to have entered 
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the chamber by the end of the experiment. By the time the final field was photographed, a 
total of 1 million cells had entered the flow chamber at a shear rate low enough to permit 
adherence (2 million cells in total when the initial perfusion at 5 dyn/cm2 is included).  
Following the recording of adhesion under flow conditions as further granulocytes entered 
the chamber, the valves were switched and wash buffer allowed to flow into the chamber. 
The wash buffer was flowed through at a 0.38 ml/min (0.5 dyn/cm2) for 180 seconds. Fields 
were then recorded as outlined above to determine the levels of firm adhesion and rolling 
adhesion along the endothelial monolayer when further granulocytes were not being 
introduced into the  chamber. Though this data was recorded, this was not used in final 
results.   
Data analysis was carried out offline. Total numbers of adherent, slow-rolling, and rolling 
cells were recorded from each series of stills and outlined in 6.2.6. The results of each 
experiment were expressed as the mean number of adhesion and rolling events  per field 
(field size 1mm2). Five fields were photographed per slide, and three slides per treatment 
were assessed; therefore the mean is the average number of events determined from the 
assessment of 15 fields under each treatment condition. Though normalisation for the 
number of cells present within the chamber (correction to number of cells/mm2/106 cell 
infused) has been carried out by other groups previously (McGettrick, et al., 2010; 
McGettrick, et al., 2009; Luu, et al., 2000), it was found in this work that the number of cells 
did not impact the number of adherent events, but that the field analysed did (with fewer 
adhesion events noted at the entry and exit points of the chamber). Therefore, normalisation 
was deemed inappropriate. Data were analysed using Mann-Whitney-U tests in SPSS v. 19 
statistical analysis software. 
6.2.8 Generation of neutrophil adhesion movies. 
 
Converted TIFF files were converted into movies using the Ulead Video Studio (version 10; 
Corel, Ottawa, Canada). Movies of neutrophil adhesion to endothelial monolayers are found 
in the accompanying material (Disc A) provided with this document (described in A.IV).   
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6.2.9 Treatment of isolated neutrophils with anti-CD18 antibody and isotype 
control. 
 
Neutrophils were isolated using a single density gradient as previously described (section 
6.2.4) and counted using haemocytometry. Neutrophils were then re-suspended to a 
concentration of 4x106 cells/ml in supplemented PBS. To differentiate between neutrophils 
and erythrocytes when cells were counted, cell suspension was mixed with 3 x PBS. 
Crennilated erythrocytes could be easily detected by haemocytometry and so were rapidly 
differentiated from neutrophils.  
To the cell suspension, anti-CD18 antibody (clone TS1/18), isotype IgG1κ (low endotoxin, 
azide-free, Biolegend) or Mouse IgG1κ isotype control (low endotoxin, azide-free, Biolegend) 
antibody was added to a final concentration of 20µg/ml.  
TS1/18 is a widely used allosteric antibody (Zhang, et al., 2012) which blocks the CD18 
component of the CD11a/CD18 and CD11b/CD18 (LFA-1 and Mac-1) ligands of ICAM-1, 
expressed on neutrophils. TS1/18 has been demonstrated to block the adhesion of both 
lymphocytes and leukocytes to activated endothelial monolayers (van Epps, et al., 1989; 
López Farré, et al., 1993; Meerschaert and Furie, 1994; Smith, et al., 1989; Carmona, et al., 
2008) and the binding of leukocytes, ligand-transfected cells, and immobilised CD18 ligands 
to  ICAM-1 (Smith, et al., 1989; Zhang, et al., 2008; Xu, et al., 2013). Previous reports have 
suggested that TS1/18 is capable of preventing leukocyte adhesion to inflammatory-mediator 
stimulated endothelial cells by between 20-50% (van Epps, et al., 1989; Smith, et al., 1988; 
Meerschaert and Furie, 1993; López Farré, et al., 1993), and so whether ICAM-1 mediates the 
adhesion of neutrophils to BLM-treated endothelium in this model, and the efficacy of this 
antibody in blocking neutrophil adhesion to TNF-α-treated endothelium in this series of 
experiments, was assessed. 
Neutrophils were incubated with the TS1/18 antibody at room temperature in the dark for 
30 minutes to allow binding. The neutrophils were then washed in supplemented PBS (3 
times the original volume of neutrophils) by centrifugation at 800 x g for 10 minutes. TS1/18-
treated cells were re-suspended to a concentration of 5x105 neutrophils/ml and used in flow 
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chamber experiments as described in 6.2.7. Following incubation with antibodies, cytospin 
slides were generated to ensure neutrophils were still present in the suspension, and had not 
become activated during the incubation with the antibodies use in this experiment. 
Neutrophils were again counted as outlined in 6.2.4, and were then used for flow chamber 
experiments as previously outlined (section 6.2.4). Images were captured and analysed 
offline as previously described (section 6.2.6). Only 6-hour experiments (incubation with BLM 
or TNF-α, or left untreated, for 6 hours) were conducted. Only concentrations of 1 and 
10μg/ml BLM were used in this series of experiments. Data were analysed using Mann-
Whitney-U tests in SPSS v. 19 statistical analysis software.   
  
6.2.10 Optimisation of anti-CD62E Treatment of Endothelial Monolayers  
 
Endothelial cells were cultured, dissociated from culture flasks, counted, seeded into flow 
chambers at a concentration of 2.5x106 cells/ml, and incubated with media changes as 
previously outlined. After 24 hours of incubation, culture medium was removed and 
replaced. Images of the monolayer were obtained prior to, and after, the change of culture 
medium. Cells were then incubated for 30 minutes, 1 hour, 2 hours, and 4 hours. Chambers 
were then subjected to flow to determine the stability of the monolayer. The chamber was 
placed on the microscope stage and the chamber connected to the flow chamber system. 
Images of the monolayer was captured prior to flow beginning. Cells were then subjected to 
flow at a shear stress of 0.5dyn/cm2 for one minute. Five images were obtained along the 
flow chamber after this period. Cells were then subject to 5 dyn/cm2 shear for one minute. 
Images were again captured after this period.   
 
6.2.11 Treatment of endothelial monolayers with anti-CD62E antibody and isotype 
control. 
 
Endothelial cells were cultured, dissociated, counted, transferred to flow chambers at a 
concentration of 2.5x106 cells/ml (2.5x105 per slide), and incubated with media changes as 
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outlined in 6.2.7. Cells were incubated for 24 hours. Prior to use in experiments, culture 
medium was aspirated and replaced by culture medium containing appropriate 
concentrations of BLM and anti-CD62E antibody (clone P2H3) (isotype IgG1κ) (to a final 
concentration of 20µg/ml) (Novus Biologicals, Cambridge, UK) or Mouse IgG1κ isotype 
control (as described in 6.2.9).  
P2H3 is a widely used anti-CD62E antibody, and  has been reported to block the adhesion of 
polymorphonucleocytes to LPS-treated HUVECs under flow by approximately 90% (Ploppa, et 
al., 2010), and the binding of metastatic tumour cells (HAL-24Luc cells) to endothelial 
monolayers to a similar degree (Martin-Satué, et al., 1998). The binding of leukocytes to 
VEGF-treated endothelial monolayers was also reduced by approximately 30% when HUVECs 
were treated with P2H3 (Kim, et al., 2001), and so even though there is no literature explicitly 
investigating the blockade of neutrophil adhesion to endothelial cells by P2H3, it may be 
expected that treatment with P2H3 would decrease such adhesion.   
HUVECs were incubated for 6 hours in antibody plus treatment (BLM or TNF-α) containing 
medium to ensure the endothelial cell monolayer had stably re-adhered to the flow chamber 
and to mirror the time used for incubation with BLM previously. Only 6-hour experiments 
(incubation with BLM or TNF-α, or left untreated, for 6 hours) were conducted. Only 
concentrations of 1 and 10μg/ml BLM were used in this series of experiments.     
Neutrophils were isolated and counted as previously described using the single-step density 
gradient technique (section 6.2.4).  Neutrophils were then re-suspended in supplemeneted 
PBS to a concentration of 5x105 cells/ml and used in flow chamber experiments as previously 
described (section 6.2.7). In this series of experiments, untreated neutrophils were flowed 
over isotype control and P2H3-treated endothelial monolayers to determine whether 
blocking endothelial adhesion molecules prevented neutrophil adhesion to the monolayers. 
Photographs of the endothelial monolayer as neutrophils were flowed through the flow 
chamber were acquired as outlined previously. Data analysis was carried out offline as 
previously described (section 6.2.6). Data were analysed using Mann-Whitney-U tests in SPSS 
v. 19 statistical analysis software. 
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6.3 Results 
 
6.3.1 The Impact of Seeding Density, Incubation Times, and Media Changes on the 
Generation of Confluent Monolayers  
 
Initially, optimisation experiments were carried out to determine the ideal cell-seeding 
concentrations for this work. Though the manufacturer suggested seeding at a concentration 
of 3-7x 105 cells/ml (3-7 x104 cells per slide, 1.2-2.8x104 cells/cm2), only 50% confluence 
would be acheived after 24 hours, and in these experiments,  a rapidly confluent monolayer 
was desirable. Therefore, several concentrations were trialled, to determine seeding 
concentration that would generate a monolayer able to withstand shear after 24 hours. The 
concentrations trialled were 2.5 x 104, 5 x 104, and 7.5 x 104, 1 x 105, 1.75 x 105, and 2.5 x 105 
cells per slide (2.5 x 105, 5 x 105, 7.5 x 105, 1 x 106, 1.75 x 106, and 2.5 x 106 cells/ml). Each 
slide held 100µl of cell suspension.    
After seeding the cells at the concentrations outlined above, slides were incubated for 4 
hours and the adherence of the cells and the confluence of the monolayer was assessed. 
However, no concentration produced a fully confluent monolayer (Fig 6.4). Thereafter, 
longer incubation times (12 and 24 hours) were trialled. Increasing incubation time appeared 
to increase the confluence of cells seeded at highest concentrations to some degree (Fig. 
6.5), though it is possible that cells merely adhered and spread more.  The confluence of the 
monolayer generated by the two lowest concentrations (2.5 x 104, 5 x 104)  did not appear to 
alter at all with even 24 hour incubation (Fig. 6.6). No further optimisation was carried out 
using these concentrations.   
Although ibidi Application Note 13 (AN13) states that a media change is only required every 
24 hours, it was observed that, after 12 and 24 hours with no media change, cells began to 
look stressed – acquiring spindle-shaped, elongated morphologies, rather than the 
characteristic cobblestone morphology (Fig 6.9A, 6.9B). Therefore, it was assessed whether a 
media change after 4 hours of incubation would improve the monolayer produced when cells 
were seeded at a density of 7.5 x 104, 1 x 105, 1.75 x 105, and 2.5 x 105 cells per slide. It 
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appeared that at the higher seeding concentrations, a media change improved the condition 
of the monolayer achieved (Fig 6.8) and did not wash away adherent cells (Fig. 6.7). 
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Figure 6.4: HUVEC monolayer confluence after 4 hour incubation when seeded at a variety of concentrations.   
         
  
The confluence of HUVECs seeded at a variety of concentrations within a flow chamber after four hours. None of the concentrations 
assessed resulted in a 100% confluent monolayer after four hours, though both the 1.7x105 and 2.5x105 cells/slide flow chambers 
produced layers that were almost 100% confluent, with only small patches without cells observed. The confluence acheived was 
directly proportional to the seeding density. These photographs are representative images of three experiments. 
2.5x104 5x104 
2.5x105 1.75x105 1x105 
7.5x104 
200μm 
7.5x104 5x104 2.5x104 
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Figure 6.5: An assessment of the impact of incubation time on HUVEC monolayer confluence.  
A1 
D3 
D2 
D1 
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B2 
B1 
A3 
A2 
Cells seeded at different concentrations incubated for various time points. Cells were seeded at a density of 7.5x104/slide (A), 1x105/slide (B), 
1.75x105/slide (C), and 2.5x105/slide (D), and allowed incubate for four (1), twelve (2), or 24 hours (3) without a media change. Both A and B failed to 
generate a confluent monolayer over this time. While C and D both generated a confluent monolayer, cells appeared to be slightly stressed, with 
some exhibiting an elongated, spindle-like morphology. Images are representative of three experiments. 
200μm 
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 Figure 6.6: An assessment of the impact of incubation time on HUVEC monolayer confluence II. 
The confluence of cells 
seeded at concentrations 
of 2.5x104/slide (A and C) 
and 5x104/slide (B and D) 
after four (A and B) and 
24 (C and D) hours. While 
increasing the incubation 
time increased the 
number of cells present in 
the slide, a confluent 
monolayer could not be 
acheived. Therefore, 
further optimisation work 
was not conducted using 
these concentrations. 
Images are representative 
of three experiments 
200μm 
A 
C 
B 
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Figure 6.7: An assessment of the impact on a fourth-hour media change on monolayer stability. 
  
A1 B1 C1 D1 
A2 B2 C2 D2 
Images showing cells seeded at a density of 7.5x104/slide (A), 1x105/slide (B), 1.75x105/slide (C), and 2.5x105/slide (D), before 
(1) and after (2) a full media change after four hours of incubation. As can be seen from these images, the full media change did 
not result in any large-scale or noticeable loss of cells, suggesting that all cells had adhered to the slide within four hours after 
initial seeding.   Images are representative of three experiments. 
200μm 
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Figure 6.8: An assessment of the impact on a fourth-hour media change on monolayer confluence. 
  
A1 
D3 
D2 
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C3 
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C1 
B3 
B2 
B1 
A3 
A2 
Cells seeded at different concentrations incubated for various time points following a full media change at 4 hours. Cells were seeded at a density of 
7.5x104/slide (A), 1x105/slide (B), 1.75x105/slide (C), and 2.5x105/slide (D), and allowed incubate for four (1), twelve (2), or 24 hours (C). Images marked 1 
show cells immediately after the 4 hour media change. While changing the media improved the condition of the monolayer over 12 and 24 hours, A and B 
failed to generate a confluent monolayer over this time. C and D both generated a confluent monolayer over 24 hours following a 4th hour media change. 
Images are representative of 3 experiments. 
200μm 
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Figure 6.9: Morphology of cells incubated for 24 hours with and without a media change.  
Cells seeded at a density of 2.5x105/slide and allowed to incubate for 24 hours without (A) and with (B) a media change after 
four hours of incubation. Without a media change, cells appears stressed and have an elonganged, spindle-like morphology 
(A). With a media change, there are fewer elongated spindle-like cells, and the morphology is rounder, more characteristic 
of the cobblestone morphology typically observed with endothelial cells (B).  
A B 
200μm 
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6.3.2 The Ability of Confluent Monolayers to Withstand Shear Stress 
 
Seeding concentrations of 1.75x105 cells/slide and 2.5x105 cells/slide (1.75x105 cells/ml and 
2.5x105cells/ml) were both able to generate a confluent monolayer. Both seeding 
concentrations were therefore assessed to determine whether the integrity of the 
monolayer would remain during, and after, flow conditions at a shear stress of 5 dyn/cm2. 
Cells seeded at both concentrations were found to withstand flow at a shear stress of 
5dyn/cm2 without any large scale loss of cells (Fig 6.10 and 6.11). Therefore, the seeding 
concentration of 2.5x105 cells per slide was chosen, and would be used for future 
experiments.   
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Figure 6.10: The ability of monolayers to withstand shear stress. 
  
0 sec. 30 sec. 60 sec. 
120 sec. 180 sec. 240 sec. 
The endothelial cell monolayer resulting from seeding cells at a density of 1.75x105 cells per slide. There was no cell 
loss when cells were exposed to a shear force of 5 dyn/cm2, and the integrity of the monolayer was maintained over 
the full four minute flowing period. Images are representative of three experiments. 
200μm 
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Figure 6.11: The ability of monolayers to withstand shear stress II. 
 
  
0 sec. 30 sec. 60 sec. 
120 sec. 180 sec. 240 sec. 
The endothelial cell monolayer resulting from seeding cells at a density of 2.5x105 cells per slide. There was no cell loss 
when cells were exposed to a shear force of 5 dyn/cm2, and the integrity of the monolayer was maintained over the full 
four minute flowing period. Images are representative of three experiments. 
200μm 
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6.3.3 The Ability of Monolayers to Withstand Treatment with BLM and TNF-α 
 
As seen in Fig. 6.11, cells seeded at 2.5x105 cells/slide generated a confluent, healthy 
monolayer able to withstand shear stress of 5 dyn/cm2. Next, it was assessed whether cells 
seeded at a density of 2.5x105 cells/slide maintained a confluent monolayer when treated 
with 0.1µg/ml, 1μg/ml, and 10μg/ml BLM, or 10ng/ml TNF-α for 6 and 24 hours. Both agents 
are cytotoxic, so the resilience of the monolayer to these agents needed determining. When 
cells were allowed to incubate for 24 hours with a 4th hour media change, treatment with 
TNF-α for 24 hours slightly altered the morphology of the monolayer. Treatment for 6 hours 
had no effect (Fig. 6.12).  However, confluence was maintained as in Fig. 6.11. 
 
 
Figure 6.12: Endothelial monolayers within a flow chamber before and after treatment 
with TNF-α 
 
Pre-treatment 
 
Pre-treatment 
 
Post-treatment 
 
Post-treatment 
200μm 
Cells treated with TNF-α (10ng/ml) for 6 hours and 24 hours before addition of TNF-α to the 
monolayer, and after the full incubation period. Images are representative of 3 experiments. 
6 Hours 24 Hours 
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Despite the slight alterations in morphology when cells were treated with TNF-α for 24 hours, 
cells remained adhered even under flow at 5 dyn/cm2 for four minutes (data not shown). 
Therefore, these conditions were deemed viable for use as a positive control in this 
experiment. The integrity of the  monolayer was also maintained after treatment with BLM; 
no large-scale cell death was observed.  
 
Figure 6.13: Endothelial monolayers within a flow chamber after BLM treatment.  
A1 B1 
A2 B2 
B3 A3 
Cells treated for 6 (A) and 24 (B) hours with 0.1µg/ml (1), 1µg/ml (2), and 10 µg/ml (3) BLM. The 
confluence of the monolayers when cells were seeded at a concentration of 2.5x105 cells/slide and 
allowed to incubate for 24 hours with a fourth hour media change (as shown in Fig. 7) was not 
diminished by treatment with BLM for 6 and 24 hours. The monolayers were also able to withstand 
shear (not shown). Images are representative of three experiments. 
200μm 
200μm 
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6.3.4 Optimisation of Neutrophil Isolation 
 
Initially, a two-step gradient protocol was used for the isolation of neutrophils from whole 
blood (Rainger, et al., 1995; McGetterick, et al., 2010). However, it was quickly found that 
this technique was not reproducible or reliable, and it was not possible to generate a distinct 
band between the two histopaque layers. Therefore, optimisation experiments were carried 
out to develop a reproducible and reliable method for isolating human neutrophils. Two 
techniques were trialled and compared.  
In the first method (Fig 16.4A), the double-density gradient technique was used. The 
granulocyte layer was extracted from between the two layers of histopaque, washed, and 
resuspended in PBS contaning calcium, magnesium, 5mM glucose, and 1.5% BSA. The 
neutrophils were then counted. In the second method (Fig 16.4B), only a single-step gradient 
was used to allow granulocytes to gather in with the erythrocyte pellet. The erythrocyte 
pellet was then lysed as outlined in 6.2.4, to leave only the granulocytes in this layer. Again, 
cells were washed and re-suspended as described above.  
In both cases, small volumes of histopaque were also extracted along with the granulocyte 
layer/ erythrocyte pellet to ensure no granulocytes were lost. This was particularly important 
in method A, as it was found that no distinct granulocyte band could be obtained. This was 
unexpected, as distinct bands of mononucleocytes and plasma, as well as distinct erythrocyte 
pellets, were routinely obtained. The reasons for the lack of granulocyte layer are unknown.  
The purity of the cell samples obtained using each of these methods was determined by 
cytospin slide generation. The results are shown in Fig. 6.15 and 6.16. Though succesful 
neutrophil isolation using the double-density gradient method was achieved, this was not 
reliable, and this method could either result in the harvest of many (Fig. 6.15A), or few 
neutrophils (Fig. 6.15C).  
 
248 
 
   
 
Figure 6.14: The separation of whole blood using the single and double density gradient 
techniques. 
 
 
 
 
 
Using the single-density method, a population of pure neutrophils could be acheived 
providing red blood cells lysis was achieved by carrying out the lysis step only once. Multiple 
attempts to lyse the erythrocytes resulted in neutrophil activation. A lysis technique in which 
the red cell pellet (from 15ml whole blood)  containing the neutrophils was re-suspended in 
40ml of deionised, sterile water (to generate a hypotonic environment) and swirled for 30 
seconds, prior to the addition of 3.6ml 10 x PBS (to create an isotonic environment), and 
  
  
 
 
 
Plasma 
Mononucleocytes 
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Granulocytes 
Erythrocytes 
 
 
 
1077 
Mononucleocytes 
 
 
 
A diagram representing the expected results of blood separation using the two-step density 
gradient method (A) and the single-step density gradient method (B). 1077 and 1119 refer 
to the densities of the histopaque used in each layer. In this experiment, when a two-layer 
density gradient was used, no clear granulocyte band was acheived at any stage.  
Erythrocytes and 
granulocytes 
Plasma 
A B 
Mononucleocytes 
nucleocytes 
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spun at 800 x g for 10 minutes, was found to lyse the vast majority of erythrocytes while 
leaving a substantial population of unactivated, therefore usable, neutrophils (Fig. 6.16). 
Some erythrocyte contamination was deemed acceptable as erythrocyte adhesion to the 
BLM-treated monolayer was not expected in this series of experiments, as discussed in 
section 6.4.3. 
 
   
  
Figure 6.15: Neutrophils isolated by the double-density gradient technique.  
Using a double-density gradient technique could result in a good neutrophil yield (A), but 
this was not always the case; the use of the same technique could also result in mediocre 
yields (B and C) or poor yields where most isolated cells were erythrocytes (B), though why 
this occurred is unknown. Shown are representative cytospin slides of five experiments (a 
total of 12 slides).   
A B 
C D 
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Figure 6.16: Neutrophils isolated by the single-density gradient technique. 
 
 
 
 
 
 
Approximately 1x107 neutrophils were needed for each series of experiments (20ml of 
neutrophil suspension at a concentration of 5x105 neutrophils/ml) to ensure sufficient cells 
to carry out all plates. Therefore, 1x107 was regarded as the threshhold level of neutrophils 
Using a single-density gradient technique often resulted in a good neutrophil yield (A, B, C), 
though a pure yield of neutrophils was often difficult to acheive using this method, with 
many cytospin slides showing erythrocyte contamination (A, B). It was possible to yield 
pure neutrophil yields with multiple washes (C, D), though this often resulted in lower 
neutrophil yields due to neutrophil activation (d). Shown are representative cytospin slides 
of five experiments (a total of 12 slides) in which the single-density gradient technique was 
used to isolate neutrophils.  
A B 
C D 
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that needed to be isolated from 15ml of whole blood. A good yield is regarded as ≥1x107 
neutrophils/ml, and a poor yield, <1x107 neutrophils/ml, when assessed by haemocytometry. 
The results of multiple optimisation experiments showed that, using the double-step density 
gradient technique, poor neutrophil yields were obtained in two out of five experiments. The 
single-density gradient yielded very good numbers of neutrophils in four out of five 
experiments (therefore adequate for conducting the experiment), and a poor yield in one, 
though this donor was found to be neutropenic. While neutrophil purity was generally less in 
cells isolated using the single-step gradient compared to the double-step gradient (Fig 6.15 
and 6.16), erythrocyte contamination was not deemed to be problematic, as erythrocytes do 
not adhere to endothelial monolayers. The single-step density gradient with a single lysis 
step was therefore chosen. 
 
6.3.5 Optimisation of Shear Stress Used in Experiments to Allow Neutrophil 
Adhesion to the Monolayer 
 
Following the optimisation of the seeding density and neutrophil isolation technique, 
monolayers were generated and treated with BLM or TNF-α as previously outlined. 
Neutrophils isolated from healthy donors using the single-step density gradient technique 
and suspended to a concentration of 5x105 cells/ml were then flowed over the monolayer for 
up to four minutes at a shear stress of 5 dyn/cm2. However, initial results showed that, at this 
shear stress, neutrophils were not able to adhere to the monolayer. Monolayers treated with 
BLM, TNF-α, or left untreated, were unable to support tethering, rolling, or adhesion. 
Neutrophils were seen to move rapidly across the field and did not appear to contact the 
endothelium (data not shown).  
Therefore, the shear stress was deemed to be too high to allow neutrophil adhesion, despite 
being physiologically relevant in the pulmonary microvasculature. The shear stress was 
therefore decreased to 1 dyn/cm2, in line with the protocol of McGetterick. Initially, it was 
determined whether a shear stress of 1 dyn/cm2 would disrupt the endothelial monolayer. 
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This was not found to be the case, and endothelial cell integrity at this shear stress was also 
maintained (Fig. 6.17). As expected, further decreases in shear stress applied to the 
endothelial monolayer also failed to disrupt the integrity (data not shown).  
However, when assessing neutrophil adhesion at a shear stress of 1 dyn/cm2, similar 
problems were encountered to when 5 dyn/cm2 was used. Though previous works by the 
Nash group have found that at a shear stress of 1 dyn, neutrophils were capable of 
adherence to the monolayer (Rainger, et al., 1995; Sheikh, et al., 2005), a different flow 
chamber set-up was used in this work, and few neutrophils adhered to the central region of 
the chamber at a shear stress of 1 dyn/cm2. This was deemed potentially due to laminar flow 
resulting from the velocity of media travelling through the chamber, calculated to be 
approximately 3.8cm/min. Though there is no current literature which adequately describes 
the flow rate of blood through human pulmonary venules and arterioles, which this 
experiment aims to model, it was decided that a lower shear stress rate, and therefore a 
lower velocity, may be required.  
Lowering the shear stress used may make the model more physiologically relevant. A shear 
stress rate of 1 dyn/cm2, used previously,  precludes integrin-mediated adhesion. It is 
possible that the upregulation of adhesin expression - such as that of VCAM-1 and ICAM-1 - 
may contribute to the recruitment of neutrophils within the pulmonary microvasculature. 
Therefore, a series of experiments assessing neutrophil adhesion to monolayers at shear 
stress rates of 0.01, 0.1, and 0.5 dyn/cm2 were conducted. The results of these experiments 
showed that, while at 0.5dyn/cm2, neutrophils adhered to the monolayer when treated with 
TNF-α, but not to the untreated monolayer, using rates slower than this resulted in large-
scale neutrophil adhesion to even the untreated monolayer. It was also very difficult to 
differentiate between slow rolling and rolling neutrophils, and non-adherent neutrophils, 
when these shear rates were used in this experiment. Therefore, a shear rate of 0.5dyn/cm2 
was used, as this both resulted in clear and analysable results, and also may potentially allow 
the adhesion of neutrophils to the monolayer initiated by integrin-mediated attachment.    
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Figure 6.17: The integrity of endothelial cell monolayers exposed to a shear stress of 1dyn/cm2 
  
0 sec. 30 sec. 60 sec. 
120 sec. 180 sec. 240 sec. 
An endothelial monolayer generated by seeding HUVECs at a density of 2.5x105 cells per slide. There was no cell loss 
when cells were exposed to a shear force of 1 dyn/cm2, and the integrity of the monolayer was maintained over the 
full four minute flowing period, as would be expected when comparing this to earlier results where a shear force of 5 
dyn/cm2 was used and the integrity of the monolayer was also maintained. 
200μm 
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6.3.6 The Identification of Adherent Neutrophils under Flow 
 
Data analysis required the assessment of the cells adherent to the monolayer, and this was 
conducted manually as outlined in 6.2.6.  Shown in Figure 6.18 is a representative image of 
neutrophils adherent to the endothelium. Adherent neutrophils are shown by yellow circles. 
Often, neutrophils accumulated in groups. No spreading neutrophils are shown. Figure 6.19 
shows a spreading neutrophil  (red circle). These cells were characterised by the phase-bright 
ring surrounding the cell with the dark inner area (the nucleus) and the slightly less 
distinctive circular shape (Zhan, et al., 2012). Few examples of spreading neutrophils were 
observed. 
As the determination of adherent neutrophils to the endothelium was dependent on the 
discretion of the investigator, the size and shape of adherent events were used as 
determinants of cell identity. The size of a human neutrophil is relatively uniform, at around 
10μm in diameter (Kolaczkowska and Kubes, 2013). Though the size of HUVECs is not 
determined, as the shape and growth habit of HUVECs is not uniform, this work has 
measured a HUVEC to be between 30-50μm long, and around 10-20μm wide, compared to 
the scale bar. Any potential adhesion events that were far greater in size, not circular, and 
not identifiable as spreading neutrophils, were deemed to be raised patches of endothelium, 
or where endothelial cell division was occuring. These were relatively common, potentially 
due to the seeding density used, and were easily identified and dismissed. Such raised 
patches are shown in Fig 6.18, denoted by blue circles. Usually, such patches were removed 
by the initial washing step in the protocol, but some remained in some experiments.  
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Figure 6.18: A representative image of neutrophils adherent to the endothelial monolayer under flow.  
A still showing neutrophils adherent to the endothelial monolayer (yellow circles) and areas of endothelial raising (blue cirlces). Neutrophils were ident-
ified by their size and shape. The image is representative of 120 images obtained for one experiment. The total number of experiments conducted was 
three per treatment condition.  
200μm 
200μm 
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Figure 6.19: A representative image of a spreading neutrophil and debris adherent to 
the endothelial monolayer. 
 
 
 
 
Occasionally, very small, non-circular, not especially phase-bright events were 
encountered. Adherent neutrophils have previously been determined to be broadly 
circular, phase bright, and of a general size (Zhan, et al., 2012). If these small events were 
deemed to be far smaller than one-third to one-fifth of the size of a HUVEC, smaller than 
a neutrophil, and non-circular, these events were regarded as cell debris and were not 
counted as neutrophils. Such criteria meant that non-adhesion events were not counted 
and the over-estimation of cell adherence was prevented. However, this phenomenon 
was uncommon; one such an occurence is highlighted above with a green circle. Finally, 
bright patches between endothelial cells were regarded to be visualisation of the 
Characteristic spreading neutrophils are marked with a red circle. Adhesion events too 
small to be neutrophils, potential cell debris, are marked with a green circle. The image 
is representative of 120 images obtained for one experiment. Three experiments were 
conducted in total. 
200μm 
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basement membrane. These were not circular and could be of any size, so were easily 
identified and also discounted immediately from adherent neutrophil counts.  
6.3.7 Neutrophil Adhesion to BLM Treated Monolayers under Flow Conditions 
 
There was an increase in the number of adherent neutrophils observed when cells were 
treated with BLM of various concentrations for 6 hours. Although there was no 
statistically singificant increase in the adhesion of neutrophils to the monolayer when 
cells were treated with the lowest concentration of BLM, the two higher concentrations 
appeared to increase neutrophil adhesion (Fig. 6.20A).  
As expected, the greatest increase in neutrophil adhesion to the monolayers was induced 
by treatment with TNF-α (10ng/ml). It is also notable that the highest number of “new” 
adhesion events – that is, events whereby neutrophils which were not previous adhered 
to the endothelium in the initial image captured slow, roll, and move along the 
endothelium, was greatest in the TNF-α-treated monolayers.  Other treatment conditions, 
however, had roughly similar numbers of “new” adhesion events (Table 6.1). Very few 
spreading events (fewer than one per field) were recorded in any of the three series of 
experiments outlined above, and so the frequency of these events was not recorded.  
When endothelial cells were treated with BLM or TNF-α for 24 hours, similar results were 
observed. There was a statistically significant increase in the number of neutrophils 
adhering to the monolayer when endothelial cells were treated with 1µg/ml or 10µg/ml 
BLM, or 10ng/ml TNF-α, for 24 hours, compared to baseline (Figure 6.20B). Again, the 
greatest number of “new” adhesion events was seen in cells treated with TNF-α (Table 
6.2), though this was of a smaller magnitude than observed when 6-hour treated 
endothelial monolayers were assessed. Adhesion of neutrophils to the monolayer did not 
increase in line with increased treatment time; both 6 hour and 24 hour treatment with 
BLM and TNF-α resulted in similar levels of adhesion. 
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Figure 6.20: Neutrophil adhesion to endothelial monolayers treated with BLM and TNF-
α for 6 and 24 hours. 
  
* 
* 
* 
* 
* 
* 
Neutrophil adhesion to endothelial cell monolayers treated with 0.1, 1, and 10µg/ml BLM, 10ng/ 
ml TNF-α, or media alone, for 6 (A) and 24 (B) hours. Statistically significant differences in neutro-
phil adhesion to the monolayer compared to baseline (p=<0.05) are denoted by an asterisk. N=3. 
A 
B 
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  New Neutrophil Adhesion Events 
  Average Per Field Total in all 5 Fields 
Treatment Condition Donor 1 Donor 2 Donor 3 Donor 1 Donor 2 Donor 3 
        
Negative Control 0.6 0.6 0.8 3 3 4 
0.1µg/ml BLM 0.8 0.8 0.8 4 4 4 
1µg/ml BLM 1.4 0.6 1 7 3 5 
10µg/ml BLM 0.2 0.8 1 1 4 5 
10ng/ml TNF-α 6.2 5 1.2 31 25 6 
 
Table 6.1: New adhesion events observed in 6 hour flow chamber experiments. 
 
 
 
 
  New Neutrophil Adhesion Events 
  Average Per Field Total in all 5 Fields 
Treatment Condition Donor 1 Donor 2 Donor 3 Donor 1 Donor 2 Donor 3 
        
Negative Control 0.4 0 0.2 2 0 1 
0.1µg/ml BLM  0.2 0 0.2 1 0 1 
1µg/ml BLM  0.2 0.4 0.6 1 2 3 
10µg/ml BLM  0.6 0.4 1 3 2 5 
10ng/ml TNF-α 2.4 0.8 2.4 12 4 12 
 
Table 6.2: New adhesion events observed in 24 hour flow chamber experiments.  
The total number of new adhesion events observed when neutrophils were flowed over 
endothelial monolayers treated with BLM or TNF-α (6 hour treatment). 
The total number of new adhesion events observed when neutrophils were flowed over 
endothelial monolayers treated with BLM or TNF-α (24 hour treatment). 
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6.3.8 Anti-CD18 Antibody-Treated Neutrophil Adhesion to Monolayers under 
Flow.  
 
To determine the adhesion molecules likely to be involved in the increased adhesion of 
neutrophils to the BLM-treated endothelium, flow experiments were carried out in which 
molecules or ligands were blocked. Initially, to assess whether ICAM-1 was involved in 
adhesion, CD18 was blocked using the TS1/18 antibody. This antibody was used at a 
concentration of 20µg/ml, deemed to be sufficient to block all CD18 molecules on 
neutrophils used in this experiment.  
It was noted that both the isotype control antibody and the CD18 antibody resulted in 
activation and therefore aggregation of neutrophils in many of these experiments. 
Whether this was the case appeared to be a donor specific phenomenon, with 
neutrophils isolated from donors of generally identical profiles (age, gender, and 
ethnicity) demonstrating very different responses to treatment with antibody. Moreover, 
the additional time required to treat the isolated neutrophils with these antibodies may 
have contributed to the activation and aggregation seen. For this reason, while n=3 was 
achieved for the experiments, eight attempts at conducting the experiments were 
required to achieve this. In four of these experiments, incomplete data was collected (as 
there were insufficient viable cells), or no viable neutrophils were present in the isolated 
samples. In one experiment, the endothelial monolayer had not formed correctly and the 
chambers were discarded. Incomplete data was discarded and only data from the three 
complete experiments was used.  
Pre-treatment of neutrophils with TS1/18 did not prevent neutrophil adhesion to BLM 
treated monolayers. The level of adhesion of TS1/18-treated and isotype-treated 
neutrophils to the endothelium was similar, and was not statistically different. However, 
pre-treatment with TS1/18 appeared to decrease the adhesion of neutrophils to TNF-α-
treated monolayers by around 30% (Fig 6.21).    
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Figure 6.21: Anti-CD18 antibody and isotype control treated neutrophil adhesion to 
BLM and TNF-α-treated endothelial monolayers under flow. 
 
 
 
  
The adhesion of isotype control treated and anti-CD18 antibody treated neutrophils 
to endothelial cell monolayers treated with 1µg/ml  and 10µg/ml BLM, 10ng/ml 
TNF-α, or left untreated for 6 hours. Statistically significant differences in neutrophil 
adhesion to the monolayer (p=<0.05) are denoted by an asterisk. N=3.  
* 
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6.3.9 Optimisation of Monolayer Treatment with Anti-E-selectin Antibody 
 
Optimisation work carried out to determine how viable endothelial monolayers were 
immediately after media changes (for use with the CD62E blocking experiments) revealed 
that, after an initial media change, there was large scale dissociation of endothelial cells 
from the flow chamber base. This was not immediate; dissociation appeared to occur 
between five and thirty minutes after the media change. This disrupted the integrity of 
the monolayer. Once dissociated (but still present in the flow chamber), endothelial cells 
were noted to re-adhere to the chamber after around four hours, but not before (one and 
two hours after the media change, there were still many non-adherent endothelial cells 
present in the flow chambers). Therefore, the minimum incubation time that could be 
used with the concurrent BLM/TNF-α and anti-CD62E antibody treatment experiments 
was four hours. Because of this, cells were concurrently treated with the two agents for 6 
hours to mirror the incubation time with BLM/TNF-α in earlier experiments. This was 
deemed to be unlikely to compromise the integrity of the endothelial monolayer. 
 
6.3.10 Adhesion of Neutrophils to Anti-E-selectin Antibody-Treated Monolayers 
under Flow. 
 
When endothelial monolayers were pre-treated with anti E-selectin antibody and 
neutrophils were rolled over the monolayer, a large decrease of around 60% in the 
adhesion of neutrophils to TNF-α-treated flow chambers was observed. However, once 
again, there was no statistically significant blockade of neutrophil adhesion to monolayers 
treated with BLM or untreated monolayers (Fig 6.22). 
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Figure 6.22: Neutrophil adhesion to anti-E-selectin and isotype control treated 
endothelial monolayers concurrently treated with BLM and TNF-α under flow. 
 
  
The adhesion of neutrophils to endothelial cell monolayers co-treated with 1µg/ml  
and 10µg/ml BLM, 10ng/ml TNF-α, or media alone, with anti-CD62E antibody or 
isotype control antibody, for 6 hours. Statistically significant differences in neutrophil 
adhesion to the monolayer  (p=<0.05) are denoted by an asterisk. N=3. 
* 
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6.3.11 The Impact of Isotype Control Antibody Treatment of Monolayer on 
Neutrophil Adhesion under Flow.  
 
In addition, the results obtained from these experiments suggest that the isotype control 
antibody used may have slightly decreased neutrophil adhesion to the endothelial 
monolayer. In all cases, neutrophil adhesion to the monolayer was slightly lower when 
untreated neutrophils were flowed over isotype control-treated HUVECs, than when 
isotype control-treated neutrophils were flowed over untreated HUVECs. However, the 
differences observed were not statistically significant, with the exception of endothelial 
monolayers treated with TNF-α (Fig 6.23). It is possible that the isotype control may have 
prevented the adhesion of neutrophils to the monolayer in these experiments, potentially 
due to the isotype control binding slightly to an adhesion molecule responsible for 
allowing neutrophil adhesion to the endothelial monolayer.    
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Figure 6.23: Neutrophil adhesion to BLM and TNF-α treated monolayers when 
neutrophils or endothelial cells were treated with isotype control antibody.  
The adhesion of isotype control-treated neutrophils to endothelial cell monolayers 
treated with 1µg/ml  and 10µg/ml BLM, 10ng/ml TNF-α, or media alone, and the 
adhesion of neutrophils to endothelial cell monolayers co-treated with 1µg/ml  and 
10µg/ml BLM, 10ng/ml TNF-α, or media alone, and  isotype control , for 6 hours. 
Statistically significant differences in neutrophil adhesion to the monolayer compared 
to baseline  (p=<0.05) are denoted by an asterisk. N=3. 
* 
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6.4 Discussion and Conclusions 
 
In this section of work, a flow chamber system was used to model the movement of 
neutrophils through the pulmonary vasculature in order to determine whether the 
increased adhesion molecule expression previously observed in endothelial cells treated 
with BLM exhibited functional relevance; that is to say, whether the adhesion molecules 
expressed by BLM-treated endothelial cells resulted in increased leukocyte adhesion to 
the monolayers. However, as this was a new system, extensive optimisation was required. 
 
6.4.1 Optimisation of Flow Chamber Seeding and Treatment 
 
Though the manufacturer’s instructions supplied with the ibidi vessels suggested using 3-
7x105 cells/ml (1.2-2.8x104 cells/cm2) per chamber and incubating for several days to 
allow a confluent monolayer to develop, a more rapid method was desirable in this work. 
Accordingly, higher seeding concentrations were trialled, and it was noted that 
concentrations of 2.5x106 cells/ml (2.5x105 cells/slide) were capable of generating a 
confluent monolayer within 24 hours. As the seeding concentration was altered, other 
factors such as incubation time and time-points of media changes required optimisation; 
by allowing cells to adhere for 24 hours, and by changing the media 4-6 hours after 
seeding, complete monolayers which could be used for experimental work were 
generated. These monolayers withstood shear stresses  ≥ 5 dyn/cm2, suggesting that 
chambers generated using this method were suitable for use. This work has provided a 
reliable method by which confluent monolayers can be generated rapidly, allowing work 
to be carried out more efficiently, and thus represents an improvement on the suggested 
methods of flow chamber seeding and endothelial monolayer generation.    
As the integrity of monolayers was maintained when cells were treated with BLM and 
TNF-α over 6 and 24 hours, this reinforces earlier observations that the concentrations of 
BLM used are not overtly toxic to endothelial cells over these time-points, and that the 
use of these concentrations is representative of in vivo processes, whereby large-scale 
endothelial death is not observed (Adamson, 1984).  
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6.4.2 Optimisation of Shear Stress for Use in Experimental Modelling 
 
Though the shear stress in the post-capillary venules and larger veins is between 1-
5dyn/cm2 (Kroll and Afshar-Khargan, 2012; Kuebler, 2009), these values are not fully 
defined, and in this work, at 5 dyn/cm2, neutrophils did not adhere to the monolayer. 
When 1 dyn/cm2 was used, few cells adhered. Thus, it may appear that, at shear stresses 
of >1 dyn/cm2, adhesion molecules expressed by BLM-treated endothelial cells do not 
have functional relevance. Therefore, to allow sufficient cells to adhere to the 
monolayers, the shear stress was decreased to 0.5 dyn/cm2. While shear stresses ≥1 
dyn/cm2 are more frequently used (McGetterick, et al., 2010; Luu, et al., 2000), there are 
several reasons for using shear stresses of 0.5dyn /cm2 in this work. 
The lower shear stress used (0.5 dyn/cm2) may have been favourable in this experimental 
set-up. Shear stresses over 1 dyn/cm2 prevent integrin-ICAM-1-mediated adhesion 
(Bahra, et al., 1998; Rainger, et al., 1995; Lawrence and Springer, 1991), a process 
inferred in neutrophil tethering and recruitment in BLM-treated rodents (Wang, et al., 
2011; Sato, et al., 2000). Thus, while shear of <1 dyn/cm2 may not be completely 
physiologically relevant, this value is poorly defined and the prevention of integrin-ICAM-
1 interactions mediating adhesion was not desirable in this work.   
Moreover, the current work is not the first to report low neutrophil adhesion to 
monolayers at a shear stress of 1 dyn/cm2. Lawrence and Springer (1991) reported that, 
as shear stress became greater than 1 dyn/cm2, neutrophil adhesion to ICAM-1 and E-
selectin harbouring bilayers decreased, with adhesion greatest at around 0.5 dyn/cm2. 
This decreased adhesion at shear stresses greater than 1 dyn/cm2 was suggested to be 
related to the location of the visualised fields. Laminar flow along the centreline, where 
the velocity is greatest, may hold neutrophils in suspension, preventing interaction with 
the monolayer. This may have occurred in the current work; flow chambers with deep 
channels were used, as these were the chambers in which the greatest range of shear 
stress could be achieved, and so neutrophils may have been held in suspension some 
distance from the monolayer.  
The low leves of adhesion when shear stresses of 1 dyn/cm2 were used in this work may 
also have been due to the time for which the experiments were conducted. While it was 
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reported that, as low numbers of neutrophils begin to adhere to the monolayer at shear 
>1dyn/cm2, disruption of laminar flow may result in turbulence, allowing increased 
neutrophil-monolayer interaction, but this is a gradual process  (Lawrence and Springer, 
1991). As the number of neutrophils that could be harvested from a single donor in this 
work was limited, it was unfeasible to run experiments for times sufficient for this 
turbulence to occur; all experiments were run for 4 minutes only, as running experiments 
for longer time periods would have meant insufficient neutrophils to run all four or five 
plates in the experiment using neutrophils extracted from a single donor.  
Therefore, the use of a lower shear stress in this work of 0.5 dyn/cm2 both allowed 
measurable results to be obtained, and ensured that ICAM-1-neutrophil ligand 
interactions, which may be physiologically relevant in the adhesion of neutrophils to BLM-
treated monolayers in vivo, were not precluded.  
 
6.4.3 Optimisation of Neutrophil Isolation and Neutrophil Identification 
 
Though the usual method for neutrophil isolation involves a double-density gradient, it 
was found that this method can be unreliable. A single-step density gradient protocol to 
isolate neutrophils was therefore used. While this resulted in some erythrocyte 
contamination of the samples, erythrocytes do not adhere to endothelial cells under 
normal conditions (de Oliveira and Saldanha, 2010; Chappey, et al., 1996; Yang, et al., 
2010). Only in conditions such as malaria, in which parasite proteins contribute to the 
erythrocyte membrane ligand milieu, and sickle cell anaemia, in which reticulocytes may 
express VLA-4, do erythrocytes adhere to endothelial adhesion molecules (Ockenhouse, 
et al., 1992; Gee and Platt, 1995; Lutty, et al., 2001; Matsui, et al., 2001; McCormick, et 
al., 1997) do erythrocytes routinely adhere to endothelial cells; donors with these 
conditions were excluded. Therefore, in this work, erythrocyte contamination of samples 
was deemed to not be a counfounding factor in the counting of adherent neutrophils.  
Neutrophils were readily identified in this work, appearing as phase-bright, circular cells 
which were either adherent to the endothelium, or seen to roll and stop on the 
endothelium. This is in line with work by Zhan, et al (2012) and the identification 
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guidelines offered by McGettrick, et al. (2010) and Luu, et al. (2010). Further, erythrocytes 
within the chamber were visualised as non-adherent blurred streaks travelling across the 
endothelium that appeared phase-dark when visualised using the QCapture Pro 6 
software. At no point did these cells adhere to the TNF-α or BLM treated endothelium. 
Therefore, the chance that erythrocyte adhesion may be mistaken for neutrophil 
adhesion was deemed negligible. As previously stated, small, non-phase bright adherence 
events, which may represent cell debris, and larger, non-circular phase-bright events, 
which represented area of endothelium, were also discounted as they did not meet the 
criteria of neutrophils.  Therefore, the identification of round, phase-bright adherent or 
rolling cells as neutrophils can be stated. Adhesion of neutrophils to the endothelium 
based on the appearance criteria outlined above was verified by Dr. Laura Sadofsky and 
an independent individual not connected to this work. 
  
6.4.4 Neutrophil Adhesion to BLM-Treated Endothelial Monolayers 
 
When endothelial monolayers are treated with various concentrations of BLM for 6 and 
24 hours, the adhesion of neutrophils to these monolayers is increased. Of course, this is 
also the case when the endothelial monolayers are treated with TNF-α. Surprisingly, the 
degree to which neutrophil adhesion is increased in both the 6 hour and the 24 hour 
stimulated monolayers is very similar, with monolayers treated for 6 hours showing 
slightly higher degrees of neutrophil adherence. In this experiment, it was expected that 
increased adherence was mediated by E-selectin – upregulated quickly and reaching a 
peak at 4-6 hours - or ICAM-1 - upregulated slowly and reaching a peak at 24 hours - or a 
combination of the two. However, these results give no clear suggestions as to which 
molecule(s) are involved in the increased adherence. Regardless, at the flow rate used 
(0.5 dyn/cm2), endothelial adhesion molecule expression in response to BLM has a 
functional consequence.  
Interestingly, the number of adherent neutrophils was similar in monolayers treated with 
BLM (shown to induce a modest increase in adhesion molecule expression) and those 
treated with TNF-α (which induced larger increases in adhesion molecule expression). The 
reasons for this are unknown. It is possible that, as photographs were taken at selected 
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points along the chamber, as outlined in the protocol of McGetterick, et al. (2010), areas 
of dense adhesion may have been missed. The chambers used in this experiment have a 
surface area of 2.5cm2, while the visualised fields were only 1mm2, leaving large areas of 
the chamber not assessed. 
Furthermore, all fields photographed were along the midline of the chamber, again in 
accordance with the McGetterick, et al. (2010) protocol. As shear stress calculations used 
with this system apply to the midline (ibidi Application Note 11), the edges were not 
assessed. The shear rate in these locations could not be guaranteed; shear stress within a 
chamber demonstrates parabolic flow profiles, with the degree of shear stress lower at 
the edges of the chamber, and the calculated shear stress applicable to the centre of the 
chamber (Lawrence and Springer, 1991; ibidi Application Note 11). Alternatively, it is 
possible that the results obtained when neutrophils were flowed over TNF-α-treated 
monolayers represent the maximum level of adhesion achievable using this number of 
neutrophils, or that the functional effect of BLM is comparable to that of TNF-α, at least in 
this system.  
These results are not similar to those of previously published works assessing neutrophil 
adherence in response to stimulation with cytokines including TNF-α, which routinely 
report greater numbers of adherent cells, between 350-700 cells/mm2/106 cells perfused 
(Luu, et al., 2010; Luu, et al., 2000; Sheikh, et al., 2005). However, these reports use more 
cells (1 x 106/ml) and a different protocol, whereby neutrophils are delivered into the 
chamber as a bolus and then washed out using PBS. It is after this wash-out stage that 
neutrophil behaviour was assessed (Sheikh, et al., 2005; Luu, et al., 2000; Luu, et al., 
2010; Burton, et al., 2011). Using such a protocol, more neutrophils enter the chamber 
before analysis occurs, though it may be questioned how rolling behaviour can be 
assessed using this method. When neutrophil behaviour was assessed during perfusion 
and not after wash-out, the results reported are more similar to that of this work 
(Rainger, et al., 1995; Sheikh, et al., 2002).     
Though both methods were used in this series of experiments initially, and data was 
collected and analysed from both during the neutrophil perfusion and after the wash-out 
step for the 6- and 24-hour BLM treatment experiments, it was decided that measuring 
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neutrophil behaviour following bolus infusion and wash-out – when a large number of 
neutrophils was present in the chamber and all non-adherent neutrophils had been 
removed from the system – was not physiologically relevant. In vivo, neutrophils would 
be present in circulation at all times, and measuring neutrophil adhesion once a large 
number of cells has entered the chamber and no more were flowing over the 
endothelium is artificial. Measuring rolling neutrophils using this model would be a 
measurement of neutrophil dissociation from the endothelium, rather than of tethering, 
slowing, and adherence.   
When data collected after wash-out was analysed, greater numbers of adherent 
neutrophils were observed in these experiments than in those where data was collected 
while neutrophils were being perfused (data not shown). The reason for this is uncertain; 
this may merely reflect the increased number of cells that have entered the chamber. 
When assessing neutrophil adhesion during perfusion, recording began when 5x105 
neutrophils had been perfused, and ended when 1x106  had been perfused (at speeds 
slow enough to adhere), while in the wash-out data, 1x106 neutrophils had been perfused 
before recording started. Alternatively,  interactions between flowing cells may have 
prevented adhesion during perfusion; in some fields, contact between adherent and non-
adherent cells under flow resulted in neutrophil detachment. As the wash-out phase 
introduces neutrophils from the tubing or upstream fields and, decreased cell counts are 
present in suspension, neutrophils may have had more opportunity to adhere or remain 
adherent as they are not “knocked off” during wash-out. Lastly, it is possible that by 
switching between neutrophil suspension and washing buffer, a disturbance in the shear 
flow rate allows neutrophils to adhere more, as  the flow rate decreases. Such cells may 
not then be dislodged as the shear stress returns to set levels.  
The use of a different  recording protocol may explain the discrepancies noted between 
this work and that of others, and this may be compounded by the differences in the 
numbers of neutrophils used. While this means the results of this work are not directly 
comparable to those of other groups, the method used here represents a more 
physiologically relevant model, and it was decided that this method would be used in  
future experiments. 
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6.4.5 Identification of Adhesion Molecules Mediating Increased Adhesion 
 
Treatment of isolated neutrophils with anti-CD18 blocking antibody was observed to 
decrease the binding of neutrophils to TNF-α-treated endothelial monolayers by 
approximately 30%, in line with previous literature (van Epps, et al., 1989; Smith, et al., 
1988; Meerschaert and Furuie, 1993; Lopez-Farré, et al., 1993), suggesting that neutrophil 
adhesion to TNF-α treated monolayers was at least in part ICAM-1 dependent. However, 
neutrophil adhesion to BLM-treated monolayers was not prevented by the addition of 
anti-CD18 antibody to neutrophil suspensions. Therefore, ICAM-1 is perhaps not involved 
in neutrophil adhesion to BLM-treated endothelial cells. This was somewhat surprising, as 
ICAM-1 was the adhesion molecule most upregulated by BLM treatment in previous 
experiments, and was clearly involved in neutrophil adhesion to TNF-α treated 
monolayers. Moreover, previous reports (albeit using murine models) have identified 
strong associations between pulmonary venule and capillary ICAM-1 expression and the 
accumulation of leukocytes at the vessel wall and in the perviascular space in rodents 
treated with BLM (Wang, et al., 2011; Sato, et al., 2000). However, the results of this work 
suggest that, in human cells, ICAM-1 is not involved in neutrophil adhesion to endothelial 
cells in response to BLM treatment.     
As neutrophil adhesion did not appear to be modulated by ICAM-1 expression, blockade 
of E-selectin was assessed to determine whether this molecule was reponsible for the 
increased adhesion noted. Again, there was a decrease in the adhesion of neutrophils to 
TNF-α treated monolayers, with around 60% of adhesion blocked. This was of a smaller 
magnitude than that reported by Ploppa, et al. (2010) and Martin-Satué, et al. (1998), but 
was still substantial. However, once again, the blockade of E-selectin did not diminish 
neutrophil adhesion to BLM-treated monolayers; there was a slight decrease in 
neutrophil adhesion, but this was not statistically significant. Based on these 
observations, it appears that one or more alternative adhesion molecules must be 
involved in, and responsible for, the increased adhesion of neutrophils to BLM-treated 
monolayers.  
Previous reports have implicated VCAM-1 in neutrophil adhesion to pulmonary vessels 
following BLM treatment in mice (Wang, et al., 2011), though the mechanisms by which 
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neutrophils utilise VLA-4 to adhere to endothelial VCAM-1 are poorly resolved. VCAM-1 
may be responsible for the increased adhesion, but as VCAM-1 upregulation in response 
to BLM was shown to be small, it is equally feasible that an adhesion molecule not 
previously analysed is responsible.   
In light of these results, future would would ideally seek to identify the adhesion molecule 
responsible for the increased neutrophil binding to BLM treated monolayers. As VCAM-1 
was the adhesion molecule upregulated by BLM that was not blocked in these 
experiments, further work to block VCAM-1 on BLM and TNF-α treated monolayers, to 
determine whether this molecule is responsible for increased adhesion, is a logical next 
step. Alternatively, a molecule not previously assessed may be involved in neutrophil 
adhesion to monolayers, and so it may be of interest to assess the expression of other 
adhesion molecules in response to BLM.  
This could include ICAM-2, implicated in leukocyte crawling along the endothelium 
(Schenkel, et al., 2004; Phillipson, et al., 2006), or the sialomucin-like GlyCAM-1, which 
like PSGL-1, binds neutrophil L-selectin, but appears more involved in lymphocyte than 
neutrophil tethering (Dwir, et al., 1998), though the potential role of this molecule in 
extravasation is very poorly resolved. Further, CD34, a sulfated sialomucin which also 
binds to neutrophil L-selectin (Wagner and Roth, 2000) may support neutrophil adhesion 
in this model, or proteins such as fibronectin may be involved; neutrophils express several 
ligands for fibronectin including VLA-4, -5, and CD18/CD11b (Williams and Solomkin, 
1999; van den Berg, et al.,  2001), endothelial cells synthesise and express fibronectin 
(Peters, et al., 1990; Jaffe and Mosher, 1978) and fibronectin may bind endothelial cells 
via interactions with integrins such as αVβ3 and α4β1 (Johansson, et al., 1997). It is 
feasible that, much like that observed with monocytes (van Gils, et al., 2009), fibronectin 
attached to endothelial ligands may support bringing interactions between endothelial 
cells and neutrophils. Alternatively, a previously undescribed molecule may play a role in 
neutrophil adhesion under these circumstances. 
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6.4.6 Technical Difficulties Encountered in Adhesion Molecule Blocking 
Experiments 
 
This particular work was fraught with technical difficulties. Primarily, that treatment with 
anti-CD18 antibody and isotype control antibody often resulted in the activation of 
isolated neutrophils, leaving no cells available to run the assay (6.3.3). There was no 
obvious reason for this; while treatment with antibodies added an extra 30 minutes to 
the experiment, neutrophils were still viable after treatment on three occasions.  
It was thought that CD18 ligation may have resulted in cell loss initially, though, while 
CD18 is implicated in a host of neutrophil responses including phagocytosis and spreading 
on the endothelial monolayer (Tan, 2010.; El Kebir and Filep, 2013; Petersen, et al., 1994; 
Suzuki, et al.2006), and the degranulation of endothelium-bound and TNF-α stimulated 
neutrophils (Schleiffenbaum, et al., 1987; Richter, et al., 1990), there are no reports of 
CD18 ligation activating suspended neutrophils, or causing neutrophil apoptosis. In fact, 
CD18 ligation appears more related to apoptosis inhibition in neutrophils (El Kabir and 
Filep, 2013). Therefore, it is as likely that the prolonged experimental time and increased 
agitation of isolated neutrophils resulted in activation, rather than this being a product of 
CD18 ligation. That the isotype control also induced such activation supports this notion. 
  
6.4.7 Non-Specific Binding of Isotype Control Antibody to Endothelial 
Monolayer 
 
Interestingly, there was a decrease in neutrophil adhesion to endothelial monolayers 
when endothelial cells were pre-treated with the isotype control antibody, compared to 
when neutrophils were treated with the isotype control. This decrease was statistically 
significant when TNF-α treated monolayers were compared. The reason for this is 
unknown, though the isotype control may have bound to one or more endothelial cell 
adhesion molecules involved in neutrophil adhesion in a non-specific manner, but not to 
neutrophil ligands involved in neutrophil adhesion to the endothelium.  
The endothelial cell molecule(s) to which the istoype control antibody binds is unknown. 
Earlier experiments identified increased levels of non-specific isotype control binding to 
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both TNF-α and BLM-treated cells, which could not be attributed to Fc receptor 
expression, and so it is unlikely this non-specific expression could be attributed to Fc 
receptors in this work; in fact, these results suggest that a molecule involved in neutrophil 
adhesion to the endothelial monolayer (expressed by the endothelial cells) may have 
been a target for isotype control binding, at least to a small degree. Further work to 
determine the molecule(s) to which the isotype control is binding is required before any 
strong conclusions may be drawn, however.   
 
6.4.8 Overall Conclusions 
 
In all, BLM treatment of endothelial cells for 6 and 24 hours increases neutrophil adhesion 
to endothelial monolayers, but this work failed to identify the adhesion molecule(s) 
responsible for this, as the blockade of neither the ICAM-1 ligand CD18, nor endothelial E-
selectin, dimished this binding. However, this is the first work to report that, using human 
cells, BLM increases neutrophil adhesiveness to endothelial cells, and  this may contribute 
to the inflammatory cell influx seen within the lungs during BPF development.  
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7 Other Chemotherapeutic Agents and 
their Effects on HUVEC Adhesion 
Molecule and Cytokine Expression and 
Release  
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7.1 Introduction 
 
BLM is not unique in its ability to induce pulmonary fibrosis; many other 
chemotherapeutic agents, such as mitomycin, carmustine, busulfan, methotrexate, 
cyclophosphamide, fludarabine, and chlorambucil are also associated with the condition 
(Barton-Burke, et al., 1996). Based on the hypothesis that the effect of BLM on the 
endothelium contributes to BPF by inducing adhesion molecule upregulation, it would be 
interesting to determine whether the upregulation of adhesion molecules is a unique 
feature of BLM treatment. If so, this would bolster the idea that endothelial adhesion 
molecule upregulation is a contributory feature to the unique fibrotic response observed.  
Drugs were selected that induce cell death via similar mechanisms to BLM, as this would 
allow the determination of whether  drugs which cause DNA-scission mediated death also 
cause adhesion molecule upregulation. As BLM has a unique mechanism of action (Dorr, 
1992), three drugs which cause cytotoxicity due to strand scission and apoptosis were 
selected;  etoposide, doxorubicin, and carboplatin. The expression of adhesion molecules 
and release of cytokines by endothelial cells treated with these agents will be assessed. In 
this case the same panel of adhesion molecules as previously assessed using BLM, and IL-
8, increased by treatment with BLM, will be tested. 
Using pulmonary microvascular endothelial cells would be more physiologically relevant; 
however, as the current work has previously shown that HUVECs, at least in response to 
BLM, are a suitable surrogate for this cell type, they will be used for these experiments. A 
literature review was conducted to determine suitable, pharmacologically revelant 
concentrations of each drug to use.   
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7.1.1 Etoposide Mechanism of Action, Pharmacokinetics, and Use 
  
Etoposide, used in the treatment of testicular cancer and lymphomas (Ando, et al., 1996), 
has a similar mechanism of action to BLM, effecting cytotoxicity by inducing both single- 
and double-strand DNA cleavage (Sinha, et al., 1988). Though a topoisomerase II inhibitor, 
etoposide does not prevent the action of topoisomerases, but “poisons” the topoisomer-
ase II enzyme by increasing the concentration of cleavage complexes. Topoisomerase II 
then generates excessive DNA breaks which may cause apoptosis (Hande, 1998). Both 
p53-mediated apoptosis and autophagic cell death have been reported to occur due to 
etoposide treatment (Mizumoto, et al., 1994; Karpinich, et al., 2002; Yoo, et al., 2012), 
and though the generally accepted mechanism of action involves typical intrinsic 
apoptosis (Grandela, et al., 2007), caspase 8 may also be involved (Liu, et al., 2011).  
Etoposide pharmacokinetics depend on whether the drug is given orally or intravenously, 
with the former resulting in variable pharmacokinetic profiles (de Jong, et al., 1997) – i.e., 
if given orally, a dose of 100-150 mg/m2 results in Cmax values of 2.8-4.4 μg/ml; if I.V.,  
between 9 and 32 μg/ml (Simon, et al., 2006; Kato, et al., 2003). Moreover, a range of 
doses are used in man dependent on the target disease, which will also impact the 
pharmacokinetics of the drug. A review of etoposide pharmacokinetics in a variety of 
doses and patient groups is shown in Table 7.1.  
Although pulmonary fibrosis is not strongly associated with etoposide, there have been 
documented cases. These include three patients with lung cancer,  one of whom received  
50mg etoposide orally, and suffered diffuse interstitial fibrosis with evidence of atypical 
AECs and leukocyte infiltration before succumbing five days after presentation (Dajczman, 
et al., 1995); another who was given 100mg/m2 etoposide (I.V.) and later 50mg/day 
etoposide (oral) and developed interstitial fibrosis and AEC hyperplasia; and a third 
treated with three doses of etoposide (80mg/m2) who developed similar diffuse alveolar 
fibrosis with bilateral interstitial infiltrates and hyperplasic AEC, which also proved fatal 
(Gurjal, et al., 1999).  While the pattern of fibrosis following etoposide delivery is similar 
to that of BLM, the development and time until fatality is faster, and immune cell 
infiltration is not fully described. However, that fibrosis occurs in a similar way suggests 
this could be of interest. 
279 
 
Table 7.1: Etoposide pharmacokinetics for up to 24 hours post-dose. 
Study  Dose and 
Dosing 
Route 
Treatment 
Group 
Cmax values 
post-dose 
Cmax values 
3H post-
dose 
Cmax 
values 6H 
post-dose 
Cmax values 
24H post-
dose 
Köhl, et al. 
(1992) 
720mg/m2 ; 
short I.V. 
infusion 
Adults 130 μg/ml 30μg/ml Not 
assessed 
5μg /ml 
Sinkule, et 
al., (1984) 
200mg/m2 ; 
30 min. I.V. 
infusion 
Children 40 μg/ml Not 
assessed 
9μg/ml 1-2μg/ml 
Schroeder, et 
al., (2004) 
500mg/m2 ; 
I.V. bolus 
Children 
prior to 
marrow 
transplant 
100μg/ml Not 
assessed 
Not 
assessed 
Up to 15 
μg/ml 
Chrzanowska, 
et al. (2011) 
60mg/kg;I.V. 
bolus 
Children 
prior to 
marrow 
transplant 
100-
500μg/ml 
Not 
assessed 
10-
100μg/ml 
1-20μg/ml 
Toffoli, et al. 
(2001) 
100mg; oral 
dosing 
Adults 4 μg/ml Not 
assessed 
2 μg/ml 1 μg/ml 
 
 
 
 
HUVECs will be incubated with etoposide for 24 hours to assess adhesion molecule 
expression and cytokine release, Cmax values achievable around 24-hours post dose were 
chosen. must be used. Based on the above data, these will be 3 μg/ml, 10 μg/ml, and 30 
μg/ml (5.1μM, 17μM, and 51μM, respectively).   
  
A definitive list of studies that have assessed the pharmacokinetics of etoposide in a range of 
patient groups for up to 24-hours post-dosing via various routes, using various total doses of 
etoposide. 
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7.1.2 Doxorubicin Mechanism of Action, Pharmacokinetics, and Use 
 
Doxorubicin (DOX) is a cytotoxic anthracycline antibiotic (Benjamin, et al., 1973) and has a 
range of cytotoxic effects including DNA synthesis inhibition and cross-linking, 
interference with DNA unwinding via helicase retardation, and both free radical 
generation and topoisomerase II inhibition leading to DNA cleavage and apoptosis; 
however, these effects and are not fully understood (Gewirtz, 1999). It is used in the 
treatment of breast cancer, Kaposi’s sarcoma, and small-cell lung cancer, with a 
recommended effective dose of 60-75mg/m2 (Chan, et al., 2004). Side-effects include 
irreversible cardiotoxicity, dependent on cumulative dose, although children and 
adolescents are very susceptible (Zhang, et al. 2009). There have been reports of 
pulmonary fibrosis following DOX therapy when combined with mitomycin C (Zappa, et 
al., 2009) and paclitaxel (Nevandunsky, et al., 2013), although this may be due to the 
latter drug in both cases (Verweij, et al., 1987; Nevandunsky, et al., 2013).  
DOX exhibits rapid distribution but slow clearance (Barpe, et al., 2010), and the 
pharmacokinetics of the drug vary widely (Frost, et al., 2002), most noticable immediately 
after dosing - Callies et al. (2002) saw a broad range of Cmax values in patients given 
75mg/m2 by IV bolus over 30 minutes, falling between 700ng/ml and 1400 ng/ml. 
Pharmacokinetics also depends on dosing route, weight, and age. Frost, et al., (2002), for 
example, noted that while patients under the age of 2 and over the age of six has similar 
plasma concentrations of doxorubicin immediately after a dose of 40mg/m2 by 24-hour 
I.V. infusion (around 50ng/ml), that seen in children aged 2-6 years was far higher - up to 
78ng/ml - though no ill effects were seen in this group.    
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Table 7.2: Doxorubicin pharmacokinetics for up to 24 hours post-dose. 
Study  Patient 
Group 
Dose and 
Route 
Plasma conc. 
immediately 
after dose 
Plasma 
conc. 6H 
after dose 
Plasma 
conc. 8H 
after dose 
Plasma 
conc. 24H 
after dose 
 
Barpe, et 
al. (2010) 
 
Normal-
weight 
females 
60mg/m2 
intravenous 
630ng/ ml 105ng/ml Not 
assessed 
40ng/ml 
Overweight 
females 
60mg/m2 
intravenous 
370ng/ml 100ng/ml Not 
assessed 
40ng/ml 
 
Speth, et 
al. (1987) 
 
 
 
Adults 
30mg/m2 
by IV bolus 
1170ng/ml - 
2110ng /ml 
Not 
assessed 
30ng/ml 9ng/ml - 
11ng/ml 
30mg/m2 
by 8 hour 
I.V. infusion 
35ng/ml - 
135ng/ml 
Not 
assessed 
10ng/ml Not 
assessable 
 
Callies, et 
al. (2002) 
Adults 75mg/m2 
30-minute 
IV infusion 
700ng/ml - 
1400 ng/ml 
30-60ng/ml Not 
assessed 
5-30ng/ml 
Bronchud, 
et al. 
(1990) 
Adult 
females 
100mg/m2 
10 minute 
IV infusion  
1100 – 
3000ng/ml 
70ng/ml ~60ng/ml 30ng/ml 
 
Twelves, 
et al. 
(1991) 
 
Adult 
females 
 
75mg/m2 
bolus doses 
Around 
1200ng/ml 
Around 
30ng/ml 
Not 
assessed 
Around 15-
20ng/ml 
25mg/m2 
bolus doses 
Around 
200ng/ml 
Around 
20ng/ml 
Not 
assessed 
Around 15-
20ng/ml 
 
 
 
As DOX pharmacokinetics vary so widely, this work will investigate only Cmax values 24 
hours after dosing. It appears that, over long periods, the dosing type and the patient 
characteristics are less determinant of the plasma DOX concentration;  24 hours after 
dosing, the plasma concentration is between 5 and 50ng/ml. Therefore, concentrations 
within this range will be used.  
  
A definitive list of studies that have investigated the pharmacokinetics of DOX for up to 24 
hours after dosing in a variety of patients at a variety of doses. 
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7.1.3 Carboplatin Mechanism of Action, Pharmacokinetics, and Use 
 
Carboplatin is a non-classical ankylating-like agent that induces cell death (Lokich and 
Anderson, 1998) via the formation of DNA intrastrand adducts, a form of cross-linking 
involving adjacent bases, leading to cell death via apoptosis as pro-apoptotic proteins 
detect damage (Siddik, 2003). Adducts may also prevent DNA replication and transcript-
ion, resulting in cell-cycle disruption (Kelland, 2007), and, as with BLM (where the number 
of DSBs determines cytotoxicity) a linear relationship between platin-DNA binding and 
cell death has been noted (Fraval and Roberts, 1979). However, unlike DOX and BLM, 
which both have severe side-effects, and the related drug oxaliplatin,  associated with the 
development of lung fibrosis (Ryu, et al., 2011; Mundt, et al., 2007), carboplatin is 
relatively side-effect free, with only myelotoxicity a known issue (Kelland, et al., 2007).   
Carboplatin requires activation to exert its effects. While cisplatin is activated by the loss 
of chloride groups, leaving reactive metabolites, carboplatin lacks these groups (St 
Germain, et al., 2010; Cepeda, et al., 2007), instead having a less reactive cyclo-
butanedicarboxylate group (Fichtinger-Schepman, et al., 1995) which makes the drug 
more stable. It is thought that reaction with carbonate results in an “open-ring”, reactive 
form of the drug. This has been suggested both in vivo and in experimental models, and  
sufficient carbonate to induce activation is thought to be present in blood and culture 
media (Di Pasqua, et al., 2006; Ciancetta, et al., 2012). 
To assess carboplatin pharmacokinetics, free platinum in plasma ultrafiltrate is generally 
measured, as this is the therapeutically active form. Total platinum is also often 
measured, but this represents free and protein-bound platinum (Alberts and Dorr, 1997), 
and may overestimate concentrations. Though some suggest that free carboplatin is not 
detectable after 10 hours, while  free platinum is (Korst, et al., 1997), others found that 
both free platinum and carboplatin are present in the plasma at comparable levels for 
around 9 to 16 hours following dosing (Elferink, et al., 1987; Mulder, et al., 1990). As 
carboplatin cannot be activated in this work prior to cell treatment, though carboplatin 
activation appears possible in culture medium (Di Pasqua, et al., 2006), studies that have 
assessed carboplatin levels will be assessed (Table 7.3). Using these concentrations, 
HUVECs will be exposed to the same level of carboplatin as endothelial cells would be in 
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vivo. A range of concentrations between 0.1 and 8μM appear appropriate; therefore, 
concentrations of 0.1, 1, and 10μM will be used. 
 
Table 7.3: Carboplatin pharmacokinetics for up to 24 hours post-dose. 
Study Patient 
Population 
Dose and 
Route 
Plasma conc. 
immediately 
after dosing.  
Plasma 
conc. 6 H 
after 
dosing.  
Plasma conc. 
12 H after 
dosing. 
Plasma conc. 
24 H after 
dosing. 
Zandvliet, 
et al. 
(2008) 
Adults with 
solid 
tumours 
(n=111). 
30 minute IV 
infusion – 
sufficient 
carboplatin to 
achieve an 
AUC of 4-6mg 
min-1 ml-1 
Around 
100μM 
Around 6 
and 20μM 
Not assessed. Between 0.3 
and 8μM 
Riccardi, 
et al. 
(1994). 
Children 400, 500, 600 
mg/m2 ;1-hour 
IV fusion 
(AUC between 
4 and 8mg 
min-1 ml-1) 
30 - 80μg/ml 
(81-216μM) 
1 - 2 μg/ml 
(2.7-
5.2μM) 
0.2 - 0.8 μg/ml 
(0.52-3μM), 
0.09 - 0.3μg 
/ml (0.27-
0.81μM 
 
 
 
 
 
Mulder, 
et al. 
(1990) 
 
 
 
Adults  
given 
carboplatin 
over 
several 
cycles. 
250 mg/m2 
dose 1 
Around 20-
40μg/ ml 
(55-110μM). 
Around 
3μg /ml 
(8μM) 
Around 0.4 – 
0.5 μg/ml (1.1 
– 1.35μM) 
0.1 – 
0.5μg/ml 
(0.27-1.35 
μM) 
250 mg/m2 
dose 2 
Around 20-
40μg/ ml 
(55-110μM). 
Around 
3μg /ml 
(8μM) 
Around 1-
2μg/ml (2.7 -
5.4μM). 
0.1-1 μg/ml 
(0.27-2.7 
μM) 
250 mg/m2 
dose 3 
Around 20-
50μg/ ml 
(55-128μM). 
Around 
3μg /ml 
(8μM) 
Around 1-
2μg/ml (2.7 -
5.4μM). 
0.1-2 μg/ml 
(0.27-5.4 
μM) 
 
 
Note that Zandvliet, et al. (2008) used doses tailored to achieve an AUC (area under the 
curve) value, representative of the total amount of carboplatin available in circulation 
from dosing to total clearance, based on the now widely used Calvert formula (Calvert, et 
al., 1989). Further, Mulder, et al. (1990) used multiple dosing - like many other drugs, 
carboplatin is often not given only as a single dose. However, it appears free carboplatin 
accumulates in the plasma with repeated dosing, while DOX and etoposide do not (Speth, 
et al., 1987; Kohl, et al., 1992). 
A definitive list of studies investigating carboplatin pharmacokinetics for up to 24 hours 
after dosing in a variety of patients, using a variety of total doses and dosing regimens. 
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7.2 Materials and Methods 
 
7.2.1 Etoposide, Doxorubicin, and Carboplatin Preparation 
 
Etoposide (>98% purity) and doxorubicin hydrochloride were purchased from Sigma 
Aldrich. Etoposide was dissolved in 100% dimethyl sulfoxide (DMSO) (Sigma Aldrich) to a 
concentration of 50mM in line with the provided product information sheet. Dissolved 
etoposide was stored at -20°C for up to one month. Doxorubicin hydrochloride was 
dissolved in PBS  to a stock concentration of 1mg/ml. This was then stored at -20°C in 
darkness for up to one month in accordance with work by Hoffman, et al., (1979) and  
Wood, et al., (1990). Carboplatin was purchased from Tocris (Tocris Biosciences, Bristol, 
United Kingdom). Carboplatin was dissolved in PBS to a stock concentration of 10mM and 
frozen at -20⁰C according to the manufacturer’s instructions. All chemotherapeutic agents 
were dissolved inendothelial cell media to required concentrations prior to use. 
 
7.2.2 Treatment of HUVECs with Etoposide, Doxorubicin, and Carboplatin 
 
Cells were cultured to confluence as outlined in 2.1. Stock solutions of etoposide, 
doxorubicin, and carboplatin were made as outlined in 2.8. When confluent, cells were 
treated with etoposide, doxorubicin, or carboplatin dissolved in serum-containing 
endothelial cell basal medium. The volume of medium was dependent on the 
experimental protocol being followed (ELISA or FACS analysis). Cells were treated with 3, 
10, and 30μg/ml etoposide (or 5.1μM, 17 μM, and 51μM etoposide, with resulting DMSO 
concentrations of 0.01%, 0.03%, and 0.1% in etoposide-contaning cell culture media); 3, 
10, and 30ng/ml doxorubicin; or 0.1, 1, and 10μM carboplatin for 24 hours. In addition, 
cells were also treated with DMSO, to act as a vehicle control, as etoposide is not soluble 
in water, PBS, or culture medium alone. Medium containing each concentration of each 
drug was generated by dilution of stock concentrations in appropriate volumes of serum-
containing endothelial cell basal medium. 
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7.2.3 HUVEC Adhesion Molecule Expression Determination Following 
Treatment with Etoposide, Doxorubicin, and Carboplatin. 
 
Cells were cultured as outlined in 2.1. To appropriate flasks, 10ml of serum-contaning 
endothelial cell basal medium contaning various concentrations of etoposide, 
doxorubicin, carboplatin, or DMSO – as outlined above - was added. Cells were treated 
for 24 hours. The negative control was HUVECs incubated in serum-contaning endothelial 
cell basal medium (10ml) without treatment. The positive control was HUVECs incubated 
in endothelial cell basal medium contaning 10ng/ml TNF-α (10ml). Both negative and 
positive control cells were incubated for 24 hours. After treatment, cells were dissociated, 
counted, resuspended to a concentration of 1 x 106 cells/ml in endothelial cell medium, 
and prepared for flow cytometry and analysed using the same range of antibodies, as 
described in 2.3, 2.4, and 2.5, respectively.  Data were analysed using Mann-Whitney-U 
tests in SPSS v. 19 statistical analysis software.  
 
7.2.4 HUVEC Cytokine Release Determination in Response to Etoposide, 
Doxorubicin, and Carboplatin Treatment 
 
Cells were cultured as outlined in 2.1 and replated as outlined in 2.7. When adherent, 3ml 
of serum-containing endothelial cell basal medium containing aforementioned 
concentrations of etoposide, doxorubicin, carboplatin, or DMSO was added. Cells were 
incubated in this treatment for 24 hours only. Negative control supernatants were 
generated as outlined in 2.7. Positive control supernatants were generated by treating 
cells with 10ng/ml TNFα. 
The supernatants were then collected as outlined in 2.7. ELISA kits were purchased from 
Biolegend. All preliminary work and supernatant handling was conducted as outlined in 
2.7. Plates were read using a plate-reader (Thermo Multiskan FC, Thermo Scientific) at the 
wavelengths instructed by the instructions provided with the kits. This was an initial 
reading at 450nm and a subsequent reading at 570nm, the second subtracted from the 
first to reduce background. Data handling was carried out in accordance with section 2.7. 
Data were analysed by Mann-Whitney-U test in SPSS v. 19 statistical analysis software.  
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7.3 Results 
 
7.3.1 Adhesion Molecule and Cytokine Expression and Release in Response to 
Etoposide, Doxorubicin, and Carboplatin 
 
The expression of ICAM-1 was significantly higher (p=0.05) in cells treated with all 
concentrations of etoposide than noted at baseline (untreated cells). The expression of E-
selectin and VCAM-1 was also increased by treatment with 3µg and 30µg, and 30µg 
etoposide, respectively.  The changes in adhesion molecule expression were far less 
substantial in cells treated with DOX compared to those treated with etoposide.  
However, there was an increase in the expression of ICAM-1, E-selectin, and VCAM-1 
when cells were treated with 30ng/ml DOX (Fig. 7.1 A-D). Carboplatin was not observed 
to significantly upregulate the expression of any of the previous noted adhesion 
molecules (data not shown). There was no effect on the expression of any adhesion 
molecule by the use of DMSO as a vehicle (data not shown). 
Treatment with all concentrations of etoposide induced a significant increase in the 
release of IL-8 by HUVECs. There was an increase in  IL-8 release in cells treated with the 
lowest concentration of DOX, but not any other concentration. There were no increases 
in the release of IL-8 by HUVECs treated with any concentration of carboplatin or DMSO 
(data not shown). 
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Figure 7.1: Adhesion molecule expression by HUVECs treated with etoposide and 
doxorubicin. 
 
 
 
The expression of ICAM-1 (A), E-selectin and VCAM-1 (B) by HUVECs treated with various 
concentrations of etoposide, and the expression of ICAM-1 (C),E-Selectin and VCAM-1 (D) 
by HUVECs treated with various concentrations of doxorubicin, and the release of IL-8 by 
HUVECs treated with various concentrations of etoposide (E) and doxorubicin (F). Note 
the different scales of the Y axes. Statistically significant differences in protein expression 
and release compared to baseline (p=0.05) are denoted by an asterisk. n=3.   
* 
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* 
* 
* 
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* 
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7.3.2 A Comparison of Adhesion Molecule Expression and Cytokine Release 
Between HUVECs Treated with Etoposide and BLM and Doxorubicin and 
BLM. 
 
Though it initially appeared that etoposide induced a more substantial increase in ICAM-1 
expression than BLM, the upregulation of ICAM-1 in HUVECs  was only significantly higher 
(p=0.05) when cells were treated with 30µg/ml etoposide than that seen when HUVECs 
were treated with BLM at concentrations of 0.1µg/ml and 1µg/ml (Fig 7.2A). The 
expression of E-selectin between cells treated with all concentrations of BLM was 
significantly different to those treated with 3 and 30µg/ml etoposide (Fig 7.2B). While 
VCAM-1 was also increased by treatment with etoposide of various concentrations, this 
was not significantly different to the increase induced by treatment of HUVECs with BLM 
(Fig 7.2C).   
The changes in adhesion molecule expression were far less substantial in cells treated 
with DOX compared to those treated with BLM. In all cases, treatment will all 
concentrations of BLM induced a significantly greater increase in adhesion molecule 
expression than treatment with all concentrations of DOX (Fig 7.3A-C). 
The release of IL-8 was significantly higher by cells treated with all concentrations of 
etoposide that those treated with all concentrations of BLM (p=0.05) (Fig 7.4A). There 
was a statistically significant difference between the level of IL-8 release induced by 
treatment with 0.1µg/ml BLM and all concentrations of doxorubicin, but there were no 
other statistically significant differences between IL-8 release profile (Fig 7.4B).  
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Figure 7.2: Comparisons of adhesion molecule expression by HUVECs treated with BLM 
and etoposide.  
* 
* 
A comparison of the expression of ICAM-1 (A), E-selectin (B) and VCAM-1 (C) by HUVECs treated 
with etoposide and BLM. Statistically significant differences in protein expression by treated cells  
(p=0.05) are denoted by an asterisk. n=3.   
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ICAM-1 Expression by HUVECs Treated
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E-Selectin Expression by HUVECs Treated
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Figure 7.3: Comparisons of adhesion molecule expression by HUVECs treated with BLM and 
doxorubicin. 
* 
* 
* 
A comparison of the expression of ICAM-1 (A), E-selectin (B) and VCAM-1 (C) by HUVECs 
treated with doxorubicin and BLM. Statistically significant differences in protein expression by 
treated cells (p=0.05) are denoted by an asterisk. n=3.   
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IL-8  Release by  HUVECs Treated with BLM and
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Figure 7.4: Comparisons of IL-8 release by HUVECs treated with BLM, etoposide, and 
doxorubicin. 
  
* 
* 
A comparison of the expression the release of IL-8 by HUVECs treated with etoposide 
and BLM (A), and doxorubicin and BLM (B). Statistically significant differences in 
protein release by treated cells  (p=0.05) are denoted by an asterisk. n=3.   
A 
B 
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7.4 Discussion and Conclusions 
 
This work was carried out to determine whether other agents which induce cell death in 
similar ways to BLM induced adhesion molecule expression. These results obtained 
suggest that the increase in adhesion molecule expression and cytokine release induced 
by BLM treatment are not unique to BLM, and that other chemotherapeutic agents 
induce a similar effect. However, not all treatments assessed induce this increase in 
expression.  
Etoposide increased the expression and release of several adhesion molecules and 
cytokines by HUVECs, which has not previously been reported. While the increase in 
ICAM-1 expression and IL-8 release was far greater than that induced by BLM, the 
increases in E-selectin and VCAM-1 expression were broadly similar. Therefore, it appears 
the effects of etoposide on HUVECs are numerous, although there is currently no known 
mechanism by which etoposide induced the upregulation of cytokines and adhesion 
molecules, although as all of the adhesion molecules are regulated at a transcriptional 
level by NF-κB activation pathways, it is feasible that etoposide is able to induce NF-κB 
activation and signalling in endothelial cells, as it appears to do in K562 leukaemia blast 
crisis cells (Morotti, et al., 2006). This would potentially be of interest to other groups.   
Increases in ICAM-1, E-selectin, and VCAM-1 expression when cells are  treated with DOX 
has also not been reported. There was also an increase in the expression of IL-8 by 
HUVECs treated with the lowest concentration of the drug used, which has also not 
previously been identified. However, this increase was potentially anomalous, and further 
repeats of this experiment may provide a more conclusive picture. However, in all but 
one case, the increase in adhesion molecule expression and cytokine release was lower in 
magnitude than that induced by treatment with BLM.  
Treatment of HUVECs with various concentrations of carboplatin had no discernable 
effect on the expression of adhesion molecules or release of cytokines, though as  it is 
thought that carboplatin requires carbonate to induce activation, it is possible that this 
activation did not occur under cell culture conditions. However, previous reports suggest 
that sufficient carbonate is present in culture medium of a physiologically relevant pH (Di 
Pasqua, et al., 2006) to activate the drug, and so this may not be the case. As previously 
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stated, oxaliplatin is associated with fibrosis, and cisplatin is known to induce ICAM-1 
expression by HUVECs (Yu, et al., 2011). However, there are no reports of adhesion 
molecule or cytokine expression, or lung fibrosis following carboplatin therapy, though 
there is a single report of pulmonary fibrosis following a combined chemotherapy 
regimen including carboplatin and vinorelbine (Kirkbride, et al., 2002). This thesis is the 
first report to suggest that carboplatin has no effect on adhesion molecule or cytokine 
expression by HUVECs.   
That BLM is not unique in inducing the increased expression of adhesion molecule and 
release of cytokines initially appears to call into question the idea that this is potentially a 
causative factor for the side-effect of BLM. If several chemotherapy agents induce 
adhesion molecule expression and cytokine release, then why does only BLM result in 
lung fibrosis with such frequency?  
However, the only chemotherapeutic agent that induced comparable or greater adhesion 
molecule expression than BLM is the only other agent which is known to induce 
pulmonary fibrosis. Though etoposide-induced pulmonary fibrosis is poorly described, it 
does appear to be quite similar to BPF, albeit with a more rapid progression rate.  Though 
there has been no report of immune cell infiltration in etoposide-induced fibrosis, this 
may be due to the low number of studies describing this condition, and more data are 
required before any conclusions can be drawn as to the nature of etoposide-induced 
pulmonary fibrosis. 
Further, it is possible that while etoposide increases adhesion molecule upregulation, this 
may not be the case in pulmonary microvascular endothelial cells, or that this 
upregulation may not be localised to the lung. It was reported that ICAM-1 upregulation 
in rodents following BLM dosing occurs in the lung within 4 hours of administration, 
occurring only later in the liver and spleen (Weiner, et al., 1998). Perhaps BLM is lung-
specific, but etoposide is not. This would require further work to elucidate.  
In conclusion, while this work suggests BLM is not unique in its ability to induce adhesion 
molecule expression, that both BLM and etoposide cause lung fibrosis and induce 
adhesion molecule upregulation suggests that adhesion molecules and cytokines 
expressed and released by endothelial cells may contribute to lung fibrosis, potentially via 
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inducing immune cell infiltration. This work may be furthered by future experiments 
assessing the expression of adhesion molecules and the release of cytokines by PMVECs 
treated with etoposide, and by determining the signalling pathways that result in this 
expression by endothelial cells treated with both BLM and etoposide. It would also be 
interesting to better assess the temporal and spatial localisation  of adhesion molecule 
expression in vivo when rodents are treated with these agents. If it were found that only 
BLM induced PMVEC adhesion molecule expression, that only BLM-induced adhesion 
molecule upregulation was localised to the lung, or that the increased expression 
occurred more quickly in the lung following dosing with BLM than etoposide, this may 
suggest why fibrosis is more commonly observed in response to BLM than etoposide. 
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8 General Discussion 
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Bleomycin (BLM) is an effective chemotherapeutic agent used in the treatment of a range 
of cancers, but has the unfortunate side effect of inducing potentially fatal pulmonary 
fibrosis in some patients (Sleijfer, et al., 2001). While the drug is often used to model 
fibrotic lung disease in animals, little is known about the development of the human form 
of the disease. Moreover, human BPF results from I.V. delivery of the drug, while the 
majority of animal modelling studies today utilise the I.T. delivery system. When I.T. 
delivery is used, the initial injury is alveolar epithelial cell damage. However, studies in 
animals using I.V. BLM delivery noted that the initial injury was to the vascular 
endothelium, suggesting this may also be the site of initial injury in man.  
In BPF induced by I.V. and I.T. delivery in rodents, and I.V. delivery in man, infiltration of 
the lung by leukocytes is a known feature of the disease. As leukocyte extravasation from 
the vasculature into the lung is dependent on endothelial adhesion molecule expression 
and on the presentation of cytokines on the endothelium, this work sought to determine 
whether exposure to relevant concentrations of BLM induced the expression of these 
molecules, and whether the expression observed had a functional relevance in leukocyte 
adhesion to the endothelium. 
 
8.1 Findings of the Work 
 
This work reported that the treatment of endothelial cells with BLM resulted in increased 
adhesion molecule expression by both HUVECs and PMVECs. In addition to previously 
reported E-selectin expression in HUVECs (Ishii and Takada, 2000; Miyamoto, et al., 2001) 
and ICAM-1 in PMVECs (Fichtner, et al., 2004), this work found, for the first time, that 
BLM increases ICAM-1 and VCAM-1 expression by HUVECs and VCAM-1 expression by 
PMVECs. This work also identified that BLM alters the release of endothelial cytokines in 
both HUVECs and PMVECs. While increased IL-8 release in response to BLM has 
previously been observed (Fichtner, et al., 2004; Miyamoto, et al., 2001), we report for 
the first time that BLM treatment increases MCP-1 release and modifies Endothelin-1 
release in both cell types. The alterations in expression and release of all of these proteins 
by HUVECs were observed to be regulated at a transcriptional level, as determined by 
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qPCR, suggesting that BLM treatment results in regulation of both the synthesis and 
expression/release of these proteins, albeit via a currently unknown mechanism.  
This work then went on to compare the expression and release of adhesion molecules 
and cytokines by HUVECs and PMVECs treated with BLM. It was found that, while HUVECs 
express more ICAM-1 in total, the magnitude increase from baseline in both cell types 
was roughly similar. However, PMVECs expressed more VCAM-1 than HUVECs, and the 
level of expression of E-selectin was greater by HUVECs than PMVECs in response to BLM. 
While BLM increased the release of both IL-8 and MCP-1 by HUVECs and PMVECs, 
HUVECs expressed more IL-8 and MCP-1 in response to BLM than PMVECs, though the 
fold-change increase from baseline was higher in PMVECs. 
The only clear difference in expression patterns arose when Endothelin-1 was assessed. In 
PMVECs, Endothelin-1 release declined in response to BLM. This was quite different from 
the results obtained from HUVECs, in which Endothelin-1 increased when cells were 
treated with 0.1 and 1µg/ml BLM, and decreased when treated with 10µg/ml BLM. The 
cause of this of this disparity – and its relevance to disease - is uncertain, however.   
Having found the molecular changes described above it was decided to investigate 
whether the increased adhesion molecule expression had any functional relevance. 
Increased neutrophil rolling and adhesion in rodent vessels following BLM administration 
has been reported by Wang, et al. (2011) and Sato, et al. (2000), and this correlated with 
both increased ICAM-1 and VCAM-1 expression in rodent lung venules and capillaries and 
with increased leukocyte infiltration of the perivascular space and the peribronchiolar 
regions. However, this phenomenon has never been reported in man, nor using human 
cells in vitro.  This thesis reported, for the first time, that the adhesion of neutrophils to 
human endothelial monolayers treated with BLM is increased compared to baseline. 
However, this did not appear to be related to endothelial ICAM-1 or E-selectin expression, 
and so an as-yet unidentified molecule may be responsible for this.  
Lastly, additional work was conducted to determine whether BLM is unique in inducing 
this adhesion molecule expression. It was observed in this work that, as well as BLM, 
etoposide and doxorubicin also have an impact on the release of IL-8 and the expression 
of adhesion molecules on endothelial cells. While the expression levels in response to 
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doxorubicin were generally lower than those observed when cells were treated with BLM, 
the adhesion molecule expression and cytokine release observed when endothelial cells 
were treated with etoposide was of a similar level to, or greater than, that observed 
when cells were treated with BLM. This thesis represents the first time that the effect of 
etoposide on endothelial adhesion molecule expression has been assessed. 
 
8.2 Implications of the Work 
 
The observations of this study represent the first step to developing a better 
understanding of the pathogenic process of BPF in man. As it stands, little is known, with 
studies assessing the lungs of patients with the disease usually being conducted at 
autopsy (Simpson, et al., 1998) and most models of disease development being  derived 
from rodent work, in which BLM is delivered I.T. and pulmonary immune cell infiltration 
may result from the pulmonary cytokine storm that follows alveolar epithelial cell injury. 
When I.V. dosing is used, as it is in man, the pulmonary vascular endothelium is the first 
lung tissue to encounter the drug. This work shows that BLM impacts the endothelium in 
a variety of ways, including increased adhesion molecule expression and proinflammatory 
cytokine release, and that BLM-treated endothelial cells are able to support increased 
neutrophil adhesion. Based on these observations, it appears possible that an early step 
of the process of human BPF development involves aberrant adhesion molecule 
expression by pulmonary vascular endothelial cells which leads to lung immune cell 
infiltration, as leukocytes adhere to, and migrate through, the endothelium at an 
increased rate, thus leading to the AEC injury which results in fibrosis development. With 
this in mind, further work  to determine the contribution of the endothelium to the 
development of this disease may unravel an as-yet unrecognised “crucial step” in the 
pathogenesis of the disease, which may increase our knowledge of how human BPF 
develops.   
As the effect of BLM on the vascular endothelium may contribute to the development of 
BPF by permitting increased lung infiltration by leukocytes, the author also suggests that a 
move away from the I.T. dosing route to model BPF in rodents would be advantageous. 
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The authors strongly believe that, if the intravenous BLM dosing route was re-instated in 
animal modelling – as was used in earlier studies such as that of Fleischer, et al. (1978) - a 
more accurate model of the pathogenic processes involved in human BPF than what is 
currently available may be developed whilst still utilising in vivo studies in animals.  
If a better understanding of the pathogenesis of human BPF can be developed based on 
the results shown here, then potential interventional or preventative therapies for the 
condition may be investigated. Currently, there is no available proven treatment for this 
disease, and there is little strong supporting data for the use of corticosteroids to treat 
BPF, though they are often given to patients with the condition. In fact, the only step 
shown to reduce BPF development once it has started is to cease dosing and wait 
(Sleijfer, et al., 2000; Reinert, et al., 2013). If endothelial cells respond to BLM, and their 
response to BLM is shown to contribute to the development of the disease, then 
preventing the expression of adhesion molecules or the release of pro-inflammatory 
cytokines using methods other than steroid therapy may be of interest.  
The results of this work may also have important implications for other fibrotic diseases, 
for example, IPF. Though generally not associated with immune cell infiltration due to the 
work of Selman and Pardo (2000), IPF may well have an inflammatory component early 
on in its development (as recently reviewed by Williamson, et al., (2015)). It may be worth 
investigating whether the observation made in this work are also seen in pulmonary 
vascular endothelial cells isolated from patients with IPF; if so, then the aberrant 
expression of adhesion molecules in IPF may contribute to the development of the 
disease. If not, then we still have a slightly improved understanding of the pathogenesis 
of the condition, as the potential role of endothelial adhesion molecules in IPF 
development is excluded.  
Lastly, though BLM is not unique in upregulating adhesion molecule expression in 
endothelial cells, that etoposide also causes pulmonary fibrosis may suggest that the 
upregulation of adhesion molecules and cytokines in the vasculature is a critical factor for 
the development of not only BPF, but also other fibrotic diseases, such as etoposide-
induced pulmonary fibrosis. Further investigation of this possibility would allow us to 
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begin to unravel the causes of these conditions, and potentially work to prevent them 
occuring in patients given such chemotherapeutic regimens. 
   
8.3  Limitations of the Work 
 
Despite the best efforts of the author, this work of course has several limitations, brought 
about by the experimental techniques used and both financial and time constraints within 
this setting.  As such, further work would be required to address these limitations.  
Firstly, while the expression of a panel of 13 adhesion molecules and the release of six 
cytokines was assessed in this work, this does not offer a complete picture of the 
adhesion molecule expression and cytokine release profiles of BLM-treated endothelial 
cells. This is a clear limitation, as of course it is impossible to assess the contribution of 
un-assessed adhesion molecules and cytokines to disease development. Moreover, while 
13 adhesion molecules were assessed in PMVECs, only three cytokines were tested due to 
resource constraints, and so the picture of PMVEC adhesion molecule expression and 
cytokine release when stimulated with BLM is yet more limited. Further work would 
ideally seek to better characterise and compare the response of both HUVECs and 
PMVECs to BLM treatment.  
Moreover, while the regulation of this increased expression and release was visualised 
using qPCR in HUVECs, such work was not carried out for PMVECs due to both financial 
and time constraints. Therefore, while it may be inferred that, as BLM appears to regulate 
adhesion molecule expression and cytokine release at a transcriptional level in HUVECs, 
this is likely to also be the case in PMVECs, this cannot be proven at this time, and further 
work to confirm this using cDNA isolated from BLM-treated PMVECs would be favourable.   
Additionally, though BLM appears to regulate adhesion molecule expression and cytokine 
release at a transcriptional level, this work was unable to identify the pathways 
responsible for this (e.g., the NF-κB pathway) or how BLM induces this (e.g., receptor 
binding), and so the author cannot report on the mechanisms responsible for adhesion 
molecule expression and cytokine release. This limits the results to a report of increased 
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protein expression and release, and increased transcript synthesis, with only conjecture 
regarding the cell signalling pathways that induce this; however, time constraints meant 
that this work was not possible.  
A further limitation of this work is the low number of repeats; when assessing cytokine 
release and adhesion molecule expression using ELISA and FACS analysis, only three 
repeats of each experiment were conducted. This is both due to time constraints – 
HUVECs and PMVECs are slow-growing in vitro – and financial constraints including the 
cost of ELISA kits, antibodies, cells, and medium. Therefore, n = 3, a minimum required for 
publication, was conducted only. 
This may affect the reliability of results, as low numbers of repeats garner mean values 
impacted strongly (and potentially skewed) by outlying results and can result in a large 
degree of standard error such as that seen when assessing Endothelin-1 release by BLM-
treated HUVECs. The use of  n = 3 also meant that normal distribution could not be 
assumed, and so poorly-powered non-parametric statistical analyses (Mann-Whitney-U 
tests) were used, which may underestimate the significance of differences observed. 
However, the author felt that with n=3, the use of this test was unavoidable. The use of a 
greater number of repeats would have not only allowed the use of more powerful 
statistical analyses, but also would have generated results less impacted by outliers with a 
smaller degree of standard error, which would have improved the reliability of the results 
and given mean values likely more representative of the true protein expression and 
release profiles of BLM-treated endothelial cells.   
The observation that etoposide, like BLM, induces adhesion molecule expression and 
cytokine release by HUVECs, suffers similar limitations. Again, 13 adhesion molecules 
were assessed, but only IL-8 release was examined, and thus a full expression and release 
profile of etoposide-treated endothelial cells cannot be presented. Further, only 3 repeats 
were conducted, and qPCR was not carried out, so this is again a superficial report. 
However, as this work was conducted to assess the uniqueness of BLM in inducing 
adhesion molecule expression and cytokine release, this series of works has achieved its 
objective.  
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While the release of IL-8 and MCP-1 – and to a lesser extent, Endothelin-1 – is reported to 
be modulated by BLM treatment in this work, no functional relevance of this was 
assessed. This limits these observations to proteomic and transcriptomic reports, with no 
allusion to the impact that this altered release may have. Thus, while this altered release 
remains an interesting observation, its role in the disease state studied cannot be 
confirmed from the results of this thesis.   
However, a greater limitation of this work lies in the report that, while neutrophils adhere 
more to BLM-treated endothelial monolayers, the adhesion molecule(s) responsible for 
this could not be identified.  In this respect, this thesis has not been able to address the 
research question – the role of endothelial adhesins in immune cell adhesion to BLM-
treated endothelial monolayers remains incompletely resolved. That this work was only 
conducted using HUVECs, and not PMVECs, may also call into the question of the 
physiological relevance of these results, as a surrogate cell type was used. However, if this 
phenomenon was also observed when PMVECs were used, and were the adhesion 
molecule(s) responsible for this increased adhesion identified, then this would greatly 
augment the impact that the novel observation of this work - that neutrophils adhere 
more to BLM-treated monolayers – has among existing literature. This, therefore, is the 
most important avenue for future in vitro work.    
A limitation inherent to each section of this report is that all work is in vitro and so no 
data demonstrate that the increased adhesion molecule expression and neutrophil 
adhesion to the endothelium observed occurs in human BPF. It seem feasible that 
increased adhesion molecule expression has functional relevance in vivo - work by Wang, 
et al. (2010) and Sato, et al. (2000) showed that ICAM-1 and VCAM-1 expression 
correlates with immune cell rolling and adhesion to the endothelium and immune cell 
infiltration of the lung in I.T.-BLM treated rodents - but it cannot be inferred that these 
processes occur in human BPF patients – or in I.V. BLM-treated rodents - from either the 
current work, or that of Wang and Sato.  
Thus, a great deal of additional work - some in vitro and much in vivo (and perhaps ex 
vivo) - is required to delineate whether increased adhesion molecule expression and 
increased neutrophil adhesion to the BLM-treated endothelium contribute to the 
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inflammation that precedes human BPF; whether this is also the case in murine BPF 
stemming from I.V. dosing; and how this immune cell adhesion to the endothelium and 
potential infiltration of the lung contributes to fibrosis development in both I.V. BLM-
treated man and mouse. Such work using rodents, and more importantly a population of 
BPF patients, was sadly not available at the Trust in which this work occurred, but would 
have been most interesting to conduct. 
 
8.4 Further Work 
 
There are several aspects of the project in which work may be carried out to not only 
further our understanding of the role of endothelial cells in fibrotic lung disease, but also 
to address some of the limitations of the thesis identified in the previous section. Firstly, 
further work could be carried out to further assess and characterise the  adhesion 
molecules and cytokines expressed and released by HUVECs and PMVECs treated with 
BLM, to build a better picture of the exact response of these cell types to BLM. Molecules 
such as L-Selectin, MAdCAM-1, and GlyCam-1, and cytokines such as MIP-1α, TNF-α, and 
IL-1β would be logical choices, and once a better understanding of the repertoire of 
proteins expressed and released by these cells types in response to BLM is gained – and 
further comparisons between adhesion molecule and cytokine expression and release 
between the two cell types has been conducted - further research may be carried out in 
the vein of this thesis.  
This work also identified that the increased expression of adhesion molecules and the 
release of proinflammatory cytokines was regulated at a transcriptional level, at least in 
HUVECs. Further work may carry on in this vein and assess whether BLM also regulates 
the increased expression and release of adhesion molecules and cytokines by PMVECs at 
a transcriptional level, if only to confirm that this process in analogous in the two cell 
types. 
However, while it appears that BLM alters adhesion molecule and cytokine expression 
and release by modulating transcription, it is unclear how this transcription modulation is 
mediated. Further work to delineate this would be of great use. BLM may interact with an 
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as-yet unidentified surface receptor on endothelial cells, resulting in signalling events 
which result in increased transcription and expression of adhesion molecules and 
cytokines. This may be assessed using a similar technique to Pron, et al. (1999), via the 
isolation of endothelial cell membranes and co-incubation of these with radioactive BLM 
prior to visualisation on a semi-denaturing gel using Coomassie Blue. Alternatively, BLM 
may induce the endothelial expression of proinflammatory factors such as TNF-α and IL-
1β, which may act in an autocrine fashion to increase adhesion molecule expression and 
cytokine release. Whether this is the case may be assessed by ELISA for these cytokines 
using supernatant from BLM-treated cells.   
Having determined the mechanism by which this occurs, it would be advantageous to 
determine the signalling pathways by which the transcription of these proteins is altered, 
as the opportunity to conduct these experiments in this thesis was not available. With the 
exception of Endothelin-1, all of the proteins seen to be expressed or released at 
increased levels in this work are regulated by NF-κB signalling (as discussed in 1.6.3 and 
4.1), and so while this work did not attempt to identify the signalling pathways involved in 
the observed increase in transcript and protein levels, it seems feasible that NF-κB may be 
involved, though signalling pathways such as JNK, P38 MAPK, ERK1/2 or PI3K may 
contribute. Further work using Western Blot to detect protein phosphorylation, or EMSA 
to assess protein binding to DNA, in response to BLM may be of assistance in unravelling 
the pathways involved. 
In this work, the functional relevance of increased cytokine release was not investigated, 
and so this would also be a logical progression of the results presented here. Increased IL-
8 and MCP-1 expression may logically result in increased leukocyte movement to the site 
of expression or presentation. In vitro assessment of the role of these chemoattractant 
cytokines - using Transwell inserts and endothelial cell / leukocyte co-cultures - to assess 
whether the migration of leukocytes to BLM-treated endothelial cells is increased, would 
confirm whether increased proinflammatory cytokine release resulted in the predicted 
increase in leukocyte migration to the site of expression, and may hint at a role for 
endothelial IL-8, MCP-1, and other cytokines in the development of BPF. 
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The role of Endothelin-1, the only protein differentially regulated by BLM treatment in 
HUVECs and PMVECs, would also be interesting to investigate. This is a potent pro-fibrotic 
cytokine (Fonseca, et al., 2009) associated with fibrotic development in the rodent BPF 
model (Mutsaers, et al., 1998; Park, et al., 1998), and while increased HUVEC Endothelin-
1 release may point towards a role in pro-fibrotic processes, the decreased release of 
Endothelin-1 by PMVECs confounds this idea. Work to determine whether endothelial 
Endothelin-1 expression plays a part in the development of human BPF would be of great 
value; the role of Endothelin-1 in the pathogenesis of other fibrotic lung diseases is, after 
all, unresolved (Williamson, et al., 2015). 
Further characterisation of the molecule(s) involved in neutrophil adhesion to BLM-
treated monolayers would also be desirable. This work reported that neutrophil adhesion 
to BLM-treated monolayers was increased compared to baseline, but was not able to 
identify the adhesion molecule responsible for this, and this is perhaps the greatest 
limitation of this body of work. ICAM-1 and E-Selectin binding blockade, while decreasing 
TNF-α mediated adhesion, did not block BLM-mediated adhesion. Experimental work 
blocking VCAM-1 would be a logical next step, to see if this is the molecule responsible for 
increased binding. If this were not the adhesion molecule responsible for increased 
adhesion, further molecules would need to be assessed, perhaps based on any finding 
from earlier supplemental work to identify other adhesion molecules expressed at 
increased levels by BLM-treated monolayers, in order to determine the protein(s) 
responsible for the increased neutrophil adhesion reported in this research. 
Of course, adhesion molecules may not be the only protein involved in this process; it is 
feasible that cytokines also play a role. IL-8, for example, increases neutrophil adhesion to 
ICAM-1 (Lomakina and Waugh, 2006), as does Endothelin-1 (Lopez Farré, et al., 1993; 
Fernandez-Patron, et al., 2001; Zouki, et al., 1999). However, the increased adhesion of 
neutrophils induced by both cytokines is related to increased CD18 ligand expression, and 
this may be blocked by anti-CD18 antibodies such as TS1/18 (Lopez Farré, et al., 1993; 
Lomakina and Waugh, 2006). This work did not observe decreased adhesion of CD18-
antibody-treated neutrophils to BLM-treated endothelial monolayers, and so it does not 
appear that increased IL-8 and Endothelin-1 release impacted neutrophil adhesion.  
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To confirm this, the blockade of cytokines (using blocking antibodies) may be utilised, to 
determine whether cytokines expressed by BLM-treated endothelial cells are increasing 
neutrophil adhesion. This may be conducted concurrently with adhesion molecule 
blockade, in an attempt to identify which (if any) cytokines are increasing neutrophil 
adhesion to which (if any) adhesion molecules.   
Additionally, other as yet unidentified endothelial cell-released cytokines may contribute 
to increased neutrophil adhesion in this model, so the identification of further endothelial 
cytokines released in response to BLM, and an investigation of their roles in neutrophil 
adhesion as outlined above, would be beneficial.  
The neutrophil adhesion work may of course be built upon using PMVECs, to see if 
increased neutrophil binding is observed using both cell types. Again,this work was not 
able to identify the molecule(s) responsible for neutrophil adhesion in this model, and 
while the expression profiles of HUVECs and PMVECs was seen to be similar in this work, 
it is possible that an as-yet unidentified adhesion molecules – which may be differentially 
expressed between the cell types - may mediate adhesion in this model. Therefore, 
assessing whether the adhesion supported by HUVECs is also supported by PMVECs will 
not only bring a further degree of physiological relevance to the work, but also confirm 
that HUVECs are a suitable surrogate for PMVECs in vitro.  
All in all, by carrying out further work and identifying the adhesion molecule(s) or other 
proteins (potentially cytokines) responsible for the increased neutrophil adhesion to 
HUVECs observed, and assessing whether this increased neutrophil adhesion is also 
observed on BLM-treated PMVECs and identifying the protein(s) responsible for this, we 
would be closer to addressing the primary research objective - and thus the primary 
limitation - of this thesis; unravelling the role of endothelial adhesins in leukocyte 
adhesion in response to pharmaceutical agents that induce pulmonary fibrosis. However, 
we would not answer the question with just this information; yet more work would be 
needed.  
The next step would be to assess whether the in vitro findings of this work apply to in vivo 
models. To determine how the observations of the neutrophil adhesion work reported 
here could apply to human disease, and the role of adhesins in the process, there are 
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several steps which may be taken, some of which involve the modelling of BPF in rodents, 
and others, the recruitment of human volunteers suffering from BPF. Initially, the focus of 
this in vivo research would be in determining whether observations from previous 
publications using I.T. BLM dosing apply to I.V.BLM dosing models, and to carry these 
results - as well as those of this thesis - forward, to investigate how I.V. BLM impacts the 
human pulmonary vascular endothelium, and whether this is contributory to disease.  
Sato, et al. (2000) and Wang, et al. (2011) both reported increased leukocyte rolling and 
adhesion in the lung venules and capillaries of BLM-dosed mice, correlating with 
increased leukocyte infiltration of the interstitium and associated with ICAM-1 and 
VCAM-1 expression, but both used I.T. dosing and so it is uncertain whether the 
behaviour of the rodent pulmonary endothelium was due to a response to BLM, or a 
response to the BLM-induced cytokine storm ongoing within the lung, caused by direct 
BLM administration to the alveoli. TNF-α expression in the lung, for example, may lead to 
endothelial adhesion molecule expression and cytokine release as the pro-inflammatory 
mediator diffuses out of the lung. 
In vivo studies using I.V. BLM dosing in rodents would combat this; if similar neutrophil 
rolling and adhesion is seen after I.V. BLM administration then it can be said that the 
impact of BLM on the pulmonary vascular endothelium may contribute to BPF 
development in rodents (as the pulmonary vascular endothelium would be the first point 
of contact within and around the lung for the circulating blood-borne drug). This may also 
go some way to explain why immune cell infiltration into the lung is observed when no 
direct intra-pulmonary injury has occurred in man following treatment with I.V. BLM. 
Therefore, the first in vivo step would be to carry out analyses analogous of those carried 
out by Sato and Wang, and to determine the adhesion molecules responsible for any 
increased neutrophil adhesion reported in rodents treated with I.V. BLM. From here, 
information gathered could be used to direct future in vivo work in human participants. 
Next, assessing vascular permeability following BLM dosing would also be of interest. It 
has been reported that endothelial tight junctions in the pulmonary vasculature are held 
in an open configuration after I.T. BLM dosing (Yin, et al., 2012), and so whether this is 
also the case after I.V. dosing would be of interest. The “holding open” of tight junctions 
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in man would not only increase the access of immune cells to the lung, but may also allow 
the formation of the reported pulmonary oedema in BPF, and potentially the movement 
of blood-borne BLM into the lung, where further damage can be caused. This, if possible 
to conduct on ex vivo samples, or in vivo in human patients using fluorochrome or 
radioactive tracer-tagged antibodies against human zona occludens proteins, would 
definitely represent an interesting avenue for research, though would perhaps fall outside 
the remit of work which may represent a continuation of this thesis. 
Lastly, in rodents, BLM induces ICAM-1 expression in the lung vasculature before it occurs 
in any other locations, and the upregulation in the lung is seen to be more severe than in 
other organs (Weiner, et al., 1994). It would be interesting to fully characterise the 
expression of adhesion molecules in the rodent pulmonary vasculature following I.V. 
dosing, and to assess the spatial and temporal localisation of these molecules. Using the 
information collected from these series of experiments, it would then be possible to go 
forward and assess such features in the lungs of BLM-treated human patients.  
While it would be challenging to conduct in vivo assessments on human patients, there 
are steps which may be taken to characterise the vascular endothelial response to BLM in 
man, and to determine whether the observations made in this thesis truly have a 
functional relevance in vivo. Should it not be possible to conduct the type of in vivo 
studies conducted in mice in humans, assessment of ex vivo tissue samples by 
immunohistochemistry, to determine adhesion molecule expression profiles in the 
vasculature – taken from the lung, and other organs - from patients suffering the disease, 
would be useful to assess the temporal and spatial arrangement of adhesion molecule 
expression in BLM-treated human patients.  Alternatively, the use of adhesion-molecule 
specific, intravenously delivered, 111Indium-tagged antibodies to patients with the 
condition (as pioneered in rodents by John, et al., (2013)) which may then be visualised 
using SPECT/CT, would allow the identification and localisation of upregulated adhesion 
molecules in the vasculature of a variety of human organs following BLM dosing and 
during the process of BPF development. 
This would enable the identification of areas in man in which the vasculature is 
particularly affected by BLM, to see if the observations by Weiner, et al. (1994) may be 
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translated to human disease. If, in humans, the upregulation of adhesion molecules 
following BLM dosing was localised to the lungs, as it appears to be in rodents, and this 
upregulation is more rapid and more severe than in any other organs, then this may 
suggest why BLM induces fibrosis in the lungs preferentially, and would contribute to 
what is already known about BPF development in humans. 
Should it be possible, then it would also be interesting to directly assess the role of 
upregulated endothelial adhesion molecules in the development of human BPF; again, 
utilising non-blocking fluorochrome- or radioactive tracer-tagged antibodies to bind to 
both the adhesion molecules of the pulmonary vasculature, and also to neutrophil 
markers (for example, CD15 or CD16), would allow any neutrophil adhesion to the 
pulmonary vascular endothelium in man following BLM dosing and the behaviour of 
neutrophils and potentially their migration through into the lung, to be recorded and 
visualised, either by SPECT/CT (John, et al., 2013), or potentially via fluorescent or 
confocal microscopy (though notably, when this was used in rodents, sacrifice was 
required (Sato, et al., 2000)). This could then potentially demonstrate the exact role of 
BLM-induced adhesins in neutrophil adhesion to the endothelium and inflammation in 
human BPF.  
In doing so, one would need to take extreme care to localise anti-adhesion molecule 
antibodies only to the lung vasculature and to avoid inducing mass neutrophilic 
degranulation, whilst also limiting the exposure of patients to undue levels of radiation if 
visualising using SPECT/CT. However, this work would provide the best evidence to date 
of the role of the endothelium and endothelial adhesion molecule expression in response 
to BLM, and their role in the development of the disease, and would represent a 
breakthrough in our knowledge of the formation of this disease whilst also signposting 
potential treatment modalities.  
If it is found that the behaviour of the endothelium and its expression and release of 
adhesion molecules and cytokines contributes to the development of BPF in man, then 
the results of the current and future work may be carried forward and applied to patients 
with other fibrotic diseases. For example, the use of immunohistochemistry to identify 
adhesion molecule expression in explanted lung tissue from patients with IPF may be 
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used to determine whether increased adhesion molecule expression in the vessels of the 
lung is also seen in this disease. Similarly, fluorochrome- or radioactive tracer-tagged 
antibodies against endothelial adhesion molecules and immune cells could be used to 
visualise both the temporal and spatial expression of adhesion molecules and their role in 
the recruitment of immune cells to the lung in this disease, if any. This would allow the 
results of this work to be translated into investigations for a much more common, but 
equally devastating, disease. It may also be possible to isolate vascular endothelial cells 
from the vasculature of IPF patients and to assess and use these cells in a similar way – 
characterising the adhesion molecules expressed and the cytokines released by these 
cells, and assessing whether IPF patient endothelial cells are able to support neutrophil 
adhesion under flow at an increased level compared to normal endothelial cells. The 
opportunities to apply this research to other fibrotic diseases are numerous, as it is 
entirely possible that IPF, like BPF, is an inflammatory disease (Williamson, et al., 2015).  
If this work is able to identify and localise the expression and release of adhesion 
molecules and cytokines by BLM-exposed endothelial cells in vivo; determine the 
contribution of this to the leukocyte tethering and inflammatory cell influx seen in BPF; 
identify which protein(s) are responsible for any increased immune cell tethering and 
influx; assess whether this contributes to fibrotic lung disease, and identify the signalling 
pathways and associated cellular receptors responsible for this BLM-induced adhesion 
molecule expression, it may then be possible to develop treatments. Such treatment 
modalities may potentially involve novel targets, such as the involved adhesion 
molecules, or may work to block signalling pathways and receptor binding leading to the 
expression of these adhesion molecules, and could replace the somewhat ineffective 
corticosteroids used today; should this be acheived, and the finding of this work 
discovered to be applicable to other fibrotic diseases such as IPF, then perhaps 
treatments for this disease may also be developed.    
The novel observation made by this work, that etoposide also induces increased adhesion 
molecule expression and cytokine release, may represent the first step in a wide avenue 
of research into this poorly characterised disease. Little is known about etoposide-
induced fibrosis, including whether it  has an inflammatory component. However, if it is 
an inflammatory condition characterised by immune cell infiltration of the lungs, there 
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may be clinical value in carrying out further work, including assessing whether other 
adhesion molecules and cytokines are expressed and released at a greater level when 
endothelial cells are treated with etoposide; confirming whether this is regulated at a 
transcriptional level by qPCR; and determining the pathways by which etoposide 
mediates this increase. Of course, assessing whether this response is also seen in in 
PMVECs, and assessing the temporal and spatial expression of adhesion molecules by 
endothelial cells in response to etoposide would also be valuable, and may be achieved in 
both man and rodents using the techniques outlined previously.  
This may identify a potential cause for etoposide induced pulmonary fibrosis: if etoposide 
induced pulmonary fibrosis does indeed have an inflammatory component, and if 
adhesion molecule expression occurs in PMVECs in response to etoposide when assessed 
in vitro; then this may feasibly be contributory to fibrosis development, and further in 
vivo work may be carried out, as outlined above. From this, it may also be concluded that 
increased pulmonary vessel endothelium adhesion molecule expression is a characteristic 
side-effect of pulmonary fibrosis-inducing chemotherapies - though this would not 
explain why fibrosis occurs so commonly in response to BLM, it would add to our 
understanding of chemotherapy-induced pulmonary fibrosis. Conversely, this 
investigation may  provide an explanation of why BLM causes pulmonary fibrosis more 
often than etoposide; BLM induces adhesion molecule upregulation in pulmonary 
vascular endothelial cells in vitro, and this is observed in the lungs before anywhere else 
in vivo, with ICAM-1 expression only occurring later in the liver and spleen (Weiner, et al., 
1994). If etoposide induces a lower level of adhesion molecule expression by PMVECs in 
vitro and in vivo, compared to BLM, or induces increased adhesion molecule expression 
preferentially in other vascular beds, e.g., the liver, this may be why BLM-induced lung 
fibrosis is so common compared to that caused by other drugs.  
 
8.5 Concluding Statement 
 
In all, this work has widened our understanding of the impact of BLM treatment on 
endothelial cells, and has demonstrated how these effects may contribute to the 
inflammation that characterises the disease. Further work may expand on this and help 
312 
 
develop a better model of BPF in humans which may aid in the alleviation of this disease, 
and potentially other fibrotic conditions. 
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A I Additional Materials and Methods 
 
 
A.I.I Generation of DEPC-treated water. 
 
DEPC-treated water was generated by combining diethylpyrocarbonate (Sigma Aldrich) 
with distilled H2O (0.1% v/v). This was agitated and autoclaved prior to storage at room 
temperature.  
 
A.I.II Generation of the IV.3 Antibody. 
 
IV.3 antibody was generated in house from supernatant collected from a murine 
hybridoma cell line (K562). In brief, K652 cells were thawed at room temperature and 
incubated in 75cm2 flasks in DMEM medium (Lonza) supplemented with FCS (10%) 
(Gibco), penicillin (100μg/ml)-streptomycin (100U/ml) (PAA, Pasching, Austria), and L-
glutamine (2nM) (Lonza). Cells were then  incubated in an atmosphere containing 5% CO2 
at 37°C until confluent. The IV.3-containing supernatant was aspirated from the flasks as 
required and stored at 4°C until required.      
 
A.I.III HEK-293 RNA Isolation for use as a Positive Control for PCR 
 
HEK-293 cells were cultured in 75cm2 flasks in DMEM medium (Lonza) supplemented with 
FCS (10%) (Gibco), penicillin (100μg/ml)-streptomycin (100U/ml) (PAA, Pasching, Austria), 
and L-glutamine (2nM) (Lonza). Cells were dissociated from culture flasks by agitation, 
and the RNA extracted and reverse transcribed to generate cDNA as outlined in section 
2.9. Preparation for PCR and PCR itself was carried out as outlined in section 3.2.6.  
 
A.I.IV Generation of 1mM EDTA in PBS.  
 
Anhydrous ethylenediamineteraacetic acid (Sigma Aldrich) (292mg) was added to PBS (1L) 
and dissolved by agitation. This was left overnight and autoclaved prior to storage at 
room temperature. 
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A.I.V Generation of 1 x TAE solution 
 
1 x TAE solution was generated by diluting 50 x TAE solution 1:49 with distilled H2O. 50 x 
TAE solution was made by combining 242g Tris base (Fisher) with 600ml distilled H2O and 
dissolving this by agitation. To this, 57.1ml acetic (Sigma Aldrich) and 100ml 0.5M EDTA 
(generated by combining 146.1g anhydrous EDTA (Sigma Aldrich) in 1L distilled H2O) was 
added, and the volume adjusted to 1L with distilled H2O. This was stored at room 
temperature.   
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A.II Standard Curves Generated for ELISA and qPCR Experiments 
 
Standard curves were generated for all ELISA and qPCR experiments carried out 
throughout this thesis. These are shown in Fig A.1-A.7. The specifications of each 
standard curve are outlined below each figure. All standard curves were generated using 
data collected from experimental work and GraphPad v.5.0.4. All standard curves met the 
defined criteria for succesful ELISA experiments and specific primer activity in qPCR.  
Note that on all graphs, cDNA quantity is expressed using logarithmic scale. Therefore, 
“1” on the x-axis in fact represents 10ng/well, while “-1” represents 0.1ng/well. 
Logarithmic scales were used to assist in the determination of primer efficiency 
calculations.   
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Treatment Isotype 
Control 
Binding 
(Geometric 
Mean) 
Treatment Isotype 
Control 
Binding 
(Geometric 
Mean) 
Treatment Isotype 
Control 
Binding 
(Geometric 
Mean) 
Untreated 5.56     
Untreated 5.04     
Untreated 7.50     
      
TNF-α 
1ng/ml 
10.27 LPS 
100ng/ml 
8.48 IFN-γ 
100u/ml 
6.02 
TNF-α 
1ng/ml 
9.79 LPS 
100ng/ml 
6.78 IFN-γ 
100u/ml 
5.01 
TNF-α 
1ng/ml 
15.31 LPS 
100ng/ml 
10.58 IFN-γ 
100u/ml 
7.35 
TNF-α 
3ng/ml 
11.26 LPS 
300ng/ml 
7.05 IFN-γ 
300U/ml 
7.24 
TNF-α 
3ng/ml 
13.42 LPS 
300ng/ml 
8.52 IFN-γ 
300U/ml 
6.63 
TNF-α 
3ng/ml 
14.6 LPS 
300ng/ml 
10.83 IFN-γ 
300U/ml 
7.54 
TNF-α 
10ng/ml 
9.17 LPS 1µg/ml 6.67 IFN-γ 
1000U/ml 
6.56 
TNF-α 
10ng/ml 
8.73 LPS 1µg/ml 17.22 IFN-γ 
1000U/ml 
6.83 
TNF-α 
10ng/ml 
12.66 LPS 1µg/ml 10.04 IFN-γ 
1000U/ml 
8.81 
TNF-α 
30ng/ml 
9.22 LPS 3µg/ml 7.87 IFN-γ 
3000U/ml 
7.69 
TNF-α 
30ng/ml 
11.59 LPS 3µg/ml 7.68 IFN-γ 
3000U/ml 
5.62 
TNF-α 
30ng/ml 
11.65 LPS 3µg/ml 12.08 IFN-γ 
3000U/ml 
9.13 
 
Table A.1: Tabulated isotype control binding to inflammatory mediator treated HUVECs.  
 
  
The binding of the isotype control antibody to HUVECs treated with inflammatory 
mediators as part of optimisation experiments (expressed as the obtained geometric 
mean). Treatment with all mediators increased the binding of the isotype control to 
HUVECs. As all experiments were conducted simultaneously, only one set of results is 
available from “untreated” cells.  
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Figure A.1: Standard curves for HUVEC cytokine ELISAs 
Standard curves achieved based on standards in cytokine ELISAs used to determine 
cytokine expression in HUVEC treated with various concentrations of BLM. All standard 
curves were generated using Prism GraphPad version 5.04. All standard curves are 
representative of ideal standard curves supplied with ELISA kit instructions. 
A B 
C D 
E 
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Figure A.2: Standard curves for PMVEC cytokine ELISAs 
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Standard curves achieved based on standards in cytokine ELISAs used to determine 
cytokine expression in PMVECs treated with various concentrations of BLM. All 
standard curves were generated using Prism GraphPad version 5.04. All standard 
curves are representative of ideal standard curves supplied with ELISA kit instructions. 
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Figure A.3: Standard curves for cytokine ELISAs using HUVECs treated with other 
chemotherapeutic agents  
  Standard curves achieved based on standards in interleukin-8 ELISAs used to determine 
expression in cells treated with A) etoposide, B) doxorubicin, C) carboplatin, and D) the 
vehicle control, dimethyl sulfoxide. All curves are representative of ideal standard curves 
supplied with ELISA kit instructions. 
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IL-8 Primer Standard Curve
-4 -3 -2 -1 0 1
15
20
25
30
35
cDNA Quantity (ng/well)
C
y
c
le
 T
h
re
s
h
o
ld
 (
C
T
)
  
         
MCP-1 Primer Standard Curve
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Slope -3.324 
Y Intercept 23.44 
R2 value 0.9766 
P value < 0.0001 
Efficiency 99.91% 
Slope -3.486 
Y Intercept 20.37 
R2 value 0.997 
P value < 0.0001 
Efficiency 93.58% 
Slope -3.337 
Y Intercept 20.86 
R2 value 0.9986 
P value < 0.0001 
Efficiency 99.37% 
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VCAM-1 Primer Standard  Curve
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Endothelin-1 Primer Standard Curve
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Figure A.4: qPCR standard curves (five-point)  
Slope -3.203 
Y Intercept 24.07 
R2 value 0.9944 
P value < 0.0001 
Efficiency 105.21% 
Slope -3.501 
Y Intercept 24.21 
R2 value 0.9872 
P value < 0.0001 
Efficiency 93.03% 
Standard curves generated based on a series of five serial dilutions of samples used for 
qPCR. Each standard curve was conducted simultaneously, in duplicate, on cDNA 
obtained from HUVECs treated with 10ng TNF-α (UBC (A), IL-8 (B), MCP-1 (C), and VCAM-
1 (D)), or 4U/ml thrombin (Endothelin-1 (E)) to induce gene expression. Relevant data 
from each standard curve is shown in the table accompanying each curve. The P value 
refers to the significance of the slope value from zero. All primers showed efficiencies 
within the acceptable 90-110% range and data will not need correcting.  
Note that on all graphs, cDNA quantity is expressed using logarithmic scale.  
D 
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PDGF-BB Primer Standard Curve
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Figure A.5: qPCR standard curves (four-point). 
 
 
  
Slope -3.202 
Y Intercept 21.84 
R2 value 0.9952 
P value < 0.0001 
Efficiency 105.26% 
Slope -3.129 
Y Intercept 24.88 
R2 value 0.9941 
P value < 0.0001 
Efficiency 108.73% 
Standard curves generated based on a series of five serial dilutions of samples used for 
qPCR. Each standard curve was conducted simultaneously, in duplicate, on cDNA obtained 
from HUVECs treated with 10ng TNF-α (E-selectin) (A), or 3U/ml thrombin (PDGF-BB) (B) to 
induce gene expression. Relevant data from each standard curve is shown in the table 
accompanying each curve. The P value refers to the significance of the slope value from 
zero. All primers showed efficiencies within the acceptable 90-110% range and data will not 
need correcting. In both cases, reliable data was not obtainable for the lowest dilution 
(0.0001ng/well) in repeated experiments, so a standard curve was made using four sets of 
results. 
Note that on all graphs, cDNA quantity is expressed using logarithmic scale.  
 
A 
B 
394 
 
TGF- Primer Standard Curve
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Figure A.6: qPCR standard curve for TGF-β (four point). 
Standard curve generated based on a series of five serial dilutions of purified samples 
used for qPCR. The standard curve was conducted simultaneously, in duplicate, on cDNA 
obtained from HUVECs and purified to ensure sufficient cDNA. The P value refers to the 
significance of the slope value from zero. The primer showed efficiency within the 
acceptable 90-110% range and data will not need correcting. Reliable data was not 
obtainable for the lowest dilution (0.0001ng/µl of purified cDNA at a concentration of 
2ng/ml) in repeated experiments, so a standard curve was made using four sets of results. 
Note that on all graphs, cDNA quantity is expressed using logarithmic scale.  
 
  
Slope -3.200 
Y Intercept 1.537 
R2 value 0.9877 
P value < 0.0001 
Efficiency 105.35% 
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 Figure A.7: qPCR standard curve for ICAM-1 (four point). 
 
Standard curve generated based on a series of five serial dilutions of lung cDNA, 
generated graciously by Rebecca Gover of PrimerDesign. The standard curve was 
conducted simultaneously, in triplicate. The P value refers to the significance of the slope 
value from zero. The primer showed efficiency within the acceptable 90-110% range and 
data will not need correcting. Reliable data was not obtainable for the lowest dilution 
(0.003ng/µl of cDNA) in repeated experiments, so a standard curve was made using four 
sets of results. 
Note that on all graphs, cDNA quantity is expressed using logarithmic scale.  
 
  
Slope -3.428 
Y Intercept 27.49 
R2 value 0.996 
P value < 0.0001 
Efficiency 95.75% 
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A.III Neutrophil Adhesion Raw Data Analysis 
 
Shown in Figure A.8 and A.9 are examples of neutrophil adhesion raw data assessment. 
Raw data was inputted into Microsoft Word and a grid placed above each image. 
Adherent neutrophils were identified and their movement under flow tracked. The 
number of neutrophils seen to be adherent at the beginning of the field which did not 
become un-adherent, the number which adhered as a new adhesion event and did not 
become un-adherent, and the number which adhered and then rolled along the 
endothelium were identified. The following were regarded a neutrophil adhesion events.  
 Cells that were adherent from the beginning of visualisation and did not un-
adhere 
 Cells that were adherent and un-adhered (but remained adherent for at least two 
frames) 
 Cells that adhered during flow and remained adherent throughout visualisation 
 Cells that adhered during flow, remained adhered for at least two frames, and 
then un-adhered 
 Rolling and slow rolling cells that met the two-frame adherence criteria outlined 
above. “Slow rolling” cell events were those seen to be moving at ≤10μm/second 
(outlined in 6.2.6.1). If cells were observed to be moving at speeds above 
10μm/second but were clearly visible and slower than non-adherent neutrophils, 
cells were deemed to be “rolling”.  
Cells that became adherent or rolled for only one frame were not counted. 
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Figure A.8: Neutrophil adhesion assessment (negative control - untreated endothelial cells) 
  An example of neutrophil adhesion assessment. Neutrophils that were adherent from the first frame and 
remained adherent are denoted by orange circles. These cells remained adherent throughout the analysis 
and represent two neutrophil adhesion events observed in this experiment. Six frames are shown only. 
200µm 
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An example of neutrophil adhesion 
assessment. New cel adhesion 
events are marked in blue circles. 
New adhesion events that results in 
rolling are denoted by yellow 
circles. Static cells (adherent from 
the first frame and remained 
adherent) are denoted by orange 
circles. Cells that were originally 
adherent and began to roll under 
shear are denoted by purple 
circles.  
Many cells met adherence criteria 
in this analysis and represent a 
snap-shot of the adhesion events 
seen in this analysis. Nine frames 
are shown only.  
Figure A.9: Neutrophil adhesion 
assessment (TNF-α treated 
endothelial cells.) 
200µm 
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A.IV Movies of Neutrophil Adhesion to Endothelial Cells Under Flow 
 
Movies of neutrophil adhesion to endothelial cells treated with 10ng/ml TNF-α under 
flow can be found in the accompanying material (Disc A). Twenty individual movies have 
been submitted with this thesis. The movies depict an experiment conducted explicity for 
the purpose of making moving images of this process and were not used as data for the 
results depicted in chapter 6. In these movies, neutrophil suspensions of a higher 
neutrophil concentration (1x106/ml) were used by way of demonstration. In standard 
experiments, concentrations of 5x105/ml neutrophils in suspension were used. In half of 
the movies submitted, neutrophils were treated with isotype control antibody as used in 
the blocking experiments, and the endothelial monolayer remained untreated. In the 
other half of the movies, the endothelial monolayer was treated with the isotype control 
antibody, and the neutrophils remained untreated.  
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Appendix B  Ethical Approval for Blood 
Collection from Volunteer Donors 
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Fig. B.1: Ethical approval for blood sample collection from volunteer donors. 
 
 
 
 
 
 
Ethical approval granted by the HYMS Ethics Board for the collection of blood samples 
from volunteer donors for use in the neutrophil adhesion assays carried out in Chapter 
6 of this thesis.  
